Placement Document
Not for Circulation and Strictly Confidential
Serial Number: ___
ALEMBIC PHARMACEUTICALS LIMITED
Registered and Corporate Office: Alembic Road, Vadodara 390 003, Gujarat, India
Telephone: +91 265 228 0550; Fax: +91 265 228 2506
E-mail: [email protected]; Website: www.alembicpharmacueticals.com; CIN: L24230GJ2010PLC061123
Alembic Pharmaceuticals Limited (our “Company" or the “Issuer”) was originally incorporated on June 16, 2010 as “Alembic Pharma Limited”, a public limited company under the Companies Act,
1956. Thereafter, our Company commenced its business on July 1, 2010, pursuant to a certificate of commencement of business issued to it by the Assistant Registrar of Companies, Gujarat, Dadra and
Nagar Haveli. Subsequently, the name of our Company was changed to “Alembic Pharmaceuticals Limited”, pursuant to a fresh certificate of incorporation consequent upon change of name dated
March 12, 2011, issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. For details with respect to changes to the name of our Company, see "General Information" on page
179.
Our Company is issuing 80,47,210 Equity Shares (as defined below) at a price of ₹932.00 per Equity Share (the “Issue Price”), including a premium of ₹930.00 per Equity Share, aggregating to
approximately ₹750.00 crore (the “Issue”). For further details, see “Summary of the Issue” on page 29.
THIS ISSUE IS BEING UNDERTAKEN IN RELIANCE UPON CHAPTER VI OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI REGULATIONS”) AND SECTION 42 OF THE COMPANIES ACT, 2013 AND OTHER
APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (“COMPANIES ACT”)
The equity shares of our Company, of face value of ₹ 2 each (the “Equity Shares”) are listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”, and together with
BSE, the “Stock Exchanges”). The closing price of the outstanding Equity Shares on BSE and NSE as on July 31, 2020 was ₹985.30 and ₹985.05 per Equity Share, respectively. In-principle approvals
under Regulation 28(1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, for listing of the Equity Shares to be issued
pursuant to the Issue, have been received from BSE and NSE on August 3, 2020. Our Company shall make applications to the Stock Exchanges for obtaining the final listing and trading approvals for
the Equity Shares to be issued pursuant to the Issue. The Stock Exchanges assume no responsibility for the correctness of any statements made, opinions expressed or reports contained herein. Admission
of the Equity Shares to be issued pursuant to the Issue for trading on the Stock Exchanges should not be taken as an indication of the merits of our Company or of the Equity Shares.
OUR COMPANY HAS PREPARED THIS PLACEMENT DOCUMENT SOLELY FOR PROVIDING INFORMATION IN CONNECTION WITH THE ISSUE.
A copy of the Preliminary Placement Document (which includes disclosures prescribed under Form PAS-4 (as defined hereafter)) has been delivered to the Stock Exchanges and a copy of this Placement
Document (which includes disclosures prescribed under Form PAS-4) has been delivered to the Stock Exchanges. Our Company shall also make requisite filings with the Registrar of Companies,
Gujarat at Ahmedabad (“RoC”), within the stipulated timeframe prescribed under the Companies Act and the Companies (Prospectus and Allotment of Securities) Rules, 2014, as amended. The
Preliminary Placement Document and this Placement Document has not been reviewed by SEBI, the Stock Exchanges, RoC or any other regulatory or listing authority and is intended only for use by
Eligible QIBs (as defined hereinafter). The Preliminary Placement Document and this Placement Document has not been and will not be filed as a prospectus with the RoC, will not be circulated or
distributed to the public in India or any other jurisdiction, and will not constitute a public offer in India or any other jurisdiction.
THE ISSUE AND THE DISTRIBUTION OF THIS PLACEMENT DOCUMENT IS BEING DONE IN RELIANCE UPON SECTION 42 OF THE COMPANIES ACT, AND OTHER
APPLICABLE PROVISIONS OF THE COMPANIES ACT AND THE RULES MADE THEREUNDER AND CHAPTER VI OF THE SEBI REGULATIONS. THIS PLACEMENT
DOCUMENT IS PERSONAL TO EACH PROSPECTIVE INVESTOR. THE ISSUE DOES NOT CONSTITUTE AN OFFER OR INVITATION OR SOLICITATION OF AN OFFER TO
THE PUBLIC OR TO ANY OTHER PROSPECTIVE INVESTOR OR CLASS OR CATEGORY OF INVESTORS WITHIN OR OUTSIDE INDIA OTHER THAN ELIGIBLE QIBs. THIS
PLACEMENT DOCUMENT SHALL BE CIRCULATED ONLY TO SUCH ELIGIBLE QIBs WHOSE NAMES ARE RECORDED BY OUR COMPANY PRIOR TO MAKING AN
INVITATION TO SUBSCRIBE TO THE EQUITY SHARES.
YOU MAY NOT AND ARE NOT AUTHORISED TO (1) DELIVER THIS PLACEMENT DOCUMENT TO ANY OTHER PERSON; OR (2) REPRODUCE THIS PLACEMENT
DOCUMENT IN ANY MANNER WHATSOEVER; OR (3) RELEASE ANY PUBLIC ADVERTISEMENT OR UTILISE ANY MEDIA, MARKETING OR DISTRIBUTION CHANNELS
OR AGENTS TO INFORM THE PUBLIC AT LARGE ABOUT THE ISSUE. ANY DISTRIBUTION OR REPRODUCTION OF THIS PLACEMENT DOCUMENT IN WHOLE OR IN
PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS INSTRUCTION MAY RESULT IN VIOLATION OF THE SEBI REGULATIONS OR OTHER APPLICABLE LAWS
OF INDIA AND OF OTHER JURISDICTIONS.
INVESTMENTS IN EQUITY SHARES INVOLVE A HIGH DEGREE OF RISK AND PROSPECTIVE INVESTORS SHOULD NOT INVEST IN THE ISSUE UNLESS THEY ARE
PREPARED TO TAKE THE RISK OF LOSING ALL OR PART OF THEIR INVESTMENT. PROSPECTIVE INVESTORS ARE ADVISED TO CAREFULLY READ THE SECTION
“RISK FACTORS” BEGINNING ON PAGE 35 BEFORE MAKING AN INVESTMENT DECISION RELATING TO THE ISSUE. EACH PROSPECTIVE INVESTOR IS ADVISED TO
CONSULT ITS OWN ADVISORS ABOUT THE PARTICULAR CONSEQUENCES OF AN INVESTMENT IN THE EQUITY SHARES TO BE ISSUED PURSUANT TO THE
PRELIMINARY PLACEMENT DOCUMENT AND THIS PLACEMENT DOCUMENT. PROSPECTIVE INVESTORS OF THE EQUITY SHARES OFFERED SHOULD CONDUCT
THEIR OWN DUE DILIGENCE ON THE EQUITY SHARES. IF YOU DO NOT UNDERSTAND THE CONTENTS OF THIS PLACEMENT DOCUMENT, YOU SHOULD CONSULT
AN AUTHORISED FINANCIAL ADVISOR.
Invitations, offers and sales of Equity Shares to be issued pursuant to the Issue shall only be made pursuant to the Preliminary Placement Document (as defined hereinafter) and this Placement Document
(as defined hereinafter) and the Confirmation of Allocation Note (as defined hereinafter). For further details, see “Issue Procedure” on page 131. The distribution of this Placement Document or the
disclosure of its contents, without our Company’s prior consent, to any person, other than Eligible QIBs and persons retained by Eligible QIBs to advise them with respect to their purchase of Equity
Shares, is unauthorised and prohibited. Each prospective investor, by accepting delivery of this Placement Document, agrees to observe the foregoing restrictions and to make no copies of this Placement
Document or any documents referred to in this Placement Document.
The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the
United States and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and
any applicable state securities laws. The Equity Shares offered in the Issue are being offered and sold only outside the United States in “offshore transactions”, as defined in and in reliance on Regulation
S under the U.S. Securities Act (“Regulation S”) and the applicable laws of the jurisdiction where those offers and sales are made. See “Selling Restrictions” on page 145 for information about eligible
offerees for the Issue and “Purchaser Representations and Transfer Restrictions” on page 152 for information about transfer restrictions that apply to the Equity Shares sold in the Issue.
The information on our Company’s website or any website directly or indirectly linked to our Company’s website or the website of the BRLMs (as defined hereinafter) or any of their respective affiliates
does not constitute nor form part of this Placement Document and prospective investors should not rely on such information contained in, or available through, any such websites for their investment in
this Issue.
This Placement Document is dated August 6, 2020.
BOOK RUNNING LEAD MANAGERS
Monarch Networth Capital Limited HDFC Bank Limited
TABLE OF CONTENTS
NOTICE TO INVESTORS .................................................................................................................................. 1
REPRESENTATIONS BY INVESTORS........................................................................................................... 3
OFFSHORE DERIVATIVE INSTRUMENTS .................................................................................................. 9
DISCLAIMER CLAUSE OF THE STOCK EXCHANGES .......................................................................... 10
PRESENTATION OF FINANCIAL AND OTHER INFORMATION ......................................................... 11
INDUSTRY AND MARKET DATA................................................................................................................. 13
FORWARD-LOOKING STATEMENTS ........................................................................................................ 14
ENFORCEMENT OF CIVIL LIABILITIES .................................................................................................. 15
EXCHANGE RATES INFORMATION .......................................................................................................... 16
DEFINITIONS AND ABBREVIATIONS ........................................................................................................ 17
SUMMARY OF BUSINESS .............................................................................................................................. 23
SUMMARY OF THE ISSUE ............................................................................................................................ 29
SELECTED FINANCIAL INFORMATION ................................................................................................... 31
RISK FACTORS ................................................................................................................................................ 35
MARKET PRICE INFORMATION ................................................................................................................ 63
USE OF PROCEEDS ......................................................................................................................................... 66
CAPITALISATION STATEMENT ................................................................................................................. 67
CAPITAL STRUCTURE ................................................................................................................................... 68
RELATED PARTY TRANSACTIONS ............................................................................................................ 71
DIVIDENDS ........................................................................................................................................................ 72
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS .................................................................................................................................................... 73
INDUSTRY OVERVIEW .................................................................................................................................. 93
OUR BUSINESS ............................................................................................................................................... 106
ORGANISATIONAL STRUCTURE ............................................................................................................. 117
BOARD OF DIRECTORS AND SENIOR MANAGEMENT ...................................................................... 118
PRINCIPAL SHAREHOLDERS AND OTHER INFORMATION ............................................................ 128
ISSUE PROCEDURE ...................................................................................................................................... 131
PLACEMENT ................................................................................................................................................... 143
SELLING RESTRICTIONS ........................................................................................................................... 145
PURCHASER REPRESENTATIONS AND TRANSFER RESTRICTIONS ............................................ 152
THE SECURITIES MARKET OF INDIA..................................................................................................... 154
DESCRIPTION OF THE EQUITY SHARES ............................................................................................... 157
STATEMENT OF SPECIAL TAX BENEFITS ............................................................................................ 161
LEGAL PROCEEDINGS ................................................................................................................................ 174
OUR STATUTORY AUDITORS.................................................................................................................... 178
GENERAL INFORMATION .......................................................................................................................... 179
FINANCIAL STATEMENTS ......................................................................................................................... 180
MATERIAL DEVELOPMENTS .................................................................................................................... 181
DECLARATION .............................................................................................................................................. 189
APPLICATION FORM ................................................................................................................................... 192
1
NOTICE TO INVESTORS
Our Company has furnished and accepts full responsibility for all the information contained in this Placement
Document and confirms that, to the best of our knowledge and belief, having made all reasonable enquiries, this
Placement Document contains all the information with respect to us, which is material in the context of the Issue.
The statements contained in this Placement Document relating to us and the Equity Shares are, in all material
respects, true, accurate and not misleading. The opinions and intentions expressed in this Placement Document
with regard to us and the Equity Shares, are honestly held, have been reached after considering all relevant
circumstances, and are based on information currently available with us and are based on reasonable assumptions.
There are no other facts in relation to us or the Equity Shares, the omission of which would, in the context of the
Issue, make any statement in this Placement Document misleading in any material respect. Further, all reasonable
enquiries have been made by us to ascertain such facts and to verify the accuracy of all such information and
statements. The information contained in this Placement Document has been provided by our Company and other
sources identified herein. Distribution of this Placement Document to any person other than the prospective
investor specified by the BRLMs or their representatives, and those persons, if any, retained to advise such
prospective investor with respect thereto, is unauthorised, and any disclosure of its contents, without prior written
consent of our Company, is prohibited. Any reproduction or distribution of this Placement Document, in whole
or in part, and any disclosure of its contents to any other person is prohibited.
Monarch Networth Capital Limited and HDFC Bank Limited (together, the “BRLMs”), have made reasonable
enquiries but have not separately verified all of the information contained in the Preliminary Placement Document
or this Placement Document (financial, legal or otherwise). Accordingly, neither the BRLMs nor any of their
affiliates including any of their respective shareholders, directors, officers, employees, counsel, representatives,
agents or affiliates make any express or implied representation, warranty or undertaking, and no responsibility or
liability is accepted by any of the BRLMs or any of their respective shareholders, directors, officers, employees,
counsel, representatives, agents or affiliates as to the accuracy or completeness of the information contained in
the Preliminary Placement Document or this Placement Document or any other information supplied in connection
with the issue of Equity Shares or their distribution.
Each person receiving this Placement Document acknowledges that such person has not relied on the BRLMs or
any of their affiliates including any of their respective shareholders, directors, officers, employees, counsel,
representatives, agents or affiliates in connection with such person’s investigation of the accuracy of such
information or such person’s investment decision, and each such person must rely on its own examination of us
and the merits and risks involved in investing in the Equity Shares to be issued pursuant to the Issue. Prospective
investors should not construe the contents of this Placement Document as legal, tax, accounting or investment
advice.
No person is authorised to give any information or to make any representation not contained in this Placement
Document and any information or representation not so contained must not be relied upon as having been
authorised by or on behalf of our Company or by or on behalf of the BRLMs. The delivery of this Placement
Document at any time does not imply that the information contained in it is correct as of any time subsequent to
its date.
The Equity Shares to be issued pursuant to the Issue have not been approved, disapproved or recommended
by the U.S. Securities and Exchange Commission, any other federal or state authorities in the United States
or the securities authorities of any non-United States jurisdiction or any other United States or non-United
States regulatory authority. No authority has passed on or endorsed the merits of the Issue or the accuracy
or adequacy of this Placement Document. Any representation to the contrary is a criminal offence in the
United States and may be a criminal offence in other jurisdictions.
The Equity Shares have not been and will not be registered under the U.S. Securities Act, or the securities laws
of any state of the United States and, unless so registered, may not be offered or sold within the United States,
except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S.
Securities Act and applicable U.S. state securities laws. For further information, see “Selling Restrictions” and
“Purchaser Representations and Transfer Restrictions” beginning on pages 145 and 152, respectively.
The subscribers of the Equity Shares offered in the Issue will be deemed to make the representations, warranties,
acknowledgments and agreements set forth in “Notice to Investors”, “Representations by Investors”, “Selling
Restrictions” and “Purchaser Representations and Transfer Restrictions” on pages 1, 3, 145 and 152,
respectively.
2
The distribution of this Placement Document may be restricted in certain jurisdictions by applicable laws. As
such, this Placement Document does not constitute, and may not be used for or in connection with, an offer or
solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorised or to any person to
whom it is unlawful to make such offer or solicitation. In particular, except for India, no action has been taken by
our Company and the BRLMs that would permit an offering of the Equity Shares or distribution of this Placement
Document in any jurisdiction, where action for that purpose is required. Accordingly, the Equity Shares may not
be offered or sold, directly or indirectly, and none of the Preliminary Placement Document, this Placement
Document or any offering material in connection with the Equity Shares may be distributed or published in or
from any country or jurisdiction, except under circumstances that will result in compliance with any applicable
rules and regulations of any such country or jurisdiction. For a description of the restrictions applicable to the
offer and sale of the Equity Shares in the Issue in certain jurisdictions, see “Selling Restrictions” and “Purchaser
Representations and Transfer Restrictions” beginning on pages 145 and 152, respectively.
In making an investment decision, the prospective investors must rely on their own examination of us, the Equity
Shares and the terms of the Issue, including the merits and risks involved. Prospective investors should not
construe the contents of this Placement Document as legal, tax, accounting or investment advice. Prospective
investors should consult their own counsel and advisors as to business, legal, tax, accounting and related matters
concerning the Issue. In addition, our Company or the BRLMs are not making any representation to any offeree
or subscriber of the Equity Shares regarding the legality of an investment in the Equity Shares by such offeree or
subscriber under applicable legal, investment or similar laws or regulations.
Each subscriber of the Equity Shares in the Issue is deemed to have acknowledged, represented and agreed that it
is an Eligible QIB and is eligible to invest in India and in our Company under applicable law, including Chapter
VI of the SEBI Regulations, Section 42 of the Companies Act and other provisions of the Companies Act, and
that it is not prohibited by SEBI or any other regulatory, statutory or judicial authority from buying, selling or
dealing in securities including the Equity Shares. Each subscriber of the Equity Shares in the Issue also
acknowledges that it has been afforded an opportunity to request from our Company and review information
relating to our Company and the Equity Shares.
This Placement Document contains summaries of certain terms of certain documents, which summaries are
qualified in their entirety by the terms and conditions of such document.
The information on our Company’s website, www.alembicpharmaceuticals.com, any website directly or indirectly
linked to the website of our Company or on the website of the BRLMs or any their respective affiliates, does not
constitute nor form part of the Preliminary Placement Document or this Placement Document. Prospective
investors should not rely on such information contained in, or available through, any such websites.
NOTICE TO INVESTORS IN CERTAIN OTHER JURISDICTIONS
For information to investors in certain other jurisdictions, see the sections “Selling Restrictions” and “Purchaser
Representations and Transfer Restrictions” on pages 145 and 152, respectively.
3
REPRESENTATIONS BY INVESTORS
References herein to “you” or “your” is to a prospective investor in the Issue. By Bidding for and/or subscribing
to any Equity Shares in the Issue, you are deemed to have represented, warranted, acknowledged and agreed to
our Company and the BRLMs, as follows:
• You are a “qualified institutional buyer” as defined in Regulation 2(1)(ss) of the SEBI Regulations and not
excluded pursuant to Regulation 179(2)(b) of the SEBI Regulations, having a valid and existing registration
under applicable laws and regulations India, and undertake to (i) acquire, hold, manage or dispose of any
Equity Shares that are Allotted (hereinafter defined) to you in accordance with Chapter VI of the SEBI
Regulations, the Companies Act and all other applicable laws; and (ii) comply with all requirements under
applicable law in this relation, including reporting obligations / making necessary filings with appropriate
regulatory authorities including RBI, in connection with this Issue or otherwise in relation to accessing the
capital markets;
• You are eligible to invest in India under applicable law, including the FEMA Rules, and have not been
prohibited by SEBI or any other regulatory authority, statutory authority or otherwise, from buying, selling,
or dealing in securities or otherwise accessing capital markets in India;
• If you are not a resident of India, but a QIB, you are an Eligible FPI, having a valid and existing registration
with SEBI under the applicable laws in India or a multilateral or bilateral development financial institution,
and are eligible to invest in India under applicable law, including the FEMA Rules, and any notifications,
circulars or clarifications issued thereunder, and have not been prohibited by SEBI or any other regulatory
authority, from buying, selling, dealing in securities or otherwise accessing the capital markets. You
confirm that you are not an FVCI;
• You will provide the information as required under the Companies Act, the PAS Rules and applicable SEBI
regulations and rules for record keeping by our Company, including your name, complete address, phone
number, e-mail address, permanent account number and bank account details;
• If you are Allotted Equity Shares, you shall not, for a period of one year from the date of Allotment, sell
the Equity Shares so acquired except on the Stock Exchanges. Further, additional restrictions are applicable
if you are within the United States. For further details in this regard, see “Selling Restrictions” and
“Purchaser Representations and Transfer Restrictions” on pages 145 and 152;
• You are aware that neither the Preliminary Placement Document nor this Placement Document have been
and will be filed as a prospectus under the Companies Act, the SEBI Regulations or under any other law in
force in India and, no Equity Shares will be offered in India or overseas to the public or any members of
the public in India or any other class of investors, other than Eligible QIBs. The Preliminary Placement
Document and this Placement Document (which includes disclosures prescribed under Form PAS-4) has
not been and will not be reviewed or affirmed by the RBI, SEBI, the Stock Exchanges, the RoC or any
other regulatory or listing authority and is intended only for use by Eligible QIBs;
• The Preliminary Placement Document and this Placement Document has been filed with the Stock
Exchanges and the Preliminary Placement Document and this Placement Document has been displayed on
the websites of our Company and the Stock Exchanges;
• You are permitted to subscribe for and acquire the Equity Shares under the laws of all relevant jurisdictions
that apply to you and that you have fully observed such laws and you have necessary capacity, have
obtained all necessary consents, governmental or otherwise, and authorisations and complied and shall
comply with all necessary formalities, to enable you to participate in the Issue and to perform your
obligations in relation thereto (including, without limitation, in the case of any person on whose behalf you
are acting, all necessary consents and authorisations to agree to the terms set out or referred to in the
Preliminary Placement Document and the Placement Document), and will honour such obligations;
• You are aware that, our Company, the BRLMs or any of their respective shareholders, directors, officers,
employees, counsel, representatives, agents or affiliates are not making any recommendations to you or
advising you regarding the suitability of any transactions it may enter into in connection with the Issue and
your participation in the Issue is on the basis that you are not, and will not, up to the Allotment, be a client
of the BRLMs. The BRLMs or any of their shareholders, directors, officers, employees, counsel,
4
representatives, agents or affiliates do not have any duties or responsibilities to you for providing the
protection afforded to their clients or customers or for providing advice in relation to the Issue and are not
in any way acting in any fiduciary capacity;
• You confirm that, either: (i) you have not participated in or attended any investor meetings or presentations
by our Company or its agents (the “Company Presentations”) with regard to our Company or the Issue;
or (ii) if you have participated in or attended any Company Presentations: (a) you understand and
acknowledge that the BRLMs may not have knowledge of the statements that our Company or its agents
may have made at such Company Presentations and is therefore unable to determine whether the
information provided to you at such Company Presentations may have included any material misstatements
or omissions, and, accordingly you acknowledge that the BRLMs have advised you not to rely in any way
on any information that was provided to you at such Company Presentations, and (b) confirm that you have
not been provided any material or price sensitive information relating to our Company and the Issue that
was not publicly available;
• Your decision to subscribe to the Equity Shares to be issued pursuant to the Issue has not been made on the
basis of any information relating to us, which is not set forth in the Preliminary Placement Document or
this Placement Document;
• You are subscribing to the Equity Shares to be issued pursuant to the Issue in accordance with applicable
laws and by participating in this Issue, you are not in violation of any applicable law, including but not
limited to the SEBI Insider Trading Regulations, the Securities and Exchange Board of India (Prohibition
of Fraudulent and Unfair Trade Practices relating to Securities Market) Regulations, 2003, as amended,
and the Companies Act;
• All statements other than statements of historical fact included in this Placement Document, including,
without limitation, those regarding us or our business strategy, plans and objectives of management for
future operations (including development plans and objectives relating to our business), are forward-
looking statements. You are aware that, such forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause actual results to be materially different
from future results, performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions regarding our present
and future business strategies and environment in which we will operate in the future. You should not place
undue reliance on forward-looking statements, which speak only as at the date of this Placement Document.
Neither our Company nor the BRLMs or any of their respective shareholders, directors, officers,
employees, counsel, representatives, agents or affiliates assume any responsibility to update any of the
forward-looking statements contained in this Placement Document;
• You are aware and understand that the Equity Shares are being offered only to Eligible QIBs on a private
placement basis and are not being offered to the general public, and the Allotment of the same shall be at
the discretion of our Company, in consultation with the BRLMs;
• You are aware that in terms of the requirements of the Companies Act, upon Allocation, our Company has
disclosed names and percentage of post-Issue shareholding of the proposed Allottees in this Placement
Document. However, disclosure of such details in relation to the proposed Allottees in this Placement
Document does not guarantee Allotment to them, as Allotment in the Issue shall continue to be at the sole
discretion of our Company, in consultation with the BRLMs;
• You are aware that if you are Allotted more than 5% of the Equity Shares in the Issue, our Company shall
be required to disclose your name and the number of the Equity Shares Allotted to you to the Stock
Exchanges and the Stock Exchanges will make the same available on their website and you consent to such
disclosures;
• You have been provided a serially numbered copy of the Preliminary Placement Document and this
Placement Document and have read it in its entirety, including in particular, “Risk Factors” on page 35;
• In making your investment decision, you have (i) relied on your own examination of us, the Equity Shares
and the terms of the Issue, including the merits and risks involved, (ii) made your own assessment of us,
the Equity Shares and the terms of the Issue, based solely on and in reliance of the information contained
in the Preliminary Placement Document and no other disclosure or representation by our Company or any
5
other party, (iii) consulted your own independent counsel and advisors or otherwise have satisfied yourself
concerning, without limitation, the effects of local laws (including tax laws), (iv) received all information
that you believe is necessary or appropriate in order to make an investment decision in respect of us and
the Equity Shares, and (v) relied upon your own investigation and resources in deciding to invest in the
Issue;
• Neither the Company nor the BRLMs nor any of their respective shareholders, directors, officers,
employees, counsel, representatives, agents or affiliates have provided you with any tax advice or otherwise
made any representations regarding the tax consequences of purchase, ownership and disposal of the Equity
Shares (including but not limited to the Issue and the use of the proceeds from the Equity Shares). You will
obtain your own independent tax advice from a reputable service provider and will not rely on the BRLMs
or any of their shareholders, directors, officers, employees, counsel, representatives, agents or affiliates,
when evaluating the tax consequences in relation to the Equity Shares (including, in relation to the Issue
and the use of proceeds from the Equity Shares). You waive, and agree not to assert any claim against, our
Company, the BRLMs or any of their respective shareholders, directors, officers, employees, counsel,
representatives, agents or affiliates, with respect to the tax aspects of the Equity Shares or as a result of any
tax audits by tax authorities, wherever situated;
• You will obtain your own independent tax advice from a reputable service provider and will not rely on the
BRLMs or any of their shareholders, directors, officers, employees, counsel, representatives, agents or
affiliates when evaluating the tax consequences in relation to the Equity Shares (including but not limited
to the Issue and the use of the proceeds from the Equity Shares). You waive, and agree not to assert any
claim against our Company or any of the BRLMs or any of their respective shareholders, directors, officers,
employees, counsel, representatives, agents or affiliates with respect to the tax aspects of the Equity Shares
or as a result of any tax audits by tax authorities, wherever situated;
• You are a sophisticated investor and have such knowledge and experience in financial, business and
investment matters as to be capable of evaluating the merits and risks of an investment in the Equity Shares.
You are experienced in investing in private placement transactions of securities of companies in a similar
nature of business, similar stage of development and in similar jurisdictions. You and any accounts for
which you are subscribing for the Equity Shares (i) are each able to bear the economic risk of your
investment in the Equity Shares, (ii) will not look to our Company and/or the BRLMs or any of their
respective shareholders, directors, officers, employees, counsel, advisors, representatives, agents or
affiliates for all or part of any such loss or losses that may be suffered in connection with the Issue, including
losses arising out of non-performance by our Company of any of its respective obligations or any breach
of any representations and warranties by our Company, whether to you or otherwise, (iii) are able to sustain
a complete loss on the investment in the Equity Shares, (iv) have no need for liquidity with respect to the
investment in the Equity Shares, (v) have no reason to anticipate any change in your or their circumstances,
financial or otherwise, which may cause or require any sale or distribution by you or them of all or any part
of the Equity Shares; and (vi) are seeking to subscribe to the Equity Shares in the Issue for your own
investment and not with a view to resell or distribute. You are aware that investment in Equity Shares
involves a high degree of risk and that the Equity Shares are therefore, a speculative investment;
• If you are acquiring the Equity Shares to be issued pursuant to this Issue for one or more managed accounts,
you represent and warrant that you are authorised in writing, by each such managed account to acquire such
Equity Shares for each managed account and hereby make the representations, warranties,
acknowledgements, undertakings and agreements herein for and on behalf of each such account, reading
the reference to “you” to include such accounts;
• You are not a ‘promoter’ of our Company as defined under Section 2(69) of the Companies Act and the
SEBI Regulations, and are not a person related to any of our Promoters, either directly or indirectly and
your Bid does not directly or indirectly represent any of our Promoters or members of our Promoter Group
or persons or entities related thereto;
• You have no rights under a shareholders’ agreement or voting agreement with our Promoters or members
of the Promoter Group, no veto rights or right to appoint any nominee director on our Board, other than the
rights acquired, if any, in the capacity of a lender not holding any Equity Shares;
• You agree in terms of Section 42 of the Companies Act and Rule 14 of the PAS Rules, that our Company
shall make necessary filings with the RoC as may be required under the Companies Act;
6
• You have no right to withdraw your Bid or revise your Bid downwards after the Bid/ Issue Closing Date
(as defined hereinafter);
• You are eligible to Bid for and hold the Equity Shares so Allotted, together with any Equity Shares held by
you prior to the Issue. Further, you confirm that your aggregate holding after the Allotment of the Equity
Shares shall not exceed the level permissible as per any applicable regulation;
• The Bid made by you would not result in triggering an open offer under the SEBI Takeover Regulations;
• The number of Equity Shares Allotted to you under the Issue, together with other Allottees that belong to
the same group or are under common control as you, pursuant to the Allotment under the Issue shall not
exceed 50% of the Issue. For the purposes of this representation:
(a) Eligible QIBs “belonging to the same group” shall mean entities where (a) any of them controls,
directly or indirectly, through its subsidiary or holding company, not less than 15% of the voting
rights in the other; (b) any of them, directly or indirectly, by itself, or in combination with other
persons, exercise control over the others; or (c) there is a common director, excluding nominee and
independent directors, amongst an Eligible QIB, its subsidiary or holding company and any other
Eligible QIB; and
(b) ‘Control’ shall have the same meaning as is assigned to it by Regulation 2(1)(e) of the SEBI
Takeover Regulations;
• You shall not undertake any trade in the Equity Shares credited to your beneficiary account until such time
that the final listing and trading approvals for such Equity Shares to be issued pursuant to this Issue, are
issued by the Stock Exchanges;
• You are aware that (i) applications for in-principle approval, in terms of Regulation 28(1)(a) of the SEBI
Listing Regulations, for listing and admission of the Equity Shares to be issued pursuant to the Issue and
for trading on the Stock Exchanges, were made and an in-principle approval has been received by our
Company from each of the Stock Exchanges, and (ii) the application for the final listing and trading
approval will be made only after Allotment. There can be no assurance that the final listing and trading
approvals for listing of the Equity Shares, to be issued pursuant to this Issue, will be obtained in time or at
all. Neither our Company nor the BRLMs nor any of their respective shareholders, directors, officers,
employees, counsel, representatives, agents or affiliates shall be responsible for any delay or non-receipt
of such final listing and trading approvals or any loss arising from such delay or non-receipt;
• You are aware and understand that the BRLMs have entered into a Placement Agreement with our
Company whereby the BRLMs have, subject to the satisfaction of certain conditions set out therein,
undertaken to use their reasonable efforts to procure subscription for the Equity Shares on the terms and
conditions set forth therein;
• The contents of the Preliminary Placement Document and this Placement Document are exclusively the
responsibility of our Company, and that neither the BRLMs nor any person acting on its behalf or any of
the counsel or advisors to the Issue has or shall have any liability for any information, representation or
statement contained in the Preliminary Placement Document or this Placement Document or any
information previously published by or on behalf of our Company and will not be liable for your decision
to participate in the Issue based on any information, representation or statement contained in the
Preliminary Placement Document or this Placement Document or otherwise. By accepting a participation
in the Issue, you agree to the same and confirm that the only information you are entitled to rely on, and on
which you have relied in committing yourself to acquire the Equity Shares is contained in this Placement
Document, such information being all that you deem necessary to make an investment decision in respect
of the Equity Shares, you have neither received nor relied on any other information, representation,
warranty or statement made by or on behalf of the BRLMs or our Company or any other person, and the
BRLMs or our Company or any of their respective affiliates, including any view, statement, opinion or
representation expressed in any research published or distributed by them, the BRLMs and their affiliates
will not be liable for your decision to accept an invitation to participate in the Issue based on any other
information, representation, warranty, statement or opinion;
7
• You understand that the BRLMs or any of their shareholders, directors, officers, employees, counsel,
representatives, agents or affiliates do not have any obligation to purchase or acquire all or any part of the
Equity Shares purchased by you in the Issue or to support any losses directly or indirectly sustained or
incurred by you for any reason whatsoever in connection with the Issue, including the non-performance by
our Company or any of its obligations or any breach of any representations or warranties by us, whether to
you or otherwise;
• You are able to purchase the Equity Shares in accordance with the restrictions described in “Selling
Restrictions” on page 145 and you have made, or are deemed to have made, as applicable, the
representations, warranties, acknowledgements, undertakings and agreements in “Selling Restrictions” on
page 145;
• You understand and agree that the Equity Shares are transferable only in accordance with the restrictions
described in “Purchaser Representations and Transfer Restrictions” and you have made, or are deemed to
have made, as applicable, the representations, warranties, acknowledgements, undertakings and agreements
in “Purchaser Representations and Transfer Restrictions” on page 152;
• You understand that the Equity Shares have not been and will not be registered under the U.S. Securities
Act or registered, listed or otherwise qualified in any other jurisdictions outside India and may not be
offered or sold within the United States except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the U.S. Securities Act. For further information, see “Selling
Restrictions” on page 145;
• If you are outside the United States, you are purchasing the Equity Shares in an "offshore transaction"
within the meaning of Regulation S under the U.S. Securities Act, and are not our Company’s or the
BRLMs’ affiliate or a person acting on behalf of such an affiliate;
• You are not acquiring or subscribing for the Equity Shares as a result of any general solicitation or general
advertising (as those terms are defined in Regulation D under the Securities Act) or “directed selling
efforts” (as defined in Regulation S).
• You agree that any dispute arising in connection with the Issue will be governed by and construed in
accordance with the laws of Republic of India, and the courts in Mumbai, India shall have exclusive
jurisdiction to settle any disputes which may arise out of or in connection with the Preliminary Placement
Document and this Placement Document.
• Each of the representations, warranties, acknowledgements and agreements set out above shall continue to
be true and accurate at all times up to and including the Allotment, listing and trading of the Equity Shares
in the Issue;
• You agree to indemnify and hold our Company, the BRLMs and their respective directors, officers,
employees, affiliates, associates, controlling persons and representatives harmless from any and all costs,
claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any
breach of the foregoing representations, warranties, acknowledgements and undertakings made by you in
the Preliminary Placement Document and in this Placement Document. You agree that the indemnity set
out in this paragraph shall survive the resale of the Equity Shares by, or on behalf of, the managed accounts;
• You acknowledge that the Preliminary Placement Document did not, and this Placement Document shall
not confer upon or provide you with any right of renunciation of the Equity Shares offered through the
Issue in favour of any person;
• You will make the payment for subscription to the Equity Shares pursuant to this Issue from your own bank
account. In case of joint holders, the monies shall be paid from the bank account of the person whose name
appears first in the application;
• You are aware that in terms of the SEBI FPI Regulations and the FEMA Rules, the total holding by each
FPI including its investor group (which means multiple entities registered as FPIs and directly or indirectly
having common ownership of more than fifty percent or common control) shall be below 10% of the total
paid-up Equity Share capital of our Company on a fully diluted basis. In terms of the FEMA Rules, for
8
calculating the aggregate holding of FPIs in a company, holding of all registered FPIs shall be included.
The existing individual and aggregate investment limits for an FPI in our Company are 10% of the total
paid-up Equity Share capital of our Company on a fully diluted basis and the sectoral cap applicable to our
Company in accordance with the FEMA Rules, respectively. Hence, Eligible FPIs may invest in such
number of Equity Shares in this Issue such that the individual investment of the FPI in our Company shall
be less than 10% of the post-Issue paid-up Equity Share capital of our Company on a fully diluted basis. In
case the holding of an FPI together with its investor group increases to 10% or more of the total paid-up
Equity Share capital, on a fully diluted basis, such FPI together with its investor group shall divest the
excess holding within a period of five trading days from the date of settlement of the trades resulting in the
breach. If however, such excess holding has not been divested within the specified period of five trading
days, the entire shareholding of such FPI together with its investor group will be re-classified as FDI,
subject to the conditions as specified by SEBI and the RBI in this regard and compliance by our Company
and the investor with applicable reporting requirements and the FPI and its investor group will be prohibited
from making any further portfolio investment in our Company under the SEBI FPI Regulations;
• You confirm that neither is your investment as an entity of a country which shares land border with India
nor is the beneficial owner of your investment situated in or a citizen of such country (in each which case,
investment can only be through the Government approval route), and that your investment is in accordance
with press note no. 3 (2020 Series), dated April 17, 2020, issued by the Department for Promotion of
Industry and Internal Trade, Government of India, and Rule 6 of the FEMA Rules;
• You are aware and understand that you are allowed to place a Bid for Equity Shares. Please note that
submitting a Bid for Equity Shares should not be taken to be indicative of the number of Equity Shares that
will be Allotted to a successful Bidder. Allotment of Equity Shares will be undertaken by our Company, in
its absolute discretion, in consultation with the BRLMs.
• Our Company, the BRLMs, their respective affiliates, directors, officers, employees, controlling persons
and others will rely on the truth and accuracy of the foregoing representations, warranties,
acknowledgements and undertakings, and are irrevocable. It is agreed that if any of such representations,
warranties, acknowledgements and undertakings are no longer accurate, you will promptly notify our
Company and the BRLMs; and
• You will make all necessary filings with appropriate regulatory authorities, including the RBI, as required
pursuant to applicable laws.
9
OFFSHORE DERIVATIVE INSTRUMENTS
Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of
Regulation 21 of the SEBI FPI Regulations, an Eligible FPI including affiliates of the BRLMs, which is registered
as a Category I FPI, may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under
the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against
securities held by it in India, as its underlying, and all such offshore derivative instruments are referred to herein
as “P-Notes”), for which they may receive compensation from the purchasers of such instruments. In terms of
Regulation 21 of SEBI FPI Regulations, P-Notes may be issued only by such persons who are registered as
Category I FPIs and they may be issued only to persons eligible for registration as Category I FPIs, subject to
exceptions provided in the SEBI FPI Regulations and compliance with ‘know your client’ requirements, as
specified by SEBI and subject to compliance with such other conditions as may be specified from the SEBI. An
Eligible FPI shall also ensure that no transfer of any instrument referred to above is made to any person unless
such FPIs are registered as Category I FPIs and such instrument is being transferred only to person eligible for
registration as Category I FPIs subject to requisite consents being obtained in terms of Regulation 21 of SEBI FPI
Regulations. P-Notes have not been and are not being offered or sold pursuant to this Placement Document. This
Placement Document does not contain any information concerning P-Notes or the issuer(s) of any P-Notes,
including any information regarding any risk factors relating thereto.
Subject to certain relaxations provided under Regulation 22(4) of the SEBI FPI Regulations, investment by a
single FPI including its investor group (multiple entities registered as FPIs and directly or indirectly, having
common ownership of more than 50% or common control,) is not permitted to be 10% or above of our post-Issue
Equity Share capital on a fully diluted basis (“Investment Restrictions”). The SEBI has, vide a circular dated
November 5, 2019, issued the operational guidelines for FPIs, designated depository participants and eligible
foreign investors (the “FPI Operational Guidelines”), to facilitate implementation of the SEBI FPI Regulations.
In terms of such FPI Operational Guidelines, the Investment Restrictions shall also apply to subscribers of P-
Notes and two or more subscribers of P-Notes having common ownership, directly or indirectly, of more than
50% or common control shall be considered together as a single subscriber of the P-Notes. Further, in the event a
prospective investor has investments as an FPI and as a subscriber of P-Notes, the Investment Restrictions shall
apply on the aggregate of the FPI investments and P-Notes positions held in the underlying company.
Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020, issued by the Department for
Promotion of Industry and Internal Trade, Government of India, investments where the entity is of a country
which shares land border with India or where the beneficial owner of the Equity Shares is situated in or is a citizen
of a country which shares land border with India, can only be made through the Government approval route, as
prescribed in the Consolidated FDI Policy dated August 28, 2017. These investment restrictions shall also apply
to subscribers of P-Notes.
Affiliates of the BRLMs which are Eligible FPIs may purchase, to the extent permissible under law, the Equity
Shares in the Issue, and may issue P-Notes in respect thereof. Any P-Notes that may be issued are not securities
of our Company and do not constitute any obligation of, claims on or interests in our Company. Our Company
has not participated in any offer of any P-Notes, or in the establishment of the terms of any P-Notes, or in the
preparation of any disclosure related to any P-Notes. Any P-Notes that may be offered are issued by, and are the
sole obligations of, third parties that are unrelated to our Company. Our Company and the BRLMs do not make
any recommendation as to any investment in P-Notes and do not accept any responsibility whatsoever in
connection with any P-Notes. Any P-Notes that may be issued are not securities of the BRLMs and does not
constitute any obligations of or claims on the BRLMs.
Bidders interested in purchasing any P-Notes have the responsibility to obtain adequate disclosures as to
the issuer(s) of such P-Notes and the terms and conditions of any such P-Notes from the issuer(s) of such P-
Notes. Neither SEBI nor any other regulatory authority has reviewed or approved any P-Notes or any
disclosure related thereto. Prospective investors are urged to consult their own financial, legal, accounting
and tax advisors regarding any contemplated investment in P-Notes, including whether P-Notes are issued
in compliance with applicable laws and regulations.
10
DISCLAIMER CLAUSE OF THE STOCK EXCHANGES
As required, a copy of the Preliminary Placement Document and this Placement Document has been submitted to
the Stock Exchanges.
The Stock Exchanges do not in any manner:
(1) warrant, certify or endorse the correctness or completeness of the contents of the Preliminary Placement
Document or this Placement Document; or
(2) warrant that the Equity Shares to be issued pursuant to the Issue, will be listed or will continue to be listed
on the Stock Exchanges; or
(3) take any responsibility for the financial or other soundness of our Company, its Promoters, its management
or any scheme or project of our Company;
and it should not, for any reason be deemed or construed to mean that the Preliminary Placement Document or
this Placement Document has been cleared or approved by the Stock Exchanges. Every person who desires to
apply for or otherwise acquire any Equity Shares may do so pursuant to an independent inquiry, investigation and
analysis and shall not have any claim against the Stock Exchanges whatsoever, by reason of any loss which may
be suffered by such person consequent to or in connection with, such subscription/acquisition, whether by reason
of anything stated or omitted to be stated herein, or for any other reason whatsoever.
11
PRESENTATION OF FINANCIAL AND OTHER INFORMATION
Certain Conventions
In this Placement Document, unless otherwise specified or the context otherwise indicates or implies, references
to “you”, “your”, “offeree”, “purchaser”, “subscriber”, “recipient”, “investors” and “potential investor” are to the
Eligible QIBs pursuant to this Issue, references to “our Company”, the “Company”, or the “Issuer” are to Alembic
Pharmaceuticals Limited on a standalone basis and references to “our”, “us”, “we”, or “Group” are to Alembic
Pharmaceuticals Limited together with our Subsidiaries, Joint Venture and Associates, on a consolidated basis.
Currency and Units of Presentation
In this Placement Document, references to ‘US$’, ‘USD’ and ‘U.S. dollars’ are to the legal currency of the United
States of America, references to ‘₹’, ‘INR’, ‘Rs.’, ‘Indian Rupees’ and ‘Rupees’ are to the legal currency of
Republic of India. All references herein to the ‘US’ or ‘U.S.’ or the ‘United States’ are to the United States of
America and its territories and possessions. All references herein to “India” are to the Republic of India and its
territories and possessions and all references herein to the ‘Government’ or ‘GoI’ or the ‘Central Government’ or
the ‘State Government’ are to the Government of India, central or state, as applicable.
References to the singular also refer to the plural and one gender also refers to any other gender, wherever
applicable. All the numbers in this Placement Document have been presented in crore, unless stated otherwise, in
line with the current of presentation used in our Audited Consolidated Financial Statements.
In this Placement Document, references to “Lakh” or “Lacs” represents “100,000”, “million” represents “10 lakh”
or “1,000,000”, “crore” or “crores” represents “10,000,000” or "10 million" or "100 lakhs”, and “billion”
represents “1,000,000,000” or "1,000 million" or "100 crore".
Except as otherwise set out in this Placement Document, certain monetary thresholds have been subject to
rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation
of the figures which precede them.
Page Numbers
Unless otherwise stated, all references to page numbers in this Placement Document are to page numbers of this
Placement Document.
Financial Data and Other Information
In this Placement Document, we have included the Audited Consolidated Financial Statements for Fiscals 2020,
2019 and 2018, prepared in line with Ind AS, notified under the Companies Act, 2013, as amended, read with the
Companies (Indian Accounting Standards) Rules, 2015, as amended.
Our Company presents its financial statements under Ind AS. Ind AS differs from accounting principles with
which prospective investors may be familiar in other countries, including generally accepted accounting principles
followed in the U.S. (“U.S. GAAP”) or International Financial Reporting Standards (“IFRS”). Our Company
does not attempt to quantify the impact of U.S. GAAP or IFRS on the financial data included in this Placement
Document, nor does our Company provide a reconciliation of its audited consolidated financial statements to IFRS
or U.S. GAAP. Accordingly, the degree to which the Audited Consolidated Financial Statements included in this
Placement Document will provide meaningful information is entirely dependent on the reader’s familiarity with
the respective Indian accounting policies and practices. Any reliance by persons not familiar with Indian
accounting practices on the financial disclosures presented in this Placement Document should accordingly be
limited.
Unless otherwise stated or unless the context requires otherwise, the financial information contained in this
Placement Document is derived from our Audited Consolidated Financial Statements. For details, see
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Financial
Statements” on pages 73 and 180, respectively.
M/s. K. S. Aiyar & Co., Chartered Accountants, the Previous Statutory Auditors, have audited the Audited
Consolidated Financial Statements, and have issued audit reports thereon. The Audited Consolidated Financial
12
Statements should be read along with the respective audit reports. M/s K.C. Mehta & Co., Chartered Accountants,
have been appointed as Statutory Auditors of our Company by the shareholders at their AGM held on July 22,
2020 for a period of five years.
The financial year of our Company commences on April 1 of each calendar year and ends on March 31 of the
following calendar year, and, unless otherwise specified or if the context requires otherwise. The terms "Fiscal",
“Fiscals” or "Fiscal year", refer to the 12 month period ending March 31 of that particular year.
13
INDUSTRY AND MARKET DATA
Information included in this Placement Document regarding market position, growth rates, industry forecasts and
other industry data pertaining to our Company’s business consists of estimates based on industry reports compiled
primarily by government bodies, data from other external sources and knowledge of the markets in which we
operate. Unless stated otherwise, statistical information included in this Placement Document pertaining to the
various sectors in which we operate has been reproduced from trade, industry and government publications and
websites. We confirm that such information and data has been accurately reproduced, and that as far as we are
aware and are able to ascertain from information published by third parties, no facts have been omitted that would
render the reproduced information inaccurate or misleading.
In this context, please note that in addition to publicly available government data (both domestic and
international), including those provided by the Pharmexcil and USFDA, we have relied on the IQVIA Research
Reports, which have been made available to our Company by IQVIA. This information is subject to change and
cannot be verified with complete certainty due to limits on the availability and reliability of the raw data and other
limitations and uncertainties inherent in any statistical survey.
Neither our Company, nor the BRLMs have independently verified this industry data, nor does the Company nor
the BRLMs make any representation regarding the accuracy of such data. Similarly, while our Company believes
that its internal estimates to be reasonable, such estimates have not been verified by any independent sources, and
neither we nor the BRLMs can assure potential investors as to their accuracy. The extent to which the market and
industry data used in this Placement Document is meaningful depends on the reader’s familiarity with and
understanding of the methodologies used in compiling such data. Such data involves risks, uncertainties and
numerous assumptions and is subject to change based on various factors, including those discussed in “Risk
Factors – We have relied on various industry sources, including publicly available data, for reproducing industry
related data in this Placement Document and such data has not been independently verified by us.” on page 54.
14
FORWARD-LOOKING STATEMENTS
Certain statements contained in this Placement Document that are not statements of historical fact constitute
'forward-looking statements'. Investors can generally identify forward-looking statements by terminology such as
'aim', 'anticipate', 'believe', 'continue', 'can', 'could', 'estimate', 'expect', 'intend', 'may', 'objective', 'plan', 'potential',
'project', 'pursue', 'shall', 'should', 'will', 'would', 'will likely result' 'is likely', 'are likely', 'believe', 'expect', 'expected
to', 'will continue', 'will achieve', or other words or phrases of similar import. Similarly, statements that describe
our strategies, objectives, plans or goals are also forward-looking statements. However, these are not the exclusive
means of identifying forward-looking statements.
All statements regarding our expected financial conditions, results of operations, business plans and prospects are
forward-looking statements. These forward-looking statements include statements as to our business strategy,
revenue and profitability (including, without limitation, any financial or operating projections or forecasts), new
business and other matters discussed in this Placement Document that are not historical facts. These forward-
looking statements contained in this Placement Document (whether made by us or any third party), are predictions
and involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual
results, performance or achievements of our Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking statements or other projections. By
their nature, market risk disclosures are only estimates and could be materially different from what actually occurs
in the future. As a result, actual future gains, losses or impact on net interest income and net income could
materially differ from those that have been estimated, expressed or implied by such forward looking statements
or other projections.
Important factors that could cause our actual results, performances and achievements to be materially different
from any of the forward-looking statements include, among others:
• Any change in the heavily regulated pharmaceutical industry, both in India and overseas leading to
difficulty in us procuring licenses, registrations and approvals including for a new product;
• Loss of one or more significant customers or a reduction in their demand for products, in India and in the
US markets;
• Impact of the COVID-19 pandemic on our business and operations in future;
• Inability to compete successfully against existing or new competitors in India and in the overseas markets;
and
• Decreased opportunities to obtain United States market exclusivity products.
Additional factors that could cause our actual results, performance or achievements to differ materially include,
but are not limited to, those discussed under the sections "Risk Factors", "Management’s Discussion and Analysis
of Financial Condition and Results of Operations", "Industry Overview" and "Our Business" and on pages 35, 73,
93 and 106, respectively.
The forward-looking statements contained in this Placement Document are based on the beliefs of our
management, as well as the assumptions made by, and information currently available to, our management.
Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time,
we cannot assure investors that such expectations will prove to be correct. Given these uncertainties, investors are
cautioned not to place undue reliance on such forward-looking statements. In any event, these statements speak
only as of the date of this Placement Document or the respective dates indicated in this Placement Document, and
neither we nor the BRLMs undertake any obligation to update or revise any of them, whether as a result of new
information, future events or otherwise. If any of these risks and uncertainties materialise, or if any of our
underlying assumptions prove to be incorrect, our actual results of operations or financial condition could differ
materially from that described herein as anticipated, believed, estimated or expected. All subsequent forward-
looking statements attributable to us are expressly qualified in their entirety by reference to these cautionary
statements.
15
ENFORCEMENT OF CIVIL LIABILITIES
Our Company is a limited liability company incorporated under the laws of India. All our Directors, Key
Management Personnel and Senior Management Personnel named in this Placement Document, except Craig
Salmon are residents of India and most of the assets of our Company are located in India. As a result, it may be
difficult or may not be possible for the prospective investors outside India to affect service of process upon our
Company or such persons in India, or to enforce against them judgments of courts outside India.
India is not a signatory to any international treaty in relation to the recognition or enforcement of foreign
judgments. However, recognition and enforcement of foreign judgments is provided for under Section 13 and
Section 44A, respectively, of the Civil Procedure Code. Section 13 of the Civil Procedure Code provides that a
foreign judgment shall be conclusive regarding any matter directly adjudicated upon between the same parties or
parties litigating under the same title, except:
(a) where the judgment has not been pronounced by a court of competent jurisdiction;
(b) where the judgment has not been given on the merits of the case;
(c) where it appears on the face of the proceedings that the judgment is founded on an incorrect view of
international law or a refusal to recognise the law of India in cases in which such law is applicable;
(d) where the proceedings in which the judgment was obtained were opposed to natural justice;
(e) where the judgment has been obtained by fraud; and
(f) where the judgment sustains a claim founded on a breach of any law then in force in India.
Section 44A of the Civil Procedure Code provides that a foreign judgment rendered by a superior court (within
the meaning of that section) in any jurisdiction outside India which the Government has by notification declared
to be a reciprocating territory, may be enforced in India by proceedings in execution as if the judgment had been
rendered by a district court in India. Under Section 14 of the Civil Procedure Code, a court in India will, upon the
production of any document purporting to be a certified copy of a foreign judgment, presume that the foreign
judgment was pronounced by a court of competent jurisdiction, unless the contrary appears on record but such
presumption may be displaced by proving want of jurisdiction. However, Section 44A of the Civil Procedure
Code is applicable only to monetary decrees not being in the nature of any amounts payable in respect of taxes or
other charges of a like nature or in respect of a fine or other penalties and does not include arbitration awards.
Each of the United Kingdom, United Arab Emirates, Singapore and Hong Kong, amongst others has been declared
by the Government to be a reciprocating territory for the purposes of Section 44A of the Civil Procedure Code,
but the United States of America has not been so declared. A judgment of a court in a jurisdiction which is not a
reciprocating territory may be enforced only by a fresh suit upon the judgment and not by proceedings in
execution. The suit must be filed in India within three years from the date of the foreign judgment in the same
manner as any other suit filed to enforce a civil liability in India. Accordingly, a judgment of a court in the United
States may be enforced only by a fresh suit upon the foreign judgment and not by proceedings in execution.
It is unlikely that a court in India would award damages on the same basis as a foreign court if an action is brought
in India. Furthermore, it is unlikely that an Indian court would enforce foreign judgments if it views the amount
of damages awarded as excessive or inconsistent with public policy of India and it is uncertain whether an Indian
court would enforce foreign judgments that would contravene or violate Indian law. Further, any judgment or
award denominated in a foreign currency would be converted into Indian Rupees on the date of such judgment or
award and not on the date of payment. A party seeking to enforce a foreign judgment in India is required to obtain
approval from the RBI to repatriate outside India any amount recovered, and any such amount may be subject to
income tax pursuant to execution of such a judgment in accordance with applicable laws.
16
EXCHANGE RATES INFORMATION
Fluctuations in the exchange rate between the Rupee and foreign currencies will affect the foreign currency
equivalent of the Rupee price of the Equity Shares traded on the Stock Exchanges. These fluctuations will also
affect the conversion into foreign currencies of any cash dividends paid in Rupees on the Equity Shares.
The following table sets forth information, for the period indicated with respect to the exchange rates between the
Rupee and the U.S. dollar (in ₹ per US$), for the periods indicated. The exchange rates are based on the reference
rates released by the RBI and Financial Benchmark India Private Limited (“FBIL”), which are available on the
website of the RBI and FBIL. No representation is made that any Rupee amounts could have been, or could be,
converted into U.S. dollars at any particular rate, the rates stated below, or at all.
(₹ per US$)
Period End(1) Average(2) High(3) Low(4)
Fiscal Ended:
March 31, 2020 75.39 70.88 76.15 68.37
March 31, 2019 69.17 69.89 74.39 64.93
March 31, 2018 65.04 64.45 65.76 63.35
Month Ended
July 31, 2020 74.77 74.99 75.58 74.68
June 30, 2020 75.53 75.73 76.21 75.33
May 31, 2020 75.64 75.66 75.93 75.39
April 30, 2020 75.12 76.24 76.81 75.12
March 31, 2020 75.39 74.35 76.15 72.24
February 29, 2020 72.19 71.49 72.09 71.14 (Source: www.rbi.org.in and www.fbil.org.in)
1. The price for the period end refers to the price as on the last trading day of the respective annual or monthly periods. 2. Average of the official rate for each Working Day of the relevant period.
3. Maximum of the official rate for each Working Day of the relevant period.
4. Minimum of the official rate for each Working Day of the relevant period.
Notes:
• If the reference rate is not available on a particular date due to a public holiday or being Saturday or Sunday, exchange rates of the
previous Working Day have been disclosed.
• The reference rates are rounded off to two decimal places.
17
DEFINITIONS AND ABBREVIATIONS
This Placement Document uses the definitions and abbreviations set forth below which you should consider when
reading the information contained herein. The following list of certain capitalised terms used in this Placement
Document is intended for the convenience of the reader / prospective investor only and is not exhaustive.
Unless otherwise specified, the capitalised terms used in this Placement Document shall have the meaning as
defined hereunder. Further, any references to any statute, rules, guidelines, regulations or policies shall include
amendments thereto, from time to time.
The words and expressions used in this Placement Document but not defined herein, shall have, to the extent
applicable, the meaning ascribed to such terms under the Companies Act, the SEBI Regulations, the SCRA, the
Depositories Act, or the rules and regulations made thereunder. Notwithstanding the foregoing, terms used in the
section “Industry Overview”, “Statement of Special Tax Benefits”, “Legal Proceedings” and “Financial
Statements” beginning on pages 93, 161, 174 and 180, respectively, shall have the meaning given to such terms
in such sections.
General terms
Term Description
“Issuer”/“Company”/“our Company” Alembic Pharmaceuticals Limited, a public limited company incorporated under
the Companies Act, 1956 and having its Registered and Corporate Office (as
hereinafter defined) at Alembic Road, Vadodara 390003, Gujarat, India.
“we”, “Group”, “us” or “our” Unless the context otherwise indicates or implies, refers to our Company together
with our Subsidiaries, Joint Venture and Associates
Company related terms
Term Description
“Articles” or “Articles of Association” Articles of association of our Company, as amended from time to time
Associates Incozen Therapeutics Private Limited, Rhizen Pharmaceuticals SA, Rhizen
Pharmaceuticals Inc. and Dahlia Therapeutics SA
Audit Committee The audit committee of our Board of Directors
Audited Consolidated Financial
Statements/Financial Statements
The audited consolidated financial statements of our Company as at and for the
Fiscals ended 2020, 2019 and 2018, which have been prepared in all material
aspects, in accordance with the recognition and measurement principles laid
down in Ind AS as per the Companies (Indian Accounting Standards) Rules,
2015 notified under Section 133 and other relevant provisions of the Companies
Act, to the extent applicable
ADL Aleor Dermaceuticals Limited
“Board of Directors” or “Board” The board of directors of our Company or any duly constituted committee
thereof
Compliance Officer Charandeep Singh Saluja, the company secretary and compliance officer of our
Company
Corporate Social Responsibility
Committee
The corporate social responsibility committee of our Board of Directors
Director(s) Director(s) on the Board of our Company
Equity Share(s) The equity shares of our Company, each having a face value of ₹ 2
Executive Chairman and CEO The executive chairman and chief executive officer of our Company, being
Chirayu Amin
Executive Director(s) The executive Director(s) of our Company, being Chirayu Amin, Pranav Amin,
Shaunak Amin and Raj Kumar Baheti
Fund Raising Committee The fund raising committee of our Board, constituted through a resolution of our
Board dated July 27, 2020, comprising of (i) Pranav Amin; (ii) Paresh Saraiya;
(iii) Shaunak Amin; and (iv) Raj Kumar Baheti
Independent Director(s) The independent Director(s) of our Company, being Krishnapuram
Ramanathan, Pranav Parikh, Paresh Saraiya and Archana Hingorani
IQVIA The IQVIA entities which have published the IQVIA Research Reports (as
defined below)
IQVIA Research Reports Research reports published by IQVIA, titled (i) “US Generics Market-Evolution
of Indian Players” (published in February 2019); (ii) “Medicine Use and
18
Term Description
Spending in the U.S” (published in May 2019); (iii) “Global Medicine Spending
& Usage Trends” (published in March 2020); (iv) “Complex Generics: Charting
a New Path” (published in 2017); (v) IQVIA TSA (published in April 2020) and
IQVIA TSA (published in March 2020), as used in this Placement Document
IQVIA TSA Corporate summary reports, as issued by IQVIA for March 2020 and April 2020,
respectively
Joint Venture Alembic Mami SPA and SPH Sine Alembic (Shanghai) Pharmaceutical
Technology Company Limited
Managing Director(s) The managing directors of our Company, being Pranav Amin and Shaunak Amin
Memorandum/Memorandum of
Association
Memorandum of association of our Company, as amended from time to time
Nomination and Remuneration
Committee
The nomination and remuneration committee of our Board of Directors
Previous Statutory Auditors The previous statutory auditors of our Company, being K.S Aiyar & Co.,
Chartered Accountants
Promoters The promoters of our Company in terms of the SEBI Regulations and the
Companies Act, being Chirayu Amin, Pranav Amin, Shaunak Amin and
Alembic Limited
Promoter Group Unless the context requires otherwise, the promoter group of our Company as
identified in accordance with Regulation 2(1)(pp) of the SEBI Regulations
Registered and Corporate Office The registered and corporate office of our Company, located at Alembic Road,
Vadodara 390 003, Gujarat, India
Rhizen Rhizen Pharmaceuticals SA
Risk Management Committee The risk management committee of our Board of Directors
“RoC” or “Registrar of Companies” Registrar of Companies, Gujarat at Ahmedabad
Senior Management Personnel Senior management personnel of our Company, as disclosed in “Board of
Directors and Senior Management” on page 118
Shareholder(s) The holder(s) of Equity Shares of our Company, unless otherwise specified in
the context thereof.
Stakeholders Relationship Committee The stakeholders relationship committee of our Board of Directors
Statutory Auditors The current statutory auditors of our Company, being M/s. K. C. Mehta & Co.,
Chartered Accountants
Subsidiaries Subsidiaries of our Company as of the date of this Placement Document, in
accordance with the Companies Act, 2013 and the applicable accounting
standards, namely: (i) Alembic Pharmaceuticals Inc.; (ii) Aleor Dermaceuticals
Limited; (iii) Alembic Global Holding SA; (iv) Alembic Pharmaceuticals
Europe Limited; (v) Alembic Pharmaceuticals Australia Pty Limited; (vi)
Alembic Pharmaceuticals Canada Limited; (vii) Alnova Pharmaceuticals SA;
(viii) Genius LLC; (ix) Okner Realty LLC; and (x) Alembic Labs LLC
Issue related terms
Term Description
“Allocated” or “Allocation” The allocation of Equity Shares following the determination of the Issue Price to
Eligible QIBs on the basis of the Application Forms submitted by them, by our
Company in consultation with the BRLMs and in compliance with Chapter VI of
the SEBI Regulations
“Allot” or “Allotment” or “Allotted” Unless, the context otherwise requires, allotment of Equity Shares to be issued
pursuant to the Issue
Allottees Eligible QIBs to whom Equity Shares are Allotted pursuant to the Issue. An
indicative format of such form is set forth in “Application Form” on page 192
Application Form The form (including any revisions thereof) which will be submitted by an Eligible
QIB for registering a Bid in the Issue during the Bid/ Issue Period
Bid(s) Indication of an Eligible QIB’s interest, including all revisions and modifications
thereto, as provided in the Application Form, to subscribe for the Equity Shares,
pursuant to the Issue. The term “Bidding” shall be construed accordingly
Bid Amount The aggregate amount determined by multiplying the price per Equity Share
indicated in the Bid by the number of Equity Shares Bid for by Eligible QIBs and
payable by the Eligible QIBs in the Issue on submission of the Application Form
Bid/Issue Closing Date August 6, 2020, which was the last date up to which Application Forms and the
Bid Amount were accepted
19
Term Description
Bid/Issue Opening Date August 3, 2020, which was the first date from which Application Forms and the
Bid Amount were accepted
Bid/Issue Period Period between the Bid/ Issue Opening Date and the Bid/ Issue Closing Date,
inclusive of both days during which Eligible QIBs could submit their Bids along
with the Bid Amount
Bidder Any prospective investor, being an Eligible QIB, who has made a Bid pursuant
to the terms of the Preliminary Placement Document and the Application Form
“Book Running Lead Managers” or
“BRLMs”
Collectively, Monarch Networth Capital Limited and HDFC Bank Limited
“CAN” or “Confirmation of Allocation
Note”
Note or advice or intimation to Successful Bidders confirming Allocation of
Equity Shares to such Successful Bidders after discovery of the Issue Price
Closing Date The date on which Allotment of Equity Shares pursuant to the Issue shall be made,
i.e. on or about August 7, 2020
Designated Date The date of credit of Equity Shares to the Allottees’ demat accounts pursuant to
the Issue, as applicable to the relevant Allottees
Eligible FPI FPIs that are eligible to Bid for Equity Shares to be Allotted in this Issue in terms
of applicable laws, other than individuals, corporate bodies and family offices
Eligible QIB(s) QIBs which are eligible to participate in this Issue and who are (i) not excluded
pursuant to Regulation 179(2)(b) of the SEBI Regulations, and (ii) not restricted
from participating in this Issue under applicable law, including the SEBI
Regulations
Escrow Account Special non-interest bearing, no-lien, current bank account without any cheques
or overdraft facilities, opened with the Escrow Bank, subject to the terms of the
Escrow Agreement, into which the Bid Amount has been deposited by Eligible
QIBs and from which refunds, if any, shall be remitted to unsuccessful Bidders,
as set out in the Application Form
Escrow Agreement Agreement dated August 3, 2020 entered into amongst our Company, the Escrow
Bank and the BRLMs for collection of the Bid Amounts and for remitting refunds,
if any, of the amounts collected, to the Bidders
Escrow Bank HDFC Bank Limited
Floor Price The floor price of ₹980.75 per Equity Share, calculated in accordance with
Chapter VI of the SEBI Regulations. Our Company has offered a discount of ₹
48.75 per Equity Share (4.97% on the Floor Price) in accordance with and in terms
of Regulation 176 of the SEBI Regulations
Issue The issue, offer and Allotment of the Equity Shares to Eligible QIBs, pursuant to
Chapter VI of the SEBI Regulations and the applicable provisions of the
Companies Act and the rules made thereunder
Issue Price ₹ 932.00 per Equity Share
Issue Size The issue of 80,47,210 Equity Shares, aggregating to approximately ₹750.00
crore
Mutual Fund A mutual fund registered with SEBI under the Securities and Exchange Board of
India (Mutual Funds) Regulations, 1996
Net Proceeds The net proceeds from the Issue, after deducting Issue related expenses, as
applicable
Placement Agreement Agreement dated August 3, 2020, entered into amongst our Company and the
BRLMs
Placement Document This placement document dated August 6, 2020, issued by our Company in
accordance with Chapter VI of the SEBI Regulations and Section 42 of the
Companies Act and rules made thereunder
Preliminary Placement Document The preliminary placement document dated August 3, 2020, for this Issue issued
in accordance with Chapter VI of the SEBI Regulations and Section 42 of the
Companies Act and the rules thereunder
“QIBs” or “Qualified Institutional
Buyers”
Qualified institutional buyers as defined under Regulation 2(1)(ss) of the SEBI
Regulations
QIP Qualified institutions placement under Chapter VI of the SEBI Regulations and
Section 42 of the Companies Act and rules made thereunder
Refund Amount The aggregate amount to be returned to the Bidders who have not been Allocated
Equity Shares for all or part of the Bid Amount submitted by such Bidder pursuant
to the Issue
Refund Intimation Letter Letters from our Company intimating the Bidders on the amount to be refunded,
if any, either in part or whole, to their respective bank accounts.
Relevant Date August 3, 2020, which is the date of the meeting of the Fund Raising Committee
of the Board, a committee duly authorised by our Board, deciding to open the
Issue
20
Term Description
Stock Exchanges Collectively, the BSE Limited and the National Stock Exchange of India Limited
Successful Bidders The Bidders who have Bid at or above the Issue Price, duly paid the Bid Amount
along with the Application Form and who are Allocated Equity Shares pursuant
to the Issue
Wilful Defaulter An entity or person categorised as a wilful defaulter by any bank or financial
institution or consortium thereof, in terms of Regulation 2(1)(lll) of the SEBI
Regulations
Working Day Any day other than second and fourth Saturday of the relevant month or a Sunday
or a public holiday or a day on which scheduled commercial banks are authorised
or obligated by law to remain closed in India
Industry Related Terms
Term Description
ANDA Abbreviated New Drug Application
ANVISA Brazilian Health Regulatory Agency
API Active Pharmaceutical Ingredient
Australian TGA Australian Therapeutic Goods Administration
B2B Business to Business
BA Bioavailability
BE Bioequivalence
CDSCO Central Drugs Standard Control Organization
cGMP current Good Manufacturing Practices
CS Central Sector Scheme
DCGI Drug Controller General of India
Developed markets Developed markets are defined by IQVIA as ten countries with high incomes
and with pharmaceutical spending greater than $10 billion, namely the United
States, Japan, Germany, France, Italy, Spain, United Kingdom, Canada, South
Korea and Australia
DMF Drug Master File
DPIIT Department for Promotion of Industry and Internal Trade
EDQM European Directorate for Quality of Medicines
EIR Establishment Inspection Report
EU European Union
GDP Gross domestic product
GDUFA Generic Drug User Fee Amendments
GMP Good Manufacturing Practices
HCV Hepatitis C virus
HIV Human Immunodeficiency Virus
HPCD Health Product Compliance Directorate
IPM Indian Pharmaceutical Market
KYC Know your customer
LOE Loss of Exclusivity
MNCs Multinational companies
MoH, Brazil Ministry of Health, Brazil
MT Metric ton
NDA New Drug Application
OSD Oral Solid Dosage
PBMs Pharmacy Benefit Manager
Paragraph IV Pursuant to use of a Paragraph IV certification, a generic manufacturer can either
challenge the validity of applicable patents in the NDA or certify that the generic
equivalent product will not infringe any patent held by the pioneer drug company
whose patent(s) is part of the NDA. The generic manufacturer
contemporaneously with its Paragraph IV certification must notify the innovator
manufacturer that it is filing a Paragraph IV certification with its ANDA
Pharmerging markets Pharmerging markets, are defined by IQVIA as countries with per capita income
below $30,000 per year and five-year absolute growth in pharmaceutical
spending greater than $1 billion. These include Algeria, Argentina, Bangladesh,
Brazil, Chile, China, Colombia, Egypt, India, Indonesia, Kazakhstan, Mexico,
21
Term Description
Nigeria, Pakistan, Philippines, Poland, Russia, Saudi Arabia, South Africa,
Thailand, Turkey and Vietnam.
Pharmexcil Pharmaceuticals Export Promotion Council of India
QC Quality Control
R&D Research and development
SIA State Implementing Agency
SME Small and Medium Enterprise
SOP Standard Operating Procedure
UK MHRA UK Medicines and Healthcare Products Regulatory Agency
USFDA United States Food and Drug Administration
WBAD Walgreens Boots Alliance Development
WHO World Health Organization
Conventional and General Terms/Abbreviations
Term Description
AGM Annual general meeting
AIF(s) Alternative investment funds, as defined and registered with SEBI under the
Securities and Exchange Board of India (Alternative Investment Funds)
Regulations, 2012
AS Accounting Standards issued by ICAI, as required under the Companies Act
AY Assessment year
BSE BSE Limited
CDSL Central Depository Services (India) Limited
CEO Chief executive officer
CFO Chief financial officer
CIN Corporate Identity Number
CSR Corporate social responsibility
Civil Procedure Code The Code of Civil Procedure, 1908
Companies Act / Companies Act, 2013 The Companies Act, 2013 and the rules, regulations, circulars, modifications
and clarifications thereunder, to the extent notified
Companies Act, 1956 The erstwhile Companies Act, 1956 along with the rules made thereunder
Depositories Act The Depositories Act, 1996
Depository A depository registered with SEBI under the Securities and Exchange Board of
India (Depositories and Participant) Regulations, 2018
Depository Participant A depository participant as defined under the Depositories Act
DIN Director Identification Number
EGM Extraordinary general meeting
FDI Foreign direct investment
FDI Policy Consolidated FDI policy issued by the Department for Promotion of Industry
and Internal Trade (formerly Department of Industrial Policy and Promotion),
Ministry of Commerce and Industry, GoI by circular D/o IPP F. No. 5(1)/2017-
FC-1 of 2017, with effect from August 28, 2017
FEMA The Foreign Exchange Management Act, 1999 and the regulations issued
thereunder
FEMA Rules The Foreign Exchange Management (Non Debt Instruments) Rules, 2019
"Financial year" or "Fiscal Year" or
"FY" or "Fiscal"
Unless otherwise stated, the period of 12 months commencing on April 1 of a
year and ending on March 31 of the next year
Form PAS-4 Form PAS-4 as prescribed under the Companies (Prospectus and Allotment of
Securities) Rules, 2014, as amended.
FPI Foreign portfolio investors as defined under the SEBI FPI Regulations and
includes a person who has been registered under the SEBI FPI Regulations.
Fugitive Economic Offender An individual who is declared a fugitive economic offender under Section 12 of
the Fugitive Economic Offenders Act, 2018
FVCI Foreign venture capital investors as defined and registered with SEBI under the
Securities and Exchange Board of India (Foreign Venture Capital Investors)
Regulations, 2000
GAAP Generally accepted accounting principles
GIR General index registrar
“GoI” or "Government" Government of India, unless otherwise specified
22
Term Description
HUF Hindu undivided family
ICAI The Institute of Chartered Accountants of India
IFRS International Financial Reporting Standards of the International Accounting
Standards Board
Ind AS Indian accounting standards converged with IFRS, as notified by the Ministry
of Corporate Affairs through the Indian Accounting Standards Rules in its
general statutory rules dated February 16, 2015
Interest Coverage Ratio Interest coverage ratio is calculated on the basis of profit before tax plus interest
expense divided by interest for the year
IPR Intellectual property rights
IT Information technology
“Lac" or "lakh" Lakhs
“NRI” or "Non-Resident Indian" A person resident outside India who is a citizen of India as defined under the
Foreign Exchange Management (Deposit) Regulations, 2016 or is an ‘Overseas
Citizen of India’ cardholder within the meaning of section 7(A) of the
Citizenship Act, 1955.
NSDL National Securities Depository Limited
NSE National Stock Exchange of India Limited
p.a. Per annum
PAS Rules Companies (Prospectus and Allotment of Securities) Rules, 2014
RBI Reserve Bank of India
Regulation S Regulation S under the U.S. Securities Act
RoC Registrar of Companies, Gujarat at Ahmedabad
"₹" or "Rs." or "Rupees" or "INR" Indian Rupees, the legal currency of the Republic of India
SCR (SECC) Rules Securities Contracts (Regulation) (Stock Exchanges and Clearing Corporations)
Regulations, 2018
SCRA Securities Contracts (Regulation) Act, 1956
SCRR Securities Contracts (Regulation) Rules, 1957
SEBI Securities and Exchange Board of India
SEBI Act The Securities and Exchange Board of India Act, 1992
SEBI FPI Regulations The Securities and Exchange Board of India (Foreign Portfolio Investors)
Regulations, 2019
SEBI Insider Trading Regulations The Securities and Exchange Board of India (Prohibition of Insider Trading)
Regulations, 2015
SEBI Listing Regulations The Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015
SEBI Regulations The Securities and Exchange Board of India (Issue of Capital and Disclosure
Requirements) Regulations, 2018
SEBI Takeover Regulations The Securities and Exchange Board of India (Substantial Acquisition of Shares
and Takeovers) Regulations, 2011
Stock Exchanges BSE and NSE, taken together
STT Securities transaction tax
"U.S.$ ", "U.S. dollar", or "USD" United States Dollar, the legal currency of the United States
"USA" "U.S. ", or "United States" The United States of America, its territories and possessions (including Puerto
Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the
Northern Mariana Islands and the District of Columbia).
U.S. Securities Act The United States Securities Act of 1933
VCF Venture capital fund
23
SUMMARY OF BUSINESS
Some of the information in the following discussion, including information with respect to our plans and
strategies, contain forward-looking statements that involve risks and uncertainties. You should read “Forward
Looking Statements” on page 14 for a discussion of the risks and uncertainties related to those statements. Our
actual results may differ materially from those expressed in or implied by these forward-looking statements. Also
read “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations- Factors affecting our Financial Results” on pages 35 and 74, respectively, for a discussion of certain
factors that may affect our business, financial condition or results of operations.
Our financial year ends on March 31 of each year, and references to a particular Fiscal are to the twelve months
ended March 31 of that year. Unless context requires otherwise, the financial information used in this section for
the Fiscals 2020, 2019 and 2018 is derived from the Audited Consolidated Financial Statement and referred to
as such. For further information, see “Financial Statements” on page 180.
We are a vertically integrated pharmaceutical company, developing, manufacturing and marketing of formulations
offered in the international markets including in markets such as the United States, European Union, etc
(“International Generics”), formulations which cater to India’s domestic formulations market (“Domestic
Formulations”) and active pharmaceutical ingredients which cater to both domestic and international markets
(“APIs”). We have a presence and sell our products in over 65 countries including the United States, India,
Europe, Canada, Australia, Brazil and South Africa. We provide a diverse suite of products under each of our
business verticals - International Generics, Domestic Formulation and APIs. Our product portfolio in the Domestic
Formulations covers numerous chronic and acute therapy areas and in the International Generics, our products
and products in pipeline include oral solids, dermatology, oncology oral solids, oncology injectables, general
injectables and ophthalmology. For Fiscal 2020, we derived 53.69%, 30.95% and 15.36% of our revenue from
operations from our International Generics, Domestic Formulations and APIs business, respectively.
We have a broad portfolio of Abbreviated New Drug Applications (“ANDAs”) for our International Generic
business filed with the United States Food and Drug Administration (“USFDA”). As of June 30, 2020, we have
received approval for 125 ANDAs including 14 ANDAs which have received tentative approval from USFDA.
Our filings in the United States focus on oral solids (oncology and non-oncology), injectable products (oncology
and non-oncology), ophthalmic and dermatological. As of March 31, 2020, we had successfully launched 76
products in the United States, which we sell through pharmacy chains, wholesalers and distributors. We
manufacture APIs for captive consumption as well as for selling to the customers in domestic and international
markets. As of March 31, 2020, we have filed 123 Drug Master Files (“DMFs”) with the USFDA for our API
products in multiple therapeutic areas, out of which 109 DMFs are active.
We have a presence in the Domestic Formulations market which caters to chronic and acute therapies including
cardiology, anti-diabetic, gynaecology, gastrology, dermatology, orthopaedic, ophthalmology, nephrology /
urology, anti-infective, cold and cough, and veterinary segment.
We rank 21 in Indian Pharma Market (“IPM”) as of March 31, 2020 (Source: March MAT data of IQVIA, TSA
March 2020) with a 1.5% market share in IPM (Source: IQVIA, TSA March 2020). Further, three of our brands
featured amongst the top 300 pharmaceutical brands in India (Source: IQVIA, TSA March 2020).
We operate three R&D centres located at Vadodara (Gujarat, India), Hyderabad (Telangana, India) and at West-
Caldwell (New Jersey, United States). We also have a USFDA approved Bioequivalence Centre, located at
Vadodara (Gujarat, India) which provides support for bioavailability (BA) and bioequivalence (BE) studies and
support our R&D activities. As of March 31, 2020, we employed about 1,100 professionals in our R&D centres
working on APIs and various dosage forms of formulations. Some our R&D efforts are also focused on developing
niche, specialty products to strengthen our product offerings. We dedicate a substantial portion of our revenue
from operations towards R&D activities. Our R&D spend as a percentage to revenue from operations has increased
from 5.92% in Fiscal 2015 to 14.00% in Fiscal 2020.
Further, owing to our strong R&D, we have been granted 911 patents worldwide (for both APIs and formulations),
including patents which have been withdrawn, abandoned or have lapsed, as of March 31, 2020.
We have one facility engaged in the manufacturing of Domestic Formulations located in Sikkim. Two of our
facilities are engaged in the manufacturing of International Generic formulations located in Gujarat out of which
one facility is operated by our joint venture. Three of our facilities for manufacturing APIs are located in Gujarat.
24
All these facilities are currently commercially operational. The manufacturing units which are responsible for
manufacturing our products which are sold in regulated markets (including the United States, Canada, United
Kingdom), comply with applicable regulations and standards and also comply with the targeted markets’
regulatory requirements, for example that of, USFDA’s current Good Manufacturing Practices (“CGMPs”), the
United Kingdom’s medicines and healthcare products regulatory agency (“MHRA”), the Brazilian Health
Regulatory Agency (“ANVISA”), European Directorate for Quality of Medicines (“EDQM”), Australian
Therapeutic Goods Administration (“TGA”), etc. As on date, the Establishment Inspection Report (“EIR”) from
USFDA is in place for each of our operational facilities, where applicable. For more details regarding our
manufacturing facilities, see “Manufacturing Process and Facilities” on page 113.
Driven by a strong management team, our consolidated revenue from operations for Fiscal 2020 was ₹ 4,605.75
crores which was up by 17.06%, compared to ₹ 3,934.68 crores for Fiscal 2019. Our Consolidated PAT for Fiscal
2020 grew by 41.83% to ₹ 828.82 crores from ₹ 584.37 crores for Fiscal 2019.
Our Strengths
The following are our key strengths which we believe enable us to compete in our principal markets:
Focused approach towards the United States formulations business
We believe that our track record of development and filing of ANDAs, ability to meet compliance standards and
ensuring timely delivery of products have been instrumental in driving our success in the United States market.
Consequently, we have been able to increase our product portfolio, deepen our relationships with existing
customers and increase the number of new customers during the past year. For the United States formulations
business, we are focused on launching products across various therapies and dosage forms to maximise existing
and emerging opportunities.
In the United States markets, historically, we started off selling our products to the companies or distributors.
Subsequently, we have set-up our own front-end office in the year 2015 to sell our products under the Alembic
label. In the year 2016, we also formed a joint venture named Aleor Dermaceuticals Limited (“ADL”) with
Orbicular Pharmaceuticals Technologies Private Limited for developing dermatology products for international
markets. During the Fiscal 2019, ADL launched its products in the United States market. As of June 30, 2020,
ADL had received nine approvals including one ANDA which has received a tentative approval.
Through Alembic Global Holding SA incorporated in Switzerland, our wholly owned subsidiary, we have made
an investment in Rhizen Pharmaceuticals SA (“Rhizen”), incorporated in Switzerland. Rhizen has been in the
past, involved in out-licensing its products to other companies in the United States market . Rhizen’s first product
was licensed out to TG Therapeutics which is undergoing a new drug application filing with the USFDA.
High compliance standards across manufacturing facilities with focus on quality assurance
We believe that quality and compliance are the key differentiators in our business and that our focus and emphasis
on maintaining requisite compliance standards across our plants is a key driver in our business. We believe that
the integrated nature of our standard operating procedures, multiple quality checks across the organisation and
round the clock audit preparedness ensures that we maintain such standard at all times.
As on date, the Establishment Inspection Report (“EIR”), which is a factual report issued by the USFDA pursuant
to an inspection it conducts on the factory premises of a company, is in place for each of our USFDA facilities.
The location of our facilities, division, the capabilities thereof and the major approvals received by each of them
is given below:
Location Division Capability Key Approvals
Panelav, Gujarat (F1) Formulations –
International Generics
Tablets, Capsules USFDA
Panelav, Gujarat (F2) Formulations –
International Generics
Oncology oral solids USFDA
Oncology injectables Awaiting FDA inspection
Karkhadi, Gujarat
(F3)
Formulations –
International Generics
General injectables
ophthalmology
Awaiting USFDA inspection
25
Jarod, Gujarat (F4) Formulations –
International Generics
Tablets, Capsules Awaiting USFDA inspection
Karkhadi, Gujarat
(ADL JV)
Formulations Various dermaceutical
formulations
USFDA
Panelav, Gujarat
(API Unit 1)
API API USFDA, ANVISA, EQDM, HPCD
(Canada), EU GMP (Germany),
WHO GMP
Panelav, Gujarat
(API Unit 2)
API API USFDA, HPCD (Canada), EU
GMP (Germany), WHO GMP
Karkhadi, Gujarat
(API Unit 3)
API API USFDA, MHRA (UK), TGA GMP
(Australia) , WHO GMP
Samardung Busty,
Sikkim (Domestic)
Domestic Formulations Tablets, Capsules WHO GMP
We believe our manufacturing facilities are capable of producing a wide range of products, enabling us to position
ourselves as suppliers to customers across the globe.
Well established presence in Domestic Formulations market
We develop, manufacture, market and sell branded pharmaceutical products in select therapeutic areas within the
chronic and acute categories of the Indian pharmaceutical market (“IPM”). Our Domestic Formulations business
accounted for 30.95%, 35.13% and 40.69% of our revenue from operations, for Fiscals 2020, 2019 and 2018,
respectively and continues to be a significant part of our growth strategy in the future.
Further, we have been consistently increasing our presence in the specialty therapies, including cardiology,
diabetes, gynaecology, ophthalmology and veterinary. Specialty remains our key focus area with 64.92% share of
our Domestic Formulation business and acute segments consisting of cough and cold and anti-infective therapies
with 35.08% share of our Domestic Formulation business, for the Fiscal 2020. Domestic Formulation business
contributed towards 30.95% of our total consolidated revenue from operations in Fiscal 2020.
We rank 21 in IPM as of March 31, 2020 (Source: March MAT data of IQVIA, TSA March 2020) with a 1.5%
market share in domestic pharma space in India (Source: IQVIA, TSA March 2020). Further, three of our brands
featured amongst the top 300 pharmaceutical brands in India (Source: IQVIA, TSA March 2020).
Our sales team comprised of around 5,000 field colleagues, as of March 31, 2020, which allows us to
commercialise our pharmaceutical products.
Strong R&D capabilities with substantial spending over last few years
We are a R&D focussed company and we believe that our strong R&D expertise are critical for our success across
businesses. Our formulations R&D activities include development of various dosage of formulations (such as
OSD and injectables, oncology and dermaceutical products) and is supported by strong dedicated teams for
analytics, documentation and IPR. We also have API development teams focused on developing and filing our
DMFs with the USFDA.
We have three R&D centres in Vadodara (Gujarat, India), Hyderabad (Telangana, India) and West-Caldwell (New
Jersey, United States) with about 1,100 R&D professionals across these centres. Our R&D activities primarily
include developing new products, improving existing products, improving /innovating drug delivery systems and
expanding product applications. Historically, we have invested significantly to augment our R&D capabilities
specifically around therapies (including cardiovascular, oncology, peptides, central nervous system),
dermaceuticals and injectables (general and oncology). We proactively scan our R&D grid to realign our product
portfolio by mapping it with the critical factors such as potential to garner desired market share by focussing on
the United States market and generate profits.
As of June 30, 2020, we have received approval for 125 ANDAs including 14 ANDAs which have received
tentative approval from USFDA. Our filings in the United States focus on oral solids (oncology and non-
oncology), injectable products (oncology and non-oncology), ophthalmic and dermatological. As of March 31,
2020, we had launched 76 products in the United States. As of March 31, 2020, we have filed 123 DMFs with the
USFDA for our API products in multiple therapeutic areas, out of which 109 DMFs are active. We spent ₹ 644.82
crore (14.00% of our total revenue from operations), ₹ 503.64 crore (12.80% of our total revenue from operations)
26
and ₹ 411.28 crore (13.14% of our total revenue from operations) in R&D expenditure during Fiscal 2020, Fiscal
2019 and Fiscal 2018, respectively. We have been granted 911 approximately patents worldwide (for both APIs
and formulations), including patents which have been withdrawn, abandoned or have lapsed, as of March 31,
2020.
Our commitment towards R&D is well evidenced from our increasing R&D spend as a percentage of total revenue
from operations, which has substantially increased from 5.92% of revenue from operations in Fiscal 2015 to
14.00% of revenue from operations in Fiscal 2020.
Vertical integration leading to operating leverage and supply reliability
We are a vertically integrated pharmaceutical company with in-house sourcing of APIs for several of our products.
We have invested financial and manpower resources in building infrastructure for the manufacture of APIs and
generic formulations in order to become a vertically integrated pharmaceutical company. We believe, our in-house
manufacturing of APIs has provided us with a competitive advantage in the generic formulations market through
helping us maintain quality control, mitigate the demand-supply fluctuations that routinely affect generics markets
and provides consistency and reliability of supply. We believe that our vertically integrated manufacturing
approach coupled with our process, supply chain and productivity efficiencies, contribute to our production cost
advantage and offers competitive advantage to us. We continue to improve and assess our programs designed to
increase efficiency and enhance economies of scale in order to further reduce costs.
Diversified product offering across therapeutic categories to various geographies
Our business is diverse in terms of therapeutic areas and geographies catered to, thereby mitigating concentration
risks. We offer a wide range of products across several major therapeutic categories, including cardiology, anti-
diabetic, gynaecology, gastrology, dermatology, orthopaedic, ophthalmology, nephrology / urology, anti-infective
and cold and cough. Our products (including products in pipeline) cover variety of dosage forms including oral
solids, dermatology, oncology oral solids, oncology injectables, general injectables and ophthalmology. We
believe that the depth and diversity of our product portfolio benefits our customers by providing them with a
single dependable source for a substantial number of their pharmaceutical requirements. Our large product
portfolio also helps us realise sales and distribution synergies. Further, we believe that a diversified product
portfolio such as ours, across various therapies and geographies, diminishes the risk associated with the
dependence on any particular product or country. No single product accounted for more than 5% of our total gross
revenues from operations for the Fiscal 2020 and our revenues were diversified across over 65 countries.
Experienced Management Team
We are led by a qualified and experienced management team with the vision and expertise to help manage and
grow our business. In addition to our Promoters, each of whom has extensive experience and a strong background
in the pharmaceutical industry, we also have a qualified strong senior management team that has significant
experience in all aspects of our business. We have been able to attract and retain senior and middle-level
management executives from top tier organizations. We believe that the knowledge and experience of our
Promoters in healthcare, along with that of our senior and middle-level management, provides us with a strong
platform as we seek to expand our business in existing markets and enter new geographies.
Our Strategies
Expand and improve our United States formulations products portfolio
Our strategy in the United States is to continue to focus on the existing and new formulations and enhance our
product portfolio by accelerating ANDA filings. Our United States formulations business has grown to ₹1,976.00
crore in Fiscal 2020, accounting for 42.90% of total revenue from operations on a consolidated for the Fiscal.
United States formulation business remains a significant growth engine for us and has grown at a CAGR of
44.28% from Fiscal 2015 to Fiscal 2020. We also believe that we have the ability to deliver quality products in a
timely manner as per the customers’ orders.
We are looking to launch new and distinct products and enhancing the value proposition of our existing products.
Our focus is on developing complex, niche products having limited competition. With this view, during the last
four Fiscals, we have significantly invested in our manufacturing and R&D capabilities with focus on expanding
and improving our current product offerings specially in the United States.
27
We are in the process of expanding our capacity to allow us to have enhanced new dosage offerings across
ophthalmology, general injectables, oncology injectables and oral solids (oncology and non-oncology) and will
be able to cater to the demand in United States generics segment. We have already started commercial production
in our dermaceuticals plant under our joint venture, ADL.
Over the years, we have invested significantly to augment our R&D capabilities across several high-growth and
high-value therapies. Our R&D expenses as a percentage to our revenue from operations have increased from
5.92% in Fiscal 2015 to 14.00% in Fiscal 2020. Bulk of our R&D investments are focused towards the United
States formulations business. We believe that this R&D focussed approach has dividends over the years and we
remain hopeful of it yielding growth in the United States business segment. In order to optimize the R&D
investments, several filters are applied by cross-functional teams before taking a product in the R&D grid.
We have experience in 505(b)(2) filings for new drug applications and paragraph IV filings for ANDAs required
by the USFDA. We filed/acquired 25, 29 and 37 ANDAs in the United States in Fiscals 2020, 2019 and 2018,
respectively. Our portfolio which was largely dominated by oral solids is now being expanded to include
ophthalmology, dermaceuticals, oncology (oral solids) and injectables (oncology and general) owing to our R&D
efforts.
Strengthen our Domestic Formulations business through consolidating our presence and venturing into new
fast growth therapy segments
Our Domestic Formulations business accounted for 30.95%, 35.13% and 40.69% of our revenue from operations
for Fiscals 2020, 2019 and 2018, respectively and continues to be a significant part of our growth strategy in the
future. In this segment, we cater to therapeutic areas such as cardiology, anti-diabetic, gynaecology, gastrology,
dermatological, orthopaedic, ophthalmology, nephrology / urology, anti-infective and cold and cough and
veterinary segment. We believe that our sales team of around 5,000 field colleagues and right product launches
are key enablers for this business. From Fiscal 2018 to Fiscal 2020, our Domestic Formulations business has
grown at a CAGR of 5.78%.
In addition to consolidating presence in our existing brands and therapeutic areas, we have also focused our efforts
on pursuing opportunities in fast growing therapeutic areas where we believe we can grow our presence, such as,
cardiology, diabetes, gynaecology and ophthalmology. Our strategy for expansion in existing and new therapeutic
areas includes extending our focus to target lifestyle disorders and the chronic category (to target products that
have to be prescribed over an extended period of time as opposed to one time incidence related medication),
identifying gaps in existing interventions, analysing patient compliance, and working with key opinion leaders,
doctors and patients through active engagement to develop, manufacture and market new indications which fulfil
an unmet need or are clinically differentiated.
We also have invested in sales force management system, which captures data at the headquarters and employee
levels, to make our sales staff more productive. Our marketing team utilises a variety of marketing techniques and
programs to promote our products. We believe that focusing on marketing will help us in enhancing emphasis on
the product coverage that we offer and improving our market share in India.
Leverage our API business to improve our competitive advantage in International Generics business
Our API business is strategically important since it allows us to backward integrate our operations. Our API
business helps us reduce cost and increase revenue margin and timely delivery of raw materials of desired quality
and quantity for our International Generics business. We believe that our presence in API production improves
our ability to maintain quality and mitigates the demand-supply fluctuations that affect generics markets thereby
providing for consistency and reliability of supply in an increasingly regulated global environment. It further
protects us from relying on external sources for our raw materials, thereby reducing risk of unfavourable terms of
supply such as high pricing and long timeline for delivery.
In our International Generics business, critical oral solids portfolio is backward integrated in terms of API
supplies. Beyond backward integration, our API business also acts as a key focus area as it continues to grow in
the regulated markets and we are a preferred vendor to our customers owing to the quality of our products and
dependability. The key strengths of our API business are our manufacturing expertise and a good compliance
track record. We have implemented several measures to enhance operational efficiency of this business including
automation of our processes to reduce contamination.
28
We have three USFDA approved API facilities, two in Panelav (Gujarat, India) and one in Karkhadi (Gujarat,
India) which underwent USFDA audits and have received EIR for each of the units. Our API facilities are located
closer to our formulations units, thereby giving us significant operational efficiencies. As of March 31, 2020, we
have filed 123 DMFs with the USFDA for our API products in multiple therapeutic areas, out of which 109 DMFs
are active.
Continue to grow our business outside of India and the United States
We intend to continue to grow our sales in existing geographies in Europe, Canada, Australia, South Africa and
Brazil by increasing our existing product portfolio in these markets. Our growth strategy will vary from country
to country depending on applicable regulatory requirements, competition in the product portfolio and
demographics. We intend to capitalise on selected products that we develop for the United States in these markets.
We are hopeful that we will be able to create a strong local presence and expertise with required infrastructure
and develop capabilities in order to grow in these potential markets.
In markets apart from India and the United States, we predominantly sell our products through distributors or
partnerships. In some markets, we work on semi exclusive basis wherein we offer exclusivity for some products
within that market / country. We identify and assess the suitability of potential marketing partners on the basis of
their strengths in that market. We would like to deepen our partnerships in these markets in order to further drive
our marketing efforts. We derived 10.79%, 12.54% and 9.15% of our revenue from operations in Fiscals 2020,
2019 and 2018, respectively, from these countries/regions.
29
SUMMARY OF THE ISSUE
The following is a general summary of the terms of the Issue. This summary should be read in conjunction with,
and is qualified in its entirety by, the more detailed information appearing elsewhere in this Placement Document,
including the sections “Risk Factors”, “Use of Proceeds”, “Placement”, “Issue Procedure” and “Description of
the Equity Shares” on pages 35, 66, 143, 131 and 157, respectively.
Issuer Alembic Pharmaceuticals Limited
Face Value ₹2 per Equity Share
Issue Price ₹932.00 per Equity Share (including a premium of ₹930.00 per Equity
Share)
Discount Our Company has offered a discount of 4.97% amounting to ₹ 48.75,
on the Floor Price in accordance with the approval of the Shareholders
accorded through their resolution dated July 22, 2020 and in terms of
Regulation 176(1) of the SEBI Regulations
Floor Price ₹980.75 per Equity Share, calculated on the basis of Regulation 176 of
the SEBI Regulations.
Issue Size Issue of 80,47,210 Equity Shares, aggregating to approximately
₹750.00 crore.
A minimum of 10% of the Issue Size, i.e., 8,04,721 Equity Shares was
made available for Allocation to Mutual Funds only and the balance
72,42,489 Equity Shares was made available for Allocation to all
Eligible QIBs, including Mutual Funds. In case of under-subscription
in the portion available for Allocation to Mutual Funds, such
undersubscribed portion may be Allotted to other Eligible QIBs.
Date of Board Resolution authorizing the Issue May 22, 2020 and July 27, 2020
Date of Shareholders’ Resolution authorizing
the Issue
July 22, 2020
Eligible Investors Eligible QIBs, to whom the Preliminary Placement Document and the
Application Form have been delivered and who are eligible to bid and
participate in the Issue.
For further details, see “Issue Procedure”, “Selling Restrictions” and
“Purchaser Representations and Transfer Restrictions” on pages 131,
145 and 152, respectively. The list of Eligible QIBs to whom the
Preliminary Placement Document and Application Form have been
delivered, has been determined by our Company in consultation with
the BRLMs.
Equity Shares issued and outstanding
immediately prior to the Issue
18,85,15,914 fully paid-up Equity Shares
Equity Shares issued and outstanding
immediately after the Issue
19,65,63,124 fully paid-up Equity Shares
Issue Procedure This Issue was made only to Eligible QIBs in reliance on Section 42
of the Companies Act, read with Rule 14 of the PAS Rules, and all
other applicable provisions of the Companies Act and Chapter VI of
the SEBI Regulations. For further details, see “Issue Procedure”
beginning on page 131.
Listing and Trading Our Company has obtained in-principle approvals dated August 3,
2020 from BSE and NSE in terms of Regulation 28(1)(a) of the SEBI
Listing Regulations for listing of the Equity Shares to be issued
pursuant to the Issue.
Our Company will make applications to each of the Stock Exchanges
after Allotment and credit of Equity Shares to the beneficiary account
with the Depository Participant to obtain final listing and trading
approval for the Equity Shares, to be issued pursuant to this Issue.
Lock-up For details of the lock-up, see “Placement – Lock-up” on page 143.
Transferability Restrictions The Equity Shares Allotted pursuant to this Issue shall not be sold for
30
a period of one year from the date of Allotment, except on the floor of
a recognised stock exchange. For details in relation to other transfer
restrictions, see “Selling Restrictions” and “Purchaser
Representations and Transfer Restrictions” on pages 145 and 152,
respectively.
Use of Proceeds The gross proceeds from the Issue aggregated to approximately
₹750.00 crore.
The net proceeds from the Issue, after deducting Issue related expenses
is expected to be approximately ₹733.57 crore.
See “Use of Proceeds” on page 66 for information regarding the use
of Net Proceeds from the Issue.
Risk Factors See “Risk Factors” beginning on page 35 for a discussion of risks you
should consider before investing in the Equity Shares.
Indian Taxation See “Statement of Special Tax Benefits” on page 161
Closing Date The Allotment of the Equity Shares is expected to be made on or about
August 7, 2020.
Ranking and dividends The Equity Shares to be issued pursuant to the Issue shall be subject to
the provisions of the Memorandum of Association and Articles of
Association and shall rank pari passu with the existing Equity Shares
of our Company, including rights in respect of dividends.
The Shareholders who hold Equity Shares as on the relevant record
date will be entitled to participate in dividends and other corporate
benefits, if any, declared by our Company after the Bid/Issue Closing
Date, in compliance with the Companies Act, SEBI Listing
Regulations and other applicable laws and regulations. Shareholders
may attend and vote in shareholders’ meetings in accordance with the
provisions of the Companies Act. Please see sections "Dividends" and
"Description of the Equity Shares" on pages 72 and 157, respectively.
Security Codes/ Symbols for the Equity Shares ISIN INE901L01018
BSE Code 533573
NSE
Symbol
APLLTD
31
SELECTED FINANCIAL INFORMATION
The following selected financial information is extracted from and should be read in conjunction with, the Audited
Consolidated Financial Statements of our Company, prepared in accordance with Companies Act and Ind AS and
the applicable rules thereunder, included elsewhere in this Placement Document. You should refer to
“Management's Discussion and Analysis of Financial Condition and Results of Operations” and “Financial
Statements” on pages 73 and 180, respectively, for further discussion and analysis of the Audited Consolidated
Financial Statements of our Company. Wherever comparatives have been included in this section, such
comparatives have been derived from the comparatives in the Audited Consolidated Financial Statements.
SUMMARY OF CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2020, MARCH 31, 2019, AND
MARCH 31, 2018 (₹ In crore)
Particulars As at March
31, 2020
As at March
31, 2019
As at March
31, 2018
I. ASSETS
(1) Non-Current Assets
(a) Property, Plant and Equipment 1,524.90 1,098.41 927.02 (b) Capital work-in-progress 1,574.10 1,341.40 910.76 (c) Goodwill - 3.61 3.77 (d) Other Intangible assets 26.94 56.43 62.59 (e) Intangible assets under development 272.08 209.83 99.39 (f) Financial Assets: -
(i) Investments 0.45 0.45 0.45
(ii) Investment accounted for using Equity
Method
17.17 48.31 41.19
(g) Other non-current assets 110.66 61.59 71.14 (2) Current Assets
(a) Inventories 1,187.53 967.26 733.93 (b) Financial Assets
(i) Trade receivables 864.75 488.92 526.34 (ii) Cash and cash equivalents 71.84 199.07 83.74
(iii) Bank balances other than cash and cash
equivalents
8.91 6.55 6.18
(iv) Others financial assets 8.65 9.10 29.97 (c) Current Tax Assets (Net) 30.98 - 3.45 (d) Other current assets 290.08 286.86 441.13 TOTAL ASSETS 5,989.05 4,777.79 3,941.05
II EQUITY AND LIABILITIES
EQUITY
(a) Equity Share capital 37.70 37.70 37.70 (b) Other Equity 3,181.71 2,681.12 2,182.44 Equity attributable to owners of the Company 3,219.41 2,718.82 2,220.14 Non-controlling interests (28.96) (0.79) 0.31 Total Equity 3,190.45 2,718.04 2,220.45 LIABILITIES
(1) Non-Current Liabilities
(a) Financial Liabilities
(i) Borrowings 886.99 499.30 500.00 (ii) Other financial liabilities 73.30 - - (b) Provisions 74.51 52.03 40.76 (c) Deferred tax liabilities (Net) 12.19 18.74 35.44 (2) Current liabilities
(a) Financial Liabilities
(i) Borrowings 860.50 429.13 207.78 (ii) Trade payables
A) Total outstanding dues of Micro and Small
enterprises
7.11 5.09 0.32
B) Total outstanding dues of others 618.82 639.25 759.00 (iii) Other financial liabilities 121.92 292.19 19.59 (b) Other current liabilities 105.06 87.99 123.29 (c) Provisions 38.19 32.39 34.41 (d) Current Tax Liabilities (Net) - 3.61 - TOTAL EQUITY AND LIABILITIES 5,989.05 4,777.79 3,941.05
32
SUMMARY OF CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE FISCALS
ENDED MARCH 31, 2020, MARCH 31, 2019 AND MARCH 31, 2018
(₹ In crore)
Particulars
For the year
ended March
31, 2020
For the Year
Ended on
March 31,
2019
For the Year
Ended on
March 31, 2018
I Revenue from Operations 4,605.75 3,934.68 3,130.81
II Other Income 4.94 9.38 7.03
III Total Income 4,610.69 3,944.06 3,137.84
IV Expenses
Cost of Materials Consumed 979.05 850.04 725.75 Purchase of Stock-in-Trade 270.93 234.93 201.87 Changes in Inventories of Finished Goods, Stock-in-
Trade, and Work in Progress
(210.59) (92.27) (42.06)
Employee Benefits Expense 906.44 746.69 622.81 Finance costs 27.16 18.41 3.40 Depreciation and amortization expense 157.32 115.23 105.46 Other Expenses 1,436.89 1,321.71 979.34 Total Expense (IV) 3,567.22 3,194.74 2,596.57
V Profit Before Tax (III-IV) 1,043.47 749.32 541.27
VI Exceptional Items 43.65
VII Profit Before Tax (V-VI) 999.82 749.32 541.27
VIII Tax Expense
(i) Current Tax 204.57 178.14 123.61 (ii) Deferred Tax (4.30) (17.29) (2.16) (iii) Short/Excess Tax Provision (1.09) (4.10) (1.10)
IX Profit after Tax Before Share of Profit of Associate
and Joint Venture (VII-VIII)
800.64 592.57 420.91
X Share of Profit/(Loss) of an associate and a joint
venture
0.05 (9.28) (8.09)
XI Profit for the period before Non-controlling Interest
(IX+X)
800.70 583.29 412.82
XII Non- controlling Interest 28.12 1.08 (0.19)
XIII Profit for the period attributable to Owners of the
Company
828.82 584.37 412.63
XIV Other Comprehensive Income
A Items that will not be reclassified to Profit and
Loss
(i) Re-measurements of post-employment benefit
obligations
(11.42) (2.47) (3.89)
(ii) Income tax relating to Re-measurements of
post-employment benefit obligations
1.97 0.53 0.83
(9.46) (1.93) (3.06) B Items that will be reclassified to Profit or Loss
(i)Exchange differences in translating the financial
statements of a foreign operations
7.64 7.76 (0.14)
7.64 7.76 (0.14) Total Other Comprehensive Income (A+B) (1.82) 5.83 (3.20)
XV Total Comprehensive Income for the year (IX+XII) 798.88 589.12 409.63 Other Comprehensive Income for the year
Attributable to:
(i) Non- controlling Interest (0.05) (0.01) - (ii) Owners of the Company (1.77) 5.84 (3.20) Total Comprehensive Income for the year
Attributable to:
(i) Non- controlling Interest (28.17) (1.09) 0.19 (ii) Owners of the Company 827.05 590.21 409.43
XVI Earnings per equity share (face value ` 2/- per share):
Basic & Diluted (in `) 43.97 31.00 21.89
33
SUMMARY OF CONSOLIDATED CASH FLOW STATEMENT FOR THE FISCALS ENDED 31
MARCH 2020, MARCH 31, 2019 AND MARCH 31, 2018
(₹ In crore)
Particulars
For the year
ended March
31, 2020
For the year
ended
March 31,
2019
For the year
ended March
31, 2018
A CASH FLOW FROM OPERATING ACTIVITIES:
Net Profit before tax after exceptional item 999.82 749.32 541.27 Adjustments for:
Depreciation and amortisation 157.32 115.23 105.46 Interest charged 27.16 18.41 3.40 Interest Income (1.73) (2.58) (0.62) Dividend Income /Gain on Sale of Investments (0.93) (2.12) (0.75) Unrealised foreign exchange gain (net) 15.95 (23.83) (15.62) Provision / write off for doubtful trade receivables 8.55 16.69 0.07 Impairment goodwill and other intangible assets 53.71 - - Impairment in value of investments, net 33.65 - - Sundry balances written Back (net) (2.82) (0.58) - Remeasurement of Defined benefit obligations (11.42) (2.47) - Loss/(Profit) on sale of Asset (1.16) (1.18) (4.82) Operating Profit before change in working capital 1,278.09 866.88 628.39 Working capital changes:
(Increase) In Inventories (220.27) (233.33) (101.18) (Increase)/Decrease in Trade Receivables (358.26) 36.19 (184.18) (Increase)/Decrease in Other Assets (18.95) 175.13 (217.64) (Decrease) In Trade Payables (21.11) (50.31) 258.84 Increase /(Decrease) In Other Liabilities (2.52) 177.09 61.60 Increase in Provisions 28.27 6.79 1.71 Cash generated from operations 685.24 978.45 447.53 Direct taxes paid (Net of refunds) (236.11) (166.48) (135.11) Net Cash inflow from Operating Activities (A) 449.13 811.96 312.42
B CASH FLOW FROM INVESTING ACTIVITIES:
Proceed from sale of assets 0.60 1.28 14.40 Government assistance - 17.15 - Interest received 1.73 2.58 0.62 Dividend /Gain on Sale of Investments received 0.93 2.12 0.75 Purchase of Property, Plant & Equipments and Capital
Advance
(672.65) (653.93) (749.36)
Investment in Associate - (14.36)
Net cash outflow on acquisition of Subsidiary
(78.41)
Intangible assets under development (62.25) (110.44) (72.39) Net Cash inflow from Investing Activities (B) (731.63) (755.60) (884.38)
C CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from borrowings 378.02 603.70 619.05 Repayment of borrowings (200.00) (604.39)
Net increase / (decrease) in working capital demand loans 431.37 221.35 - Payment of lease liabilities (17.49) -
Increase in Restricted Bank Balances other than Cash &
Cash Equivalents
(0.02) (0.38) 0.35
Dividends paid (including distribution tax) (325.97) (90.91) (90.76) Interest and other finance costs (including borrowing cost
capitalised)
(111.06) (70.34) (26.02)
Net Cash inflow from Financing Activities (C) 154.85 59.04 502.63
I. Net (decrease)/increase in cash and cash equivalents
(A+B+C)
(127.64) 115.40 (69.34)
II. (a) Cash and cash equivalents at the beginning of the
Year
199.07 83.74 153.08
(b) Effect of exchange differences on restatement of
foreign currency cash and cash equivalents
0.41 (0.07) -
III. Cash and cash equivalents at the end of the Year (I+II) 71.84 199.07 83.74
IV. Cash and cash equivalents at the end of the Year
Balances with Banks 71.48 198.84 83.41
34
Particulars
For the year
ended March
31, 2020
For the year
ended
March 31,
2019
For the year
ended March
31, 2018
Cash on hand 0.36 0.23 0.34 Cash and cash equivalents 71.84 199.07 83.74
35
RISK FACTORS
This section should also be read together with the sections titled “Our Business”, “Industry Overview”,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and “Financial
Statements” on pages 73, 93, 106 and 180 respectively, as well as the other financial information included in this
Placement Document.
An investment in equity shares involves a high degree of risk. Investors should carefully consider all the
information disclosed in this Placement Document, including the risks and uncertainties described below, before
making any investment decision relating to the Equity Shares or the Issue. The risks described below are those
that we consider to be the most significant to our business, results of operations and financial conditions as on
the date of this Placement Document. However, these are not the only risks relevant to us or the Equity Shares or
the pharmaceutical sector in which we currently operate. Additional risks and uncertainties, not presently known
to us or that we currently deem immaterial may also impair our business prospects, results of operations and
financial condition in the future. If any or some combination of the risks described below, or other risks that are
not currently known or are currently deemed immaterial actually occur, our business prospects, results of
operations and financial condition could be adversely affected, the trading price of the Equity Shares could
decline, and investors may lose all or part of the value of their investment.
Any potential Investor should pay particular attention to the fact that we are subject to a highly regulated sector
in India and abroad. The financial and other related implications of the risk factors, wherever quantifiable, have
been disclosed in the risk factors mentioned below. However, there are certain risk factors where the financial
impact is not quantifiable and, therefore, cannot be disclosed in such risk factors. In making an investment
decision, prospective investors must rely on their own examination of us on a consolidated basis and the terms of
the Issue, including the merits and risks involved. Investors should consult their respective tax, financial and legal
advisors about the particular consequences of an investment in this Issue.
This Placement Document also contains forward-looking statements that involve risks and uncertainties. Our
actual results could differ materially from those anticipated in these forward-looking statements as a result of
certain factors, including the considerations described below and elsewhere in this Placement Document. For
further information, see “Forward-Looking Statements” on page 14.
INTERNAL RISK FACTORS
1. The pharmaceutical industry is heavily regulated and our business activities require various approvals,
licenses, registrations and permissions, both in domestic as well as in overseas jurisdictions in which we
operate. If there is any change to such regulatory architecture to our disadvantage, our business,
financial condition and results of operations may be adversely affected.
The development, testing, manufacturing, marketing and sale of pharmaceutical products are subject to
extensive regulation in India as well as in overseas jurisdictions in which we operate. Our products, as well
as the facilities where we manufacture them, require extensive testing, government reviews and approvals
before they can be marketed. To conduct our business, we need product registrations and other approvals
granted by authorities in India, the United States and various other countries’ foreign governmental
authorities and health regulatory bodies. The cost and time taken to acquire such authorizations and
approvals in a timely and regular manner is substantial. Governmental authorities in India, the United States
and other countries to which we supply our products, impose different rules and regulations on research,
development, manufacture, and testing to ensure the safety of pharmaceutical products. There can be delays
in obtaining required clearances from regulatory authorities of these countries after applications are filed,
especially in the U.S.A, wherein lies a significant portion of our operations. Whether or not a product is
approved in India, regulatory authorities in most of the markets to which we export products must approve
that product before we can begin to supply it to those countries. Any failure or delay in obtaining regulatory
approvals, or the implementation of any new standards or conditions for obtaining such approvals, or
maintaining or renewing the existing permits and approvals, could impact the supply and marketing of our
products in a timely manner and, in turn, affect our financial condition and results of operations. Further,
failure to maintain compliance with regulatory requirements may also result in administrative actions, such
as fines, warning letters, refusal to approve pending applications (including ANDA filings), product
seizures, refusal to permit the import of products into the destination country, or restrictions on marketing
or manufacturing. For risks associated with failure to renew, maintain or obtain permits or approvals
required to operate our manufacturing facilities and sale of products in India, see “We require a large
36
number of approvals and licenses in the ordinary course of business, and the failure to obtain or retain
them in a timely manner may adversely affect our business and financial condition and results of
operations” on page 47. Additionally, existing regimes in relation to available tax benefits are subject to
change unfavorably in the future, which may in turn adversely affect our business prospects in India and in
overseas jurisdictions.
Further, there may also be uncertainty relating to pricing and other regulations which vary widely from
country to country. The regulations applicable to our existing and future products may also change. Any
change in the regulations, enforcement procedures or regulatory policies set by the USFDA, MHRA (U.K),
TGA (Australia), ANVISA (Brazil), DCGI (CDSCO, India) , HPCD (Canada), EDQM, Bahagian
Regulatori Farmasi Negara (Malaysia) and other regulatory agencies could increase the costs or time of
development of our products and delay or prevent sales of our products. We cannot determine what effect
changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or
adopted, may have on our business in the future.
2. In the United States and many of the international markets in which we sell our products, the approval
process for a new product can be complex, lengthy and expensive. If we fail to obtain such approvals in
a timely and cost efficient manner, or at all, our business, prospects, results of operations and financial
condition could be adversely affected.
Our international generics business contributed to 53.69% of our total revenue from operations as on March
31, 2020. In the United States and many of the international markets in which we sell our products, the
approval process for a new product can be complex, lengthy and expensive. The time taken to obtain
approvals varies by country but generally takes between six months and several years from the date of
application.
If we fail to comply with applicable statutory or regulatory requirements, there could be a delay in the
submission or grant of approval for marketing new products. Moreover, if we fail to comply with the
conditions attached to such approvals, licenses, registrations and permissions once received, the relevant
regulatory body may suspend, curtail or revoke our ability to market such products. Further, we may be
required to defend our applications in a legal proceeding or otherwise, which may lead to an increase in
time or costs for obtaining such approvals. If we fail to obtain such approvals, licenses, registrations and
permissions, in a timely and cost efficient manner or at all, our business, prospects, results of operations
and financial condition could be adversely affected.
Further, we market our products in various countries overseas, where we are subject to risks related to
complying with a wide variety of local laws, including restrictions on the import and export of certain
intermediates, drugs, technologies and multiple and possibly overlapping tax structures. In many
jurisdictions, the regulatory requirements are still evolving and are subject to changes which may, at times,
be unclear or inconsistent. If we fail to comply with such regulations, it could lead to restrictions on sale of
products, enforced shutdowns and other sanctions imposed by relevant authorities, as well as the
withholding or delay in receipt of regulatory approvals for our new products.
3. Our markets are highly competitive, both globally and domestically, and if we are unable to compete
successfully against existing or new competitors, our revenues could decline and our future profitability
could be affected.
The international generics market and the domestic formulations markets are both highly competitive.
Players in these industries face high entry barriers such as high capital investments, operational costs,
manufacturing complexities, stricter compliance requirement (because of the sterile nature of products) and
high-quality standards resulting in limited competition in the market. Growing competition in the domestic
and/or international markets may subject us to pricing pressures and require us to reduce the prices of our
products and services in order to retain or attract customers, which may have a material adverse effect on
our revenues and profit margins. Our competitors may have access to greater financial, marketing, technical
and other resources. As a result, they may be able to devote more resources to the research and
development, manufacture, marketing and sale of their products, receive more support from independent
distributors, initiate or withstand substantial price competition or more readily take advantage of acquisition
or other opportunities.
In addition to competition from established market participants, new entrants to the markets in which we
37
operate, could substantially reduce our market share or make our products commercially unviable. Most of
our international products are generic versions of branded products and we are dependent on the loss of
patent protection and exclusivity of such products for the commercialization of our products. As patents
for branded products and related exclusivity periods expire or are ruled invalid, the first generic
pharmaceutical manufacturer to receive regulatory approval for a generic version of the reference product
is generally able to achieve significant market penetration and higher margins on that product as such
manufacturer will be granted a 180-day period of marketing exclusivity by the USFDA. As competing
generic manufacturers receive regulatory approval on specific product, market share, revenue and gross
profit typically decline for the original generic entrant. In addition, as more competitors enter into a specific
generic market, the average selling price per unit dose of the particular product typically declines for all
competitors. Our ability to sustain our level of market share, revenue and gross profit attributable to a
particular generic pharmaceutical product is significantly influenced by the number of competitors in that
product’s market and the timing of that product’s regulatory approval and launch in relation to competing
approvals and launches.
The launch of our generic products could also be delayed because branded drug manufacturers may, among
other things: make last minute modifications to existing product claims and labels, thereby requiring
generic products to reflect this change prior to the drug being approved and introduced in the market; file
new patents for existing products prior to the expiration of a previously issued patent, which could extend
patent protection for additional years; file patent infringement suits which may result in delay for a specific
period in the approval of generic versions by the relevant authorities; develop and market their own generic
versions of their products, either directly or through other generic pharmaceutical companies, which are
known as authorised generics; make changes in the overall product formulation, which would require fresh
development and approval processes for such products; and switch product availability from a prescription-
only to an over-the-counter basis, which would require relabeling and further regulatory approvals.
4. Any manufacturing or quality control problems may damage our reputation and expose us to litigation
or other liabilities, which could adversely affect our results of operations and financial condition.
We are required to meet stringent quality standards and specifications for manufacturing and storage of our
products. We are liable for the quality of our products for the entire duration of the shelf life of the product
and are exposed to claims resulting from quality control issues including manufacturing defects or
negligence in storage or handling, which may lead to the deterioration of our products.
In certain foreign jurisdictions, the quantum of damages, especially punitive, awarded in cases of product
liability can be extremely high. After our products reach the market, certain developments could adversely
affect demand for our products, including the regulatory review of products that are already marketed, new
scientific information, greater scrutiny in advertising and promotion, the discovery of previously unknown
side effects or the recall or loss of approval of products that we manufacture, market or sell.
The existence, or even threat, of a major product liability claim could damage the brand image of our
products, our reputation and affect consumers’ views of our other products. These and any other adverse
associations with our products, including with respect to their efficacy, side effects, regulatory actions
against our products, and adverse publicity arising thereto, may adversely affect our business, results of
operations and financial condition. Any loss of our reputation or brand image may adversely affect our
ability to enter into additional business contracts in the future.
For further details, please refer to “We are susceptible to product liability claims and associated risks of
litigation that could expose us to material liabilities, loss in revenues and increased expenses and thus may
have a material adverse effect on our business and financial condition. Failure to obtain product liability
insurance may result in us being compelled to pay substantial damages” on page 38.
5. Our success is dependent on our sales and distribution arrangements with our distributors and
customers for the sale of our products. If any of these arrangements is terminated for any reason, or if
our distributors or marketing partners fail to fulfill their obligations under the relevant agreements or
otherwise do not effectively sell or market our products, or if our relationships with any of our
distributors and customers are disrupted, our business, financial condition and results of operations may
be adversely affected.
In India, we supply products to distributors. In markets such as the United States and Europe, our primary
business model is B2B. We market and distribute our products either directly through our Subsidiaries or
38
indirectly, through supply, distribution and other arrangements with various global companies and local
distributors.
In relation to our B2B business model, our success in many markets depends on our B2B distributors, in
particular their sales expertise and relationships with their end customers. Accordingly, the performance of
our distributors and their ability to reach out to treatment providers and promote our products are crucial
to the future growth of our business. Our distributors may not continue to be successful in marketing and
promoting our products. They may terminate their relationships with us, or may fail to commit the
necessary resources to purchase and market our products to the level of our expectations. Our customers
also can terminate their agreement with us for a particular product if the market authorisation cannot be
obtained by such customer due to a technical deficiency or a breach of other obligations attributed to the
dossier owned by the Company. Our reliance on our distributors may also make it more difficult for us to
accurately forecast the results of our operations.
Our dependence on partnerships with our B2B distributors to market some of our products may subject us
to a number of risks, including:
• not being able to control the amount and timing of resources that these partners may devote to the
marketing of our products; and
• significant changes in their business strategy that may adversely affect their willingness or ability to
fulfill its obligations under any arrangement.
Additionally, the B2B distributors we work with may make important marketing and other commercial
decisions concerning our products without our input. As a result of these arrangements, some of the
variables that may affect our business are not exclusively within our control. Further, our arrangements
with these partners may be terminated upon breach of contractual obligation. We may not be able to
renegotiate these contract arrangements on reasonable terms or find suitable alternatives in the future. In
addition, if we fail to maintain our relationships with these distributors, or they decide to increase their in-
house development or production capabilities, licensing of and marketing for our products and pipeline
could be adversely affected, demand for our products could decrease and our business could be materially
and adversely affected. As a result, our reliance on, and inability to control these B2B distributors on whom
we rely for the sale and marketing of our products could adversely affect our business, financial condition
and results of operations.
6. If our API production is interrupted or we fail to produce or procure high-quality API in the quantities
we require in a cost-effective manner, sales of our products could be delayed or interrupted.
The manufacture of APIs is complex, and we may experience problems during the manufacture of APIs
for a variety of reasons, including equipment malfunction, failure to follow specific protocols and
procedures, manufacturing quality concerns, problems with raw materials, lack of technical know-how,
natural disaster related events or other environmental factors. If our vendors fail to provide the raw
materials or technical know-how required for APIs for any reason, or supply to our competitors, our
manufacture of APIs could be disrupted, which in turn may delay or interrupt the production of our
formulations. Similarly, if any approval or license for our APIs production facilities is suspended, the
production and supply of APIs could be adversely affected. We also procure APIs that are not manufactured
in-house by us externally from our vendors If, for any reason, we are unable to produce ourselves or procure
from our vendors sufficient quantities of APIs on a timely basis (including for reasons beyond our
reasonable control), the manufacture or supply of our products or exhibit batches could be disrupted, which
may decrease our sales revenue or otherwise negatively impact our operations. Additionally, if we are
unable to continue to produce APIs in a relatively cost-effective manner for reasons such as increases in
the material input costs and labour costs, the increased production cost may erode some of our competitive
advantage, increase our operating expenses and reduce our profit margins.
7. We are susceptible to product liability claims and associated risks of litigation that could expose us to
material liabilities, loss in revenues and increased expenses and thus may have a material adverse effect
on our business and financial condition. Failure to obtain product liability insurance may result in us
being compelled to pay substantial damages.
Our business exposes us to claims for injuries allegedly resulting from the use of our products. We may be
held liable for, or incur costs related to, liability claims if any of our products causes injury or is found
39
unsuitable during development, manufacture, sale or use. These risks exist even with respect to products
that have received, or may in the future receive, regulatory approval for commercial use. For example, our
products may have expired or cause side-effects to consumers or lack adequate efficacy. In the event our
products cause or are perceived to cause severe side effects, the sales of such products may decrease, which
may have an adverse effect on our revenues and profitability.
We have experienced cases of voluntary product recalls in the last ten years. In a recent case of a voluntary
product recall in June 2020, 19,153 bottles of Aripiprazole tablets marketed by us in the US, were recalled
by us for a labelling mix up. In foreign jurisdictions, such as the United States, in which we intend to
expand further for future sale and distribution of our products, precedents show that the quantum of
damages, especially punitive, awarded in cases of product liability is extremely high. Deterioration in our
quality controls could also result in product liability claims against us.
Actual or claimed defects in our manufacturing facilities and/or product quality could give rise to claims,
liabilities, costs and expenses, relating to loss of life, personal injury, damage to property, damage to
equipment and facilities, inefficient operating processes, loss of production or suspension of operations. If
a supplier fails to meet quality standards, it could also expose us to the risk of product liability claims. If
we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities. The consequential liabilities and costs could have a material adverse effect on our business,
financial condition and results of operations. Moreover, while our Company maintains a comprehensive
general liability insurance, which covers product liability claims, any unsuccessful product liability claims
would likely require us to spend money on litigation, divert management’s time, damage our reputation
and impair the marketability of our products.
8. The COVID-19 pandemic, or any future pandemic or widespread public health emergency, could
materially and adversely impact our business, financial condition and results of operations.
Since first being reported in December 2019, the outbreak of COVID-19 has spread globally. The World
Health Organization declared the outbreak of COVID-19 to be a public health emergency of international
concern on January 30, 2020, and a global pandemic on March 11, 2020.
The COVID-19 pandemic has had, and any future pandemic or widespread public health emergency could
have, repercussions across regional and global economies and financial markets. The outbreak of COVID-
19 in many countries, including India and the United States, has significantly and adversely impacted
economic activity and has contributed to significant volatility and negative pressure in financial markets,
and it is possible that the outbreak of COVID-19 will cause a prolonged global economic crisis, recession
or depression, despite monetary and fiscal interventions by governments and central banks globally.
While we believe that our business has not been adversely impacted by the current wave of the pandemic,
the global impact of the outbreak has been rapidly evolving. As cases of COVID-19 have continued to be
identified in additional countries, many jurisdictions, including the governments of India, the United States
and the other markets in which we conduct business, have reacted by instituting restrictive measures
including invoking lock downs and quarantines, requiring the closure of non-essential businesses and
placing restrictions on the types of businesses that may continue to operate, mandating restrictions on travel,
implementing “shelter-in-place” rules and “stay-at-home” orders, and enforcing remote working
regulations. No prediction can be made of when any of the restrictions currently in place will be relaxed or
expire, or whether or when further restrictions will be announced. Although some governments are
beginning to ease or lift these restrictions, the impacts from the severe disruptions caused by the effective
shutdown of large segments of the global economy remain unknown.
On March 24, 2020, the Government of India ordered a national lockdown in response to the spread of
COVID-19. Our business was determined to be operating in an essential industry, which allowed us to
continue our operations subsequent to the introduction of the lockdown in India, subject to certain
adjustments in working patterns, however, there can be no assurance that further restrictions will not be
introduced or that we will continue to retain such essential status.
There can be no assurance that there will not be any material impact on our operations if the outbreak of
COVID-19 is not effectively controlled. Further, we may be required to quarantine employees that are
suspected of being infected of COVID-19, as well as others that have come into contact with those
employees or shut down our manufacturing facilities which could have an adverse effect on our business
40
operations. If any of our suppliers (including suppliers from whom we source raw materials from
international markets) are affected by COVID-19 to the extent our supply chain is disrupted, this may affect
our ability to meet the demand of our customers.
The full extent to which the COVID-19 pandemic, or any future pandemic or widespread public health
emergency impacts our business, operations and financial results will depend on numerous evolving factors
that we may not be able to accurately predict at this time, including: the scope, severity, and duration of the
pandemic; actions taken by governments, business and individuals in response to the pandemic; the effect
on customer demand for and ability to pay for our products; the impact on our capital expenditure and drug
development projects; disruptions or restrictions on our employees’ and suppliers’ ability to work and
travel; volatility in foreign exchange rates; any extended period of remote work arrangements; and strain
on our or our customers’ business continuity plans, and resultant operational risk.
9. Decreased opportunities to obtain United States market exclusivity products may adversely affect our
revenues and profits.
In the United States, we aspire to focus on those formulations/products which are either difficult to
formulate / manufacture and has limited competition. We derived 42.90%, 32.73% and 29.39% of our
revenue from operations during Fiscals 2020, 2019 and 2018, respectively, from the formulations sales
within the United States. Our ability to achieve continued growth and profitability through sales of generic
pharmaceuticals is dependent on our success in challenging patents, developing non-infringing products or
developing products with increased complexity to provide opportunities with United States market
exclusivity or limited competition. The failure to continue to develop such opportunities could adversely
affect our sales and profitability. To the extent that we succeed in being the first to market a generic version
of a branded product, and particularly if we are the only company authorized to sell during the 180-day
period of exclusivity granted by the USFDA, as provided under the Drug Price Competition and Patent
Term Restoration Act of 1984 (the “Hatch-Waxman Act”), our sales, profits and profitability can be
substantially increased in the period following the introduction of such product and prior to a competitor’s
introduction of an equivalent product. Even after the exclusivity period ends, there is often continuing
benefit from being the first generic product in the market. However, we believe that the number of
significant new generic products for which exclusivity is available, and the size of those product
opportunities, has decreased in recent years. Additionally, increasingly we share the 180-day exclusivity
period with other generic competitors, which diminishes the commercial value of the exclusivity. The 180-
day market exclusivity period is triggered by commercial marketing of the generic product or, in certain
cases, can be triggered by a final court decision that is no longer subject to appeal holding the applicable
patents to be invalid, unenforceable or not infringed. However, the exclusivity period can be forfeited by
our failure to obtain tentative approval of our product within a specified statutory period or to launch a
product following such a court decision. The Hatch-Waxman Act also contains other forfeiture provisions
that may deprive the first Paragraph IV filer of exclusivity if certain conditions are not met, some of which
may be outside our control. Accordingly, we may face the risk that our exclusivity period is forfeited before
we are able to commercialize a product and therefore may not be able to exploit a given exclusivity period
for specific products.
10. We derive a significant portion of our revenues from operations in the United States market, from a few
customers. A loss of one or more such significant customers or a reduction in their demand for products
could adversely affect our business, financial condition and results of operations.
We derive a significant portion of our net revenues from operations in the United States market from a few
customers. The loss of one or more of these significant customers or a reduction in the amount of business
we obtain from them could have an adverse effect on our business, financial condition and results of
operations. We cannot assure you that we will be able to maintain historic levels of business from our
significant customers or that we will be able to significantly reduce customer concentration in the future.
11. We may not be able to sustain effective implementation of our business and growth strategy, which may
adversely affect our business and results of operations.
The success of our business will depend greatly on our ability to effectively implement our business and
growth strategy. For further details, please see “Our Business – Our Strategies” on page 109.
In pursing our growth strategy, we will require additional capital investments and cash outlays, which may
have a material impact on our results of operations. As our product portfolio and product pipeline grow,
41
we may require additional personnel on our project management, in-house quality assurance and R&D
teams to work with our partners on quality assurance, regulatory affairs and product development. As a
result, our operating expenses and capital requirements may increase significantly. Our ability to manage
our growth effectively requires us to forecast accurately our sales, growth and manufacturing capacity and
to expend funds to improve our operational, financial and management controls, reporting systems and
procedures. We may also be exposed to certain other risks, including difficulties arising from operating a
larger and more complex organisation; the failure to (i) efficiently and optimally allocate management,
technology and other resources across our organisation, (ii) compete effectively with competitors and (iii)
increase our production capacity; the inability to control our costs; and unforeseen legal, regulatory,
property, labour or other issues.
For instance, as we continue our growth by expanding our manufacturing facilities and introducing new
products, the construction of new manufacturing facilities and the expansion of existing manufacturing
facilities are capital intensive, require significant time and are subject to certain risks that could result in
delays or cost overruns, which could require us to expend additional capital and adversely affect our
business and operating results. Such potential events include shortages and late delivery of building
materials and facility equipment; delays in the delivery, installation, commissioning and qualification of
our manufacturing equipment; seasonal factors, such as a long and intensive wet season that limits
construction; labour disputes; design or construction changes with respect to building spaces or equipment
layout; delays or failure in securing the necessary governmental approvals, building sites or land use rights;
and technological capacity and other changes to our plans for new manufacturing facilities necessitated by
changes in market conditions. Delays in the construction or expansion of any of our manufacturing facilities
could result in a loss or delayed receipt of earnings and an increase in financing costs which would
adversely affect our business and results of operations.
Additionally, if our existing manufacturing facilities are harmed or rendered inoperable by factors such as
increased competition as more players enter into these geographies, general economic conditions, laws and
regulations, both Indian and international, and other natural or man-made disasters, including earthquakes,
fire, floods, acts of terrorism and power outages, it may render it difficult or impossible for us to efficiently
operate our business for some time, or require us to shut major part of our operations, which may adversely
affect our business, financial condition, result of operations and cash flows. For instance, in Fiscal 2018, a
fire broke out in our facility in Algeria, maintained through our Joint Venture, Alembic Mami SPA, leading
to a complete destruction of the facility. Subsequently, in Fiscal 2020, our Company has fully provided for
the diminution in value of investment in Alembic Mami SPA. Our Company does not carry any further
liability towards Alembic Mami SPA or third party on account of this arrangement. We cannot assure you
that any such future force majeure instances will not have a material adverse effect on our business,
financial condition, result of operations.
There can be no assurance that our growth strategy will be successfully implemented or completed or that
if completed, they will result in the anticipated growth in our revenues or improvement in our results of
operations. We also cannot assure you that we will be able to continue to expand further, or at the same
rate. Our ability to invest in overseas or Indian companies may be constrained by Indian and foreign laws.
Further, we expect our growth strategy to place significant demands on our management, financial and
other resources and require us to continue developing and improving our operational, financial and other
internal controls. We cannot assure you that our existing or future management, operational and financial
systems, procedures and controls will be adequate to support future operations or establish or develop
business relationships beneficial to future operations. Failure to manage growth effectively may have an
adverse effect on our business, results of operations and prospects.
12. We intend to selectively pursue Paragraph IV filing opportunities in the United States, which may not
be successful, may result in extensive and expensive litigation which we may not be successful in
defending, and which may adversely affect our business, prospects, results of operations and financial
condition.
A Paragraph IV filing in the United States is made when an ANDA applicant believes its product or the
use of its product does not infringe on patents or where the applicant believes that such patents are not valid
or enforceable. If successful, Paragraph IV filings enable the filer to launch the product in the United States
prior to the expiry of the patent and could include the grant of a 180 day exclusivity period for marketing
the generic product. These products are often difficult and expensive to manufacture. Innovators will often
seek to restrict or will challenge the grant of a successful Paragraph IV filing which, if determined against
42
the ANDA applicant, may result in expensive litigation.
We may elect to market a generic product before any court decision is rendered or while an appeal from a
lower court decision is pending. If the final court decision is adverse to us, we could be required to cease
sales of the infringing products and face substantial liability for patent infringement. These damages may
be significant as they may be measured differently in various jurisdictions, including by royalties on our
sales or by the profits lost by the patent owner.
13. Our business success depends on the strength of our brand, product image and reputation. Any failure
to maintain and enhance, or any damage to, our brand, product image or reputation could materially
and adversely affect the level of market recognition of, and trust in, our products.
We consider that our success depends to a significant extent on our brand, product image and reputation.
If we or those distributors who operate under our brand fail to maintain and enhance, or if there is any
damage to, our or our distributors’ brand image or reputation, the demand for our products may be
materially and adversely affected.
Many factors that are important to maintaining and enhancing our brand, product image and reputation are
not entirely within our control, and such factors may materially and adversely affect our brand, product
image and reputation. Such factors include, among other things, our ability to continue to:
• effectively control our product quality and effectiveness;
• increase brand recognition among existing and potential customers through various means of
marketing and promotional activities; and
• effectively protect our trademarks and trade names.
Furthermore, any negative publicity in relation to our products can damage our brand, product image and
reputation. It is an inherent business risk that the treatments using our products may lead to undesirable or
unexpected outcomes, including complications, injuries and even deaths in extreme cases. Such undesirable
or unexpected outcomes may lead to complaints, claims, and/or legal actions against us which may
materially and adversely affect our brand, product image and reputation.
14. We rely substantially on Alembic Pharmaceuticals Inc, our subsidiary in the United States, to generate
earnings from the United States and any decline in its earnings could adversely affect our results of
operations.
We undertake a significant volume of our operations in the United States through Alembic Pharmaceuticals
Inc, our subsidiary, on whom we are entirely dependent for our business earnings at a consolidated level.
We cannot assure you that our Material Subsidiary will generate sufficient earnings and cash flows to pay
dividends or otherwise distribute sufficient funds to enable us to meet our obligations, pay interest and
expenses or declare dividends.
15. We have incurred significant capital expenditure during the last three Fiscals.
During Fiscal 2020, 2019 and 2018, we incurred capital expenditure of ₹ 897.48 crore, ₹ 818.27 crore and
₹ 922.83 crore, respectively. A significant amount of our capital expenditure was aimed at increasing our
manufacturing and research capabilities and capacities.
There can be no assurance that our expansion plans will be implemented as planned or on schedule, or that
we will achieve our increased planned output capacity or operational efficiency. If we experience
significant delays or mishaps in the implementation of the expansion plans or if there are significant cost
overruns, then the overall benefit of such plans to our revenues and profitability may decline. To the extent
that the planned expansion does no produce anticipated or desired output, revenue or cost-reduction
outcomes, our profitability and financial condition will be adversely affected.
16. Our ability to invest in overseas subsidiaries and joint ventures may be constrained by Indian and foreign
laws, which could adversely affect our growth strategy and business prospects.
Under Indian foreign investment laws, an Indian company is permitted to invest in overseas joint ventures
43
or wholly owned subsidiaries, upto a certain specific threshold of the Indian company's net worth as at the
date of its last audited balance sheet (subject to certain exceptions), and any financial commitment
exceeding USD 1 billion (or its equivalent) in a financial year will require prior approval of the RBI, even
if the total financial commitment of the Indian company is within the aforementioned limit. This limitation
also applies to any other form of financial commitment by the Indian company, including in terms of any
loan, guarantee or counter guarantee issued by such Indian company. Further, there may be limitations
stipulated in the host country for foreign investment.
Investment or financial commitment not complying with the stipulated requirements is permitted with prior
approval of the RBI. Additionally, there are also further requirements specified under the Companies Act,
2013 in relation to any acquisition that we propose to undertake in the future. These limitations on overseas
direct investment could constrain our ability to acquire or increase our stake in overseas entities as well as
to provide other forms of financial assistance or support to such entities, which may adversely affect our
growth strategy and business prospects.
17. If we are unable to protect our intellectual property and proprietary information (including process
patents and trademarks), or if we infringe the intellectual property rights of others, our business,
financial condition and results of operations may be adversely affected.
As of June 30, 2020, we owned 574 registered trademarks, including our logo. We have trademark
applications pending, any of which may be subject to governmental or third-party objection, which could
prevent the maintenance or issuance of the same. Further, we also market certain products wherein we have
not obtained any trademark protection. While we are a generics player, we also enjoy a certain degree of
process patent protection. We have been granted 911 patents worldwide (for both APIs and formulations),
including patents which have been withdrawn, abandoned or have lapsed, as of March 31, 2020.
We may not always be able to safeguard our intellectual property from infringement or passing off, both
domestically and internationally, since we have operations in several countries and may not be able to
respond to infringement or passing off activity occurring without our knowledge. Further, we are also
subject to the risk arising from our patents being challenged, annulled or violated. Certain proprietary
knowledge may be leaked, either inadvertently or willfully, at various stages of the production process. In
the event that the confidential technical or proprietary information in respect of our products or business
becomes available to third parties or to the general public, any competitive advantage we may have over
other companies in the generics industry could be compromised. Moreover, our existing trademarks and
patents may expire, and there can be no assurance that we will renew them after expiry.
We seek to launch generic pharmaceutical products either where patent protection or other regulatory
exclusivity of equivalent branded products have expired, where patents have been declared invalid or where
products do not infringe on the patents of others. However, due to our marketing and distribution activities
in many parts of the world, we may manufacture or sell products that may infringe intellectual property
rights of others that could subject us to potentially high-value claims for infringement. The manufacture
use and sale of generic versions of products has been subject to substantial litigation in the pharmaceutical
industry which mostly relate to the validity and infringement of patents or proprietary rights of third parties.
If our products were found to be infringing on the intellectual property rights of a third-party, we could be
required to cease selling the infringing products, causing us to lose future sales revenue from such products
and face substantial liabilities for patent infringement, in the form of either payment for the innovator’s lost
profits or a royalty on our sales of the infringing product. Any litigation, regardless of the merits or eventual
outcome, would be costly and time consuming and we could incur significant costs and/or a significant
reduction in revenue in defending the action and from the resulting delays in manufacturing, marketing or
selling any of our products subject to such claims. Our insurance cover may also not extend to these claims
or sufficiently cover them.
18. The availability of counterfeit drugs, such as drugs manufactured by other companies and passed off as
our products, could adversely affect our goodwill and results of operations.
Entities in India and abroad could pass off their own products as ours, including counterfeit or pirated
products. For example, certain entities could imitate our brand name, packaging materials or attempt to
create look-alike products. As a result, our market share could be reduced due to replacement of demand
for our products and decreases in our goodwill and the market registration of our products. The proliferation
of unauthorized copies of our products, and the time and attention lost to defending claims and complaints
44
about spurious products, could decrease our revenue and have an adverse effect on our goodwill, financial
condition and results of operations.
19. If we inadvertently infringe on the patents of others, our business may be adversely affected.
We operate in an industry characterized by extensive patent litigation, including both litigation by innovator
companies relating to purported infringement of innovative products and processes by generic
pharmaceuticals and litigation by competitors or innovator companies to delay the entry of a product into
a market. Patent litigation can result in significant damages being awarded and injunctions that could
prevent the manufacture and sale of certain products or require us to pay significant royalties in order to
manufacture or sell such products. While it is not possible to predict the outcome of patent litigation, we
believe any adverse result of such litigation could include an injunction preventing us from selling our
products or payment of significant damages or royalty, which would affect our ability to sell current or
future products or prohibit us from enforcing our patent and proprietary rights against others. The
occurrence of any of these risks could adversely affect our business, financial condition and results of
operations.
20. Our business subjects us to various operational risks in multiple countries that could materially
adversely affect our business, results of operations and prospects.
We have a presence and sell our products in over 65 countries including the United States, India, Europe,
Canada, Australia, Brazil and South Africa. As a result of our existing and expanding international
operations, we are subject to risks inherent to establishing and conducting operations on an international
scale, including:
• cost structures and language factors associated with managing and coordinating our international
operations;
• compliance with a wide range of regulatory requirements, foreign laws, including immigration,
labour and tax laws;
• ability to obtain the necessary approval from Indian authorities, the USFDA and other foreign
regulatory authorities, as applicable, for the products which we intend to sell;
• difficulty in managing foreign operations;
• potential difficulties with respect to protection of our intellectual property rights in some countries
which may result in infringement by others of our intellectual property rights;
• social, economic, political, geopolitical conditions and adverse weather conditions, such as natural
disasters, civil disturbance, terrorist attacks, war or other military action;
• outbreaks of diseases, such as COVID-19, resulting in a widespread health crisis; and
• fluctuation in the exchange rate.
The growth in size or scope of our business, expansion of our footprint in existing regions in which we
operate and entry into new markets also will expose us to regulatory regimes with which we have no prior
direct experience and expansion into new product areas could lead to our becoming subject to additional
or different laws and regulations. If any of these risks materialise, it could have a material adverse effect
on our business, results of operations and prospects.
21. A majority of our Indian manufacturing facilities are located in the State of Gujarat and due to such
geographical concentration, are subject to risks pertaining to disruptions in or lack of basic
infrastructure, which could increase our manufacturing costs or interrupt our operations.
A majority of our manufacturing units are located at different locations in the state of Gujarat. Accordingly,
we are exposed to risks including regulatory changes, natural or man-made disasters, political agitations,
workforce disruptions and disruptions in infrastructure facilities, such as power, water and other utilities,
45
to majority of our Indian manufacturing facilities. Such disruptions could require us to limit or cease
production at our manufacturing facilities or incur additional costs towards upgrading our units or to find
alternatives sources to manufacture our products, which we may not be able to obtain in a timely manner,
or at all. Such events may have an adverse effect on our business, financial condition or results of
operations.
22. We depend on third-party vendors for raw materials and services, any disruption, deficiency in service or
increase in cost of which could adversely affect our business and results of operations.
We depend on third-party vendors and suppliers for a number of services and raw materials including timely
supply of specified raw materials, equipment, contract manufacturing, formulation or packaging services
and maintenance services. We expect our reliance on these third-party vendors to continue to increase as
we expand our business. Although we actively manage these third party relationships to ensure continuity
of services and supplies on time and to required specifications, some events beyond our control could result
in these third parties to experience disruptions, provide lower-quality service or increase the prices of their
products or services.
Should we experience a disruption in the supply, or quality, of these services or products, or if such contracts
for services expire, we may not be able to find a replacement or renew our contracts, as the case may be, in
a timely fashion, commercially acceptable terms or at all, or if there are significant increases in the cost of
these supplies (due to factors outside of our control, such as general economic conditions, competition for
resources, production levels, transportation costs, the construction, operation and maintenance of the
transportation infrastructure in the regions in which we operate, and import duties), our business, financial
condition and results of operations may be adversely affected.
23. Stricter marketing norms prescribed by a new code of conduct in India for companies doing business in
the pharmaceuticals industry could affect our ability to effectively market our products which may affect
our profitability.
In December 2014, the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers of the
Government of India announced details of the Uniform Code of Pharmaceutical Marketing Practices
(“UCPMP”), which became effective across India from January 1, 2015. The UCPMP is a voluntary code
which, among other things, provides detailed guidelines about promotional materials, conduct of medical
representatives, physician samples, gifts and relationships with healthcare professionals. For example,
under the UCPMP, pharmaceutical companies may not supply or offer any gifts, pecuniary advantages or
benefits in kind to persons qualified to prescribe or supply drugs. Further, the managing director or the
chief executive officer of the company is responsible for ensuring adherence to the UCPMP and a self-
declaration is required to be submitted by the managing director or the chief executive officer within two
months of the closure of every financial year to the industry association. Although these guidelines are
voluntary in nature, they may be made mandatory in the future and we may be required to spend a
considerable amount of time and resources to conform to the requirements of the UCPMP.
Further, pursuant to a notification dated October 8, 2016, the Indian Medical Council (Professional
Conduct, Etiquette and Ethics) Regulations, 2002 were amended to require that doctors in India are required
to provide prescriptions to patients in terms of generic pharmaceutical names instead of particular brand or
trade names of medicines. Our business relies, in part, on doctors, including specialists and super
specialists, who prescribe our products identified by their brand names, particularly in our chosen
therapeutic areas. In the event doctors, including specialists and super specialists, are unable to or are
restricted from prescribing our brands, the demand for, and volume of sales of, our products may decrease,
which may have an adverse effect on our business, results of operations and financial condition.
24. Patent laws allowing innovator companies to extend their patents could delay the introduction of generic
products and adversely affect our business.
In many countries, patent holders have the option of extending the terms of their patents. The United States
Patent and Trademark Office allows companies to extend the terms of their patents, inter alia to make up
for the time lost while awaiting USFDA approval. The USFDA also allows for exclusivity to be extended
in specific cases. Companies are also known to make additional patents publicly known close to expiry of
a patent for a particular molecule, which effectively extends the patent life and delays competition. If a
company introduced, authorized or assisted another company to bring an authorized generic product to the
46
market, then the generic market value of a product for which we intend to file a patent challenge may be
reduced. The extension of patent terms or the extension of exclusivity in the marketplace by these or other
means may delay our introduction of generic products and may adversely affect our business.
25. Consolidation of pharmaceutical industry participants may affect our ability to effectively compete with
other pharmaceutical companies in the development and sale of products and technologies, which may
adversely affect our business, results of operations and financial condition.
Our competitors, which include major multinational corporations, may consolidate, and the strength of
combined companies could affect our competitive position in all of our business areas. Consolidated
corporations may have greater financial, manufacturing, research and development, marketing and other
resources, broader product ranges and larger, stronger sales forces, which may make them more competitive
than us. Furthermore, if one of our competitors or their customers acquires any of our customers or suppliers,
we may lose business from the customer or lose a supplier of a critical raw material or component, which
may adversely affect our business, results of operations and financial condition.
26. If innovator pharmaceutical companies are successful in limiting the use of generics through their
legislative, regulatory and other efforts, introductions of our generic products may be delayed.
Many pharmaceutical companies increasingly have used state and federal legislative and regulatory means
to delay generic competition.
These efforts have included:
• pursuing new patents for existing products that may be granted just before the expiration of earlier
patents, which could extend patent protection for additional years or otherwise delay the launch of
generics;
• selling the brand product as an authorized generic, either by the brand company directly, through an
affiliate or by a marketing partner;
• attaching patent extension amendments to non-related federal legislation;
• engaging in state-by-state initiatives to enact legislation that restricts the substitution of some generic
drugs, which could have an impact on products that we are developing; and
• seeking patents on methods of manufacturing certain active pharmaceutical ingredients.
If pharmaceutical companies or other third parties are successful in limiting the use of generic products
through these or other means, introductions of our generic products may be delayed, and our business,
prospects, results of operations, and financial condition may be adversely affected.
27. If we do not successfully develop new products or continue our product portfolio expansion in a timely
and cost-effective manner through extensive R&D, our business, financial condition and results of
operations may be adversely affected.
Our future results of operations depend, to a significant degree, on our ability to successfully develop new
products and continue our product portfolio expansion in a timely and cost-effective manner. The
development and commercialization of new products are complex, time-consuming, costly and involves a
high degree of business risk. We may encounter unexpected delays in the launch of these products or these
products, if and when fully commercialized by our distributors, may not perform as we expect.
The success of our new product offerings will depend on several factors, including our ability to properly
anticipate customer needs; obtain timely regulatory approvals; establish collaborations with suppliers and
customers; develop and manufacture our products in a timely and cost-effective manner through our R&D
efforts; and successfully market and sell our products. In addition, the development and commercialization
of new products is characterized by significant upfront costs, including costs associated with R&D, product
development activities, obtaining regulatory approvals, building inventory and sales and marketing.
Furthermore, the development and commercialization of new products is subject to inherent risks, including
the possibility that any new product may:
47
• fail to receive or encounter unexpected delays in obtaining necessary regulatory approvals;
• be difficult or impossible to manufacture on a large scale;
• be uneconomical to market;
• fail to be developed prior to the successful marketing of similar or superior products by third
parties; and
• infringe on the proprietary rights of third parties.
28. We require a large number of approvals and licenses in the ordinary course of business, and the failure
to obtain or retain them in a timely manner may adversely affect our business and financial condition
and results of operations.
We are required to obtain and maintain a number of statutory and regulatory licenses, permits and approvals
for carrying out our business and for each of our manufacturing facilities under various central, state and
local governmental rules and regulations in India and abroad. A majority of these approvals are granted for
a limited duration and require renewal. While we have applied for some of these approvals, we cannot
assure you that such approvals will be issued or granted to us in a timely manner, or at all. If we do not
receive such approvals or are not able to renew the approvals in a timely manner, our business and
operations may be materially adversely affected. For instance, with respect to our domestic formulations
facility in Sikkim, we have made a renewal application to the State Pollution Control Board, Sikkim
(“SPCB”) to obtain consent to operate our facility as well as to handle hazardous wastes, which is pending
grant of renewal on account of COVID-19.
Further, the licenses, permits and approvals required by us are subject to several conditions and we cannot
assure you that we will be able to continuously meet such conditions, which may lead to cancellation,
revocation or suspension of the relevant licenses, permits and approvals. If there is any failure by us to
comply with the applicable regulations or if the regulations governing our business are amended, we may
incur increased compliance costs, be subject to penalties, have our licenses, approvals and permits revoked
or suffer a disruption in our operations, any of which may materially adversely affect our business and
results of operations.
29. Our Company is involved in certain legal proceedings. Any adverse decision in such proceedings may
have an adverse effect on our business, financial condition and results of operations.
We are involved in certain legal proceedings which are pending at different levels of adjudication before
various courts, tribunals and other authorities. We can give no assurance that these legal proceedings will
be decided in our favour. Such proceedings could divert our management’s time and attention and consume
financial resources. Any adverse order or direction in these cases by the concerned authorities even though
not quantifiable, could have an adverse impact on our business and reputation. Any fine or imprisonment
may adversely affect our business, prospects, results of operations and reputation. For further details, please
see “Legal Proceedings” on page 174.
30. We may be required to conduct clinical trials for some of our products in the future. Clinical drug
development involves a lengthy and expensive process with uncertain outcomes, and we may be unable
to achieve successful results in our clinical trials.
Before obtaining regulatory approvals for the sale of some of our drug candidates in the future, we may be
required to conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates
in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete
and are uncertain as to the outcomes. A failure of one or more of our clinical trials can occur at any stage
of testing.
We may also experience numerous adverse events during clinical trials that could delay or prevent our
ability to successfully complete clinical trials, including:
• regulators may not authorise us or our investigators to commence a clinical trial or conduct a clinical
trial at a prospective trial site;
48
• clinical trials of our drug candidates may produce negative or inconclusive results, and we may
decide, or regulators may require us, to conduct additional clinical trials or abandon the relevant
drug development programmes;
• patient enrolment may be insufficient or slower than we anticipate or patients may drop out at a
higher rate than we anticipate;
• we might have to suspend or terminate clinical trials of our drug candidates for various reasons,
including a finding of a lack of clinical response or a finding that participants are being exposed to
unacceptable health risks;
• regulators or ethics committees may require that we or our investigators suspend or terminate clinical
trials for various reasons, including non-compliance with regulatory requirements;
• the cost of clinical trials of our drug candidates may be greater than we anticipate and we may not
be able to obtain sufficient funding to complete our clinical trials;
• the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of
our drug candidates may be insufficient or inadequate; and
• our drug candidates may cause adverse events, have undesirable side effects or other unexpected
characteristics, which cause us or our investigators to suspend or terminate the trials and may have
an adverse financial impact on us.
31. We rely extensively on our operational support systems, including products processing systems and
information technology systems, the failure of which could adversely affect our business, financial
condition and results of operations.
We depend extensively on the capacity and reliability of the quality assurance, quality control, product
development and information technology systems supporting our operations. Our systems are subject to
damage or incapacitation by natural disasters, human error, power loss, sabotage, computer viruses,
hacking, acts of terrorism and similar events or the loss of support services from third parties. Any failure
or disruption in the operation of these systems or the loss of data due to such failure or disruption may
affect our ability to plan, track, record and analyze work in progress and sales, process financial
information, manage product lifecycle, payables and inventory or otherwise conduct our normal business
operations, which may increase our costs and materially adversely affect our business and results of
operations. There can be no assurance that we will not encounter disruptions in the future. Any disruption
in the use of, or damage to, our systems may adversely affect our business, financial condition and results
of operations.
32. Our contracts are governed by the laws of various countries and disputes arising from such contracts
may be subject to the exclusive jurisdiction of courts situated in such countries.
Most of the contracts executed with our distributors and customers are governed by the laws of the country
in which the distributor or customer is incorporated. Further, any disputes related to such contracts may be
subject to the exclusive jurisdiction of courts situated in such countries. Any lawsuits with respect to such
disputes must be instituted in a court having jurisdiction over the contract, which may cause difficulty for
our Company to manage such suits and to obtain enforcement of awards and may also lead to greater costs
for managing such litigation.
33. Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing,
reimbursement and related matters could adversely affect the marketing, pricing and demand for our
products.
Our success will depend in part on the extent to which government and health administration authorities,
private health insurers and other third-party payers will pay for our products. Increasing expenditures for
healthcare has been the subject of considerable public attention in almost every jurisdiction where we
conduct business. Both private and governmental entities are seeking ways to reduce or contain healthcare
costs by limiting both coverage and the level of reimbursement for new therapeutic products. In many
49
countries in which we currently operate, including India, pharmaceutical prices are subject to regulation.
Price controls operate differently in different countries and can cause wide variations in prices between
markets. Currency fluctuations can aggravate these differences. The existence of price controls can limit
the revenues we earn from our products. For example, in India, prices of certain pharmaceutical products
are determined by the Drug (Prices Control) Order, 2013 (“DPCO”), promulgated by the Indian
government and administered by the National Pharmaceutical Pricing Authority (“NPPA”). If the prices
of more of our products are administered or determined by NPPA or other similar authorities outside India,
it would impact our ability to determine pricing for our products, which in turn may have an adverse impact
on our profitability.
34. We are dependent upon the experience and skill of our management team and key employees. If we are
unable to attract and retain qualified personnel, our results of operations may be adversely affected.
Our business and operations are led by a highly qualified, experienced and capable management team. We
are also supported by qualified personnel possessing a range of qualifications in the field of science at
postgraduate and graduate levels, the loss of whose services may significantly delay or prevent the
achievement of our business objectives. Competition among pharmaceutical companies for qualified
employees, particularly R&D personnel, is intense and the ability to retain and attract qualified individuals
is critical to our success.
Our success significantly depends upon the continued service of our management and key personnel. If we
lose the services of any of the management team or key personnel, we may be unable to locate suitable or
qualified replacements, and may incur additional expenses to recruit and train new personnel, which could
adversely affect our business operations and ability to continue to manage and expand our business.
Furthermore, as we expect to continue to expand our operations and develop new products, we will need
to continue to attract and retain experienced management, R&D and sales personnel.
Moreover, we do not maintain key person insurance to insure against the loss of key personnel. There can
be no assurance that we will be able to retain and attract such individuals in the future on acceptable terms,
or at all, and the failure to do so may have an adverse effect on our business, prospects, results of operations
and financial condition.
35. We may not be able to correctly assess the demand for our products, which may adversely affect our
business, financial condition and results of operations.
Our production and distribution processes require us to anticipate the demand for our products based on
the feedback received from our own marketing personnel, distributors and partners. Accurate assessment
of market demand requires significant investment in our sales and marketing network and training of
marketing personnel. There is no guarantee that our estimate of market demand in India or foreign countries
in which we sell our products will be accurate. In the event that we overestimate the demand for our
products, we may have expended resources in manufacturing excess products and paid taxes, export costs,
insurance costs, distribution expenses, storage and warehousing and other related expenditures. Our
products have a limited expiry period and in the event of excess production, we might have to bear the cost
of expiry and destruction of these goods. In the event that we underestimate the market demand, or fail to
order a sufficient volume of supplies and input materials from our third-party suppliers, we may be unable
to meet customer orders and lose out on sales opportunities that our competitors may capitalise on. Failure
to meet customer orders may also occur because existing manufacturing facilities and other equipment do
not have sufficient capacity or we have an inaccurate level of inventory holding. Accordingly, any incorrect
assessment of the demand for our products may adversely affect our business, financial condition and
results of operations.
36. If we fail to keep pace with evolving technological standards in the pharmaceutical industry, create new
products or intellectual property, or respond to changes in market demand or customer requirements,
our business and financial results could be adversely affected.
The pharmaceutical industry is characterized by rapid advancements in technology fueled by high expenses
incurred on R&D. These advancements result in the frequent introduction of new products and significant
price competition. To meet our customers’ needs as well as keep pace with our competitors, we regularly
update existing technology and develop new technology for our pharmaceutical manufacturing activities.
50
However, rapid and frequent advancements in technology and market demand changes can often render
existing technologies and equipment obsolete, requiring substantial new capital expenditures and/or write-
downs of assets. The cost of implementing new technologies and upgrading our manufacturing facilities as
well as R&D could be significant and higher than initially anticipated and could adversely affect our
business, prospects, results of operations and financial condition. In addition, when we develop a new
product or an advanced version of an existing product, we may encounter obstacles that may delay
development and consequently increase our expenses, and we typically incur significant costs and effort
upfront to market, promote and sell the new product offering.
The commercial success of the products and technologies we develop will depend upon the acceptance of
these products by customers and competition in the market. It is difficult for us to predict whether recently
introduced products, or the products that we are currently developing, will be commercially successful. If
our new products or enhancements do not achieve adequate acceptance in the market, this may ultimately
force us to abandon a potential product in which we have already invested substantial time and resources,
and our competitive position will be impaired, our revenue will be diminished and the effect on our
operating results may be particularly acute because of the significant research, development, marketing,
sales and other expenses we will have incurred in connection with the new product or enhancement.
In addition, our competitors may have filed patent applications or hold patents relating to products or
processes which compete with those we are developing. There is no guarantee that our pending applications
will result in any patent being granted, or that the patents we have been granted will result in the
commercialization of products.
37. A relatively small group of products may generate a significant portion of our net revenues from
operations from time to time and our prospects, business, financial condition and results of operations
may be materially and adversely affected if products in these products do not perform as well as expected
or if competing products become available or gain wider market acceptance.
From time to time, sales of a limited number of products may represent a significant portion of our revenues
from operations. At any time, our net revenues from operations from these such products may decline as a
result of increased competition, regulatory action, pricing pressures or fluctuations in the demand for or
supply of such products. Similarly, in the event of any breakthroughs in the development of alternatives,
our products may become obsolete or be substituted by such alternatives. Further in relation to the United
States our revenues may decline as a result increase in competition and price erosion resulting from changes
to the regulatory regime for product approvals and ANDA filings. Any such material adverse developments
with respect to the sale or use of any of our products, or failure to successfully introduce new products,
could adversely affect our business, financial condition and results of operations.
38. If we improperly handle any of the hazardous materials used in our business and accidents result, we
could face significant liabilities that would lower our profits.
In our research and development and manufacturing activities, we handle and use certain hazardous
materials, chemicals, biologics, viruses and other explosive, toxic and combustible materials. If improperly
handled or subjected to the wrong conditions, these materials could hurt our employees and other persons,
cause damage to our properties and harm the environment (including with respect to residential areas
located in close proximity to our manufacturing facilities). For example, laws in India limit the amount of
hazardous and pollutant discharge that our manufacturing facilities may release into the air and water. The
discharge of raw materials that are chemical in nature or of other hazardous substances into the air, soil or
water beyond these limits may cause us to be liable to regulatory bodies or third parties. In addition, we
may be required to incur costs to remedy the damage caused by such discharges, pay fines or other penalties
for non-compliance. Also, increase in business and operations in our plants, and the consequent hiring of
new employees, can pose increased safety hazards. Such hazards need to be addressed through training,
industrial hygiene assessments and other safety measures and, if not carried out, can lead to industrial
accidents. Any of the foregoing could subject us to significant litigation or adversely impact our other
litigation matters then outstanding, which could lower our profits in the event we were found liable, and
could also adversely impact our reputation. In a worst case scenario, this could also result in a government
forced shutdown of our manufacturing plants, which in turn could lead to product shortages that delay or
prevent us from fulfilling our obligations to customers and would harm our business and financial results.
39. The proceeds raised in this Issue are subject to the discretion of our management as well as to market
51
and credit risks, pending utilization.
Although we intend to use the net proceeds received from the Issue in accordance with the “Use of Proceeds”
section on page 66, such use is subject to the discretion of our management. Pending utilization for the
purposes described in the “Use of Proceeds” section in this Placement Document, we intend to temporarily
invest funds in instruments that we deem to be creditworthy, including money market mutual funds and
deposits with banks. Factors such as interest rates, exchange rates and the creditworthiness of the
counterparties, among others, may have an adverse effect on these investments which may result in our
inability to use the proceeds raised in this Issue in the manner indicated.
40. Any future issuance of Equity Shares may dilute prospective investors' shareholding and sales of our
Equity Shares by our Promoters or other major shareholders may adversely affect the trading price of
the Equity Shares.
Any future issuance of Equity Shares by us, such as a primary offering or pursuant to a preferential
allotment, may dilute your shareholding in us, adversely affect the trading price of our Equity Shares and
could affect our ability to raise capital through an issuance of our securities. In addition, any perception by
investors that such issuances or sales might occur could also affect the trading price of our Equity Shares.
Additionally, the disposal of Equity Shares by any of our significant shareholders or our Promoters, any
future issuance of Equity Shares by any of our significant shareholders or Promoters, any future issuance
of Equity Shares by us or the perception that such issuances or sales may occur may significantly affect the
trading price of the Equity Shares. We cannot assure you that we will not issue Equity Shares or that such
shareholders will not dispose of, pledge or encumber their Equity Shares in the future.
41. We could be adversely affected by violations of anti-bribery laws worldwide.
The pharmaceutical industry is highly regulated and pharmaceutical companies are subject to various anti-
bribery regulations worldwide, and even minor irregularities can potentially give rise to significant
consequences. Anti-bribery laws worldwide, especially U.S. Foreign Corrupt Practices Act (the “FCPA”)
generally prohibit companies and their intermediaries from making improper payments to government
officials for the purpose of obtaining or retaining business. Pharmaceutical companies are particularly at
risk of anti-bribery law violations because health care systems in some countries are often owned or
operated by government agencies. Therefore, during the course of business activities, interactions with
individuals considered to be government officials can be more frequent than in other industries. As a result,
there is heightened exposure to potential corruption risk, and over the past few years, a number of
pharmaceutical and other healthcare companies have been prosecuted under anti-bribery laws for a variety
of activities, such as providing free trips, free goods, grants and other monetary benefits to doctors and
hospitals. Our policies mandate compliance with these laws, which often carry substantial penalties.
However, our internal control policies and procedures may not always protect us from acts committed by
our affiliates, employees or agents which may violate these laws and regulations. Violations of anti-bribery
laws and regulations could result in fines and penalties, criminal sanctions against us, our officers or our
employees, prohibitions on the conduct of our business and on our ability to offer our products in one or
more countries, and could also materially affect our brand, our international growth efforts, our ability to
attract and retain employees, our business, and our operating results. There can be no assurance that our
partners, our employees, contractors, or agents will not subject us to potential claims or penalties. Any
violations of these laws, or allegations of such violations, could have a material adverse effect on our
business, financial position, and results of operations.
42. We appoint contract labour for carrying out certain of our operations and we may be responsible for
paying the wages of such workers if the independent contractors through whom such workers are hired
default on their obligations, and such obligations could have an adverse effect on our results of
operations and financial condition.
In addition to our employees, in order to retain flexibility and control costs, we appoint independent
contractors who in turn engage on-site contract labour for performance of certain of our operations.
Although we do not engage these labourers directly, we may be held responsible for any wage payments
including social security contributions to be made to such labourers in the event of default by such
independent contractors. Any requirement to fund their wage requirements may have an adverse impact on
our results of operations and financial condition. Thus, any such order from a regulatory body or court may
52
have an adverse effect on our business and results of operations.
43. A certain portion of our business operations are being conducted on leased or licensed premises. Our
inability to seek renewal or extension of such leases and/or leave & licenses may adversely affect our
business operations.
A certain portion of our business operations are being conducted on premises leased from third parties or
availed on a lease and license basis from third parties. While there are currently no instances of non-
compliance of the terms of our lease agreements, there can be no assurance that there will be no such non-
compliance leading to termination of such leases in the future. Any change in the terms and conditions of
the lease agreements and any premature termination of such lease agreements may have an adverse impact
on our business operations.
Any adverse impact on the title and ownership rights of the owners from whose premises we operate, breach
of the contractual terms of any lease deeds, or any inability to renew such agreements on acceptable terms
may also affect our business operations. In addition, the terms of certain of our leases require us to obtain
the lessor’s prior consent for certain actions, including making structural alterations to the leased premises,
which may be required if we were to undertake an expansion in the future.
There can be no assurance that we will be able to renew these leasing arrangements at commercially
favourable terms, or at all. If we are unable to renew all or any of our leasing arrangements, it may cause
disruptions in our business and we may incur substantial costs associated with shifting to new premises, all
of which may adversely affect our business operations.
44. Our insurance coverage may not adequately protect us against all losses. To the extent that we suffer
loss or damage which is not covered by insurance or exceeds our insurance coverage, our results of
operations and financial performance could be adversely affected.
We maintain insurance policies for our manufacturing facilities in India, including buildings, machinery
and inventories, consequential damages such as loss of profit, coverage for risks during the shipment of
products, public liability coverage, product liability coverage such as in cases of product recalls. In addition,
we also maintain insurance policies covering directors’ and officers’ liability, personal accidents,
environmental damages, terrorist acts and war related events. For further details, please see “Our Business
– Insurance” on page 115.
While we believe that the insurance coverage which we maintain would be reasonably adequate to cover
the normal risks associated with the operation of our business, we cannot assure you that any claim under
the insurance policies maintained by us will be honored fully, in part or on time, or that we have taken out
sufficient insurance to cover all our losses. Our insurance policies may not provide adequate coverage in
certain circumstances and are subject to certain deductibles, exclusions and limits on coverage. In addition,
our insurance coverage expires from time to time. We apply for the renewal of our insurance coverage in
the normal course of our business, but we cannot assure you that such renewals will be granted in a timely
manner, at acceptable cost or at all. To the extent that we suffer loss or damage for which we did not obtain
or maintain insurance, and which is not covered by insurance or exceeds our insurance coverage or where
our insurance claims are rejected, the loss would have to be borne by us and our results of operations, cash
flows and financial condition may be adversely affected.
45. Changes in trade policies may affect us.
Given the scale of our international operations, any change in policies by the countries in which we operate,
in terms of tariff and non-tariff barriers, from which our suppliers import or export their raw materials or
components, or countries to which we export our products, may have an adverse effect on our profitability.
Furthermore, we import various raw materials (including APIs) that are not produced in-house by us.
There is currently significant uncertainty about the future relationship between the United States and
various other countries, most significantly China, with respect to trade policies, treaties, government
regulations and tariffs. The current government of the United States has called for substantial changes to
their foreign trade policy with respect to China and other countries, including the possibility of imposing
greater restrictions on international trade and significant increases in tariffs on goods imported into the
United States, this may also have an impact on Asian markets. Such imposition of tariffs, trade restrictions
53
and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively
impact our sales. Given the relatively fluid regulatory environment in China and the United States and
uncertainty regarding how the United States or other foreign governments will act with respect to tariffs,
international trade agreements and policies, a trade war, further governmental action related to tariffs or
international trade policies, or additional tax or other regulatory changes in the future could occur and could
directly and adversely impact our financial results, cash flows and results of operations.
46. The United Kingdom’s vote to leave the European Union may possibly have uncertain effects and could
adversely affect us.
On June 23, 2016, the electorate in the U.K. voted in favour of leaving the European Union ("EU")
(“Brexit”). Thereafter, on March 29, 2017, the country formally notified the EU of its intention to withdraw
pursuant to Article 50 of the Lisbon Treaty. The withdrawal of the U.K. from the EU took effect on January
31, 2020. The effects of Brexit will depend on agreements the U.K. makes to retain access to EU markets
subsequently. Brexit creates an uncertain political and economic environment in the U.K. and potentially
across other EU member states for the foreseeable future and such uncertainties could impair or limit our
ability to transact business in the member EU states.
Further, Brexit could adversely affect European and worldwide economic or market conditions and could
contribute to instability in global financial markets, and the value of the British pound sterling currency or
other currencies, including the euros. We are exposed to the economic, market and fiscal conditions in the
U.K. and the EU and to changes in any of these conditions. Depending on the terms reached regarding
future access to EU markets, it is possible that there may be adverse practical and/or operational
implications on our business.
A significant amount of the regulatory regime that applies to us in the U.K. is derived from EU directives
and regulations. However, Brexit could change the legal and regulatory framework within the U.K. where
we operate and is likely to lead to legal uncertainty and potentially divergent national laws and regulations
as the U.K. determines which EU laws to replace or replicate. Consequently, no assurance can be given as
to the impact of Brexit and, in particular, no assurance can be given that our operating results, financial
condition and prospects would not be adversely impacted by the result.
47. If third parties on whom we rely for clinical trials do not perform their obligations as contractually
required or as we expect, and do not comply with cGMP, we may not be able to obtain regulatory
approval for or commercialize our products.
We depend on independent clinical investigators, contract research organizations and other third-party
service providers to conduct clinical trials and pre-clinical investigations of our new products and expect
to continue to do so. We also collaborate with other parties having technical and/ or business capabilities
to conduct early stage testing of products we intend to develop. We rely on such parties for successful
execution of our clinical trials, but we do not control many aspects of their activities. Third parties may
also not complete activities on schedule or may not conduct our studies in accordance with applicable trial,
plans and protocols. Nonetheless, we are responsible for confirming that each of our clinical trials is
conducted in accordance with its general investigational plan and protocol. If third parties fail to carry out
their obligations, product development, approval and commercialization could be delayed or prevented or
an enforcement action could be brought against us.
Our reliance on these third parties does not relieve us of our responsibility to comply with the regulations
and standards of the USFDA and other regulatory authorities related to good clinical practices. In particular,
these third-party manufacturers and service providers must comply with cGMP and their failure to do so
could result in warning or deficiency letters from regulatory authorities, which could interfere with or
disrupt their ability to complete our studies on time, thereby affecting our product approval process or even
forcing a withdrawal of our product which may adversely affect our business, financial condition and
results of operations.
48. The acquisition of other companies, businesses or technologies could result in operating difficulties,
dilution and other adverse consequences.
As part of our existing growth strategy, we may from time to time pursue strategic acquisitions of
companies, products and technologies or enter into partnerships to strengthen our product and technology
54
infrastructure. We cannot assure you that we will be able to identify suitable acquisition, strategic
investment or joint venture opportunities at acceptable cost and on commercially reasonable terms, obtain
the financing necessary to complete and support such acquisitions or investments, integrate such businesses
or investments or that any business acquired or investment made will be profitable. If we attempt to acquire
companies outside of India, we may not be able to satisfy certain regulatory requirements for such
acquisitions.
In addition, acquisitions and investments involve a number of risks, including possible adverse effects on
our operating results, exposure to future funding obligations, diversion of management’s attention, failure
to retain key personnel, currency risks, risks associated with unanticipated events or liabilities, possible
contravention of applicable laws in relation to investment and transfer of shareholding, including any pre-
emptive rights of existing shareholders of such entities and difficulties in the assimilation of the operations,
technologies, systems, services and products of the acquired businesses or investments, as well as other
economic, political and regulatory risks. Failure to achieve successful integration of any future acquisitions
or investments could have a material adverse effect on our business, financial condition and results of
operations. Future acquisitions could result in potentially dilutive issuances of our equity securities, the
incurrence of debt, contingent liabilities or amortization expenses, or write-offs of goodwill, any of which
could harm our financial condition and may have an adverse impact on the price of our Equity Shares.
Accordingly, integrating acquired business in a timely or efficient manner may not be possible for our
Company, and which could in turn adversely affect our opportunities to yield the benefits of acquisition.
49. We have relied on various industry sources, including publicly available data, for reproducing industry
related data in this Placement Document and such data has not been independently verified by us.
We have relied on various publicly and privately available sources, including from the websites of USFDA,
Pharmexcil, the IQVIA Research Reports and others (together, the “Industry Reports”) for industry
related data that has been disclosed in this Placement Document. The Industry Reports use certain
methodologies for market sizing and forecasting. We have not independently verified such data and
therefore, while we believe them to be true, we cannot assure you that they are complete or reliable.
Accordingly, investors should read the industry related disclosure in this Placement Document in this
context. Industry sources and publications are also prepared based on information as of specific dates and
may no longer be current or reflect current trends. Industry sources and publications may also base their
information on estimates, projections, forecasts and assumptions that may prove to be incorrect. While
industry sources take due care and caution while preparing their reports, they do not guarantee the accuracy,
adequacy or completeness of the data. Accordingly, investors should not place undue reliance on, or base
their investment decision solely on this information. For further details, please see “Industry Overview” on
page 93.
50. We have contingent liabilities and our financial condition could be adversely affected if any of these
contingent liabilities materializes.
As of March 31, 2020, our financial statements disclosed the following contingent liabilities as per Ind AS
37 – Provisions, Contingent Liabilities and Contingent Assets, as derived from the Audited Consolidated
Financial Statements are as follows: (in ₹ crores)
Particulars As of March
31, 2020
Letters of credit and guarantees 113.40
Liabilities Disputed in appeals 3.67
Claims against the Company not acknowledged as debt 0.35
Export obligation against advance license 0.03
Disputed liability in respect of Ministry of Industry, Department of Chemicals and
Petrochemicals in respect of price of Rifampicin allowed in formulations and landed cost
of import
0.35
51. Our Directors and key management personnel may have interests other than reimbursement of expenses
incurred and normal remuneration or benefits in our Company.
Our Directors and key management personnel may be interested in our Company to the extent of the Equity
55
Shares held by them in our Company, and any dividends, bonuses or other distributions on such Equity
Shares. For further details, see “Board of Directors and Senior Management” on page 118.
52. We have entered into transactions with related parties. We will continue to enter into such transactions
and there can be no assurance that we could not have achieved more favourable terms had such
transactions not been entered into with related parties.
We have entered into transactions with several related parties, including our Promoters, Directors and Key
Managerial Personnel which were carried out in compliance with applicable laws. For further details, see
“Related Party Transactions” on page 71.
While we believe that all such transactions have been conducted on an arms-length basis, there can be no
assurance that we could not have achieved more favourable terms had such transactions not been entered
into with related parties. Furthermore, it is likely that we will continue to enter into related party
transactions in the future. There can be no assurance that these or any future related party transactions that
we may enter into, individually or in the aggregate, will not have an adverse effect on our business and
results of operations. Further, the transactions with our related parties may potentially involve conflicts of
interest. There can also be no assurance that any dispute that may arise between us and related parties will
be resolved in our favour.
53. Our Promoters will be able to exercise significant influence and control over our Company after the
Issue and may have interests that are different from those of our other shareholders.
As of June 30, 2020 our Promoters and Promoter Group hold 72.97% of the issued and outstanding Equity
Shares of our Company. By virtue of their shareholding, our Promoters and Promoter Group will have the
ability to exercise significant control and influence over our Company and our affairs and business,
including the appointment of Directors, the timing and payment of dividends, the adoption of and
amendments to our Memorandum and Articles of Association, the approval of a merger, amalgamation or
sale of substantially all of our assets and the approval of most other actions requiring the approval of our
shareholders. The interests of our Promoters and Promoter Group may be different from or conflict with
the interests of our other shareholders and their influence may result in change of management or control
of our Company, even if such a transaction may not be beneficial to our other shareholders.
54. Our ability to pay dividends in the future will depend upon our future earnings, financial condition, cash
flows, working capital requirements, capital expenditures and restrictive covenants in our financing
arrangements.
While we have paid dividends in the past, we cannot assure you that dividends will be paid in the future
and, if so, the level of such future dividends. The declaration, payment and amount of any future dividends
is subject to the discretion of our Board, and will depend on a number of factors including, our earnings,
availability of profits, capital requirements and overall financial condition, as well as the provisions of
relevant laws in India from time to time.
55. Some of our lenders have imposed certain restrictive conditions on us under our financing arrangements.
This may limit our ability to pursue our business and limit our flexibility in planning for, or reacting to,
changes in our business or industry. Further, we will require a significant amount of cash to meet our
obligations under such financing arrangements, which we may not be able to generate.
Certain of our financing agreements include conditions and restrictive covenants, including the requirement
that we obtain consent or intimation from our respective lenders prior to carrying out certain activities and
entering into certain transactions. Specifically, in some of our financing agreements, prior consent from the
respective lender is required for inter alia the amendment of our memorandum and articles of association
and changing our capital structure. While for purposes of this Issue, we have obtained all the applicable
consents from our various lenders in terms of the relevant facility documentation, these restrictions may
limit our flexibility in responding to business opportunities, competitive developments and adverse
economic or industry conditions. A breach of any of these covenants or a failure to pay interest or
indebtedness when due under any of our financing arrangements, could result in a variety of adverse
consequences, including the termination of one or more of our credit facilities, levy of penal interest, the
enforcement of any security provided, acceleration of all amounts due under such facilities and cross-
defaults under certain of our other financing agreements, any of which may adversely affect our business,
56
financial condition and results of operations. We cannot assure you that we will continue to comply with
all conditions and restrictive covenants under our financing agreements in the future.
If the obligations under any of our financing agreements are accelerated, we may have to dedicate a
substantial portion of our cash flow from operations to make payments under such financing documents,
thereby reducing the availability of cash for our working capital requirements and other general corporate
purposes. Further, during any period in which we are in default, we may be unable to obtain further
financing or any refinancing of our debt could be at higher rates with more onerous covenants, which could
further restrict our business operations. Additionally, third parties may also have concerns over our
financial position and it may be difficult to market our financial products. Any of these circumstances or
other consequences could adversely affect our business, credit rating, prospects, financial condition and
results of operations. Moreover, any such action initiated by our lenders could adversely affect the price of
the Equity Shares.
EXTERNAL RISK FACTORS
1. Our revenue is derived from business in India and a slowdown in economic growth in India could cause
our business to suffer.
We derive revenue from our operations in India, accordingly, our performance and the growth of our
business are necessarily dependent on the health of the overall Indian economy. A slowdown in the Indian
economy could adversely affect the policy of the Government of India towards the industry in which we
operate, which may in turn adversely affect our financial performance and our ability to implement our
business strategy.
The Indian economy’s growth momentum moderated significantly in Fiscal 2018 and 2019 as compared to
previous years. According to the Indian Central Statistics Organization, India’s real GDP growth decreased
from 7.0% in Fiscal 2018 to 6.1% in Fiscal 2019. According to the Indian Central Statistics Organization,
industrial sector growth slowed to 7.6% in Fiscal 2019. As per various sources, the Indian economy has
slowed further in Fiscal 2020. In particular, a number of governments and organizations have revised GDP
growth forecasts for 2020 downwards in response to the economic slowdown caused by the spread of
COVID-19, and it is possible that the COVID-19 pandemic will cause a prolonged global economic crisis
or recession. The Indian economy is also influenced by economic and market conditions in other countries,
particularly emerging market conditions in Asia. A loss of investor confidence in other emerging market
economies or any worldwide financial instability may adversely affect the Indian economy, which could
materially and adversely affect our business and results of operations and the market price of the Equity
Shares.
Further, other factors which may adversely affect the Indian economy are scarcity of credit or other
financing in India, resulting in an adverse impact on economic conditions in India and scarcity of financing
of our developments and expansions; volatility in, and actual or perceived trends in trading activity on,
India’s principal stock exchanges; changes in India’s tax, trade, fiscal or monetary policies, like political
instability, terrorism or military conflict in India or in countries in the region or globally, including in
India’s various neighbouring countries; occurrence of natural or man-made disasters; infectious disease
outbreaks or other serious public health concerns; prevailing regional or global economic conditions,
including in India’s principal export markets; and other significant regulatory or economic developments
in or affecting India.
2. Changing regulations in India, including in relation to finance and taxation laws, could lead to new
compliance requirements that are uncertain.
The regulatory environment in which we operate is evolving and is subject to change. The Government of
India may implement new laws or other regulations that could affect our businesses, which could lead to
new compliance requirements. New compliance requirements could increase our costs or otherwise
adversely affect our business, financial condition and results of operations. Further, the manner in which
new requirements will be enforced or interpreted can lead to uncertainty in our operations and could
adversely affect our operations.
For example, as of July 1, 2017, a national goods and service tax (“GST”) in India replaced taxes levied
by central and state governments with a unified tax regime in respect of the supply of goods and services
57
for all of India. However, given the recent introduction of GST in India, the practice regarding the
implementation of, and compliance with, GST is still evolving. Our business and financial performance
could be adversely affected by any unexpected or onerous requirements or regulations resulting from the
introduction of GST or any changes in laws or interpretation of existing laws, or the promulgation of new
laws, rules and regulations relating to GST, as it is implemented. Any changes to the GST rate or rules and
regulations surrounding GST and the related uncertainties with respect to the implementation of GST may
have a material adverse effect on our business, financial condition and results of operations.
Further, as GST is implemented, there can be no assurance that we will not be required to comply with
additional procedures or obtain additional approvals and licenses from the government and other regulatory
bodies or that they will not impose onerous requirements and conditions on our operations. Any such failure
to achieve compliance may result in increased cost on account of non-compliance with the GST and may
adversely affect our business and results of operations.
The Finance Act, 2020 has, amongst others things, provided a number of amendments to the direct and
indirect tax regime, including, without limitation, a simplified alternate direct tax regime and that dividend
distribution tax will not be payable in respect of dividends declared, distributed or paid by a domestic
company after March 31, 2020, and accordingly, such dividends would not be exempt in the hands of the
shareholders, both resident as well as non-resident.
3. Natural calamities, terrorist attacks, civil disturbances, outbreaks of contagious diseases, power outages
and other disruptions could have a negative impact on the Indian economy and could cause our business
to suffer and the trading price of the Equity Shares to decrease.
India has experienced natural calamities such as earthquakes, floods and drought in the recent past. The
extent and severity of these natural disasters determine their impact on the Indian economy. For example,
in May 2020, the eastern states of India, including Odisha and West Bengal received significant rainfall
due to cyclone Amphan and further the locust plague in India and South Asian countries, may have a long-
term impact in the agricultural economy of India, predominantly in Fiscal 2021 and the near future. An
erratic monsoon season could also adversely affect sowing operations for certain crops and result in a
decline in the growth rate of the agricultural sector. Further, prolonged spells of below normal rainfall in
the country or other natural calamities could have a negative impact on the Indian economy, adversely
affecting our business and potentially causing the trading price of the Equity Shares to decrease. India has
from time to time experienced instances of social, religious and civil unrest and hostilities between
neighbouring countries. Military activity or terrorist attacks in the future could influence the Indian
economy by disrupting communications and making travel more difficult and such political tensions could
create a greater perception that investments in Indian companies involve higher degrees of risk. Events of
this nature in the future, as well as social and civil unrest within other countries in Asia, could influence
the Indian economy and could have a material adverse effect on the market for securities of Indian
companies, including the Equity Shares. A number of countries in Asia, including India, as well as countries
in other parts of the world, are susceptible to contagious diseases and, for example, have had confirmed
cases of diseases such as the highly pathogenic H7N9, H5N1 and H1N1 strains of influenza in birds and
swine and more recently, the COVID-19 virus. Certain countries in Southeast Asia have reported cases of
bird-to-human transmission of avian and swine influenza, resulting in numerous human deaths. As a result,
any present or future outbreak of avian or swine influenza or other contagious disease could have a material
adverse effect on our business and the trading price of the Equity Shares.
4. We may be affected by competition law in India and abroad and any adverse application or interpretation
of the Competition Act could adversely affect our business.
The Competition Act regulates practices having an appreciable adverse effect on competition in the relevant
market in India. Under the Competition Act, any formal or informal arrangement, understanding or action
in concert, which causes or is likely to cause an appreciable adverse effect on competition is considered
void and results in the imposition of substantial monetary penalties. Further, any agreement among
competitors which directly or indirectly involves the determination of purchase or sale prices, limits or
controls production, supply, markets, technical development, investment or provision of services, shares
the market or source of production or provision of services by way of allocation of geographical area, type
of goods or services or number of customers in the relevant market or directly or indirectly results in bid-
rigging or collusive bidding is presumed to have an appreciable adverse effect on competition. The
Competition Act also prohibits abuse of a dominant position by any enterprise. On March 4, 2011, the
58
Government issued and brought into force the combination regulation (merger control) provisions under
the Competition Act with effect from June 1, 2011. These provisions require acquisitions of shares, voting
rights, assets or control or mergers or amalgamations that cross the prescribed asset and turnover based
thresholds to be mandatorily notified to and pre-approved by the CCI. Additionally, on May 11, 2011, the
CCI issued Competition Commission of India (Procedure in regard to the transaction of business relating
to combinations) Regulations, 2011, as amended, which sets out the mechanism for implementation of the
merger control regime in India. The Competition Act aims to, among others, prohibit all agreements and
transactions which may have an appreciable adverse effect on competition in India. Consequently, all
agreements entered into by us could be within the purview of the Competition Act. Further, the CCI has
extra-territorial powers and can investigate any agreements, abusive conduct or combination occurring
outside India if such agreement, conduct or combination has an appreciable adverse effect on competition
in India. However, we cannot predict the impact of the provisions of the Competition Act on the agreements
entered into by us at this stage. We are not currently party to any outstanding proceedings, nor have we
received notice in relation to non-compliance with the Competition Act or the agreements entered into by
us. However, if we are affected, directly or indirectly, by the application or interpretation of any provision
of the Competition Act, or any enforcement proceedings initiated by the CCI, or any adverse publicity that
may be generated due to scrutiny or prosecution by the CCI or if any prohibition or substantial penalties
are levied under the Competition Act, it would adversely affect our business, results of operations and
prospects. Further, our business prospects and results of operations in overseas jurisdictions may also be
adversely affected by virtue of any unfavourable changes to the existing competition law regime.
5. It may not be possible for investors to enforce any judgment obtained outside India against us, the
Placement Agents or any of their directors and executive officers in India respectively, except by way of
a law suit in India.
The enforcement of civil liabilities by overseas investors in the Equity Shares, including the ability to effect
service of process and to enforce judgments obtained in courts outside of India may be adversely affected
by the fact that the Company is incorporated under the laws of the Republic of India and all of its executive
officers and directors reside in India. As a result, it may be difficult to enforce the service of process upon
the Company and any of these persons outside of India or to enforce outside of India, judgments obtained
against the Company and these persons in courts outside of India.
India is not a party to any international treaty in relation to the recognition or enforcement of foreign
judgments. Recognition and enforcement of foreign judgments is provided for under Section 13, Section
14 and Section 44A of the Code of Civil Procedure, 1908 (“Civil Code”) on a statutory basis. Section 44A
of the Civil Code provides that where a certified copy of a decree of any superior court, within the meaning
of that Section, in any country or territory outside India which the Government has by notification declared
to be in a reciprocating territory, it may be enforced in India by proceedings in execution as if the judgment
had been rendered by a district court in India. However, Section 44A of the Civil Code is applicable only
to monetary decrees not being in the same nature of amounts payable in respect of taxes, other charges of
a like nature or in respect of a fine or other penalties and does not apply to arbitration awards (even if such
awards are enforceable as a decree or judgment).
The United Kingdom, United Arab Emirates, Singapore and Hong Kong, among others, have been declared
by the Government to be reciprocating territories for the purposes of Section 44A of the Civil Code. The
United States has not been declared by the Government of India to be a reciprocating territory for the
purposes of Section 44A of the Civil Code. A judgment of a court of a country which is not a reciprocating
territory may be enforced in India only by a suit upon the judgment under Section 13 of the Civil Code,
and not by proceedings in execution. Section 13 of the Civil Code provides that foreign judgments shall be
conclusive regarding any matter directly adjudicated upon except: (i) where the judgment has not been
pronounced by a court of competent jurisdiction; (ii) where the judgment has not been given on the merits
of the case; (iii) where it appears on the face of the proceedings that the judgment is founded on an incorrect
view of international law or refusal to recognize the law of India in cases to which such law is applicable;
(iv) where the proceedings in which the judgment was obtained were opposed to natural justice; (v) where
the judgment has been obtained by fraud; and/ or (vi) where the judgment sustains a claim founded on a
breach of any law then in force in India. The suit must be brought in India within three years from the date
of judgment in the same manner as any other suit filed to enforce a civil liability in India.
Further, there are considerable delays in the disposal of suits by Indian courts. It may be unlikely that a
court in India would award damages on the same basis as a foreign court if an action is brought in India.
59
Furthermore, it may be unlikely that an Indian court would enforce foreign judgments if it viewed the
amount of damages awarded as excessive or inconsistent with public policy in India. A party seeking to
enforce a foreign judgment in India is required to obtain prior approval from the RBI under FEMA to
repatriate any amount recovered pursuant to execution and any such amount may be subject to income tax
in accordance with applicable laws. Any judgment or award in a foreign currency would be converted into
Indian Rupees on the date of the judgment or award and not on the date of the payment.
6. Rights of shareholders under Indian laws may differ from the laws of other jurisdictions.
Our Articles of Association and Indian law govern our corporate affairs. Indian legal principles related to
these matters and the validity of corporate procedures, Directors’ fiduciary duties and liabilities, and
shareholders’ rights may differ from those that would apply to a company in another jurisdiction.
Shareholders’ rights including in relation to class actions, under Indian law may not be as extensive as
shareholders’ rights under the laws of other countries or jurisdictions. Investors may have more difficulty
in asserting their rights as one of our shareholders than as a shareholder of a company in another
jurisdiction.
7. Any downgrade of India’s debt rating by an independent agency may adversely affect our ability to raise
financing.
Any adverse revisions to India’s credit ratings for domestic and international debt by international rating
agencies may adversely affect our ability to raise additional financing and the interest rates and other
commercial terms at which such additional financing is available. This could have an adverse effect on our
capital expenditure plans, business, financial condition and the price of our Equity Shares.
8. Fluctuation in the exchange rate between the Indian Rupee and foreign currencies may have an adverse
effect on the value of our Equity Shares, independent of our operating results.
Our Equity Shares are quoted in Indian Rupees on the Stock Exchanges. Any dividends in respect of our
Equity Shares will be paid in Indian Rupees and subsequently converted into the relevant foreign currency
for repatriation, if applicable. Any adverse movement in currency exchange rates during the time that it
takes to undertake such conversion may reduce the net dividend to foreign investors. In addition, any
adverse movement in currency exchange rates during a delay in repatriating outside India the proceeds
from a sale of Equity Shares, for example, because of a delay in regulatory approvals that may be required
for the sale of Equity Shares, may reduce the proceeds received by Shareholders. For example, the exchange
rate between the Rupee and the U.S. dollar has fluctuated substantially in recent years, and may continue
to fluctuate substantially in the future, which may have an adverse effect on the trading price of our Equity
Shares and returns on our Equity Shares, independent of our operating results.
RISKS RELATING TO THE ISSUE AND THE EQUITY SHARES
1. The Issue Price of the Equity Shares may not be indicative of the market price of the Equity Shares after
the Issue.
The Issue Price of the Equity Shares has been determined by our Company in accordance with applicable
prevailing regulations. This price has been determined on the basis of applicable law and may not be
indicative of the market price for the Equity Shares after the Issue. The market price of the Equity Shares
could be subject to significant fluctuations after the Issue, and may decline below the Issue Price. We
cannot assure you that you will be able to resell your Equity Shares at or above the Issue Price. There can
be no assurance that an active trading market for the Equity Shares will be sustained after this Issue, or that
the price at which the Equity Shares have historically traded will correspond to the price at which the Equity
Shares will trade in the market subsequent to this Issue.
2. The trading price of our Equity Shares may be subject to volatility and you may not be able to sell the
Equity Shares at or above the Issue Price.
The trading price of our Equity Shares may fluctuate after the Issue due to a variety of factors, including
our results of operations and the performance of our business, competitive conditions, general economic,
political and social factors, the performance of the Indian and global economy and significant developments
in India’s fiscal regime, economic liberalisation, deregulation policies and procedures or programs
60
applicable to our business, adverse media reports on our Company, volatility in the Indian and global
securities market, performance of our competitors, the Indian financial services industry and the perception
in the market about investments in the financial services industry, changes in the estimates of our
performance or recommendations by financial analysts and announcements by us or others regarding new
projects, strategic partnerships, joint ventures, or capital commitments. In addition, if the stock markets in
general experience a loss of investor confidence, the trading price of our Equity Shares could decline for
reasons unrelated to our business, financial condition or operating results. The trading price of our Equity
Shares might also decline in reaction to events that affect other companies in our industry even if these
events do not directly affect us. Each of these factors, among others, could adversely affect the price of our
Equity Shares.
3. Your ability to acquire and sell Equity Shares offered in the Issue is restricted by the distribution,
solicitation and transfer restrictions set forth in this Placement Document.
No actions have been taken to permit a public offering of the Equity Shares offered in the Issue in any
jurisdiction. As such, your ability to acquire Equity Shares offered in the Issue is restricted by the
distribution and solicitation restrictions set forth in this Placement Document. For further information, see
“Selling Restrictions” on page 145. Furthermore, the Equity Shares offered in the Issue are subject to
restrictions on transferability and resale. For further information, see “Purchaser Representations and
Transfer Restrictions” on page 152. You are required to inform yourself about and observe these
restrictions. Our representatives, our agents and us will not be obligated to recognize any acquisition,
transfer or resale of the Equity Shares offered in the Issue made other than in compliance with applicable
law.
4. Investors may be subject to Indian taxes arising out of capital gains on the sale of the Equity Shares and
dividend received.
Under current Indian tax laws, unless specifically exempted, capital gains arising from the sale of equity
shares in an Indian company is generally taxable in India. A securities transaction tax (“STT”) is levied on
and collected by an Indian stock exchange on which equity shares are sold. Further, any gain realized on
the sale of listed equity shares held for more than 12 months may be subject to long-term capital gains tax
in India at the specified rates depending on certain factors, such as whether the sale is undertaken on or off
the stock exchanges, the quantum of gains and any available treaty exemptions. Accordingly, you may be
subject to payment of long-term capital gains tax in India, in addition to payment of STT, on the sale of
any Equity Shares held for more than 12 months. Meanwhile, in addition to payment of STT, any gain
realized on the sale of listed equity shares held for a period of 12 months or less will be subject to short-
term capital gains tax in India.
In case of a non-resident shareholder, capital gains arising from the sale of equity shares of an Indian
company will be exempt from taxation in India in cases where the exemption from taxation in India is
provided under a treaty between India and the country of the shareholder residence who is initiating the
sale. However, Indian tax treaties generally do not limit India’s ability to impose tax on capital gains. As
such, selling shareholders that are residents of other countries may be liable for tax in India as well as in
their own jurisdiction on gains from the sale of the Equity Shares. However, depending on the prevailing
tax laws of such shareholder’s country of residence, the shareholder may be given tax credits for taxes
payable in India against the taxes paid by him or her in his or her country of residence, thereby reducing
such shareholder’s overall tax liability.
Further, the Finance Act, 2019, which has been notified with effect from April 1, 2019, stipulates the sale,
transfer and issue of securities through exchanges, depositories or otherwise to be charged with stamp duty.
The Finance Act has also clarified that, in the absence of a specific provision under an agreement, the
liability to pay stamp duty in case of sale of securities through stock exchanges will be on the buyer, while
in other cases of transfer for consideration through a depository, the onus will be on the transferor. The
stamp duty for transfer of securities other than debentures, on a delivery basis is specified at 0.015% and
on a non-delivery basis is specified at 0.003% of the consideration amount. These amendments have come
into effect from July 1, 2020.
The Finance Act, 2020 has also provided a number of amendments to the direct and indirect tax regime,
including, without limitation, a simplified alternate direct tax regime and that dividend distribution tax will
not be payable in respect of dividends declared, distributed or paid by a domestic company after March 31,
61
2020, and accordingly, such dividends would not be exempt in the hands of the shareholders, both resident
as well as non-resident.
Our Company cannot predict whether any tax laws or other regulations impacting it will be enacted or
predict the nature and impact of any such laws or regulations or whether, if at all, any laws or regulations
would have a material adverse effect the Company’s business, financial condition and results of operations.
5. Foreign investors are subject to foreign investment restrictions under Indian law that limit our
Company’s ability to attract foreign investors, which may adversely affect the market price of the Equity
Shares.
The foreign investment in our Company is governed by inter-alia the FEMA, as amended, the FEMA
Regulations, the FEMA Rules. A company based in India may issue equity instruments to a person resident
outside India subject to entry routes, sectoral caps and attendant conditionalities prescribed in the FEMA
Rules. Under these foreign exchange rules currently in force in India, transfers of our Equity Shares
between non-residents and residents and issuances of shares to non-residents by our Company are permitted
(subject to certain exceptions), subject to compliance with inter alia certain applicable pricing and reporting
requirements. If such issuances or transfers of shares are not in compliance with such requirements or fall
under any of the specified exceptions, then prior approval of the RBI will be required. Further, the
Government of India on April 22, 2020 amended the FEMA Rules pursuant to which any investment into
India under Rule 6 of the FEMA Rules by an entity of a country, which shares land border with India or
the beneficial owner of an investment into India who is situated in or is a citizen of any such country shall
require the approval of the Government of India.
In addition, shareholders who seek to convert the Indian Rupee proceeds from a sale of Equity Shares in
India into foreign currency and repatriate that foreign currency from India will require a no-objection or
tax clearance certificate from the income tax authority. Additionally, the Government of India may impose
foreign exchange restrictions in certain emergency situations, including situations where there are sudden
fluctuations in interest rates or exchange rates, where the Government of India experiences extreme
difficulty in stabilising the balance of payments, or where there are substantial disturbances in the financial
and capital markets in India. These restrictions may require foreign investors to obtain the Government of
India’s approval before acquiring Indian securities or repatriating the interest or dividends from those
securities or the proceeds from the sale of those securities. There can be no assurance that any approval
required from the RBI or any other government agency can be obtained on any particular terms, or at all.
6. The Equity Shares are subject to transfer restrictions.
The Equity Shares that are being offered are not required to be registered under the U.S. Securities Act.
Therefore, the Equity Shares may be transferred or resold only in a transaction registered under or exempted
from the registration requirements of the U.S. Securities Act and in compliance with any other applicable
securities laws. Pursuant to the SEBI Regulations, for a period of 12 months from the date of Allotment of
the Equity Shares in the Issue, QIBs subscribing Equity Shares in the Issue may only sell their Equity
Shares on BSE or NSE and may not enter into any off-market trading in respect of these Equity Shares.
There is no assurance that the restriction will not have an impact on the price and liquidity of the Equity
Shares.
7. Investors to the Issue are not allowed to withdraw or revise their Bids downwards after the Bid/ Issue
Closing Date.
In terms of the SEBI Regulations, investors in the Issue are not allowed to withdraw their Bids or revise
their Bids downwards after the Issue Closing Date. The Allotment of Equity Shares in this Issue and the
credit of such Equity Shares to the investor’s demat account with the depository participant could take
approximately seven days and up to 10 days from the Issue Closing Date. However, there is no assurance
that material adverse changes in the international or national monetary, financial, political or economic
conditions or other events in the nature of force majeure, material adverse changes in the business, results
of operation or financial condition of the Company, or other events affecting the investor’s decision to
invest in the Equity Shares, would not arise between the Issue Closing Date and the date of Allotment of
Equity Shares in the Issue. Occurrence of any such events after the Issue Closing Date could also adversely
impact the market price of the Equity Shares. The investors shall not have the right to withdraw their Bids
or revise their Bids downwards in the event of any such occurrence. The Company may complete the
62
Allotment of the Equity Shares even if such events may limit the investors’ ability to sell the Equity Shares
after the Issue or cause the trading price of the Equity Shares to decline.
8. There may not be an active or liquid market for our Equity Shares, which may cause the price of the
Equity Shares to fall and may limit your ability to sell the Equity Shares.
The price at which the Equity Shares will trade after this Issue will be determined by the marketplace and
may be influenced by many factors, including, our financial results and the financial results of the
companies in the businesses we operate in; the history of, and the prospects for, our business and the sectors
in which we compete; the valuation of publicly traded companies that are engaged in business activities
similar to us; and significant developments in India’s economic liberalization and deregulation policies.
The trading price of our Equity Shares might also decline in reaction to events that affect other companies
in our industry even if these events do not directly affect us. Each of these factors, among others, could
adversely affect the price of our Equity Shares. As a result, investors in the Equity Shares may experience
a decrease in the value of the Equity Shares regardless of our operating performance or prospects and may
limit your ability to sell the Equity Shares.
9. Investors will be subject to market risks until the Equity Shares credited to the investors’ demat account
are listed and permitted to trade.
Investors can start trading the Equity Shares Allotted to them only after they have been credited to an
investors’ demat account, are listed and permitted to trade. Since the Equity Shares are currently traded on
the Stock Exchanges, investors will be subject to market risk from the date they pay for the Equity Shares
to the date when Equity Shares Allotted are listed and permitted to trade. Further, there can be no assurance
that the Equity Shares Allotted to an investor will be credited to the investor’s demat account in a timely
manner or that trading in the Equity Shares will commence in a timely manner.
63
MARKET PRICE INFORMATION
As on the date of this Placement Document, 18,85,15,914 Equity Shares have been issued, subscribed and paid
up. The Equity Shares have been listed on BSE and NSE since September 20, 2011. The Equity Shares are listed
and actively traded on NSE under the symbol APLLTD and BSE under the scrip code 533573.
On July 31, 2020, the closing price of the Equity Shares on BSE and NSE was ₹985.30 and ₹985.05 per Equity
Share, respectively. Since the Equity Shares are available for trading on BSE and NSE, the market price and other
information for each of BSE and NSE has been given separately.
(i) The following tables set forth the reported high, low, average market prices and the trading volumes of the
Equity Shares on the Stock Exchanges on the dates on which such high and low prices were recorded and
the total trading turnover for Fiscals 2020, 2019 and 2018:
BSE
Fiscal High (₹) Date of
high
Number
of Equity
Shares
traded on
the date
of high
Total
turnover of
Equity
Shares
traded on
date of high
(₹ crores)
Low
(₹)
Date of
low
Number of
Equity
Shares
traded on
the date of
low
Total
turnover of
Equity
Shares
traded on
date of low
(₹ crores)
Average
price for the
year (₹)
2020 671.40 February
19, 2020
23,472 1.55 449.00 March 23,
2020
6,303 0.30 547.69
2019 649.15 September
26, 2018
4,048 0.26 415.90 June 5,
2018
8,734 0.37 555.74
2018 627.60 April 11,
2017
5,383 0.34 479.30 Septembe
r 20, 2017
6,463 0.31 537.66
(Source: www.bseindia.com)
NSE
Fiscal High (₹) Date of
high
Number
of
Equity
Shares
traded
on the
date of
high
Total
turnover of
Equity
Shares
traded on
date of high
(₹ crores)
Low
(₹)
Date of
low
Number
of Equity
Shares
traded on
the date
of low
Total
turnover of
Equity
Shares
traded on
date of low (₹
crores)
Average
price for the
year (₹)
2020 674.60 February
19, 2020
481,687 31.64 445.40 March 23,
2020
156,564 7.34 547.79
2019 654.25 September
21, 2018
171,702 11.10 418.15 June 5,
2018
7,035 0.30 556.26
2018 629.95 April 11,
2017
35,895 2.25 480.75 September
20, 2017
30,959 1.49 538.38
(Source: www.nseindia.com)
Note:
1. High, low and average prices are based on the daily closing prices. 2. In case of two days with the same closing price, the date with the higher volume has been chosen.
3. In the case of a year, average price for the year represents the average of the closing prices on each day of each year.
64
(ii) The following tables set forth the reported high, low and average market prices and the trading volumes of
the Equity Shares on the Stock Exchanges on the dates on which such high and low prices were recorded
during each of the last six months, as applicable:
BSE
Month,
year
High
(₹)
Date of
high
Numbe
r of
Equity
Shares
traded
on date
of high
Total
turnover
of Equity
Shares
traded on
date of
high (₹
crores)
Low (₹) Date of
low
Numbe
r of
Equity
Shares
traded
on
date of
low
Total
turnover
of Equity
Shares
traded on
date of low
(₹ crores)
Averag
e price
for the
month
(₹)
Equity Shares traded
in the month
Volume Turnover(₹i
n crores)
July 2020 1,014.
05
July 20,
2020
68,038 6.93 887.10 July 6,
2020
19,983 1.79 953.88 768,499 75.22
June 2020 945.95 June 19,
2020 49,099 4.58 800.60
June 9,
2020 19,944 1.63 881.57 481,586 43.22
May 2020 897.65 May 21,
2020 17,319 1.54 751.75
May 5,
2020 10,241 0.78 831.55 362,527 30.51
April 2020 817.90 April 27,
2020 107,653 8.72 537.70
April 3,
2020 19,084 1.04 665.59 618,833 45.31
March
2020 659.25
March
03, 2020 14,780 0.97 449.00
March
23,
2020
6,303 0.30 563.20 282,696 16.79
February
2020 671.40
February
19, 2020 23,472 1.55 617.70
Februar
y 4,
2020
7,861 0.49 642.53 183,535 11.91
(Source: www.bseindia.com)
NSE
Month,
year High (₹)
Date of
high
Number
of
Equity
Shares
traded
on date
of high
Total
turnover of
Equity
Shares
traded on
date of high
(₹ crores)
Low
(₹)
Date of
low
Numbe
r of
Equity
Shares
traded
on date
of low
Total
turnover of
Equity
Shares
traded on
date of low
(₹ crores)
Averag
e price
for the
month
(₹)
Equity Shares traded
in the month
Volume
Turnover
(₹ in
crores)
July
2020
1,011.45 July 20,
2020
942,698 96.02 887.50 July 6,
2020
223195 20.00 953.88 12,849,38
5
1,257.69
June
2020 946.50
June 19,
2020 682,717 63.87 800.60
June 9,
2020 574,819 47.24 881.54 8,828,654 785.31
May
2020 898.05
May 22,
2020 808,034 72.41 750.80
May 5,
2020 480,970 36.85 831.17 9,089,310 754.00
April
2020 817.30
April 27,
2020
2,271,52
8 184.02 533.45
April 1,
2020 142,618 7.66 665.06
14,393,22
6 1,051.25
March
2020 661.20
March, 3,
2020 191,933 12.65 445.40
March
23,
2020
156,564 7.34 562.46 3,766,427 213.48
Februar
y 2020 674.60
February
19, 2020 481,687 31.64 617.50
Februar
y 4,
2020
146,448 9.09 642.70 4,586,367 296.14
(Source: www.nseindia.com)
Note:
1. High, low and average prices are based on the daily closing prices.
2. In case of two days with the same closing price, the date with the higher volume has been chosen.
3. In the case of a month, average price for the month represents the average of the closing prices on each day of each month.
(iii) The following table set forth the details of the number of Equity Shares traded on the Stock Exchanges
and the turnover during Fiscals 2020, 2019 and 2018:
65
Fiscal Number of Equity Shares Traded Turnover (In ₹ crores)
BSE NSE BSE NSE
2020 2,655,369 28,711,651 154.52 1,661.71
2019 2,940,097 19,988,254 169.58 1,116.08
2018 2,508,007 17,400,363 139.32 942.26 (Source: www.bseindia.com and www.nseindia.com)
(iv) The following tables set forth the market price on the Stock Exchanges on July 28, 2020, being the first
working day following the approval of the Board for the Issue:
BSE
Open High Low Close Number of Equity Shares traded Volume
(₹ crores)
967.00 982.75 963.30 976.45 13,312 1.30 (Source: www.bseindia.com)
NSE
Open High Low Close Number of Equity Shares traded Volume
(₹ crores)
970.00 982.00 963.00 977.85 4,24,039 41.27 (Source: www.nseindia.com)
66
USE OF PROCEEDS
The gross proceeds of this Issue are approximately ₹750.00 crore. The net proceeds of this Issue, after deducting
fees, commissions and expenses relating to this Issue are approximately ₹733.57 crore (“Net Proceeds”).
Purpose of this Issue
Our Company proposes to utilize the Net Proceeds for funding growth and expansion opportunities, working
capital requirements, pre-payment and /or repayment of outstanding borrowings and general corporate purposes,
as may be permissible under the applicable law and approved by our Board or a duly constituted committee
thereof.
The Net Proceeds are proposed to be deployed towards the purpose set out above and are not proposed to be
utilized towards any specific project. Accordingly, the requirement to disclose (i) the break-up of cost of the
project (ii) means of financing such project, and (iii) proposed deployment status of the proceeds at each stage of
the project, is not applicable.
Our Company intends to deploy the entire Net Proceeds towards the purpose set out above by March 31, 2022.
The proposed deployment of funds from the Net Proceeds are based on internal management estimates based on
current market conditions and have not been appraised by any bank or financial institution or other independent
agency. Our Company may have to revise these estimates from time to time on account of various factors beyond
our control, such as market conditions, competitive environment, costs of commodities, interest or exchange rate
fluctuations.
In accordance with applicable laws, we undertake to not utilize proceeds from the Issue unless Allotment is made
and the corresponding return of Allotment is filed with the RoC, or final listing and trading approvals are received
from each of the Stock Exchanges, whichever is later.
As permissible under applicable laws, our Company’s management will have flexibility in deploying the Net
Proceeds. The amounts and timing of any expenditure will depend on, among other factors, the amount of cash
generated by our operations, competitive and market developments and the availability of acquisition or
investment opportunities on terms acceptable to us. Pending utilization of the Net Proceeds, our Company intends
to invest the funds in creditworthy instruments, including money market, mutual funds, and deposits with banks.
Such investments will be in accordance with the investment policies approved by the Board and/ or a duly
authorized committee of the Board, from time to time, and in accordance with applicable laws.
Our Company shall disclose the utilization of funds raised through QIP in its annual report every year until such
funds are fully utilized.
Neither our Promoters nor our Directors are making any contribution either as a part of this Issue or separately in
furtherance of the use of the Net Proceeds.
67
CAPITALISATION STATEMENT
The following table sets forth the capitalisation of our Company, on a consolidated basis, as at March 31, 2020
and as adjusted to give effect to the Issue.
This table should be read in conjunction with “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” on pages 35 and 73, respectively.
(₹ in crore, except ratio)
Particulars As at March 31, 2020
(on a consolidated basis)
As adjusted for the Issue
(on a consolidated basis)*
Indebtedness
Short-term Borrowings
- Secured borrowings 0.04 0.04
- Unsecured borrowings 860.46 860.46
Long-term Borrowings
- Secured borrowings
- Unsecured borrowings 886.99 886.99
Total Indebtedness (A) 1,747.49 1,747.49
Shareholders’ Funds
- Equity Share Capital 37.70 39.31
- Other Equity 3,181.71 3,930.10
Total Shareholders’ Funds (B) 3,219.41 3,969.41
Total Capitalisation (A+B) 4,966.90 5,716.90
Debt/Equity ratio 0.54 0.44
*Note- The figures for the respective financial statements line items under post-Issue column are derived after considering the proposed impact
due to the Issue (assuming that the Issue is subscribed as per terms in accordance with the resolution approved by the Fund Raising Committee
of the Board of Directors at their meeting dated August 3, 2020) and not considering any other transactions or movements for such financial statements line items after March 31, 2020. Accordingly, the post-Issue column has been adjusted to reflect the number of Equity Shares proposed
to be issued pursuant to the Issue and the related proceeds from the Issue. The aforesaid amounts do not include any Issue related expenses.
68
CAPITAL STRUCTURE
The equity share capital of our Company, as at the date of this Placement Document, is set forth below:
(In ₹ crore, except Equity Share data)
Aggregate value at face value#
A AUTHORISED SHARE CAPITAL^
20,00,00,000 Equity Shares 40.00
B ISSUED, SUBSCRIBED AND PAID-UP CAPITAL BEFORE THE ISSUE
18,85,15,914 Equity Shares 37.70
C PRESENT ISSUE IN TERMS OF THIS PLACEMENT DOCUMENT(1)
80,47,210 Equity Shares aggregating to approximately ₹750.00 crore 1.61
D PAID-UP CAPITAL AFTER THE ISSUE
19,65,63,124 Equity Shares 39.31
E SHARE PREMIUM ACCOUNT
Before the Issue Nil
After the Issue(2) 748.39 1. The Issue has been authorised by the Board of Directors pursuant to its resolution passed on May 22, 2020 and July 27, 2020. The Shareholders
have authorised and approved the Issue by way of a special resolution passed at their AGM held on July 22, 2020. 2. The securities premium account after the Issue is calculated on the basis of Gross Proceeds
# Except for share premium account. ^ The records currently maintained by the RoC, erroneously indicate the authorised share capital of our Company to be ₹48 crores. Our Company
has written to the RoC on multiple occasions, requesting for this error to be rectified in the RoC master data, including by way of its letter dated October 22, 2019.
Equity share capital history of our Company
The following table sets forth details of allotments of Equity Shares by our Company, since incorporation:
Date of
allotment
No. of equity
shares
allotted
Cumulative
No. of equity
shares
Face
value
(In ₹)
Issue price
per equity
share (In
₹)
Reason for allotment
Nature of
consideration
(Cash/Other
than cash)
June 22, 2010 2,50,000 2,50,000 2 2 Initial subscription to the
Memorandum of
Association
Cash
June 28, 2010 5,47,50,000 5,50,00,000 2 2 Further issue Cash
April 15, 2011 13,35,15,914 18,85,15,914 2 - Allotment of equity
shares pursuant to the
Scheme of Demerger
approved by the High
Court of Gujarat
pursuant to an order
dated January 24, 2011,
in the ratio of one Equity
Share each by our
Company, for every one
equity share held by the
shareholders of Alembic
Limited
Other than
cash
Proposed Allottees in the Issue
In compliance with the requirements of Chapter VI of the SEBI Regulations, Allotment shall be made by our
Company, in consultation with the BRLMs, to Eligible QIBs only, on a discretionary basis.
69
The names of the proposed Allottees and the percentage of Post-Issue capital that may be held by them is set forth
below:
Sr. No. Name of the proposed Allottees
Percentage of the
Post-Issue share
capital held (%)^# 1. TATA MULTICAP FUND 0.17
2. TATA RETIREMENT SAVINGS FUND-PROGRESSIVE PLAN 0.08
3. TATA RETIREMENT SAVINGS FUND-MODERATE PLAN 0.10
4. TATA RETIREMENT SAVINGS FUND-CONSERVATIVE PLAN 0.00
5. TATA VALUE FUND - SERIES 1 0.07
6. TATA VALUE FUND - SERIES 2 0.03
7. TATA MID CAP GROWTH FUND 0.08
8. TATA MUTUAL FUND -TATA EQUITY P/E FUND 0.67
9. HDFC LIFE 0.82
10. RELIANCE CAPITAL TRUSTEE COMPANY LTD - A/C NIPPON INDIA GROWTH FUND 0.19
11. BARODA DYNAMIC EQUITY FUND 0.04
12. BARODA ELSS 96 FUND 0.01
13. BARODA EQUITY SAVING FUND 0.00
14. BARODA HYBRID EQUITY FUND 0.02
15. BARODA MIDCAP FUND 0.01
16. BARODA MULTICAP FUND 0.04
17. BARODA CONSERVATIVE HYBRID FUND 0.00
18. MAHINDRA MANULIFE ELSS KAR BACHAT YOJANA 0.02
19. MAHINDRA MANULIFE MID CAP UNNATI YOJANA 0.05
20. MAHINDRA MANULIFE TOP 250 NIVESH YOJANA 0.02
21. PGIM INDIA TRUSTEES PRIVATE LIMITED A/C PGIM INDIA LARGE CAP FUND 0.03
22. PGIM INDIA TRUSTEES PRIVATE LIMITED A/C PGIM INDIA HYBRID EQUITY FUND 0.01
23. PGIM INDIA TRUSTEES PRIVATE LIMITED A/C PGIM INDIA MID CAP OPPORTUNITIES
FUND 0.01
24. PGIM INDIA TRUSTEES PRIVATE LIMITED A/C PGIM INDIA DIVERSIFIED EQUITY FUND 0.01
25. LIC LARGE & MID CAP FUND 0.05
26. UTI HEALTHCARE FUND 0.03
27. EDELWEISS TOKIO LIFE INSURANCE CO LTD EQUITY MIDCAP FUND 0.01
28. EDELWEISS TOKIO LIFE INSURANCE CO LTD EQUITY TOP 250 FUND 0.00
29. VESPERA FUND LIMITED 0.12
30. IDFC CORE EQUITY FUND 0.08
31. IDFC MULTICAP FUND 0.40
32. IDFC STERLING VALUE FUND 0.12
33. BAJAJ ALLIANZ LIFE INSURANCE COMPANY LTD 0.27
34. SUNDARAM INDIA MIDCAP FUND 0.04
35. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP SERIES I 0.01
36. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES II 0.01
37. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES III 0.01
38. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES IV 0.01
39. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES V 0.00
40. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP - SERIES VI 0.00
41. SUNDARAM MUTUAL FUND A/C SUNDARAM EMERGING SMALL CAP-SERIES VII 0.00
42. SUNDARAM MUTUAL FUND A/C SUNDARAM SELECT MICRO CAP SERIES - XII 0.01
43. SUNDARAM MUTUAL FUND A/C SUNDARAM SELECT MICRO CAP SERIES - XIV 0.01
44. SUNDARAM MUTUAL FUND A/C SUNDARAM SELECT MICRO CAP SERIES - XV 0.00
45. SUNDARAM MUTUAL FUND A/C SUNDARAM SELECT MICRO CAP SERIES - XVI 0.00
46. SUNDARAM MUTUAL FUND A/C SUNDARAM SELECT MICRO CAP - SERIES - XVII 0.00
47. SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM TAX ADVANTAGE FUND -
SERIES - III 0.00
48. SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM TAX ADVANTAGE FUND -
SERIES IV 0.00
49. SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM MICRO CAP TAX
ADVANTAGE FUND SERIES V 0.00
50. SUNDARAM MUTUAL FUND A/C SUNDARAM LONG TERM MICRO CAP TAX
ADVANTAGE FUND - SERIES - VI 0.00
51. SUNDARAM MUTUAL FUND A/C SUNDARAM MID CAP FUND 0.27
52. INDIA OPPORTUNITIES GROWTH FUND LTD PINEWOOD STRATEGY 0.14
70
^ The shareholding data is based on the beneficiary position data of the Company as on June 30, 2020 and includes the Allocation made in the Issue.
# The post-Issue shareholding pattern (in percentage terms) of the proposed Allottees has been disclosed on the basis of their respective DP
ID and Client ID.
Note:
(i) Subject to receipt of funds and allotment in this Issue.
Pre-Issue and Post-Issue shareholding pattern:
Sr. No. Category
Pre-Issue as of June 30, 2020 Post-Issue
Number of Equity
Shares held
% of share
holding
Number of Equity
Shares held*
% of share
holding
A. Promoter’s holding#
1. Indian
Individual 96,64,175 5.13 96,64,175 4.92
Bodies corporate 12,68,88,818 67.31 12,68,88,818 64.55
Sub-total 13,65,52,993 72.44 13,65,52,993 69.47
2. Foreign promoters
Individual 10,06,980 0.53 10,06,980 0.51
Bodies corporate - - - -
Sub-total 10,06,980 0.53 10,06,980 0.51
Sub-total (A) 13,75,59,973 72.97 13,75,59,973 69.98
B. Non - Promoter’s holding
3. Institutional investors 2,71,40,688 14.40 3,51,87,898 17.90
4. Non-institutional investors - - - -
(a) Bodies Corporates (including
private corporate bodies, if
any)
8,38,810 0.45 8,38,810 0.43
(b) Directors and relatives 24,234 0.01 24,234 0.01
(c) Resident individuals (including
Indian public, if any)
2,04,23,568 10.83 2,04,23,568 10.39
(d) Others [including Non-resident
Indians (NRIs)]
25,28,641 1.34 25,28,641 1.29
Sub-total (B) 5,09,55,941 27.03 5,90,03,151 30.02
Total (A+B) 18,85,15,914 100.00 19,65,63,124 100.00 # Includes the shareholding of the members forming part of Promoter Group.
* The post-Issue shareholding pattern of our Company reflects the shareholding of the institutional investors category on basis of the
Allocation made in the Issue, and reflects the shareholding of all other categories as of June 30, 2020.
No change in control in our Company will occur consequent to the Issue.
Other confirmations
• Our Company has not allotted securities on preferential basis or private placement or by way of rights issue
in the last one year preceding the date of this Placement Document.
• Our Company has not made any allotments for consideration other than cash, in the last one year preceding
the date of this Placement Document.
• Our Equity Shares have been listed for a period of at least one year prior to the date of issuance of the AGM
notice dated May 22, 2020, to the Shareholders for the approval of this Issue.
• Our Company shall not make any subsequent qualified institutions placement until the expiry of two weeks
from the date of this Issue. Further, Equity Shares allotted pursuant to this Issue shall not be sold by the
Allottee for a period of one year from the date of allotment, except on the Stock Exchanges.
71
RELATED PARTY TRANSACTIONS
For details of the related party transactions as per the requirements under Ind AS 24, as notified under section 133
of the Companies Act, 2013 read with Ind AS rules as amended for Fiscals 2020, 2019 and 2018, see “Financial
Statements” on page 180.
72
DIVIDENDS
The declaration and payment of final dividend, if any, will be recommended by our Board and approved by our
Shareholders at their discretion, subject to the provisions of the Articles of Association and the applicable laws,
including the Companies Act.
Our Board may also, from time to time, declare interim dividends. Our Board has approved and adopted a formal
dividend distribution policy in terms of Regulation 43A of the SEBI Listing Regulations, effective from July 29,
2016. For further information, see “Description of the Equity Shares” on page 157.
Details of dividends declared by our Company in Fiscals 2020, 2019, and 2018, are set out below:
Particulars Fiscal 2020 Fiscal 2019 Fiscal 2018
Face value of Equity Shares (in ₹ per share) 2.00 2.00 2.00
Dividend (Interim) per share (in ₹) 7.00 0.00 0.00
Dividend (Special) per share (in ₹) 3.00 0.00 0.00
Dividend (Final) per share (in ₹) 0.00 5.50 4.00
Total Dividend per share (in ₹) 10.00 5.50 4.00
Total Dividend (₹ in crores) 188.52 103.68 75.41
Dividend Rate (in %) 500 275 200
Dividend distribution tax (₹ in crores) 12.46 21.31 15.50
The amounts declared as dividend in the past are not necessarily indicative of dividend which may be declared by
our Company, if any, in the future. There is no guarantee that any dividends will be declared or paid in the future.
For a summary of some of the restrictions that may materially affect our ability to declare or pay dividends, see
“Risk Factors” on page 35.
The Equity Shares to be issued in connection with this Issue shall qualify for dividend declared in respect of the
Fiscal in which they have been Allotted. However, investors are cautioned to not rely on past dividends as an
indication of the future performance of our Company or for an investment in the Equity Shares offered in the
Issue.
73
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The following discussion and analysis of our financial condition and results of operations for Fiscals 2018, 2019
and 2020 included herein is derived from and should be read together with the Audited Consolidated Financial
Statements, included in this Placement Document. For further information, see “Selected Financial Information”
and “Financial Statements” on pages 31 and 180, respectively. Unless otherwise specified, all financial
information is presented on a consolidated basis.
This discussion contains forward-looking statements and reflects our current views with respect to future events
and financial performance. Actual results may differ materially from those anticipated in these forward-looking
statements as a result of certain factors such as those described under “Forward-Looking Statements” and “Risk
Factors” beginning on pages 14 and 35, respectively, and elsewhere in this Placement Document.
Our Fiscal ends on March 31 of each year. Accordingly, all references to a particular Fiscal are to the 12 months
ended March 31 of that year.
We prepare our financial statements in accordance with Indian Accounting Standards (Ind AS) notified under the
Companies (Indian Accounting Standards) Rules, 2015 (as amended). The financial statements reflect applicable
statutory requirements, regulatory guidelines and accounting practices in India. These requirements, guidelines
and practices change from time to time and, in accordance with (Ind AS), adjustments to reflect such changes are
made on a prospective basis. For the purposes of a comparative analysis in the discussion below, previous years’
figures have been reclassified wherever necessary.
Overview
We are a vertically integrated pharmaceutical company, developing, manufacturing and marketing of formulations
offered in the international markets including in markets such as the United States, European Union, etc
(“International Generics”), formulations which cater to India’s domestic formulations market (“Domestic
Formulations”) and active pharmaceutical ingredients which cater to both domestic and international markets
(“APIs”). We have a presence and sell our products in over 65 countries including the United States, India,
Europe, Canada, Australia, Brazil and South Africa. We provide a diverse suite of products under each of our
business verticals - International Generics, Domestic Formulation and APIs. Our product portfolio in the Domestic
Formulations covers numerous chronic and acute therapy areas and in the International Generics, our products
and products in pipeline include oral solids, dermatology, oncology oral solids, oncology injectables, general
injectables and ophthalmology. For Fiscal 2020, we derived 53.69%, 30.95% and 15.36% of our revenue from
operations from our International Generics, Domestic Formulations and APIs business, respectively.
We have a broad portfolio of Abbreviated New Drug Applications (“ANDAs”) for our International Generic
business filed with the United States Food and Drug Administration (“USFDA”). As of June 30, 2020, we have
received approval for 125 ANDAs including 14 ANDAs which have received tentative approval from USFDA.
Our filings in the United States focus on oral solids (oncology and non-oncology), injectable products (oncology
and non-oncology), ophthalmic and dermatological. As of March 31, 2020, we had successfully launched 76
products in the United States, which we sell through pharmacy chains, wholesalers and distributors. We
manufacture APIs for captive consumption as well as for selling to the customers in domestic and international
markets. As of March 31, 2020, we have filed 123 Drug Master Files (“DMFs”) with the USFDA for our API
products in multiple therapeutic areas, out of which 109 DMFs are active.
We have a presence in the Domestic Formulations market which caters to chronic and acute therapies including
cardiology, anti-diabetic, gynaecology, gastrology, dermatology, orthopaedic, ophthalmology, nephrology /
urology, anti-infective, cold and cough, and veterinary segment.
We rank 21 in Indian Pharma Market (“IPM”) as of March 31, 2020 (Source: March MAT data of IQVIA, TSA
March 2020) with a 1.5% market share in IPM (Source: IQVIA, TSA March 2020). Further, three of our brands
featured amongst the top 300 pharmaceutical brands in India (Source: IQVIA, TSA March 2020).
We operate three R&D centres located at Vadodara (Gujarat, India), Hyderabad (Telangana, India) and at West-
Caldwell (New Jersey, United States). We also have a USFDA approved Bioequivalence Centre, located at
Vadodara (Gujarat, India) which provides support for bioavailability (BA) and bioequivalence (BE) studies and
support our R&D activities. As of March 31, 2020, we employed about 1,100 professionals in our R&D centres
74
working on APIs and various dosage forms of formulations. Some our R&D efforts are also focused on developing
niche, specialty products to strengthen our product offerings. We dedicate a substantial portion of our revenue
from operations towards R&D activities. Our R&D spend as a percentage to revenue from operations has increased
from 5.92% in Fiscal 2015 to 14.00% in Fiscal 2020.
Further, owing to our strong R&D, we have been granted 911 patents worldwide (for both APIs and formulations),
including patents which have been withdrawn, abandoned or have lapsed, as of March 31, 2020.
We have one facility engaged in the manufacturing of Domestic Formulations located in Sikkim. Two of our
facilities are engaged in the manufacturing of International Generic formulations located in Gujarat out of which
one facility is operated by our joint venture. Three of our facilities for manufacturing APIs are located in Gujarat.
All these facilities are currently commercially operational. The manufacturing units which are responsible for
manufacturing our products which are sold in regulated markets (including the United States, Canada, United
Kingdom), comply with applicable regulations and standards and also comply with the targeted markets’
regulatory requirements, for example that of, USFDA’s current Good Manufacturing Practices (“CGMPs”), the
United Kingdom’s medicines and healthcare products regulatory agency (“MHRA”), the Brazilian Health
Regulatory Agency (“ANVISA”), European Directorate for Quality of Medicines (“EDQM”), Australian
Therapeutic Goods Administration (“TGA”), etc. As on date, the Establishment Inspection Report (“EIR”) from
USFDA is in place for each of our operational facilities, where applicable. For more details regarding our
manufacturing facilities, see “Manufacturing Process and Facilities” on page 113.
Driven by a strong management team, our consolidated revenue from operations for Fiscal 2020 was ₹ 4,605.75
crores which was up by 17.06%, compared to ₹ 3,934.68 crores for Fiscal 2019. Our Consolidated PAT for Fiscal
2020 grew by 41.83% to ₹ 828.82 crores from ₹ 584.37 crores for Fiscal 2019.
Factors affecting our Financial Results
The following is a discussion of certain factors that have had, and continue to have, a significant effect on our
financial results:
Revenue Generation
We earn our revenue from domestic sale and export of our products. We derive a significant portion of our revenue
from our export sales. Also, we continuously endeavor to provide quality products to our customers. Accordingly
any decrease in our exports may affect our revenues and these may be impacted by such quality products.
Strengthen our Domestic Formulations business through consolidating our presence and venturing into new
fast growth therapy segments
We develop, manufacture and commercialize branded pharmaceutical products in select therapeutic areas within
the chronic and acute categories of the Indian pharmaceutical market. Our Domestic Formulations business
accounted for 30.95%, 35.13% and 40.69% for Fiscals 2020, 2019 and 2018, respectively and continues to be a
significant part of our growth strategy in the future. Further, we have been increasing our presence in the specialty
therapies, including cardiology, diabetes, gynecology, ophthalmology and veterinary. Specialty remains our key
focus area with 64.92% share of our consolidated revenue and acute segments consisting of cough and cold and
anti-infective therapies with 35.08% share of our revenue from operations for Fiscal 2020.
Our strategy for expansion in existing and new therapeutic areas includes extending our focus to target lifestyle
disorders and the chronic category (to target products that have to be prescribed over an extended period of time
as opposed to one time incidence related medication), identifying gaps in existing interventions, analyzing patient
compliance, and working with key opinion leaders, doctors and patients through active engagement to develop,
manufacture and market new indications which fulfil an unmet need or are clinically differentiated.
We believe that this focused sales strategy has in the past helped us and will continue to help us in enhancing
emphasis on specialist coverage. Further, we intend to continue updating our portfolio in India, which we believe
would allow us to strengthen our position in the market. If we are unable to expand and strengthen our Domestic
Formulations business through these strategies, it may affect our results of operations.
Expand and improve our United States formulations products portfolio
75
Our strategy in the United States is to continue to focus on the existing and new formulations and enhance our
product portfolio by accelerating ANDA filings. Our US formulations business has grown to ₹ 1,976.00 crores in
Fiscal 2020, accounting for 42.90% of total revenue on a consolidated basis for the Fiscal. US formulation
business remains a significant growth engine for us. We wish to offer a comprehensive range of products under
dermatology, oncology and ophthalmology therapies and cater to the strong demand in US generics segment. Our
focus is on developing complex, niche products having limited competition.
The specific timing of our new product launches is subject to a variety of factors, some of which are beyond our
control including the timing of USFDA approval for ANDAs currently under review or that we file with respect
to new products with the USFDA or other regulators. The timing of these and other new product launches may
have a significant impact on our results of operations.
Expiring Patents
Our operations are also directly relates to the expiry of patents for pharmaceutical products. As existing patents
held by other pharmaceutical companies expire, we can commence the marketing and sale of generic versions of
such products, subject to approval from concerned regulatory authority. Alternatively, certain regulatory
authorities such as the USFDA grant periods of exclusivity to generic drug companies that are the “first to file”
applications for the marketing and sale of their pharmaceutical formulations. Our ability to develop marketable
generic versions of pharmaceutical formulation going “off-patent” in a cost effective, efficient and timely manner,
and to protect such generic versions from legal challenges, may affect our results of operations.
Efficient production across the manufacturing facilities with focus on quality assurance
Our ability to increase our cost efficiency is dependent on the efficient management of our production costs. The
availability of key raw materials at competitive prices is critical and price fluctuations may adversely affect our
margins and, as a result, our results of operations. Any unavailability of these raw materials would impact our
production.
In addition, in order to increase our profits, we have maintained robust quality system across the organisation to
ensure absolute compliance. Attaining and maintaining this level of quality requires considerable expense and
planning. If we are unable to achieve and preserve the necessary level of quality in our manufacturing processes
and facilities in the future, our financial condition and results of operations may be adversely affected.
Research and Development
We are a R&D focused company and we believe that our strong R&D expertise is critical for our success in
International Generics business. This process is both time consuming and costly, and involves a high degree of
business risk. To develop our product pipeline, we commit substantial time, funds and other resources. Our
investment in research and development for future products could result in higher costs without a proportionate
increase in revenues. In addition, we must adapt to rapid changes in our industry due to technological advances
and scientific discoveries. If we are unable to cope up with these changes, our business and results of operations
could be adversely affected.
Although we strive to keep our technology, facilities and machinery current with the latest international standards,
the technologies, facilities and machinery we currently employ may become obsolete. The cost of implementing
new technologies, upgrading our manufacturing facilities and retaining our research staff could be significant and
could adversely affect our profitability.
Regulatory approvals
We intend to broaden our revenue base in India as well as several in existing geographies by increasing our
existing product portfolio in various markets. As a result, our products are subject to regulation by numerous
Indian and foreign regulatory agencies. Each of these agencies requires us to comply with laws and regulations
governing the development, testing, manufacturing, labelling, marketing and distribution of our products and we
are required to maintain various approvals, licenses, registrations and permissions for our business activities.
Our business, prospects, results of operations and financial condition could be adversely affected if we fail to
76
obtain, or comply with applicable conditions that may be attached to, our approvals, licenses, registrations and
permissions. We continue to file for approvals for our new products with various other government and regulatory
agencies. Any delay in the grant of approvals for new products, or any withdrawal of approval for existing
products would adversely affect our results of operations.
Competition
Our products are exposed to intense competition from products commercialized or under development by
competitors in all our therapeutic areas across geographies. Our business, prospects, results of operations and
financial condition could be adversely affected if our competitors gain significant market share in areas in which
we are focused. Many of our competitors may have greater financial, manufacturing, research and development,
marketing and other resources, more experience in obtaining regulatory approvals, greater geographic reach,
broader product ranges and stronger sales forces. Further, in global markets, we compete with local companies,
multinational corporations and companies from other emerging markets. In addition, as we grow our International
Generics business, we expect competition from major international generic manufacturers. We also operate in a
rapidly consolidating industry. Our competitors are consolidating, and the strength of the combined companies
could affect our competitive position in all of our business areas.
Accordingly, our results of operations depend significantly on various factors such as the demand for our products
in the markets we operate in, our ability to manage our growth strategy and expansion plans, including our ability
to grow our exports and our ability to grow and manage our distribution network in India.
Foreign currency exchange fluctuations
Our products are typically priced in Indian Rupees for our sales in India, in U.S. Dollars for sales in the United
States and in Euros for sales in the European countries. Similarly, for other jurisdictions where we sell our
products, we price the products in other freely convertible currencies in accordance with local convention. A
portion of our costs, including labour, raw materials, packing materials, transportation costs and capital
expenditures are incurred in currencies other than Indian Rupees. Additionally, we also procure a portion of our
inventory and incur capital expenditures from outside India and, as a result, incur such costs in currencies other
than Indian Rupees. As a consequence, we are exposed to currency rate fluctuations between the Indian Rupee
and U.S. dollars and other foreign currencies.
Impact of Covid-19
The COVID-19 pandemic and the preventative or protective actions that governments around the world have
taken to counter the effects of the pandemic have resulted in a period of economic downturn and business
disruption in India, as well as in countries where our customers and suppliers are located. The World Health
Organization declared the outbreak of COVID-19 to be a public health emergency of international concern on
January 30, 2020, and a global pandemic on March 11, 2020. On March 24, 2020, the Government of India
ordered a national lockdown in response to the spread of COVID-19.
While our business has not been materially affected adversely by the current wave of the pandemic, the global
impact of the outbreak has been rapidly evolving. As cases of COVID-19 have continued to be identified in
various countries, many jurisdictions, including the governments of India, the United States and the other markets
in which we conduct business, have reacted by instituting restrictive measures including invoking lock downs
and quarantines, requiring the closure of non-essential businesses and placing restrictions on the types of
businesses that may continue to operate. Although we have been declared an essential business and have been
able to adjust our business to continue operating during the lockdown, there was no significant impact of COVD-
19 on our financial condition and results of operations for the financial year 2020. However, events beyond our
control may unfold in the future, which makes it difficult for us to predict the impact that COVID-19 will have
on us, our customers or suppliers in the future. We continue to closely monitor the effect that COVID-19 may
have on our business and results of operations. To the extent, the COVID-19 pandemic adversely affects us, it
may also significantly increase the effect of the aforementioned factors affecting our results of operations.
Components of Income and Expenditure
The principal components of our income and expenditure are explained below.
Total Income: Our total income comprises of revenue from operations and other income.
77
Revenue from operations
Our Revenue from operations majorly comprises of revenue from domestic sales and export of our products.
Revenue from operations also includes export incentives, royalty and other miscellaneous operating revenue.
Other Income
Our other Income comprises of dividend received, insurance claims, lease rent income, profit on sale of assets,
profit on sale of investments, interest income and other miscellaneous income.
Total Expenses: Our total expenses comprise of cost of materials consumed, purchase of stock-in trade, changes
in inventories of finished goods, stock-in trade and work-in-progress, employee benefit expenses, finance cost,
Depreciation and Amortisation Expenses and other expenses.
Cost of Materials Consumed
Cost of material consumed comprises the opening stock and purchase of raw and packing materials during the
year and is reduced by closing stock, during our production process.
Purchase of Stock-in trade
Purchase of stock-in trade comprises of purchases of goods in a particular year.
Changes in Inventories
Changes in inventories of finished goods and work-in-progress, comprises the change in opening and closing
stock of the finished goods and work-in-progress manufactured by us. Change in stock in trade comprises of
change in opening and closing stock of the same.
Employee Benefit Expenses
Our employee benefit expense includes salaries and wages, contribution to provident and other funds, and staff
welfare expenses.
Finance Costs
Our finance costs comprise of interest on term loans taken from banks, interest on non-convertible debentures
and interest on other financial liabilities.
Depreciation and Amortisation Expenses
Property, plant and equipment and intangible assets are depreciated and amortised over periods corresponding to
their estimated useful lives.
Other Expenses
Our other expenses primarily include consumption of stores, spares, laboratory material and analytical expense;
power and fuel; sales promotion, service fees and commission; freight and forwarding charges; travelling
expenses; legal & professional fees and external research & development.
Significant Accounting Policies
Our significant accounting policies are summarized below:
1. Statement of compliance
Our Audited Consolidated Financial Statements are prepared in accordance with Indian Accounting
Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as
amended).
2. Principles of consolidation
The Audited Consolidated Financial Statements of the Company and its subsidiaries have been
consolidated on a line-by-line basis by adding together the book values of like items of assets, liabilities,
income and expenses, after eliminating intra-group balances and intra-group transactions resulting in
unrealised profits as per Ind As 110 “Consolidated Financial Statements” specified under Section 133 of
the Companies Act, 2013 read with Companies (Accounts) Rules, 2015.
Investment and share of profit of associate and Joint Venture have been consolidated as per the equity
78
method as per Ind AS 28 – “Investments in Associates” and “Ind AS 111 Joint Arrangements” respectively
specified under Section 133 of the Companies Act, 2013 read with Companies (Accounts) Rules 2015.
For the purposes of presenting the consolidated financial statements, the assets and liabilities of Group’s
foreign operations, are translated to the Indian Rupees at exchange rates at the end of each reporting period.
The income and expenses of such foreign operations are translated at the average exchange rates for the
period. Resulting foreign currency differences are recognised as Foreign Currency Translation Reserve
through other comprehensive income.
The Group accounts for its share of post-acquisition changes in net assets of associates, after eliminating
unrealised profits resulting from transactions between the Group and its associates to the extent of its share,
through its Consolidated Statement of Profit and Loss and Other Comprehensive Income, if any, to the
extent such change is attributable to the associates’ Statement of Profit and Loss and through its reserves,
if any, for the balance.
Change in Ownership interest
Changes in the Group’s ownership interest in subsidiaries that do not result in the group losing control over
the subsidiaries are accounted for as equity transactions.
3. Basis of preparation of financial statements
Our Audited Consolidated Financial Statements have been prepared in accordance with Indian Accounting
Standards (Ind AS) as prescribed under Section 133 of the Act to be read with Rule 3 of the Companies
(Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment
Rules, 2016. These comprises of the Balance Sheet, Statement of Profit and Loss, Cash Flow Statement,
Statement of Changes in Equity and the Notes to Financial Statements. We have consistently applied
accounting policies to all periods presented in these Financial Statements.
4. Basis of measurement
The Audited Consolidated Financial Statements have been prepared on a historical cost convention on the
accrual basis, except for certain financial instruments that are measured at fair value, viz derivatives,
employee benefit plan assets. Functional and Presentation Currency the financial statements are presented
in Indian rupees, which is the functional currency of the Company.
5. Significant accounting judgments, estimates and assumptions
The preparation of financial statements requires the management to make judgements, estimates and
assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the
accompanying disclosures, and the disclosure of contingent liabilities. Actual results may differ from these
estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any change in these
estimates and assumptions will generally be reflected in the financial statements in current period or
prospectively, unless they are required to be treated retrospectively under relevant accounting standards. In
particular, information about significant areas of estimates and judgements in applying accounting policies
that have the most significant effect on the amounts recognised in the financial statements includes financial
instruments, useful lives of property, plant and equipment and intangible assets, valuation of inventories,
measurement of defined benefit obligations and actuarial assumptions, provisions and other accruals, sales
returns, chargebacks, allowances and discounts, recoverability/recognition of deferred tax assets,
Assessment of functional currency, Contingencies.
6. Property, plant and equipment (PPE)
Property, Plant and Equipment is stated at cost, net of accumulated depreciation and accumulated
impairment losses, if any. Cost comprises of the purchase price net of eligible input tax credit, and any
attributable cost of bringing the assets to its working condition for its intended use, including the cost of
replacing parts and borrowing costs for long-term construction projects if the recognition criteria are met.
The cost and related accumulated depreciation are eliminated from the financial statements upon sale or
retirement of the asset and the resultant gains or losses are recognized in the statement of profit and loss.
Assets to be disposed are reported at the lower of the carrying value or the net realisable value less cost to
sell. We have adopted, “Cost Model” for accounting for our Property Plant and Equipment.
79
7. Capital work-in-progress
Projects under construction wherein assets are not ready for use in the manner as intended by the
management are shown as Capital Work-In-Progress.
8. Intangible assets
Intangible assets are stated at cost less provisions for amortisation and impairments. Software licenses fees
are charged to statement of profit and loss when incurred.
9. Intangible assets under development
Intangible assets consisting of development expenditure of certain products are amortised on straight line
method from the date they are available for use, over the useful life of the assets (5-20 years), as estimated
by the Management.
10. Impairment of assets
The carrying values of assets / cash generating units at each balance sheet date are reviewed for impairment,
if any indication of impairment exists. If the carrying amount of the assets exceed the estimated recoverable
amount, an impairment loss is recognised for such excess amount. The impairment loss is recognised as an
expense in the Statement of Profit and Loss.
11. Borrowing cost
Borrowing costs attributable to the acquisition and/or construction of an asset that necessarily takes a
substantial period of time to get ready for use in the manner as intended by management, are capitalised as
part of the cost of the asset. All other borrowing costs are expensed in the period in which they are incurred.
12. Inventories
Inventories consist of Raw Materials, Stores and Spares, Packing Materials, Work-in-Progress, Goods in
Transit and Finished Goods and are measured at the lower of cost and net realisable value. Cost includes
expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred
in bringing them to their existing location and condition. In the case of Finished Goods and Work-in-
Progress, cost includes an appropriate share of overheads based on normal operating capacity. Net
realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of
completion and selling expenses.
13. Trade receivables
Trade receivables are carried at original invoice amount less any provisions for doubtful debts. Provisions
are made where there is evidence of a risk of non-payment, taking into account ageing, previous experience
and general economic conditions. When a trade receivable is determined to be uncollectable it is written
off, firstly against any provision available and then to the Statement of Profit and Loss.
14. Financial instruments
We recognize financial assets and financial liabilities when it becomes a party to the contractual provisions
of the instrument.
(a) Financial Assets
(i) Initial recognition and measurement
We recognize financial assets when it becomes a party to the contractual provisions of the
instrument. All financial assets are recognized at fair value on initial recognition, except for
trade receivables which are initially measured at transaction price. Transaction costs that are
directly attributable to the acquisition of financial assets that are not at fair value through
80
profit or loss are added to the fair value on initial recognition. Regular way trade of financial
assets are accounted for at trade date.
(ii) Subsequent measurement
For the purpose of subsequent measurement, financial assets are classified in four categories:
• Financial assets at amortised cost:
A financial asset is subsequently measured at amortised cost, if it is held within a
business model whose objective is to hold the asset in order to collect contractual cash
flows and the contractual terms of the financial asset give rise on specified dates to
cash flows that are solely payments of principal and interest on the principal amount
outstanding. After initial measurement, debt instruments are subsequently measured at
amortised cost using the effective interest rate method, less impairment, if any.
• Financial assets at fair value through other comprehensive income
A financial asset is subsequently measured at fair value through other comprehensive
income if it is held within a business model whose objective is achieved by both
collecting contractual cash flows and selling financial assets and the contractual terms
of the financial asset give rise on specified dates to cash flows that are solely payments
of principal and interest on the principal amount outstanding. The Company has made
an irrevocable election for its investments which are classified as equity instruments
to present the subsequent changes in fair value in other comprehensive income based
on its business model.
• Financial assets at fair value through profit or loss
Financial assets which are not classified in any of the above categories are
subsequently fair valued through profit or loss.
• De-recognition:
Our company derecognizes a financial asset when the contractual rights to the cash
flows from the financial asset expire or it transfers the financial asset and the transfer
qualifies for de-recognition under Ind. AS 109.
• Investments in subsidiaries and associates
Our Company has elected to recognise its investments in subsidiaries and associates at
cost in the separate financial statements in accordance with the option available in Ind
AS 27, ‘Separate Financial Statements’.
(b) Financial Liabilities
(i) Initial recognition and measurement
Our Company’s financial liabilities include trade and other payables, loans and borrowings
including bank overdrafts, financial guarantee contracts and derivative financial instruments.
Financial liabilities are classified, at initial recognition, at fair value through profit and loss
or as those measured at amortised cost.
(ii) Subsequent measurement
The subsequent measurement of financial liabilities depends on their classification as follows:
• Financial liabilities at fair value through profit and loss
Financial liabilities at fair value through profit and loss include financial liabilities held
for trading. The Company has not designated any financial liabilities upon initial
recognition at fair value through profit and loss.
• Financial liabilities measured at amortised cost
After initial recognition, interest bearing loans and borrowings are subsequently
measured at amortised cost using the effective interest rate method except for those
designated in an effective hedging relationship.
• De-recognition
81
A financial liability (or a part of a financial liability) is derecognized from the company’s
balance sheet when the obligation specified in the contract is discharged or cancelled or
expires.
(c) Derivative Financial Instruments
Our company holds derivative financial instruments such as foreign exchange forward and option
contracts to mitigate the risk of changes in exchange rates on foreign currency exposures. The
counter party for these contracts is generally a bank and these are not designated as hedges under
Ind AS 109, Financial Instruments. Any derivative that is either not designated as hedge, or is so
designated but is ineffective as per Ind AS 109, is categorized as a financial asset or financial
liability, at fair value through profit or loss. Derivatives not designated as hedges are recognized
initially at fair value and attributable transaction costs are recognized in the statement of profit and
loss when incurred. Subsequent to initial recognition, these derivatives are measured at fair value
through profit or loss. Assets/liabilities in this category are presented as current assets/current
liabilities if they are either held for trading or are expected to be realized within 12 months after the
balance sheet date.
15. Cash and cash equivalents
Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits
with an original maturity of three months or less, which are subject to an insignificant risk of changes in
value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-
term deposits, as defined above.
16. Operating cycle
Based on the nature of products / activities of our Company and the normal time between acquisition of
assets and their realisation in cash or cash equivalents, our Company has determined its operating cycle as
12 months for the purpose of classification of its assets and liabilities as current and non-current.
17. Revenue Recognition
Revenue from contracts with customers is recognised on satisfaction of performance obligation, when
control of the goods is passed to customer, at an amount that reflect the consideration our company expects
to receive. The point at which control passes is determined based on terms of agreement with customer or
as per general industry / market practice. Estimated future returns are calculated based on specific
methodology and assumptions. The methodology and assumptions used to estimate returns are monitored
and adjusted regularly in the light of contractual and legal obligations, past trend & experience and
projected market conditions. Revenue is recognised net of such future expected return and actual return.
Variable consideration arises on the sale of goods as a result of profit sharing arrangement and various
deductions including charge back. Revenue recognition in case of profit sharing is highly uncertain hence
the same is recognised based on reasonable certainty of revenue. Our company enters into development
and marketing collaborations and out-licences of our company’s compounds or products to other parties.
These contracts give rise to fixed and variable consideration from upfront payments, development
milestones, sales-based profit sharing and royalties. Income dependent on the achievement of milestone is
recognised when the related event occurs and it is highly probable that significant reversal in the amount
of cumulative revenue recognised will not occur. Sales-based royalties on a licence of intellectual property
are recognised on confirmation of actual sales. GST and other taxes on sales are excluded from revenue.
Income from operations includes Export benefits available under prevalent schemes are recognised to the
extent considered receivable. Other income is comprised of interest income, Gain / loss on investments,
dividend income and Insurance claim. Dividend income and other income is recognized when the right to
receive payment is established.
18. Research and Development Expense
All revenue expenses related to research and development including expenses in relation to development
of product/processes and expenses incurred in relation to compliances with international regulatory
authorities in obtaining of Abbreviated New Drug Applications (ANDA) and Drug Master Files (DMF)
are charged to the statement of profit and loss in the year in which it is incurred.
82
Development expenditure of certain nature is capitalised when the criteria for recognising an intangible
asset are met, usually when a regulatory filing is intended to be made in a major market and approval is
considered highly probable.
19. Employee benefits
(a) Defined Benefit Obligation Plans:
(i) Gratuity Defined Benefit Obligation Plans:
Our Company operates a defined benefit gratuity plan which requires contributions to be made
to a separately administered fund by the Life Insurance Corporation of India (LIC) and HDFC
Life Insurance Company Ltd. The cost of providing benefits under the defined benefit plan is
determined using the projected unit credit method. The service cost and the net interest cost are
charged to the Statement of Profit and Loss. Actuarial gains and losses arise due to difference
in the actual experience and the assumed parameters and also due to changes in the assumptions
used for valuation. The Company recognizes these re-measurements in the Other
Comprehensive Income (OCI).
(ii) Provident Fund
Our Company’s contribution to provident fund, administered through a Company managed
trust, is recognised as an expense in the Statement of Profit and Loss.
(b) Defined Contribution plans
Superannuation fund is administered by the HDFC Life Insurance Company Ltd. The contribution
to superannuation fund, Contribution to pension fund, ESIC, EDLI and Labour Welfare Fund are
recognised as an expense in the statement of profit and loss. Under defined contribution plans
Provident Fund, is contributed to Government administrated Provident Fund by subsidiaries.
(c) Leave Liability
Our Company has a policy to allow accumulation of leave by employees up to certain days.
Accumulated leave liability as at the yearend is provided as per actuarial valuation. The cost of
providing benefits under the defined benefit plan is determined using the projected unit credit
method. Actuarial gains and losses arise due to difference in the actual experience and the assumed
parameters and also due to changes in the assumptions used for valuation. Our Company recognizes
these actuarial gains and losses in the statement of Profit and Loss, as income or expense.
20. Depreciation / Amortisation
Depreciation is calculated on a straight-line basis as per the specified life of the assets as provided in
schedule II to the Companies Act, 2013.
Class of Assets- Tangible Range of useful life
Building 05 - 60 Years
Plant & Equipment 03 - 22 Years
Furniture & Fixtures 10 Years
Vehicles 08 - 10 Years
Office Equipment 05 Years
Class of Assets- Intangible Range of useful life
Goodwill 10 Years
Other Intangible Asset 08 Years
The management, based on internal technical evaluation, believes that the useful lives as given above
best represent the period over which the assets are expected to be used. The useful lives for certain assets
is different From the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013,
and the same is considered in the above range of useful life. Leasehold Land is amortized over the period
of lease. Depreciation methods, useful lives and residual values are reviewed periodically, including at
each financial year end. Depreciation on PPE added during the year is provided on pro rata basis from
the month of addition. Depreciation on sale / disposal of PPE is provided pro-rata up to the preceding
month of disposal/discarding.
83
Impairment
At each balance sheet date, our Company reviews the carrying values of its property, plant and equipment
and intangible assets to determine whether there is any indication that the carrying value of those assets
may not be recoverable through continuing use. If any such indication exists, the recoverable amount of
the asset is reviewed in order to determine the extent of impairment loss (if any). Where the asset does
not generate cash flows that are independent from other assets, our Company estimates the recoverable
amount of the cash generating unit to which the asset belongs. Recoverable amount is the higher of fair
value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are
discounted to their present value using a pretax discount rate that reflects current market assessments of
the time value of money and the risks specific to the asset for which the estimates of future cash flows
have not been adjusted. An impairment loss is recognised in the statement of profit and loss as and when
the carrying value of an asset exceeds its recoverable amount. Where an impairment loss subsequently
reverses, the carrying value of the asset (or cash generating unit) is increased to the revised estimate of
its recoverable amount so that the increased carrying value does not exceed the carrying value that would
have been determined had no impairment loss been recognised for the asset (or cash generating unit) in
prior years. A reversal of an impairment loss is recognised in the statement of profit and loss immediately
21. Leases
As lessee
Initial measurement
Lease Liability: At the commencement date, a Company measure the lease liability at the present value of
the lease payments that are not paid at that date. The lease payments shall be discounted using incremental
borrowing rate. Right-of-use assets: initially recognised at cost, which comprises the initial amount of the
lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus
any initial direct costs less any lease incentives.
Subsequent measurement
Lease Liability: Company measure the lease liability by (a) increasing the carrying amount to reflect
interest on the lease liability; (b) reducing the carrying amount to reflect the lease payments made; and (c)
re-measuring the carrying amount to reflect any reassessment or lease modifications. Right-of-use assets:
subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets
are depreciated from the commencement date on a straight line basis over the shorter of the lease term and
useful life of the under lying asset.
Impairment:
Right of use assets are evaluated for recoverability whenever events or changes in circumstances indicate
that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable
amount (i.e. the higher of the fair value less cost to sell and the value in-use) is determined on an individual
asset basis unless the asset does not generate cash flows that are largely independent of those from other
assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which
the asset belongs.
Short term Lease
Short term lease is that, at the commencement date, has a lease term of 12 months or less. A lease that
contains a purchase option is not a short-term lease. If the company elected to apply short term lease, the
lessee shall recognise the lease payments associated with those leases as an expense on either a straight-
line basis over the lease term or another systematic basis. The lessee shall apply another systematic basis
if that basis is more representative of the pattern of the lessee’s benefit.
As a lessor
Leases for which the company is a lessor is classified as a finance or operating lease. Whenever the terms
of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is
classified as a finance lease. All other leases are classified as operating leases. Lease income is recognised
in the statement of profit and loss on straight line basis over the lease term.
22. Foreign Exchange Transactions
84
Transactions in foreign currencies are initially recorded by our Company at the rate of exchange prevailing
on the date of the transaction. Monetary assets and monetary liabilities denominated in foreign currencies
remaining unsettled at the end of the year are converted at the exchange rate prevailing on the reporting
date. Differences arising on settlement or conversion of monetary items are recognised in statement of
profit and loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are
recorded using the exchange rates at the date of the transaction. In respect of forward cover contracts, the
mark to market loss / gain as at the reporting date is charged to Statement of Profit and Loss. In respect of
options contracts to mitigate the probable foreign exchange fluctuation risk, the options contracts are fair
valued and the resultant variation as at the reporting date is charged to Statement of Profit and Loss.
23. Taxes
(a) Current income tax
Income tax expense is recognised in the statement of profit and loss except to the extent that it relates
to items recognised in Other Comprehensive Income (OCI) or directly in equity, in such case it is
recognised in OCI or directly in equity respectively. Current income tax for current and prior periods
is recognized at the amount expected to be paid to or recovered from the tax authorities, using the
tax rates and tax laws that have been enacted or substantively enacted on the reporting date. Our
company offsets current tax assets and current tax liabilities, where it has a legally enforceable right
to set off the recognized amounts and where it intends either to settle on a net basis, or to realize the
asset and settle the liability simultaneously.
(b) Deferred tax
Deferred income tax assets and liabilities are recognized for all temporary differences arising
between the tax bases of assets and liabilities and their carrying amounts in the financial
statements. Deferred tax assets are reviewed at each reporting date and are reduced to the extent
that it is no longer probable that the related tax benefit will be realized. The benefit of credit
against the payment made towards Minimum Alternate Tax for the earlier years is available in
accordance with the provisions of the section 115J (AA) of income tax act 1961 over the period
of subsequent 15 assessment year and it is recognised to the extent of deferred tax liability in view
of the certainty involved of its realisation against reversal of deferred tax liability.
24. Provisions, Contingent Liabilities and Contingent Assets
(a) Provisions
Provisions are recognised when our Company has a present obligation (legal or constructive) as a
result of a past event, it is probable that an outflow of resources embodying economic benefits
will be required to settle the obligation and a reliable estimate can be made of the amount of the
obligation. The expense relating to a provision is recognised in the statement of profit and loss or
balance sheet as the case may be.
(b) Contingent Liabilities
Contingent liability is disclosed for (i) Possible obligations which will be confirmed only by the
future events not wholly within the control of our company or (ii) Present obligations arising from
past events where it is not probable that an outflow of resources will be required to settle the
obligation or a reliable estimate of the amount of the obligation cannot be made.
(c) Contingent Assets
Contingent Assets are not recognised in the financial statements. Contingent Assets if any, are
disclosed in the notes to the financial statements.
25. Earnings per share
Basic earnings per equity share are computed by dividing the net profit attributable to the equity holders of
the company by the weighted average number of equity shares outstanding during the period. Diluted
earnings per equity share is computed by dividing the net profit attributable to the equity holders of the
company by the weighted average number of equity shares considered for deriving basic earnings per equity
share and also the weighted average number of equity shares that could have been issued upon conversion
of all dilutive potential equity shares. The dilutive potential equity shares are adjusted for the proceeds
85
receivable had the equity shares been actually issued at fair value (i.e. the average market value of the
outstanding equity shares). Dilutive potential equity shares are deemed converted as of the beginning of
the period, unless issued at a later date. Dilutive potential equity shares are determined independently for
each period presented. The number of equity shares and potentially dilutive equity shares are adjusted
retrospectively for all periods presented for any share splits and bonus shares issues including for changes
effected prior to the approval of the financial statements by the Board of Directors.
26. Government Grant
Government grants are recognised when there is reasonable assurance that the grant will be received and
the company will comply with conditions attached to the grant. Accordingly, Government grants is
deducted to calculate the carrying amount of the asset, and is recognised in profit or loss over the life of a
depreciable asset as a reduced depreciation expense. Government grant related to specific expenses are
shown as other income in the Statement of Profit and Loss.
Results of Operations
The table below sets forth a summary of our financial results containing significant items of our income and
expenditure for Fiscal 2020, 2019 and 2018.
(₹ in Crores)
Particulars
Fiscal 2020 Fiscal 2019 Fiscal 2018
Amount % of Total
Income Amount
% of Total
Income Amount
% of Total
Income
Revenue from Operations 4,605.75 99.89 3,934.68 99.76 3,130.81 99.78
Other Income 4.94 0.11 9.38 0.24 7.03 0.22
Total Income 4,610.69 100.00 3,944.06 100.00 3,137.84 100.00
Cost of Materials
Consumed
979.05 21.23 850.04 21.55 725.75 23.13
Purchase of Stock-in
trade
270.93 5.88 234.93 5.96 201.87 6.43
Changes in Inventories (210.59) (4.57) (92.27) (2.34) (42.06) (1.34)
Employee Benefit
Expenses
906.44 19.66 746.69 18.93 622.81 19.85
Finance Cost 27.16 0.59 18.41 0.47 3.40 0.11
Depreciation and
Amortisation
157.32 3.41 115.23 2.92 105.46 3.36
Other Expenses 1,436.89 31.16 1,321.71 33.51 979.34 31.21
Total Expenses 3,567.22 77.37 3,194.74 81.00 2,596.57 82.75
Profit/ (loss) Before
exceptional items and
Tax
1,043.47 22.63 749.32 19.00 541.27 17.25
Exceptional Item 43.65 0.95 - - - -
Profit Before Tax 999.82 21.69 749.32 19.00 541.27 17.25
Tax Expenses
Current Tax 204.57 4.44 178.14 4.52 123.61 3.94
Deferred Tax (4.30) (0.09) (17.29) (0.44) (2.16) (0.08)
Short/ Excess Tax
Provision
(1.09) (0.02) (4.10) (0.10) (1.10) (0.03)
Profit after Tax before
share of Profit of
Associate and Joint
Venture
800.64 17.37 592.57 15.02 420.91 13.41
Share of Profit/ (loss) of
associate and joint
venture
0.05 - (9.28) (0.24) (8.09) (0.26)
Profit/(Loss) for the
year before non-
controlling interest
800.70 17.37 583.29 14.79 412.82 13.16
Non-controlling Interest 28.12 0.61 1.08 0.03 (0.19) (0.01)
Profit for the Year
(attributable to Owners) 828.82 17.98 584.37 14.82 412.63 13.15
86
Particulars
Fiscal 2020 Fiscal 2019 Fiscal 2018
Amount % of Total
Income Amount
% of Total
Income Amount
% of Total
Income
Other Comprehensive
Income (1.82) (0.04) 5.83 0.15 (3.20) (0.10)
Total Comprehensive
Income for the year 798.88 17.33 589.12 14.94 409.63 13.05
Total Comprehensive
Income for the year
Attributable to
Non- Controlling interest (28.17) (0.61) (1.09) (0.03) 0.19 0.01
Owners of the Company 827.05 17.94 590.21 14.96 409.43 13.05
Results for Fiscal 2020 compared with Fiscal 2019
Total Income
Our total income increased by 16.90% from ₹ 3,944.06 Crores in Fiscal 2019 to ₹ 4,610.69 Crores in Fiscal 2020.
This is due to the factors mentioned below:
Revenue from Operations: Our revenue from operations increased by 17.06% from ₹ 3,934.68 Crores in Fiscal
2019 to ₹ 4,605.75 Crores in Fiscal 2020. This increase was mainly due to an increase in the export sales of our
products.
Other Income: Our other income decreased by 47.33% to ₹ 4.94 Crores in Fiscal 2020 from ₹ 9.38 Crores in
Fiscal 2019. This decrease was primarily due to decrease in dividend and interest income.
Total Expenses
Our total expenses increased by 11.66% from ₹ 3,194.74 crores in Fiscal 2019 to ₹ 3,567.22 Crores in Fiscal
2020. This is due to the factors mentioned below:
Cost of materials consumed: Cost of materials consumed increased by 15.18% from ₹ 850.04 Crores in Fiscal
2019 to ₹ 979.05 Crores in Fiscal 2020. This increase was primarily due to an increase in sales.
Purchase of Stock-in trade: Purchase of stock in trade increased by 15.32% from ₹ 234.93 Crores in Fiscal 2019
to ₹ 270.93 Crores in Fiscal 2020. This increase was primarily due to an increase in sales.
Changes in Inventories: Our changes in inventories of finished goods, stock-in trade and work-in-progress
changed by 128.23% to ₹ (210.59) Crores in Fiscal 2020 from ₹ (92.27) Crores in Fiscal 2019. This was primarily
due to higher level of closing stock of finished goods at end of Fiscal 2020 compared to Fiscal 2019.
Employee Benefit Expenses: Our Employee Benefit expenses increased by 21.39% from ₹ 746.69 Crores in Fiscal
2019 to ₹ 906.44 Crores in Fiscal 2020. This increase is mainly due to increase in number of employees and
accordingly increase in salaries and wages and contribution to provident and other funds.
Finance Cost: Our Finance Cost increased by 47.53% from ₹ 18.41 Crores in Fiscal 2019 to ₹ 27.16 Crores in
Fiscal 2020. This was primarily due to the utilization of working capital loan taken by our Company during the
Fiscal 2020.
Depreciation and Amortisation: Our depreciation and amortisation expenses increased by 36.53% to ₹ 157.32
Crores in Fiscal 2020 from ₹ 115.23 Crores in Fiscal 2019. This was due to increase in property, plant and
equipment. Our Property, plant and Equipment & right to use assets increased to ₹ 1,524.90 Crores in Fiscal 2020
from ₹ 1,098.41 Crores in Fiscal 2019. Further, increase in amortisation expenses was due to additions in the
intangible assets in the Fiscal 2020.
Other Expenses: Our other expenses increased by 8.71% from ₹ 1,321.71 Crores in Fiscal 2019 to ₹ 1,436.89
Crores in Fiscal 2020. This was primarily due to increase in certain expenses like consumption of stores, spares,
laboratory material and Analytical Expense; power and fuel; freight and forwarding charges; legal & professional
fees and external research & development.
Total tax Expenses: Our total tax expenses increased by 27.07% to ₹ 199.18 Crores in Fiscal 2020 from ₹ 156.75
87
Crores in Fiscal 2019. This was due to our higher profit. Our current tax increased to ₹ 204.57 Crores in Fiscal
2020 from ₹ 178.14 Crores in Fiscal 2019.
Profit for the year: Due to the above mentioned factors, our profit for the year increased by ₹ 217.41 Crores or
37.27%, from ₹ 583.29 Crores in Fiscal 2019 to ₹ 800.70 Crores in Fiscal 2020.
Profit for the year attributable to owners: Our profit attributable to owners increased by 41.83%. We recorded
the profit attributable to the owners of our Company ₹ 828.82 Crores in Fiscal 2020 compared to ₹ 584.37 Crores
in Fiscal 2019.
Total Comprehensive Income for the Year: The total comprehensive income for the year which comprises of
profit and other comprehensive income for the year was ₹ 798.88 Crores in Fiscal 2020 compared to ₹ 589.12
Crores in Fiscal 2019.
Results for Fiscal 2019 compared with Fiscal 2018
Total Income
Our total income increased by 25.69% to ₹ 3,944.06 Crores in Fiscal 2019 from ₹ 3,137.84 Crores in Fiscal 2018.
This is due to the factors mentioned below:
Revenue from Operations: Our revenue from operations increased by 25.68% to ₹ 3,934.68 Crores in Fiscal 2019
from ₹ 3,130.81 Crores in Fiscal 2018. This increase was mainly due to an increase in the export sale of our
products and royalty income.
Other Income: Our other income increased by 33.43% from ₹ 7.03 Crores in Fiscal 2018 to ₹ 9.38 Crores in
Fiscal 2019. This increase was primarily due to increase in dividend income, insurance claims, profits on
temporary investments and interest income.
Total Expenses
Our total expenses increased by 23.04% to ₹ 3,194.74 crores in Fiscal 2019 from ₹ 2,596.57 Crores in Fiscal
2018. This is due to the factors mentioned below:
Cost of materials consumed: Cost of materials consumed increased by 17.13% to ₹ 850.04 Crores in Fiscal 2019
from ₹ 725.75 Crores in Fiscal 2018.
Purchase of Stock-in trade: Purchase of stock in trade increased by 16.38% to ₹ 234.93 Crores in Fiscal 2019
from ₹ 201.87 Crores in Fiscal 2018. This increase was primarily due to an increase in sales volume.
Changes in Inventories: Our changes in inventories of finished goods, stock-in trade and work-in-progress
changed by 119.38% from ₹ (42.06) Crores in Fiscal 2018 to ₹ (92.27) Crores in Fiscal 2019. This was primarily
due to higher level of closing stock at end of Fiscal 2019 compared to Fiscal 2018.
Employee Benefit Expenses: Our Employee Benefit expenses increased by 19.89% to ₹ 746.69 Crores in Fiscal
2019 from ₹ 622.81 Crores in Fiscal 2018. This increase was mainly due to increase in number of employees and
increase in their salaries and wages and accordingly, increase in contribution to provident and other funds. Also,
staff welfare expenses increased from ₹ 13.77 Crores in Fiscal 2018 to ₹ 20.6 Crores in Fiscal 2019.
Finance Cost: Our Finance Cost increased by 441.47% to ₹ 18.41 Crores in Fiscal 2019 from ₹ 3.40 Crores in
Fiscal 2018. This was primarily due to the higher utilization of working capital loan during the year.
Depreciation and Amortisation: Our depreciation and amortisation expenses increased by 9.26% to ₹ 115.23
Crores in Fiscal 2019 from ₹ 105.46 Crores in Fiscal 2018. This was due to increase in property, plant and
equipment. Our Property, plant and Equipment increased from ₹ 927.02 Crores in Fiscal 2018 to ₹ 1,098.41
Crores in Fiscal 2019.
Other Expenses: Our other expenses increased by 34.96% to ₹ 1,321.71 Crores in Fiscal 2019 from ₹ 979.34
Crores in Fiscal 2018. This was primarily due to increase in certain other expenses like consumption of stores,
spares, laboratory material and analytical expense; power and fuel; freight and forwarding charges; legal &
professional fees; publicity expenses, service fees and commission; rates and taxes; repairs and maintenance;
88
travelling expenses and Expenses on CSR activities. Also, there was increase in bad debts written-off from ₹ 0.07
Crores in Fiscal 2018 to ₹ 16.53 Crores in Fiscal 2019.
Total tax Expenses: Our total tax expenses increased by 30.25% from ₹ 120.35 Crores in Fiscal 2018 to ₹ 156.75
Crores in Fiscal 2019. This was due to our higher profit. Our current tax increased from ₹ 123.61 Crores in Fiscal
2018 to ₹ 178.14 Crores in Fiscal 2019.
Profit for the year: Due to the above mentioned factors, our profit for the year increased by ₹ 170.47 Crores or
41.29%, from ₹ 412.82 Crores in Fiscal 2018 to ₹ 583.29 Crores in Fiscal 2019.
Profit for the year attributable to owners: Our profit attributable to owners increased by 41.62%. We recorded
the profit attributable to the owners of our Company ₹ 584.37 Crores in Fiscal 2019 compared to ₹ 412.63 Crores
in Fiscal 2018.
Total Comprehensive Income for the Year: The total comprehensive income for the year which comprises of
profit and other comprehensive income for the year was ₹ 589.12 Crores in Fiscal 2019 compared to ₹ 409.63
Crores in Fiscal 2018.
Liquidity and Capital Resources
Historically, we have been able to finance our working capital and other requirements through cash generated
from our operations, bank loans and facilities and issuance of non-convertible debentures and commercial papers.
We have relied on cash from internal resources and loans from banks and financial institutions to finance the
expansion of our business and operations. From time to time, we may continue to obtain loan facilities to finance
our working capital requirements.
Cash Flows
The following table sets forth our cash flows for Fiscal 2020, Fiscal 2019 and Fiscal 2018.
(₹ in crores)
Particulars Fiscal 2020 Fiscal 2019 Fiscal 2018
Net Cash Flow inflow from Operating Activities 449.13 811.96 312.42
Net Cash Flow inflow/ (outflow) from Investing Activities (731.63) (755.60) (884.38)
Net Cash Flow inflow/ (outflow) from Financing Activities 154.85 59.04 502.63
Net Increase/(Decrease) in Cash and Cash Equivalents (127.64) 115.40 (69.34)
Cash and Cash Equivalents at the beginning of the year 199.07 83.74 153.08
Cash and Cash Equivalents at the end of the year 71.84 199.07 83.74
Operating Activities
Our net cash flow from operating activities was ₹ 449.13 Crores in Fiscal 2020. Our operating profit before
working capital changes was ₹ 1,278.09 Crores in Fiscal 2020, which was primarily adjusted by increase in trade
receivables of ₹ 358.26 Crores and increase in inventories of ₹ 220.27 Crores. Also, the direct taxes paid (net of
refund) were ₹ 236.11 Crores.
Our net cash flow from operating activities was ₹ 811.96 Crores in Fiscal 2019. Our operating profit before
working capital changes was ₹ 866.88 Crores in Fiscal 2019, which was primarily adjusted by increase in other
liabilities of ₹ 177.09 Crores, decrease in other assets of ₹ 175.13 Crores and increase in inventories of ₹ 233.33
Crores. Also, the direct taxes paid (net of refund) were ₹ 166.48 Crores.
Our net cash flow from operating activities was ₹ 312.42 Crores in Fiscal 2018. Our operating profit before
working capital changes was ₹ 628.39 Crores in Fiscal 2018, which was primarily adjusted by increase in trade
receivables of ₹ 184.18 Crores, increase in other assets of ₹ 217.64 Crores and increase in trade payables of ₹
258.84 Crores. Also, the direct taxes paid (net of refund) were ₹ 135.11 Crores.
Investing Activities
Net cash flow used in investing activities was ₹ 731.63 Crores in Fiscal 2020. This was primarily on account of
purchase of property, plant and equipment, intangible assets and capital Advance of ₹672.65 Crores.
89
Net cash flow used in investing activities was ₹ 755.60 Crores in Fiscal 2019. This was primarily on account of
purchase of property, plant and equipment, intangible assets and Capital Advance of ₹653.93 Crores.
Net cash flow used in investing activities was ₹ 884.38 Crores in Fiscal 2018. This was primarily on account of
purchase of property, plant and equipment, intangible assets and Capital Advance of ₹749.36 Crores.
Financing Activities
Net cash flow from financing activities in Fiscal 2020 was ₹154.85 Crores which primarily consisted of proceeds
from borrowings of ₹378.02 Crores and increase in working capital demand loans of ₹431.37 Crores. This was
partly offset by repayment of borrowings of ₹200.00 Crores, dividends paid of ₹ 325.97 Crores and interest and
other finance costs of ₹111.06 Crores.
Net cash flow from financing activities in Fiscal 2019 was ₹59.04 Crores which primarily consisted of proceeds
from borrowings of ₹603.70 Crores and increase in working capital demand loans of ₹221.35 Crores. This was
partly offset by repayment of borrowings of ₹604.39 Crores and dividends paid of ₹ 90.91 Crores.
Net cash flow from financing activities in Fiscal 2018 was ₹502.63 Crores which primarily consisted of proceeds
from borrowings of ₹619.05 Crores. This was partly offset by dividends paid of ₹ 90.76 Crores.
Interest Coverage Ratio
The Interest Coverage Ratio of our Company for Fiscals 2020, 2019 and 2018 is as mentioned below:
(₹ in crores, except interest coverage ratio) Sr
No. Year Fiscal 2020 Fiscal 2019 Fiscal 2018
Interest Charged to P&L 27.16 18.41 3.40
Add: Interest Capitalised 83.21 60.20 22.61
A Total Interest 110.37 78.61 26.01
Profit Before Tax, Minority interest but after Exceptional
Items
999.82
749.32
541.27
Add: Interest Charged to P&L 27.16 18.41 3.40
B Earnings Before Interest, Tax, Minority Interest but
after Exceptional Items
1,026.98
767.73
544.67
Interest Coverage Ratio = (B/A) times 9.30 9.77 20.94
Borrowings
As on March 31, 2020, the total current and non-current borrowings of our company aggregated to ₹ 1,747.49
Crores, which includes current borrowings of ₹ 860.50 Crores and non-current borrowings of ₹ 886.99 Crores.
Secured Borrowings:
(₹ in Crores)
Particulars As on March 31, 2020
Current
Working Capital Demand Loan 0.04
Total 0.04
Unsecured Borrowings:
(₹ in Crores)
Particulars As on March 31, 2020
Current
Working Capital Demand Loan 310.46
90
Commercial Paper 550.00
Non- current
Term Loan 387.53
Non-convertible Debentures 499.46
Total 1,747.45
In the event, any of our lenders declare an event of default, this could lead to acceleration of our repayment
obligations, termination of one or more of our financing agreements or force us to sell our assets, any of which
could adversely affect our business, results of operations and financial condition.
Off-Balance Sheet Items
We do not have any other off-balance sheet arrangements, derivative instruments or other relationships with any
entity that have been established for the purposes of facilitating off-balance sheet arrangements.
Related Party Transactions
For details in relation to the related party transactions, see "Related Party Transactions" beginning on page 71.
Contingent Liabilities and Commitments
As on March 31, 2020 our contingent liabilities and commitments were as follows:
(₹ in Crores)
Particulars Amount
1. Estimated amount of contracts net of advances remaining to be executed on capital
accounts
269.18
2. Contingent Liabilities
(a) Letters of credit and Guarantees 113.40
(b) Liabilities Disputed in appeals
Excise duty 0.24
Sales Tax 3.43
(c) Claims against the company not acknowledged as debt 0.35
(d) Export obligation against advance license 0.03
(e) Disputed liability in respect of Ministry of Industry, Department of Chemicals and
Petrochemicals in respect of price of Rifampicin allowed in formulations and landed cost
of import
0.35
Total 386.98
Capital Expenditures
In Fiscal 2018, Fiscal 2019 and Fiscal 2020, our capital expenditure was ₹ 922.83 Crores, ₹ 818.27 Crores and ₹
897.48 Crores, respectively. The following table sets forth our capital expenditures for the periods indicated:
(₹ in Crores)
Particulars Fiscal
2020 2019 2018
Tangible Asset 569.72 277.19 239.07
Capital Work in progress 232.70 430.64 541.48
Intangible Asset 32.81 - 69.89
Intangible Asset under Development 62.25 110.44 72.39
Total 897.48 818.27 922.83
The increase in our capital expenditure for tangible assets is primarily on account of plant and equipment,
buildings and R&D Equipment purchased in Fiscal 2018, Fiscal 2019 and Fiscal 2020. While the increase in
capital expenditure for intangible assets under development is primarily on account of development related
91
expenditure of various products including intangible asset received on investment.
Changes in Accounting Policies
Except as disclosed in this Placement Document, there have been no changes in our accounting policies during
Fiscals 2018, 2019 and 2020, except for the changes as necessitated by applicable laws.
Quantitative and Qualitative Disclosures about Market Risk
We are exposed to various types of market risks during the normal course of business. Market risk is the risk that
the fair value or future cash flows of a financial instrument will fluctuate on account of changes in market prices.
Market risk comprises of, interest rate risk, foreign Exchange Risk, Credit Risk, liquidity risk, inflation and
commodity price risk.
Interest Rate Risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate on
account of changes in market interest rates. Interest rates for borrowings have been volatile in India in recent
periods. Our exposure to the risk of changes in market interest rates relates primarily to the long term debt
obligations
Foreign Exchange Risk
Changes in currency exchange rates influence our results of operations. Foreign exchange risk is the risk that the
fair value of future cash flows of financial instruments will fluctuate due to the change in foreign currency
exchange rates. Our foreign exchange risk arises from our foreign operations, foreign currency revenues and
expenses. We have obtained external commercial borrowings We use foreign exchange option contracts, to
mitigate the risk of changes in foreign currency exchange rates in respect of certain business transactions and
recognized assets and liabilities. These foreign currency options contracts are not intended for trading or
speculative purposes but for mitigating currency risk.
Credit Risk
Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer
contract, leading to a financial loss. We are subject to the risk that our counterparties under various financial or
customer agreements will not meet their obligations. We are exposed to credit risk from our operating activities
(primarily trade receivables) and from our investing activities including deposits with banks, mutual funds and
other financial instruments.
We extend credit to customers in normal course of business. We consider factors, such as, credit track record in
the market and past dealings for extension of credit to customers. We monitor the payment track record of our
customers Outstanding customer receivables are regularly monitored. In Fiscal 2018, Fiscal 2019, Fiscal 2020
our net trade receivables were ₹ 526.34 crores, ₹ 488.92 crores and ₹ 864.75 crores, respectively.
Liquidity Risk
Liquidity risk is the risk that we may not be able to meet our present and future cash and collateral obligations
without incurring unacceptable losses. Liquidity risk management implies maintaining sufficient cash and
marketable securities and the availability of funding through an adequate amount of credit facilities to meet
obligations when due. We monitor our risk to a shortage of funds, which considers the maturity of both our
financial investments and financial assets (i.e. trade receivables and other financial assets) and projected cash
flows from operations.
Commodity Price Risk
We are exposed to market risk with respect to the prices of raw material and other components used in our
products. The costs for these raw materials and components are subject to fluctuation based on commodity prices.
The cost of raw materials and other components may also fluctuate based on their availability from suppliers. In
the normal course of business, we purchase these raw materials and components pursuant to the mid/ short term
supply agreements.
Inflation
In recent years, India has experienced relatively high rates of inflation. While we believe inflation has not had
any material impact on our business and results of operations, inflation generally impacts the overall economy
and business environment and hence could affect us.
92
Competitive Conditions
We operate in a competitive environment. See sections, “Our Business”, “Industry Overview”, “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations –Factors
Affecting our Financial Results - Competition” on pages 106, 93, 35 and 76 respectively.
Reservations, qualifications or adverse remarks of auditors in the last five Fiscals immediately preceding
the year of issue of this Placement Document and their impact on the financial statements and financial
position of our Company and the corrective steps taken and proposed to be taken by our Company for each
of the said reservations or qualifications or adverse remarks
There are no reservations, qualifications, matters of emphasis or adverse remarks of our statutory auditors in their
respective reports on our audited consolidated financial statements and audited standalone financial statements as
at and for the last five Fiscals preceding the date of this Placement Document.
Other than as disclosed in "Material Developments" and elsewhere in this Placement Document, there are no other
material developments which have taken place after March 31, 2020.
93
INDUSTRY OVERVIEW
The information contained in this section is derived from the various publicly available industry reports prepared
by recognised agencies. Neither we, nor any other person connected with the Offer has independently verified this
information. Industry sources and publications generally state that the information contained therein has been
obtained from sources generally believed to be reliable, but their accuracy, completeness and underlying
assumptions are not guaranteed and their reliability cannot be assured. Industry publications are also prepared
based on information as of specific dates and may no longer be current or reflect current trends. For the
information contained in this section, we have also relied substantially on the IQVIA Research Reports. The
IQVIA Research Reports have been prepared on the basis of information as of specific dates which may no longer
be current or reflect current trends, and opinions in the IQVIA Research Reports may be based on estimates,
projections, forecasts and assumptions that may prove to be incorrect. The IQVIA Research Reports are not a
comprehensive evaluation of the industry, the Company or the Equity Shares and all material within the IQVIA
Research Reports should be deemed as expressions of opinion which are subject to change without notice.
Global Pharmaceuticals Market – Size & Growth
As per IQVIA, Global Medicine Spending and Usage Trends - March 2020, Global medicine spending growth is
consistent with the increased global use of medicine and is expected to exceed $1.1 trillion in 2024. Global
spending has steadily increased from 2009–2019 with a 10-year CAGR of 4.2% and spending reaching $955
billion in 2019. This reflects a 23% jump from $777 billion in 2014.
Exhibit *: Global Medicine Net Market Size and Growth 2009, 2014 & 2019 (Constant USD, Bn)
Source: IQVIA, Global Medicine Spending and Usage Trends - March 2020
Developed markets have been slightly steadier, with 2.6% and 3.3% CAGRs in net market size from 2009–2014
and 2014–2019, respectively. However, the developed markets remain biggest contributor to global market size,
comprising of 64% of spending as of 2019 and is expected to comprise 60–61% of spending in 2024. On the other
hand, Pharmerging markets have seen the fastest growth, with a 12.2% CAGR from 2009–2014 and 7.7% CAGR
from 2014–2019. In 2019, Pharmerging markets comprised 26% of global pharmaceuticals spending and is
expected to rise to 28–30% of spending in 2024. However, overall global growth is expected to moderate to 2–
5% through 2024.
Going forward, the developed markets are expected to see an average CAGR between 1–4% through 2024, below
the historical 3.3% CAGR from 2014–2019. In these markets, medicine spending reached $609 billion in 2019,
with a slight increase in five-year CAGRs from 2.6% to 3.3%.
Pharmerging markets are expected to show a strong growth of 5–8% CAGR through 2024, against less than the
7.7% CAGR in the past five years (see Exhibit 4). Most Pharmerging market growth has been driven by access
expansions, leading to greater volume use and adoption of more novel therapies. These include specialty
medicines, which are projected to contribute more to spending than in previous periods. However, most of the
products used in these countries are non-original products, which aids in keeping spending low despite expanding
volume. As a result, projections suggest most countries will have slower growth than historical CAGRs.
455 519 609
95168
244
78
90
102
0
200
400
600
800
1000
1200
2009 2014 2019
Developed Pharmerging Rest of World
94
Factors affecting the Global Healthcare Spending
As per IQVIA, Global Medicine Spending and Usage Trends - March 2020, the observed and projected spending
growth is slowing due to continued effects of pricing controls and increasing brand LOEs, and are offset by
continued high numbers of new medicines. The following factors are described in greater detail below.
New products
New product growth is projected to contribute $165 billion over the next five years, up from $126 billion in the
past five. It also reflects the effects of market access and price controls in many markets that may contribute to
slower growth. The IQVIA Institute estimates approximately 270 (~54 per year) new molecular entities (NMEs)
are expected to be approved between 2020 and 2024, compared to 236 from 2015–2019, and 200 from 2010–
2014, contributing to the rise in new brand spending. From 2015–2019, new brands comprised 4–7% of brand
spending and are expected to consistently comprise 5% from 2020– 2024. New brand spending growth is largely
driven by oncology, autoimmune, other immunology treatments and many other niche and orphan treatments. As
a result, specialty spending is expected to comprise a greater proportion of new brand spending in 2024, reaching
78%, or $130 billion of the projected $165 billion spending in developed markets. New products spending growth
is expected to be offset by declining price growth, particularly in the United States, and older products growing
more slowly. The deceleration of spending growth in the face of rising specialty products and spending indicates
countries and payers are succeeding at controlling price negotiations.
Impact of brand losses of exclusivity (LOE)
Brand LOEs will result in $139 billion less in brand sales at invoice-level in developed markets, an increase in
LOE impact compared with the $107 billion seen in the past five years. The largest losses are projected in 2023,
with an expected $39 billion in losses in this year alone. Significant products contributing to brand LOEs in 2023
include sitagliptin (Januvia), adalimumab (Humira), liraglutide (Victoza), and lisdexamfetamine (Vyvanse) with
combined projected losses of nearly $15 billion. From 2020–2024, these products are predicted to generate losses
of or greater than $2.7 billion each. Importantly, the losses are not calculated at net prices, meaning losses could
be slightly less when accounting for rebates, which are typically discontinued post-expiry. Additionally, some
losses are offset by generic uptake and increased uptake overall, meaning payer savings could be less than the
stated amounts. The timing of expiries and generic entry are particularly volatile and based on litigation and other
factors.
Exhibit *: Developed Markets Lower Brand Invoice Spending Due to Loss of Exclusivity ( Constant USD, Bn)
Source: IQVIA, Global Medicine Spending and Usage Trends - March 2020
Continued emergence of breakthrough therapies
With market dynamics shifting, including the rise in specialty products for smaller patient populations, the
likelihood of breakthrough therapies coming to market that significantly impact patient care or provide a cure will
increase, but are not expected to impact broad patient populations. Breakthrough therapies are not expected to
escalate spending growth, as was observed with the advent of highly effective HCV treatments. In the period of
2014–2015, HCV treatments accounted for $26.5 billion of new brand spending growth, nearly 30% of all new
brand spending growth in developed markets in those two years. This impact on spending trends was
unprecedented, and there is no clear pipeline therapy with similar characteristics expected to be commercially
21.3 22.7 23.6
16.4
22.7 21.8 22.0
30.0
38.9
26.2
0.0
10.0
20.0
30.0
40.0
50.0
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Total losses per year
95
available in the next five years. While innovative gene therapies will reach the market shortly, the approvals and
subsequent availability are expected to come gradually. As a result, in developed markets, novel payment
infrastructure is already being explored to manage these high-cost therapies, potentially lessening their impact on
spending growth.
Declining Prices on an invoice-basis
As a result of these pressures, growth due to price changes is expected to be lower than historical trends, including
on a net-basis. In the United States, brand prices have been increasing more slowly on an invoice basis over the
past five years, slowing from 13.5% to 5.5%. They are expected to continue slowing, growing by 4–7% through
2024. The higher invoice price increases in earlier years were understood to be the result of several outlier products
with more sizeable price increases on an invoice-basis but offset by larger rebates, and therefore, such increases
are not present on a net-basis. Additionally, net prices in the United States also see slowing growth, from 4.3% in
2014 down to 0.3% in 2018, with growth expected in the range of -1–2% through 2024. The differences between
invoice and net prices in the United States are influenced by a variety of factors, such as negotiated discounts and
rebates, statutory fees and subsidies, and the use of consumer coupons. All of these reduce net prices and
contribute to the lower net trend. Generally, invoice price increases have been offset by greater discounts and
rebates. In other developed countries, dynamics similar to historical periods are expected, with brand invoice
growth projected to be -4 – -1%, or -5–2% on a net-basis. Increasingly negotiated discounts are being employed
alongside direct setting of list prices with governments, resulting in smaller differences between invoice and net,
but a broadly similar dynamic over time. Most developed countries do not allow prices to rise after a product
launches and invoice price declines are typically the result of the government restructuring prices, which are
further reduced on a net-basis by negotiations on specific products.
Exhibit *: Developed Markets Protected Brands Invoice and Net Price Growth
Year United States brand invoice price
growth
United States brand net price growth
(estimated)
2014 13.5% 4.3%
2015 11.2% 1.6%
2016 8.7% 2.9%
2017 7.1% 2.1%
2018 5.5% 0.3%
2019E 4-7% (-1 to -2)%
2020E 4-7% (-1 to -2)%
2021E 4-7% (-1 to -2)%
2022E 4-7% (-1 to -2)%
2023E 4-7% (-1 to -2)%
2024E 4-7% (-1 to -2)%
Source: IQVIA, Global Medicine Spending and Usage Trends - March 2020
United States Pharmaceuticals Market
The United States is the world’s largest pharmaceuticals market with estimated medical spending of USD 510
billion for fiscal year 2019 which is expected to go up to USD 605 – 635 billion (Source: IQVIA, Global Medicine
Spending and Usage Trends - March 2020). Driven by factors such as large healthcare spending, high per-capita
income, and strong research and development investments, the pharmaceutical market in the United States has
witnessed an upward surge over the past few years, growing at a CAGR of 4.3% over 2014 to 2019. Additionally,
the United States represents world’s biggest and most important market for pharmaceuticals and the share of
Generics has increased steadily in the pharmaceutical market, in terms of both revenue and prescriptions.
The United States is characterised by high per capita consumption, with citizen consume large amounts of
medicine and generally prefer branded drugs. Annual per capita spending will rise to USD1,179. Patented drugs
account for the majority of the market (75%), and this will continue to increase marginally over the next 10-year
forecast period, despite the uptake of generic drugs increasing as a cost-containment mechanism. Pharmaceutical
spending as a percentage of GDP is 1.9%, which is well above the global average of 1.5%. of the global GDP.
Despite increased accessibility to healthcare provision in the US, which will occur as a result of the nation's
healthcare reform, the rising financial burden on healthcare insurance providers, the slow growth rates for
consumer spending and the limited scope for market expansion (due to maturity) will lead to constraining the
pharmaceutical sales growth rates in low single-digit figures over the medium-term. However, In the long-term,
96
generic pharmaceuticals market is expected to grow faster than the overall pharmaceuticals market in the US, due
to greater government involvement in state healthcare, likely acceleration of pricing restrictions and insurance
providers activism to bring down the per capita pharmaceutical burden. Implementation of an effective universal
health insurance system will enable drug makers to gain better access to a patient population of as many as 42mn
people without health insurance.
The overall level of generic dispensing of prescription medicines has risen from 75% in 2009 to 90% in 2018 (As
per IQVIA, Medicine Use and Spending in the US report – May 2019). The market accessible to generics,
measured as that part of the market where generics have launched, has risen from 80% of prescriptions to 92%
over ten years.
Exhibit *: Generic (Branded and Unbranded) Market Share, % of Total Rx
Source: IQVIA, Medicine Use and Spending in the US report
Exhibit*: Percent of Market Accessible to Generics, % of Total Rx
Source: IQVIA, Medicine Use and Spending in the US report
Opportunities in the Complex generics space
The U.S. Food and Drug Administration (FDA) defines a generic drug as one that is identical or bioequivalent, to
a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics,
and intended use. A simple generic is a copy of a small molecule reference drug and is chemically identical to its
branded counterpart. A complex generic is a generic that could have a complex active ingredient, complex
formulation, complex route of delivery, or complex drug device combinations.
As per IQVIA (Report titled “Complex Generics – Charting a new path, December 2017”), Generics developers
who can adapt their clinical development to address these added challenges while still achieving speed to market
can benefit from exclusivity and considerable return on investment. While cheaper than branded options, complex
generics offer biopharma companies the opportunity to capture additional value commensurate with the associated
additional risk and patient benefit.
As per IQVIA, Complex Generics – Charting a new path, December 2017, key considerations for pursuing
complex generics include:
Assess regulatory requirements for complex generics development
Simple generics generally have a clear development roadmap which usually includes guidance from the FDA
Office of Generic Drugs (OGD) describing endpoints and data required for U.S. approval. With complex generics,
developers are less likely to find regulatory guidance, which adds uncertainty and risk to the planning and design
process. Having a clear regulatory strategy that leads to product approval is crucial for these projects. To ensure
75%78%
80%
84%86% 87% 88% 89% 90% 90%
70%
75%
80%
85%
90%
95%
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
80%83%
85%88% 89% 90% 91% 92% 92% 92%
70%
75%
80%
85%
90%
95%
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
97
they are on the right path, developers should meet with regulators early on to present their development strategy
and review their study design and comparability studies before they move forward. This enables developers to
optimize their program, streamline filings, and avoid surprises during the marketing application assessment
process.
Planning & Study Design
In most cases with complex generics, the plan will require clinical studies beyond what is typical of a simple
generic product, and that should be taken into account from the outset. When planning these trials, the time,
location, and cost of recruiting in a particular region, especially if there is competition for patients and/or site
resources, should be taken into account.
Site Selection
Companies interested in pursuing complex generics should choose partners who can navigate the unique
challenges in finding trial sites that have the expertise, interest, and access to targeted patient populations. In many
cases, the sites most capable of delivering these projects may not be interested in participating in a generics trial,
while those that are interested may lack the experience to manage the additional investigational requirements that
complex generics trials require. To minimize the risk, pharmaceutical companies should look for partners who
have extensive site networks, and the ability and willingness to educate novice site leaders who are interested in
expanding their offerings and taking on more complex projects. Because these support strategies require additional
education, tools, and oversight to these sites, pharmaceutical companies should begin working with their partners
on site outreach strategies early on in the research process.
Compliance
Companies need to carefully evaluate whether they have the equipment, training, knowledge, leadership, and
commitment to follow compliance rules especially in the face of pressure to cut time and cost from the project.
Along with managing the rapid timelines and complex development process, pharmaceutical companies must be
rigorous in their adherence to good manufacturing and compliance planning to avoid regulatory issues that could
delay regulatory approval. Often, the development phase is rushed to expedite regulatory submission, and
manufacturing and QC managers bemoan the fact that R&D staff did not take adequate care in creating,
transferring, and validating analytical methods and manufacturing processes. All of these compromises increase
compliance risks for any development project, but with complex generics projects compliance concerns get more
complicated – especially when working with novice sites and manufacturers, or those that have only worked on
simple generics projects. Complex generics development plans generally require more nuanced methods and
rigorous testing to meet all efficacy, safety, and equivalence goals. They also face increased compliance risks in
the transition process from pilot project to manufacturing where processing issues can impact identity, quality,
purity, potency, and consistency from batch to batch.
Evolution of the United States Generics Markets
As per IQVIA, US Generic Market – Evolution of Indian Players report, February 2019, the use of generics has
increased substantially in the years following passage of the Hatch-Waxman Act for a number of reasons namely;
a) strengthened mechanisms promoting generic use, such as tiered formularies with lower patient co-payments for
generic than for brand-name drugs, and commercial insurance and public coverage plan restrictions limiting
formulary coverage to generics in certain therapeutic categories; and b) state laws allowing generic forms to be
substituted automatically by pharmacists for brand-name drugs prescribed by physicians, so long as physicians
have not specified that the prescription must be ‘‘dispensed as written’’. Attractiveness of the United States
generics market has resulted in a rise in the number of ANDA applications received by the FDA, which has further
undertaken initiatives to ease out the overall approval process. The FDA introduced Generic Drug User Fee
Amendments (GDUFA) to quicken delivery of safe and effective generic drugs to the public, and reduce costs to
the industry. GDUFA was instrumental in improving ANDA approval rates, that have catapulted to ~65 ANDA
approvals/month from ~40 in 2012. With the incoming GDUFA II, the review time for ANDA standard
application is expected to cut down further to 8-10 months.
98
Exhibit *: USFDA – ANDA Approvals & Tentative Approvals
Source: USFDA (Financial Year from October to September)
*FY2019-20 Data up to May, 2020.
The increasing ANDA approvals have resulted in increase in market share of generic drugs among prescriptions
from 72% in 2008 to 90% in 2017, as per IQVIA. This has primarily been driven by the entry of generic players
across therapies and loss of exclusivity of patented products in the past decade. Within the past 5 years, drugs
worth USD 83Bn have gone off-patent with another USD 72Bn worth of small molecule drugs slated to go off-
patent in the next 5 years 2017 onwards.
The increasing number of players filing ANDA applications for similar therapies has resulted in a highly
competitive market with significant price erosion. The price impact of having a greater number of generic drugs
for the same indication is dramatic. As per IQVIA analysis, on average, the first generic competitor prices its
product at ~70%-80% of the brand-name manufacturer. However, the entry of a second generic manufacturer
reduces the average generic price to ~40%-50% of the branded drug price. In recent times, multiple generic players
(5 or more) have been entering at once, thereby resulting in price dips of ~50% of the innovator within the 1st
year of launch. As additional generic manufacturers market the product, the prices continue to fall with average
generic prices dipping to less than 5% of the innovator in products with >10 generic players.
The decline in generic prices was further been augmented by the rising trend in distributor consolidation. About
a decade ago, United States had more than 10 pharmaceutical distributors contributing to ~80% of the United
States generic market. However, the last decade has been witness to consolidation so much that the top 3 players
— WBAD, Red Oak and McKesson OneStop, have contributed to >80% of the United States generics market.
With increasing consolidation in the pharma supply chain, among wholesalers, PBMs, and retail pharmacies, the
bargaining power of these vertically integrated players has improved drastically, leading to pricing pressure on
small and medium sized generic players. Increased bargaining power has resulted in a 4% – 5% discount in
average generic sourcing cost.
Exhibit x: US Generics Market Size (USD Bn)
Source: IQVIA, US Generic Market – Evolution of Indian Players report, February 2019
440 409492
651
763 781
935
467
95 91 120184 174 190
236
113
0
200
400
600
800
1000
2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19 2019-20*ANDA Approvals Tentative Approvals
4758
6876 77
71 69 7379 83 86
0
20
40
60
80
100
2012 2013 2014 2015 2016 2017 2018E 2019E 2020E 2021E 2022E
99
Key Considerations for United States generics business
As per IQVIA, US Generic Market – Evolution of Indian Players report, February 2019, the rising number of
players targeting the United States generics market, a ramp-up in approval rates, consolidation among distributors
(top 3 controlling 90% of the market) in the United States and the falling number of products going off-patent
over the past few years, have driven significant crowding and pricing pressure in the United States generics
market. With affordable healthcare being a key focus area for the United States government, the outlook for
generics prices is expected to remain competitive in the near future. While all generic companies are vulnerable
to pricing pressure, we believe that the smaller sized players and new entrants will be most affected due to their
vanilla portfolios. Few well established pharmaceutical companies have already started pursuing strong growth
trajectories, through diversification to specialty portfolio.
Regulatory Compliance
Adherence to the cGMP (current good manufacturing practices) as per USFDA guidelines, is sacrosanct to prevent
regulatory clampdown on company facilities. India has the highest number of USFDA approved finished dosage
facilities outside the United States. Hence, the relevance of Indian facilities is high in the global context. USFDA
has increased the frequency of its inspections to once or even twice a year, compared to once in two to three years
earlier. The prior intimation time for plant inspection has also been slashed from 25-30 days to as little as 24
hours. Further, the USFDA has intensified scrutiny on drug manufacturing facilities as companies are now being
penalized for lapses such as inappropriate clothing of employees, improper washing conditions and inadequate
lighting, apart from issues relating to data integrity, batch failure investigations or improper quality control
systems. Companies failing to adhere to USFDA guidelines have faced the brunt of not getting timely approvals
in the past.
Time to Market
Given the competition in the generic space, lead time to approval becomes very critical, which in turn is a function
of timing of filing, quality of work done to prove bioequivalence and establishing robust manufacturing processes
that would enable upscaling from lab to commercial level. Submission of complete and satisfactory data can
substantially reduce time of correspondence between ANDA filing company and USFDA, thereby reducing
approval time. Timely approval needs to be backed by timely launch of the product in the market, as delay in
launching of generics post approval has the potential of hampering the benefits that a company can enjoy in the
market.
Portfolio Selection
When aiming for a revenue-rich portfolio, generic finished-dose companies must critically evaluate multiple
criteria like loss of exclusivity, market data, availability of generics, manufacturing requirements and costs,
forecasted competition etc. in order to increase the likelihood of success, and limit the risk of failure.
As per IQVIA, US Generic Market – Evolution of Indian Players report, February 2019, in the past, it has been
observed that large Indian players have only launched 75-80%of approved ANDAs. Wasted costs and time
associated with product failures result in huge financial loss – typical cost of ANDA development for Indian
players vary from INR 3-5 cr depending on the type of formulation (simple generic vs. complex generic). This
demonstrates how product identification is one of the most crucial strategic consideration for generic finished-
dose companies
Overview of the United States Regulations on Drug approvals
The food and drug administration (USFDA) within the U.S. Department of Health and Human Services regulates
the drug approval system in United States. The main consumer watchdog in this system is FDA’s Center for Drug
Evaluation and Research (CDER).
Process of ANDA filing with USFDA
ANDA contains data submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, for
review and ultimate approval of a generic drug product. Once ANDA is approved, an applicant may manufacture
and market the generic drug product to provide a safe, effective, low cost alternative to the public. All approved
products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence
100
Evaluations (Orange Book). Generic drug applications are termed "abbreviated" because they are generally not
required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead,
generic applicants must scientifically demonstrate that their product is bioequivalent (performs in the same manner
as the innovator drug).
• Para I: A Para I filing is made by the applicant when there is no listed patent that is the subject of the ANDA
has been submitted to FDA.
• Para II: A Para II filing is made when the applicant plans to sell the generic drug for which patent is already
expired.
• Para III: A Para III filing is made when the applicant does not have any plans to sell the generic drug until
the original drug is off patent.
• Para IV: A Para IV filing for the launch of generic drug is made when the applicant believes its product or
the use of its product does not infringe on the innovator's patents or where the applicant believes such patents
are not valid or enforceable.
An ANDA applicant filing a Para IV certification must notify the proprietor of the patent. The patent holder may
bring a patent infringement suit within 45 days of receiving such notification. If the patent owner brings a patent
infringement charge in a timely manner against the ANDA applicant, then the USFDA suspends the approval of
the ANDA until the date of the court’s decision that the listed drug patent is either invalid or not infringed the
date on which the listed drug patent expires, Once the branded drug company indicates its intent to begin a patent
infringement suit against the generic company as a result of the paragraph IV filing, the USFDA is prohibited
from approving the drug in question for thirty months or until such time that the patent is found to be invalid or
not infringed. If, prior to the expiration of thirty months, the court holds that the patent is invalid or would not be
infringed, then the USFDA approves the ANDA when that decision occurs. Conversely, if the court holds that the
patent is valid and would be infringed by the product proposed in the ANDA prior to the expiration of thirty
months, then the USFDA does not approve the ANDA until the patent expires.
If a generic company is the first to file its ANDA with a Paragraph IV certification and prevails in the subsequent
lawsuit, that generic company is granted a period of market exclusivity of 180 days. The 180-day exclusivity
incentive can be significant for a generic company as it would be the only generic version in the market. So, it can
price its product slightly below the branded version for six months, take market share from the branded product,
and maintain its price point before other generics enter the market and erode the price and segment margins. The
additional profit for a generic firm can be enormous if the product it challenges is a so-called blockbuster or
megabrand.
As an alternate path to FDA approval for new indications or improved formulations of previously-approved
products, a company may file a Section 505(b)(2) New Drug Application (“NDA”), instead of a “stand-alone” or
“full” NDA. Section 505(b)(2) permits the submission of an NDA where at least some of the information required
for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained
a right of reference. The FDA may also require companies to perform additional studies or measurements to
support the change from the approved product. The FDA may then approve the new formulation for all or some
of the label indications for which the referenced product has been approved, or the new indication sought by the
Section 505(b)(2) applicant.
This approval route was designed to encourage innovation and to eliminate costly and time-consuming duplicative
clinical studies. The 505(b)(2) applicant may qualify for three or five years of market exclusivity, depending on
the extent of the change to the previously approved drug and the type of clinical data included in the NDA. This
distinguishes a 505(b)(2) from an ANDA, where exclusivity can be held for only 180 days. A 505(b)(2) application
may also be eligible for orphan drug or pediatric exclusivity.
Benefits to the players; the drug is generally eligible for the exclusive right to market for 180 days. This helps the
manufacturer to have a first mover advantage. It is a valuable opportunity to maximize profit margins without any
competition and can garner market share.
On the other hand, to challenge a patent in court, the generic applicant that submitted para IV certification must
notify the brand sponsor and any patent holder of the submission of the ANDA and patent challenge. Further, if
the brand product sponsor or the patent holder files an infringement suit against the applicant within 45 days of
101
the notification, unless the patent expires or is judged to be invalid or not infringed before that time, FDA approval
to market the generic drug is postponed for 30 months, which is commonly referred to as the “30-month stay”
gives the brand product sponsor and patent holder a prescribed amount of time to assert patent rights in the court
before a generic competitor is approved and market the drug.
Indian Pharmaceuticals Market
The Indian Pharmaceuticals Market is the third largest in the World in terms of volume and tenth largest in terms
of value , as per Fiscal Year 2020 Annual Report of the Department of Pharmaceuticals, Government of India, the
Indian pharmaceutical industry. The total size of the industry (including drugs & medical devices) is around
US$43 billion (Rs.3,01,000 crore) and is currently having a growth rate of 7-8% in drug sector and 15- 16% in
medical device sector. Total exports (drugs and medical devices) are to the tune of US$20 billion (Rs.1,47,420
crore) of which drugs form around 90% of the total exports. The imports amount to around Rs. 72,800 crore of
which medical devices form around 52%. India is the largest provider of generic drugs globally. Access to
affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest
suppliers of low-cost vaccines in the world. Because of low price and high quality, Indian medicines are preferred
worldwide, thereby rightly naming the country “the pharmacy of the world”. The Pharmaceutical sector currently
contributes around 1.72% to the country’s GDP.
Overview of the Domestic formulations market
The Indian Pharmaceuticals Market is valued at INR 148 thousand Crores as at March 31st, 2020 and is growing
at a CAGR of 9% from Fiscal year 2016 to 2020, as per IQVIA TSA, April 2020. Multinational companies
(‘MNCs’) contribute to 20% of Indian Pharmaceuticals Market while there are about 80% contribution coming in
from the domestic companies. MNCs have grown at a CAGR of 7% from Fiscal year 2016 to 2020 while domestic
companies have grown relatively faster at a CAGR of 10% during the same period. In terms of Rx growths while
the quantum of Rxs is generated by generalists the value per Rx is higher for Super specialists and mass speciality
and they continue to remain important levers for propelling IPM growths. Amongst the Zones while there is almost
equal share from across Zones in terms of growth East is showing promise and there are many companies who
are developing East zone and that is one important growth lever for them from Geography standpoint.
Exhibit*: Zone wise sales split
Zone Contribution % %CAGR from Fiscal 2016 to 2020
North 27% 8%
South 26% 8%
East 24% 12%
West 23% 9%
Source: IQVIA, TSA, April 2020
Top therapies like Cardiac, Respiratory and Antidiabetic have contributed strongly and consistently to the industry
growth whereas Dermaceuticals has seen a recent slowdown overall owing to slowing of Antifungal therapy
within Dermaceuticals.
Exhibit*: Therapy wise Break-up of Indian Pharmaceuticals Market
Therapy % Market Share Growth for Fiscal
Year 2020
% CAGR from Fiscal
Year 2016 to 2020
Cardiac 12.2% 12% 10%
Anti-Infective 12.1% 10% 6%
Gastro-Intestinal 10.1% 6% 7%
Anti-Diabetic 9.8% 11% 14%
Respiratory 8.3% 13% 11%
Nutrition 7.7% 7% 9%
Pain 7.7% 8% 8%
Dermaceuticals 7.4% 5% 12%
Neurology / CNS 5.9% 8% 8%
Gynecology. 4.9% 5% 8%
Source: IQVIA, TSA, April 2020
Export Remains a Key Focus for Indian Pharmaceuticals Companies
102
As per Fiscal Year 2020 Annual Report of the Department of Pharmaceuticals, Government of India, Indian
pharma exports are destined to more than 200 countries including highly regulated markets of US, West Europe,
Japan and Australia. India exported pharmaceuticals to the tune of Rs. 1,33,910 crore with a recorded growth of
10.72% in 2018-19. Drug formulations & Biologicals was the third largest among the principal commodities
exported by India during 2018-19. India exports largely to USA, UK, South Africa and Russia. Imports of drugs
during 2018-19 was of Rs. 35,000 crore with bulk drugs and intermediates comprising 63% of the total
pharmaceutical imports followed by Drug Formulations and Biologicals (36%). India imports largely from China,
USA, Italy and Germany. The country has had surpluses in pharmaceutical trade as shown in the table below:
Exhibit *: Export and import in pharmaceutical sector since 2010-11 (USD bn)
Source: Annual Report 2019-20, The Department of Pharmaceuticals, Government of India
India accounts for 20% of global exports in generics. India’s Pharma exports mainly consist of Drug Formulations
and Biologicals up to 77% followed by Bulk drugs and intermediates up to 21%.
The Global pharma industry is historically dominated by United States of America, Western Europe and Asia
Pacific countries. While China, the second largest pharmaceutical market in the world and largest Pharmerging
market, is expected to hold its ranking during the next five years, the Pharmerging markets would make up nine
out of top twenty pharma markets. The global pharma invoice spending during 2019 as per IQVIA is
approximately USD $1,250 billion of which developed market (USD $821 billion) followed by Pharmerging
market (USD $357.7 billion), followed by Rest of the world market (USD $71 billion).
Exhibit *: Region wise India's pharmaceuticals exports during April-March (USD in million)
Region FY18 FY19 Change % Contribution %
North America 5348.00 6145.67 14.92 32.12
Africa 3346.97 3436.44 2.67 17.96
EU 2752.64 3003.91 9.13 15.70
ASEAN 1181.45 1310.14 10.89 6.85
LAC 1135.15 1308.30 15.25 6.84
Middle East 869.05 1074.11 23.60 5.61
South Asia 764.33 812.84 6.35 4.25
CIS 733.17 788.27 7.52 4.12
Asia (excluding Middle East) 627.30 693.62 10.57 3.62
Oceania 320.25 340.84 6.43 1.78
Other European Countries 150.99 162.86 7.86 0.85
Other America 52.48 57.38 9.33 0.30
Grand Total 17281.78 19134.38 10.72 100.00
Source: Pharmexcil, Annual Report 2019.
10.23
12.8014.15 14.65 15.13
16.61 16.45 16.91
18.75
3.774.63 4.92 4.69 4.87 4.89 4.45 4.89
5.65
0
2
4
6
8
10
12
14
16
18
20
2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19Export Import
103
While the pharmaceuticals industry’s information in USA markets have been elaborately discussed above, some
information on the other important markets are given hereunder.
European Markets: As per Pharmexcil, India’s Export to EU has increased from USD 2.75 billion in Fiscal year
2018 to USD 3 billion in Fiscal Year 2019 growing by 9.13% in the year and contributes to 15.7% of total
pharmaceuticals exports. From a medical spending prospective, UK & Germany remain key markets in Europe.
As per Pharmexcil, the German pharmaceutical market continues to lead Western Europe in terms of commercial
attractiveness. Substantial chronic disease burden, coupled with advanced healthcare infrastructure and easy
access to services, will continue to support this potential. However, caution to be exercised as Government, like
many others in Europe, are controlling costs through various measures and impacting on generics too.
For countries like France, cost-containment will remain high on the government's agenda and the pharmaceutical
market will remain a target of cost containment, posing challenges to drug makers, as per Pharmexcil. However,
a large and ageing population, high per capita spending on medicines and continued efforts by the government to
expand and improve access to healthcare will continue to secure France's position as one of the leading
pharmaceutical markets worldwide.
United Kingdom: The UK's pharmaceutical market is among the largest European markets. Medical expenditure
was USD 44.63 billion in 2017 and is expected to grow further to USD 51 billion by fiscal year 2021. As per
Pharmexcil, Generic drug market was at $ 12 billion in 2016. At a CAGR rate of 3.7% till 2021, the generic
market is forecasted to touch $ 14.4 bn. 84% of the prescriptions generated are of generic drugs. An ageing
population, a preference for innovative medicines and the population's access to new and advanced healthcare
technologies will result in the continued growth of the UK's pharmaceutical market.
Canada: It is a significant manufacturing base for pharmaceutical companies as well as a market in its own right.
Canada boasts of one of the best state sponsored Health care systems and high pharmaceutical health expenditure.
As per Pharmexcil, in 2017 Canada’s Pharma market was of the size USD 20.5 billion and has grown by 5%. It
is forecasted to grow by 8.4% in 2018 and reach $ 22.3 billion.
Canada’s historically high generic prices are now being targeted for downward price revisions. The margin of
difference between a generic and patented drug offers virtually no incentive to choose a generic. Generic drug
uptake in Canada is significantly less than patented medicines. This is due to several factors. Firstly, the price of
generic drugs is not significantly cheaper than their patented counterparts. Patented drugs have a regulatory
approval board which has some influence over pricing; however, there is no equivalent in place for generic
products. Drug pricing is generally allocated by province or territory, which can cause further discrepancies
between medicines in difference areas. Generic drug prescribing practices are still in need of greater
encouragement.
Brazil: Brazil has traditionally been Latin America’s largest pharmaceutical market. A peculiarity of the domestic
pharmaceutical market is the relatively low price of medicines in comparison to other large markets in the
Americas. As per Pharmexcil, by 2022, Brazilian Pharma market is expected to touch $ 31 bn. The fastest growing
drug sector in Brazil is bioequivalent generics, a trend that shows no signs of abating. While generic products
represent a large proportion of domestic consumption in volume terms, by value they account for 30% of total
prescription drug sales and 22% of total drug expenditure. Brazil's generic drug sector is the largest in Latin
America. It was valued at $ 5.25 billion. Forecast show it is likely to touch $ 6.5 bn by 2022 with a CAGR of
4.5%
China: It’s Pharma market is estimated at $ 140.3 billion in 2017 having grown by 29% as per Pharmexcil. It is
the largest market in Asia Pacific Region and second largest in the world. In 2018 the market is expected to reach
$ 142.26 Billion. China’s rapid ageing of the population and rising incomes will lead to a surge in demand for
medicines and quality healthcare services. Forecast of pharmaceutical sales show market may reach USD372.4bn
in 2027 with a CAGR of 9%.
Generic drug market spending to increase from USD 76.27 bn in 2017 to USD125bn by 2022, with a CAGR of
10%. In 2017, generic drugs accounted for 63.47% of total sales. Latest forecasts show that by 2018 ending market
is likely to touch $ 90.6 bn with 18 % growth.
South Africa: It’s pharmaceutical market size, makes it the key sub-Saharan market. MNCs are on the defensive
due to its, tough pricing environment which helps the generic industry. As per Pharmexcil, pharmaceutical sales
were around $ 3.2 billion in 2017 and is expected to grow around 19% in 2018 and touch $ 3.9 billion. The focus
104
on cost containment, combined with a growing middle class and single exit pricing structure, and the thrust
government gives to local production in South Africa will drive greater demand for generic medicines. $1.2 billion
market in 2017 is expected to touch $ 1.4 bn in 2018. South Africa remains amongst top 5 Pharmaceuticals export
market for India with USD 619 million in fiscal year 2019 worth of pharma exports growing at 6.19% growth
over fiscal year 2018.
Recent key Policies affecting the Indian Pharmaceuticals Industry
National Pharmaceutical Pricing Policy 2012
The Department of Pharmaceuticals notified the National Pharmaceutical Pricing Policy-2012 (NPPP-2012) on
07.12.2012 with the objective to put in place a regulatory framework for pricing of drugs to ensure availability of
required medicines – “essential medicines” – at reasonable prices, while providing sufficient opportunity for
innovation and competition to support the growth of industry, thereby meeting the goals of employment and
shared economic well-being for all. The Government is now contemplating to introduce a new National
Pharmaceutical Policy with the following objectives:
• Making essential drugs accessible at affordable prices to the common masses;
• Providing a longer-term stable policy environment for the pharmaceutical sector;
• Making India sufficiently self-reliant in end-to-end indigenous drug manufacturing;
• Ensuring world class quality of drugs for domestic consumption & exports;
• Creating an environment for R&D to produce innovator drugs;
• Ensuring growth and development of the Indian Pharma Industry.
Foreign Direct Investments
FDI up to 100% in pharmaceutical sector is permissible through automatic route for greenfield investment and up
to 74% for brownfield investment. Beyond 74%, FDI in pharmaceutical sector for Brownfield investment is
permissible through Government approval route. Union Cabinet in its meeting held on 24.05.2017 approved the
abolition of the Foreign Investment Promotion Board (FIPB). The administrative Ministries/ Departments are to
process applications for FDI requiring Government approval. The proposals relating to Pharmaceutical Sector are
being handled by this Department, based on the Standard Operating Procedure (SOP) issued by Department for
Promotion of Industry and Internal Trade (DPIIT) and in consultation with related Government Agencies. After
abolition of FIPB, under approval route, Department of Pharmaceuticals has approved 25 FDI proposals worth
Rs. 2,496 crores approximately till now. Pharmaceutical is among the top eight sectors of India attracting FDI.
FDI in medical devices is under automatic route for both brownfield and greenfield sectors.
Umbrella Scheme – Development of Pharmaceuticals Industry
The Department of Pharmaceuticals, Government of India, has an umbrella scheme namely ‘Scheme for
Development of Pharmaceutical Industry’. Its objective is to increase the efficiency and competitiveness of
domestic pharmaceutical industry so as to enable them to play a lead role in the global market and to ensure
accessibility, availability and affordability of quality pharmaceuticals for mass consumption. This scheme is a
Central Sector Scheme (CS) with a total financial outlay of Rs. 480 crore for a three-year period starting from
2017-18 to 2019-20 and comprises the following five sub-schemes:
(a) Assistance to Bulk Drug Industry for Common Facility Centre: This sub-scheme proposes financial
assistance for setting up of Common Facility Centres (CFCs) in Bulk Drug Parks in the country at a total
cost of Rs. 200 crores for 2018- 2020. Financial assistance may be provided for creation of common
facilities under any upcoming Bulk Drug Park promoted by State Governments/State Corporations. The
Scheme would be implemented through a one-time grant-in-aid to be released to a State Implementing
Agency (SIA) set up for the purpose.
(b) Assistance to Medical Device Industry for Common Facility Centre: This sub-scheme proposes
financial assistance for setting up of Common Facility Centres(CFCs) in Medical Device Parks in the
105
country at a total cost of Rs. 100 crore for 2018-2020. Financial assistance may be provided for creation of
common facilities under any upcoming Medical Device Park promoted by State Governments/State
Corporations. The Scheme would be implemented through a one-time grant-in-aid to be released to a State
Implementing Agency (SIA) set up for the purpose.
(c) Assistance for Cluster Development: This is an existing scheme of the Department, earlier known as
Cluster Development Programme for Pharma Sector (CDP-PS), now being subsumed under the umbrella
scheme. Under the scheme, financial assistance would be provided for creation of common facilities in any
pharma clusters including Bulk Drug, Medical Device, Ayurvedic, Unani and Cosmetics Units. Some of
the indicative activities under the Common facilities include Common Testing Facilities, Training Centre,
R&D Centers, Effluent Treatment Plant and Common Logistics Centre.
(d) Pharmaceutical Promotion and Development Scheme (PPDS): The Objective of Pharmaceutical
Promotion & Development Scheme (PPDS) is promotion, development and export promotion in
Pharmaceutical sector by extending financial support for conducting seminars, conferences, exhibitions,
mounting delegations to and from India for promotion of exports as well as investments, conducting
studies/ consultancies, for facilitating growth, exports as well as critical issues affecting Pharma sector.
(e) Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS): The main objective of the
scheme is to facilitate Small and Medium Pharma Enterprises (SMEs) to upgrade their plant and machinery
to World Health Organization (WHO)-Good Manufacturing Practices (GMP) standards so as to enable
them to participate and compete in global markets. Assistance in the form of interest subvention against
sanctioned loan by any scheduled commercial bank/financial institution, both in Public and Private sector
will be provided to 250 pharma SMEs of proven track record.
106
OUR BUSINESS
Some of the information in the following discussion, including information with respect to our plans and
strategies, contain forward-looking statements that involve risks and uncertainties. You should read “Forward
Looking Statements” on page 14 for a discussion of the risks and uncertainties related to those statements. Our
actual results may differ materially from those expressed in or implied by these forward-looking statements. Also
read “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations- Factors affecting our Financial Results” on pages 35 and 74, respectively, for a discussion of certain
factors that may affect our business, financial condition or results of operations.
Our financial year ends on March 31 of each year, and references to a particular Fiscal are to the twelve months
ended March 31 of that year. Unless context requires otherwise, the financial information used in this section for
the Fiscals 2020, 2019 and 2018 is derived from the Audited Consolidated Financial Statement and referred to
as such. For further information, see “Financial Statements” on page 180.
Overview
We are a vertically integrated pharmaceutical company, developing, manufacturing and marketing of formulations
offered in the international markets including in markets such as the United States, European Union, etc
(“International Generics”), formulations which cater to India’s domestic formulations market (“Domestic
Formulations”) and active pharmaceutical ingredients which cater to both domestic and international markets
(“APIs”). We have a presence and sell our products in over 65 countries including the United States, India,
Europe, Canada, Australia, Brazil and South Africa. We provide a diverse suite of products under each of our
business verticals - International Generics, Domestic Formulation and APIs. Our product portfolio in the Domestic
Formulations covers numerous chronic and acute therapy areas and in the International Generics, our products
and products in pipeline include oral solids, dermatology, oncology oral solids, oncology injectables, general
injectables and ophthalmology. For Fiscal 2020, we derived 53.69%, 30.95% and 15.36% of our revenue from
operations from our International Generics, Domestic Formulations and APIs business, respectively.
We have a broad portfolio of Abbreviated New Drug Applications (“ANDAs”) for our International Generic
business filed with the United States Food and Drug Administration (“USFDA”). As of June 30, 2020, we have
received approval for 125 ANDAs including 14 ANDAs which have received tentative approval from USFDA.
Our filings in the United States focus on oral solids (oncology and non-oncology), injectable products (oncology
and non-oncology), ophthalmic and dermatological.As of March 31, 2020, we had successfully launched 76
products in the United States, which we sell through pharmacy chains, wholesalers and distributors. We
manufacture APIs for captive consumption as well as for selling to the customers in domestic and international
markets. As of March 31, 2020, we have filed 123 Drug Master Files (“DMFs”) with the USFDA for our API
products in multiple therapeutic areas, out of which 109 DMFs are active.
We have a presence in the Domestic Formulations market which caters to chronic and acute therapies including
cardiology, anti-diabetic, gynaecology, gastrology, dermatology, orthopaedic, ophthalmology, nephrology /
urology, anti-infective, cold and cough, and veterinary segment.
We rank 21 in Indian Pharma Market (“IPM”) as of March 31, 2020 (Source: March MAT data of IQVIA, TSA
March 2020) with a 1.5% market share in IPM (Source: IQVIA, TSA March 2020). Further, three of our brands
featured amongst the top 300 pharmaceutical brands in India (Source: IQVIA, TSA March 2020).
We operate three R&D centres located at Vadodara (Gujarat, India), Hyderabad (Telangana, India) and at West-
Caldwell (New Jersey, United States). We also have a USFDA approved Bioequivalence Centre, located at
Vadodara (Gujarat, India) which provides support for bioavailability (BA) and bioequivalence (BE) studies and
support our R&D activities. As of March 31, 2020, we employed about 1,100 professionals in our R&D centres
working on APIs and various dosage forms of formulations. Some our R&D efforts are also focused on developing
niche, specialty products to strengthen our product offerings. We dedicate a substantial portion of our revenue
from operations towards R&D activities. Our R&D spend as a percentage to revenue from operations has increased
from 5.92% in Fiscal 2015 to 14.00% in Fiscal 2020.
Further, owing to our strong R&D, we have been granted 911 patents worldwide (for both APIs and formulations),
including patents which have been withdrawn, abandoned or have lapsed, as of March 31, 2020.
107
We have one facility engaged in the manufacturing of Domestic Formulations located in Sikkim. Two of our
facilities are engaged in the manufacturing of International Generic formulations located in Gujarat out of which
one facility is operated by our joint venture. Three of our facilities for manufacturing APIs are located in Gujarat.
All these facilities are currently commercially operational. The manufacturing units which are responsible for
manufacturing our products which are sold in regulated markets (including the United States, Canada, United
Kingdom), comply with applicable regulations and standards and also comply with the targeted markets’
regulatory requirements, for example that of, USFDA’s current Good Manufacturing Practices (“CGMPs”), the
United Kingdom’s medicines and healthcare products regulatory agency (“MHRA”), the Brazilian Health
Regulatory Agency (“ANVISA”), European Directorate for Quality of Medicines (“EDQM”), Australian
Therapeutic Goods Administration (“TGA”), etc. As on date, the Establishment Inspection Report (“EIR”) from
USFDA is in place for each of our operational facilities, where applicable. For more details regarding our
manufacturing facilities, see “ Manufacturing Process and Facilities” on page 113.
Driven by a strong management team, our consolidated revenue from operations for Fiscal 2020 was ₹ 4,605.75
crores which was up by 17.06%, compared to ₹ 3,934.68 crores for Fiscal 2019. Our Consolidated PAT for Fiscal
2020 grew by 41.83% to ₹ 828.82 crores from ₹ 584.37 crores for Fiscal 2019.
Our Strengths
The following are our key strengths which we believe enable us to compete in our principal markets:
Focused approach towards the United States formulations business
We believe that our track record of development and filing of ANDAs, ability to meet compliance standards and
ensuring timely delivery of products have been instrumental in driving our success in the United States market.
Consequently, we have been able to increase our product portfolio, deepen our relationships with existing
customers and increase the number of new customers during the past year. For the United States formulations
business, we are focused on launching products across various therapies and dosage forms to maximise existing
and emerging opportunities.
In the United States markets, historically, we started off selling our products to the companies or distributors.
Subsequently, we have set-up our own front-end office in the year 2015 to sell our products under the Alembic
label. In the year 2016, we also formed a joint venture named Aleor Dermaceuticals Limited (“ADL”) with
Orbicular Pharmaceuticals Technologies Private Limited for developing dermatology products for international
markets. During the Fiscal 2019, ADL launched its products in the United States market. As of June 30, 2020,
ADL had received nine approvals including one ANDA which has received a tentative approval.
Through Alembic Global Holding SA incorporated in Switzerland, our wholly owned subsidiary, we have made
an investment in Rhizen Pharmaceuticals SA (“Rhizen”), incorporated in Switzerland. Rhizen has been in the
past, involved in out-licensing its products to other companies in the United States market . Rhizen’s first product
was licensed out to TG Therapeutics which is undergoing a new drug application filing with the USFDA.
High compliance standards across manufacturing facilities with focus on quality assurance
We believe that quality and compliance are the key differentiators in our business and that our focus and emphasis
on maintaining requisite compliance standards across our plants is a key driver in our business. We believe that
the integrated nature of our standard operating procedures, multiple quality checks across the organisation and
round the clock audit preparedness ensures that we maintain such standard at all times.
As on date, the Establishment Inspection Report (“EIR”), which is a factual report issued by the USFDA pursuant
to an inspection it conducts on the factory premises of a company, is in place for each of our USFDA facilities.
The location of our facilities, division, the capabilities thereof and the major approvals received by each of them
is given below:
Location Division Capability Key Approvals
Panelav, Gujarat (F1) Formulations –
International Generics
Tablets, Capsules USFDA
Panelav, Gujarat (F2) Formulations – Oncology oral solids USFDA
108
International Generics Oncology injectables Awaiting FDA inspection
Karkhadi, Gujarat
(F3)
Formulations –
International Generics
General injectables ophthalmic Awaiting USFDA inspection
Jarod, Gujarat (F4) Formulations –
International Generics
Tablets, Capsules Awaiting USFDA inspection
Karkhadi, Gujarat
(ADL JV)
Formulations Various dermaceutical
formulations
USFDA
Panelav, Gujarat
(API Unit 1)
API API USFDA, ANVISA, EQDM, HPCD
(Canada), EU GMP (Germany),
WHO GMP
Panelav, Gujarat
(API Unit 2)
API API USFDA, HPCD (Canada), EU
GMP (Germany), WHO GMP
Karkhadi, Gujarat
(API Unit 3)
API API USFDA, MHRA (UK), TGA GMP
(Australia) , WHO GMP
Samardung Busty,
Sikkim (Domestic)
Domestic Formulations Tablets, Capsules WHO GMP
We believe our manufacturing facilities are capable of producing a wide range of products, enabling us to position
ourselves as suppliers to customers across the globe.
Well established presence in Domestic Formulations market
We develop, manufacture, market and sell branded pharmaceutical products in select therapeutic areas within the
chronic and acute categories of the Indian pharmaceutical market (“IPM”). Our Domestic Formulations business
accounted for 30.95%, 35.13% and 40.69% of our revenue from operations, for Fiscals 2020, 2019 and 2018,
respectively and continues to be a significant part of our growth strategy in the future.
Further, we have been consistently increasing our presence in the specialty therapies, including cardiology,
diabetes, gynaecology, ophthalmology and veterinary. Specialty remains our key focus area with 64.92% share of
our Domestic Formulation business and acute segments consisting of cough and cold and anti-infective therapies
with 35.08% share of our Domestic Formulation business, for the Fiscal 2020. Domestic Formulation business
contributed towards 30.95% of our total consolidated revenue from operations in Fiscal 2020.
We rank 21 in IPM as of March 31, 2020 (Source: March MAT data of IQVIA, TSA March 2020) with a 1.5%
market share in domestic pharma space in India (Source: IQVIA, TSA March 2020). Further, three of our brands
featured amongst the top 300 pharmaceutical brands in India (Source: IQVIA, TSA March 2020).
Our sales team comprised of around 5,000 field colleagues, as of March 31, 2020, which allows us to
commercialise our pharmaceutical products.
Strong R&D capabilities with substantial spending over last few years
We are a R&D focussed company and we believe that our strong R&D expertise are critical for our success across
businesses. Our formulations R&D activities include development of various dosage of formulations (such as
OSD and injectables, oncology and dermaceutical products) and is supported by strong dedicated teams for
analytics, documentation and IPR. We also have API development teams focused on developing and filing our
DMFs with the USFDA.
We have three R&D centres in Vadodara (Gujarat, India), Hyderabad (Telangana, India) and West-Caldwell (New
Jersey, United States) with about 1,100 R&D professionals across these centres. Our R&D activities primarily
include developing new products, improving existing products, improving /innovating drug delivery systems and
expanding product applications. Historically, we have invested significantly to augment our R&D capabilities
specifically around therapies (including cardiovascular, oncology, peptides, central nervous system),
dermaceuticals and injectables (general and oncology). We proactively scan our R&D grid to realign our product
portfolio by mapping it with the critical factors such as potential to garner desired market share by focussing on
the United States market and generate profits.
As of June 30, 2020, we have received approval for 125 ANDAs including 14 ANDAs which have received
tentative approval from USFDA. Our filings in the United States focus on oral solids (oncology and non-
oncology), injectable products (oncology and non-oncology), ophthalmic and dermatological. As of March 31,
2020, we had launched 76 products in the United States. As of March 31, 2020, we have filed 123 DMFs with the
109
USFDA for our API products in multiple therapeutic areas, out of which 109 DMFs are active. We spent ₹ 644.82
crore (14.00% of our total revenue from operations), ₹ 503.64 crore (12.80% of our total revenue from operations)
and ₹ 411.28 crore (13.14% of our total revenue from operations) in R&D expenditure during Fiscal 2020, Fiscal
2019 and Fiscal 2018, respectively. We have been granted 911 approximately patents worldwide (for both APIs
and formulations), including patents which have been withdrawn, abandoned or have lapsed, as of March 31,
2020.
Our commitment towards R&D is well evidenced from our increasing R&D spend as a percentage of total revenue
from operations, which has substantially increased from 5.92% of revenue from operations in Fiscal 2015 to
14.00% of revenue from operations in Fiscal 2020.
Vertical integration leading to operating leverage and supply reliability
We are a vertically integrated pharmaceutical company with in-house sourcing of APIs for several of our products.
We have invested financial and manpower resources in building infrastructure for the manufacture of APIs and
generic formulations in order to become a vertically integrated pharmaceutical company. We believe, our in-house
manufacturing of APIs has provided us with a competitive advantage in the generic formulations market through
helping us maintain quality control, mitigate the demand-supply fluctuations that routinely affect generics markets
and provides consistency and reliability of supply. We believe that our vertically integrated manufacturing
approach coupled with our process, supply chain and productivity efficiencies, contribute to our production cost
advantage and offers competitive advantage to us. We continue to improve and assess our programs designed to
increase efficiency and enhance economies of scale in order to further reduce costs.
Diversified product offering across therapeutic categories to various geographies
Our business is diverse in terms of therapeutic areas and geographies catered to, thereby mitigating concentration
risks. We offer a wide range of products across several major therapeutic categories, including cardiology, anti-
diabetic, gynaecology, gastrology, dermatology, orthopaedic, ophthalmology, nephrology / urology, anti-infective
and cold and cough. Our products (including products in pipeline) cover variety of dosage forms including oral
solids, dermatology, oncology oral solids, oncology injectables, general injectables and ophthalmology. We
believe that the depth and diversity of our product portfolio benefits our customers by providing them with a
single dependable source for a substantial number of their pharmaceutical requirements. Our large product
portfolio also helps us realise sales and distribution synergies. Further, we believe that a diversified product
portfolio such as ours, across various therapies and geographies, diminishes the risk associated with the
dependence on any particular product or country. No single product accounted for more than 5% of our total gross
revenues from operations for the Fiscal 2020 and our revenues were diversified across over 65 countries.
Experienced Management Team
We are led by a qualified and experienced management team with the vision and expertise to help manage and
grow our business. In addition to our Promoters, each of whom has extensive experience and a strong background
in the pharmaceutical industry, we also have a qualified strong senior management team that has significant
experience in all aspects of our business. We have been able to attract and retain senior and middle-level
management executives from top tier organizations. We believe that the knowledge and experience of our
Promoters in healthcare, along with that of our senior and middle-level management, provides us with a strong
platform as we seek to expand our business in existing markets and enter new geographies.
Our Strategies
Expand and improve our United States formulations products portfolio
Our strategy in the United States is to continue to focus on the existing and new formulations and enhance our
product portfolio by accelerating ANDA filings. Our United States formulations business has grown to ₹1,976.00
crore in Fiscal 2020, accounting for 42.90% of total revenue from operations on a consolidated for the Fiscal.
United States formulation business remains a significant growth engine for us and has grown at a CAGR of
44.28% from Fiscal 2015 to Fiscal 2020. We also believe that we have the ability to deliver quality products in a
timely manner as per the customers’ orders.
We are looking to launch new and distinct products and enhancing the value proposition of our existing products.
Our focus is on developing complex, niche products having limited competition. With this view, during the last
110
four Fiscals, we have significantly invested in our manufacturing and R&D capabilities with focus on expanding
and improving our current product offerings specially in the United States.
We are in the process of expanding our capacity to allow us to have enhanced new dosage offerings across
ophthalmology, general injectables, oncology injectables and oral solids (oncology and non-oncology) and will
be able to cater to the demand in United States generics segment. We have already started commercial production
in our dermaceuticals plant under our joint venture, ADL.
Over the years, we have invested significantly to augment our R&D capabilities across several high-growth and
high-value therapies. Our R&D expenses as a percentage to our revenue from operations have increased from
5.92% in Fiscal 2015 to 14.00% in Fiscal 2020. Bulk of our R&D investments are focused towards the United
States formulations business. We believe that this R&D focussed approach has dividends over the years and we
remain hopeful of it yielding growth in the United States business segment. In order to optimize the R&D
investments, several filters are applied by cross-functional teams before taking a product in the R&D grid.
We have experience in 505(b)(2) filings for new drug applications and paragraph IV filings for ANDAs required
by the USFDA. We filed/acquired 25, 29 and 37 ANDAs in the United States in Fiscals 2020, 2019 and 2018,
respectively. Our portfolio which was largely dominated by oral solids is now being expanded to include
ophthalmology, dermaceuticals, oncology (oral solids) and injectables (oncology and general) owing to our R&D
efforts.
Strengthen our Domestic Formulations business through consolidating our presence and venturing into new
fast growth therapy segments
Our Domestic Formulations business accounted for 30.95%, 35.13% and 40.69% of our revenue from operations
for Fiscals 2020, 2019 and 2018, respectively and continues to be a significant part of our growth strategy in the
future. In this segment, we cater to therapeutic areas such as cardiology, anti-diabetic, gynaecology, gastrology,
dermatological, orthopaedic, ophthalmology, nephrology / urology, anti-infective and cold and cough and
veterinary segment. We believe that our sales team of around 5,000 field colleagues and right product launches
are key enablers for this business. From Fiscal 2018 to Fiscal 2020, our Domestic Formulations business has
grown at a CAGR of 5.78%.
In addition to consolidating presence in our existing brands and therapeutic areas, we have also focused our efforts
on pursuing opportunities in fast growing therapeutic areas where we believe we can grow our presence, such as,
cardiology, diabetes, gynaecology and ophthalmology. Our strategy for expansion in existing and new therapeutic
areas includes extending our focus to target lifestyle disorders and the chronic category (to target products that
have to be prescribed over an extended period of time as opposed to one time incidence related medication),
identifying gaps in existing interventions, analysing patient compliance, and working with key opinion leaders,
doctors and patients through active engagement to develop, manufacture and market new indications which fulfil
an unmet need or are clinically differentiated.
We also have invested in sales force management system, which captures data at the headquarters and employee
levels, to make our sales staff more productive. Our marketing team utilises a variety of marketing techniques and
programs to promote our products. We believe that focusing on marketing will help us in enhancing emphasis on
the product coverage that we offer and improving our market share in India.
Leverage our API business to improve our competitive advantage in International Generics business
Our API business is strategically important since it allows us to backward integrate our operations. Our API
business helps us reduce cost and increase revenue margin and timely delivery of raw materials of desired quality
and quantity for our International Generics business. We believe that our presence in API production improves
our ability to maintain quality and mitigates the demand-supply fluctuations that affect generics markets thereby
providing for consistency and reliability of supply in an increasingly regulated global environment. It further
protects us from relying on external sources for our raw materials, thereby reducing risk of unfavourable terms of
supply such as high pricing and long timeline for delivery.
In our International Generics business, critical oral solids portfolio is backward integrated in terms of API
supplies. Beyond backward integration, our API business also acts as a key focus area as it continues to grow in
the regulated markets and we are a preferred vendor to our customers owing to the quality of our products and
dependability. The key strengths of our API business are our manufacturing expertise and a good compliance
111
track record. We have implemented several measures to enhance operational efficiency of this business including
automation of our processes to reduce contamination.
We have three USFDA approved API facilities, two in Panelav (Gujarat, India) and one in Karkhadi (Gujarat,
India) which underwent USFDA audits and have received EIR for each of the units. Our API facilities are located
closer to our formulations units, thereby giving us significant operational efficiencies. As of March 31, 2020, we
have filed 123 DMFs with the USFDA for our API products in multiple therapeutic areas, out of which 109 DMFs
are active.
Continue to grow our business outside of India and the United States
We intend to continue to grow our sales in existing geographies in Europe, Canada, Australia, South Africa and
Brazil by increasing our existing product portfolio in these markets. Our growth strategy will vary from country
to country depending on applicable regulatory requirements, competition in the product portfolio and
demographics. We intend to capitalise on selected products that we develop for the United States in these markets.
We are hopeful that we will be able to create a strong local presence and expertise with required infrastructure
and develop capabilities in order to grow in these potential markets.
In markets apart from India and the United States, we predominantly sell our products through distributors or
partnerships. In some markets, we work on semi exclusive basis wherein we offer exclusivity for some products
within that market / country. We identify and assess the suitability of potential marketing partners on the basis of
their strengths in that market. We would like to deepen our partnerships in these markets in order to further drive
our marketing efforts. We derived 10.79%, 12.54% and 9.15% of our revenue from operations in Fiscals 2020,
2019 and 2018, respectively, from these countries/regions.
Description of our Business
We are a vertically integrated pharmaceutical company, developing, manufacturing and marketing of International
Generics, Domestic Formulations and APIs. In the pharmaceutical value chain our business operations are
classified in two broad categories: (i) Formulations; and (ii) API. Our formulations business is further categorized
into: (i) Domestic Formulations; and (ii) International Generics business, primarily to the United States, Europe,
Canada, Australia, South Africa and Brazil. We manufacture and captively consume APIs for our formulations
and sell APIs in domestic and international markets.
The following table provides a summary of the contribution of each of our businesses to our revenue from
operations from each business line for Fiscals 2020, 2019 and 2018:
(₹ in crore)
Business Line Fiscal 2020
% of
revenue
from
operations
Fiscal 2019
% of
revenue
from
operations
Fiscal 2018
% of
revenue
from
operations
Formulations
International Generics 2,472.84 53.69% 1,782.20 45.29% 1,206.38 38.53%
India Branded 1,425.32 30.95% 1,382.32 35.13% 1,273.83 40.69%
Total Formulations 3,898.16 84.64% 3,164.52 80.43% 2,480.21 79.22%
APIs
Exports 542.75 11.78% 647.42 16.45% 549.04 17.54%
Domestic 164.84 3.58% 122.74 3.12% 101.56 3.24%
Total APIs 707.59 15.36% 770.16 19.57% 650.60 20.78%
Revenue from Operations 4,605.75 100.00% 3,934.68 100.00% 3,130.81 100.00%
112
International Generics business
We manufacture generic formulation products for sale outside India. Our primary markets are (a) the United
States; (b) rest of the world, with a focus on Europe, Canada, Australia, Brazil and South Africa. Our focus is
primarily on niche therapeutic areas and complex products in these markets. Our core strength lies in developing
and manufacturing pharmaceutical products in-house, which we primarily commercialise through our distribution
network.
• United States generics business
In the United States, we aspire to focus on those formulations/products which are either difficult to formulate /
manufacture and has limited competition. United States is currently our largest market and we derived 42.90%,
32.75% and 29.39% of our revenue from operations during Fiscals 2020, 2019 and 2018, respectively, from the
formulations sales within the United States. From Fiscal 2018 to Fiscal 2020, our generics business in the United
States has grown at a CAGR of 46.55%. As of June 30, 2020, we have received approval for 125 ANDAs including
14 ANDAs which have received tentative approval from USFDA.
We have launched 76 products in the United States market as of March 31, 2020, of which 69 products are sold
directly by us through our own front-end marketing team and seven are sold through our partners. We would
typically enter into Master Service Agreements with our distributors for sale of our formulations in the United
States. Finished products are manufactured at our formulation plants in India and are shipped to third party
warehouse in Indianapolis, United States. Our front-end sales team generates sales orders based on order received
from end customers in United states and subsequently these products are invoiced and shipped from the
warehouse.
Further, certain of our distributor contracts / wholesaler contracts contain obligations for us to meet minimum
supply obligations, subject to exceptions for inability to supply due to reasons beyond our control. As per the
terms of such minimum supply obligations, we may be required to pay penalties, which are typically calculated
based of the amount of the shortfall in the supply, calculated for each product being supplied.
• Rest of the World Generic business
Outside of India and United States, we sell our formulation products in rest of the world which includes
geographies such as Europe, Canada, Australia, South Africa and Brazil. We derived 10.79%, 12.54% and 9.15%
of our revenue from operations during Fiscals 2020, 2019 and 2018, respectively, from such
countries/geographies. In terms of revenue from operations, we have grown our business outside of India and
United States at a CAGR of 31.72% from Fiscal 2018 to Fiscal 2020.
Domestic Formulations Business
India is our second largest market and we derived 30.95%, 35.13%, 40.69% of our total revenue from operations
during Fiscals 2020, 2019 and 2018, respectively, from our Domestic Formulations business. In India, our
products are primarily focused on the cardiology, diabetes, gynaecology, gastrology, anti-infectives and cough
and cold segments. Some of the key brands are Azithral, Althrocin, Wikroryl, Roxid, Rekool, Zeet, Tellzy, Ulgel
and Gestofit, amongst others. Our Domestic Formulations business has grown at a CAGR of revenue from
operations at 5.78% for the last three Fiscals.
The table below lists out our key therapeutic areas as of March 31, 2020:
Therapy Therapy Growth %
(ORG)(1)
Alembic Market
Share % (ORG)
(1)
Alembic Growth
% (ORG) (1)
Alembic Growth
% (PRIM)
Anti-Diabetic 13 1.5 3 3
Cardio 12 2.1 7 6
Nephrology / Urology 11 2.1 4 6
Ophthalmology 11 1.4 2 8
Gynaecology 10 2.6 0 3
Orthopaedic 9 1 13 4
Gastrology 9 1.5 -3 -9
Dermatology 9 0.4 -10 -12
113
Therapy Therapy Growth %
(ORG)(1)
Alembic Market
Share % (ORG)
(1)
Alembic Growth
% (ORG) (1)
Alembic Growth
% (PRIM)
Cold & Cough 18 4.9 20 13
Anti - Infective 13 3 14 10
Overall 11 1.5 7 5
(1) Source: IQVIA, TSA March 2020
API Business
Our API business is strategically important since it allows us to backward integrate our operations. We
manufacture API products which are used for captive consumption and are also sold to customers for various
international markets. Our API business helps us vertically integrate and thus reduce cost and increase revenue
margin and timely delivery of raw materials of desired quality and quantity for our formulations business. Our
backward integration of formulations business ensures steady supply of APIs at an equitable cost, minimizing any
market fluctuations. In the United States formulations portfolio, a majority of our products are backward
integrated. It further protects us from relying on external sources for our raw materials, thereby reducing risk of
unfavourable terms of supply such as high pricing and long timeline for delivery.
As of March 31, 2020, we have filed 123 DMFs with the USFDA for our API products in multiple therapeutic
areas, out of which 109 DMFs are active. From this segment we derived 15.36%, 19.57% and 20.78% of our
revenue from operations during Fiscals 2020, 2019 and 2018, respectively.
Research & Development
Over the past few years, we have been focusing on R&D and have invested in R&D to augment our R&D
capabilities across several therapies. We have three R&D facilities in Vadodara (Gujarat, India), Hyderabad
(Telangana, India) and West-Caldwell (New Jersey, United States) with a team of about 1,100 professionals across
centres.
In addition to the above, we also have a Bioequivalence Centre, located at Vadodara (Gujarat, India) which
services to support R&D activities. The centre is inspected by various regulatory agencies, such as USFDA,
Bahagian Regulatori Farmasi Negara (Malaysia), ANVISA (Brazil) and DCGI (CDSCO).
As of June 30, 2020, we have received approval for 125 ANDAs including 14 ANDAs which have received
tentative approval from USFDA. We spent 14.00%, 12.80%, and 13.14% of total revenue from operations in R&D
expenditure during Fiscal 2020, 2019 and 2018, respectively.
Manufacturing Process and Facilities
We have the capability to manufacture APIs and finished-formulation dosages. We have fully integrated
manufacturing support systems at each of our facilities, including quality assurance, quality control, regulatory
affairs and inventory control. The existence of these support systems enable us to complete and deliver our
products to our customers while also monitoring regulatory compliance. Each of our manufacturing sites has an
on-site quality unit with clearly defined functions supported by a corporate quality group. All of our plants have
waste management and environment protection systems and comply with the laws on environmental pollution.
Each of our manufacturing facilities is compliant with cGMP, as applicable.
We have three API manufacturing facilities and six formulation production facilities in India of which three are
commercially operational. The table set forth below certain details in relation to our manufacturing facilities:
Location Division Dosage Form Status
Panelav, Gujarat (F1) Formulations - International
Generics
General oral solids Commercially operational
Panelav, Gujarat (F2) Formulations - International
Generics
Oncology oral solids Commercial production yet
to start
Oncology injectables Awaiting FDA inspection
Karkhadi, Gujarat (F3) Formulations - International
Generics
General injectables
ophthalmic
Awaiting FDA inspection
114
Location Division Dosage Form Status
Jarod, Gujarat (F4) Formulations - International
Generics
General oral solids Awaiting FDA inspection
Karkhadi, Gujarat (ADL
JV)
Formulations Various dermaceuticals
formulations
Commercially operational
Panelav, Gujarat (API Unit
1)
API - Commercially operational
Panelav, Gujarat (API Unit
2)
API - Commercially operational
Karkhadi, Gujarat (API Unit
3)
API - Commercially operational
Samardung Busty, Sikkim
(Domestic)
Domestic Formulations General oral solids and
liquids
Commercially operational
Raw Materials
For our International Generic formulations, APIs are manufactured in-house as well as procured from domestic
and international suppliers. Arrangements with raw material and packing material suppliers are subject to, among
other things, regulatory requirements, various import duties and other government clearances. We generally do
not have long term contracts with any of our suppliers and we source raw materials from multiple suppliers on
purchase order basis. However, in certain cases, we enter into long term supply contracts with certain suppliers
for certain raw materials.
The total cost of our raw materials, packaging materials and excipients during Fiscal 2020 amounted to ₹ 1,039.39
crore.
We have in-house planning and inventory control teams that works alongside the manufacturing team to determine
procurement requirements for manufacturing finished products, creating production plans and ensuring
availability of raw materials and packaging materials. These teams monitor inventory and finished products
against various factors, including capacity, availability of labour and minimum and maximum stocks. For this
purpose Information Technology systems are extensively used. These teams also aims to identify alternate
suppliers for our raw materials requirements, including API.
Quality Control
We believe that maintaining high standard of quality of our products is critical to our brand and continued success.
Across our various manufacturing facilities, we have put in place various systems for ensuring consistent quality,
efficacy and safety of our products.
Our facilities are regularly inspected for compliance with cGMP. We are compliant with standards set by WHO,
USFDA and such other regulatory authorities. Our audit procedures are also regularly updated to comply with
any changes in international regulatory requirements, such as those of the USFDA. Some of our manufacturing
facilities have received approvals from USFDA, EDQM, MHRA, TGA, ANVISA and have received
accreditations from WHO, certificate of GMP compliance of a manufacturer (Freie Und Hansestadt Hamburg,
Germany), certificate of GMP compliance of a manufacturer (Danish Medicines Agency, Denmark), amongst
others.
Sales and Distribution
We market and distribute our products in many countries, either directly through our Subsidiaries or indirectly,
through supply, distribution and other arrangements with various global companies and local distributors.
Our export markets include geographies such as the United States, Canada, Brazil, Europe, Australia and South
Africa. Apart from United States, we predominantly sell products in the international geographies through
distributors or partnerships. We identify and assess the suitability of potential marketing partners on the basis of
their strengths in that market.
In the United States, we have our own front-end marketing team responsible for marketing and distribution of
products. In United States, we have a lean team of 12 people on our front end through which we market bulk of
our products. However, we also have a few products in this market which we sell through our marketing partners.
115
In India, our sales team comprises of around 5,000 field colleagues, as of March 31, 2020. Our nationwide sales
force is comprised of representatives that typically have significant pharmaceutical sales experience in their
respective geographic regions.
Our APIs are sold in more than 50 countries including in India through dedicated relationships with large
formulators and distributors.
Competition
The global pharmaceutical market can broadly be divided into advanced regulated markets and emerging markets.
Emerging markets such as Africa and South East Asia have less onerous entry barriers in terms of regulatory
requirements, including with respect to qualification processes and intellectual property rights. The advanced
regulated markets such as the United States have stricter regulatory entry barriers. As a result, there is a premium
for quality and regulatory compliance along with more transparent economics in the advanced regulated markets.
We compete with companies in the Indian market based on therapeutic and product categories, and within each
category, upon dosage strengths and drug delivery. Our principal competitors for the export of generic
formulations from India include, among others, Aurobindo Pharma Limited, Sun Pharmaceuticals Industries
Limited, Dr. Reddy’s Laboratories Limited, Lupin Limited, Cipla Limited and Alkem Limited. Further, in global
markets, we compete with local companies, multinational corporations and companies from other emerging
markets. In addition, as we grow our International Generic formulations business, we expect competition from
major International Generic manufacturers.
Patent and Trademarks
We own products and process patents for various pharmaceutical processes and technologies. We have been
granted 911 approximately patents worldwide (for both APIs and formulations), including patents which have
been withdrawn, abandoned or have lapsed, as of March 31, 2020. Further, as of June 30, 2020, we owned 574
registered trademarks, including our logo.
Regulatory and Environmental Matters
Our products sold in developed markets are subject to regulation by their respective government entities, including
the USFDA, EDQM, MHRA, TGA, ANVISA, WHO, Health Product Compliance Directorate, Canada amongst
others. To varying degrees, each of these agencies requires us to adhere to laws and regulations governing the
development, testing, manufacturing, labelling, marketing and distribution of our products, in their respective
regions.
We develop and implement work safety measures and standards to ensure a safe working environment at our
manufacturing facilities and seek to ensure that the work we undertake does not pose any danger to our employees
or the general public. We comply with applicable health and safety regulations. We implement efforts to educate
our employees in occupational, health and safety procedures.
We are also subject to significant national and state environmental laws and regulations regarding the discharge,
emission, storage, handling and disposal of a variety of substances that may be used in or produced from our
operations at our facilities. Failure to comply with the applicable laws and regulations may subject us to penalties
and may also result in the closure of our facilities.
Insurance
We have industrial all risk policy for our manufacturing facilities insuring all of our assets such as buildings, plant
and machinery, furniture, fixtures and fittings, stocks and stocks from risks such as fire, earthquake and machinery
breakdown. We maintain a global product liability insurance, clinical trials insurance, director and officer’s
liability insurance and comprehensive general liability insurance (covering product liability) for the products that
we manufacture and sell. We also maintain medical insurance policies for our employees. We believe that our
insurance coverage is consistent with industry standards for companies in India.
Our policies are subject to customary exclusions and customary deductibles. For additional details relating to our
product liability insurance, see “Risk Factors - Our insurance coverage may not adequately protect us against all
116
losses. To the extent that we suffer loss or damage which is not covered by insurance or exceeds our insurance
coverage, our results of operations and financial performance could be adversely affected.” on page 52.
Employees
As of March 31, 2020, we had 11,576 full-time employees, excluding contract labourers. Our personnel policies
are aimed at recruiting talented individuals and promoting the development of their skills, including through in-
house as well as external training programmes.
Properties
Our Registered and Corporate Office is located at Alembic Road, Vadodara - 390 003 and is occupied by us on a
leave and license basis. The other properties we have availed on a leave and license basis and own serve as
locations for manufacturing facilities and R&D centres.
Corporate Social Responsibility
We conduct and undertake our social responsibility activities primarily through Alembic CSR Foundation to drive
our corporate responsibility initiatives. We have identified education, health, water, sanitation & hygiene, sports,
art & culture, environment, livelihood, rural development projects, and slum area development as our primary
focus areas.
117
ORGANISATIONAL STRUCTURE
Alembic Global Holding SA (AGH)
(Switzerland)
ALEMBIC PHARMACEUTICALS LIMITED (APL) (India)
Incozen Therapautics
Pvt Ltd
(Hyderabad, India)
Alembic Global
Holding SA (DMCC &
RAKTZ
Branch - Dubai
Alembic Mami
SPA
(Algeria)
SPH Sine Alembic
(Shanghai)
Pharmaceutical
Technology
Company Limited
(China)
Alembic
Pharmaceuticals
Inc. (USA)
Aleor Dermaceuticals
Limited (India)
Alembic Labs
LLC
Okner Realty
LLC
Rhizen
Pharmaceuticals
SA (Switzerland)
DAHLIA
Therapeutics
SA
(Switzerland)
Rhizen
Pharmaceuticals
Inc. (USA)
Rhizen
Pharmaceuticals
SA DMCC
Alembic
Pharmaceuticals
Europe Limited
(Malta)
Alembic
Pharmaceuticals
Australia Pty
Limited
(Australia)
Alembic
Pharmaceuticals
Canada Limited
(Canada)
Alnova
Pharmaceuticals
SA
(Switzerland)
Genius LLC
(Ukraine)
Branch
44% JV 49% JV Branch 50%
Associate
100% Subsidiary
50% Associate 100% Subsidiary 60% Subsidiary
118
BOARD OF DIRECTORS AND SENIOR MANAGEMENT
Board of Directors
The general supervision, direction and management of our Company, its operations and business are vested in the
Board, which exercises its powers subject to the Memorandum of Association and Articles of Association of our
Company and as per the requirements of applicable law. The composition of our Board is governed by the
provisions of the Companies Act, 2013, the Articles of Association of our Company and the SEBI Listing
Regulations. The Articles of Association of our Company provide that the number of directors shall not be less
than three and not more than fifteen. At present, our Company has eight Directors on its Board, comprising four
Executive Directors and four Non-Executive Independent Directors, inclusive of our Executive Chairman and
CEO and one woman Independent Director. Our Board is compliant with the corporate governance requirements
of the SEBI Listing Regulations.
Pursuant to the provisions of the Companies Act, at least two-third of the total number of Directors, excluding
Independent Directors, are liable to retire by rotation, with one-third of such number retiring at each AGM.
Additionally, in accordance with the Articles of Association of our Company, if the number of Directors retiring
is not three or a multiple of three, then the nearest number to one-third are liable to retire by rotation. A retiring
Director is eligible for reappointment. Further, as per the provisions of Companies Act, an Independent Director
may be appointed for a maximum of two consecutive terms of up to five consecutive years each. However, the
reappointment of an Independent Directors for a second consecutive term shall, amongst other things, be on the
basis of the performance evaluation report and approved by the Shareholders by way of a special resolution.
The following table sets forth details regarding the Board of Directors as of the date of this Placement Document:
S.No. Name, Address, Occupation, DIN, Term and
Nationality
Age (in
years) Designation
1. Chirayu Amin
Address:
F-10/195, Race Course Circle,
Gotri Road, Vadodara, Gujarat,
India- 390007
Occupation: Business
DIN: 00242549
Term: For a period of five years with effect from
April 1, 2016 to March 31, 2021
Nationality: Indian
73
Executive Chairman and CEO
2. Pranav Amin
Address:
F-10/195, Race Course Circle,
Gotri Road, Vadodara, Gujarat,
India- 390007
Occupation: Business
DIN: 00245099
Term: For a period of five years with effect from
April 1, 2016 to March 31, 2021
Nationality: Indian
44
Managing Director
119
S.No. Name, Address, Occupation, DIN, Term and
Nationality
Age (in
years) Designation
3. Shaunak Amin
Address:
F-10/195, Race Course Circle,
Gotri Road, Vadodara, Gujarat,
India- 390007
Occupation: Business
DIN: 00245523
Term: For a period of five years with effect from
May 2, 2018 to May 1, 2023
Nationality: Indian
42 Managing Director
4. Raj Kumar Baheti
Address:
B-2-302 Orcadia,
Nautilus Complex,
Off Vasna Road, Vadodara,
Gujarat, India- 390007
Occupation: Service
DIN: 00332079
Term: For a period of five years with effect from
April 1, 2016 to March 31, 2021
Nationality: Indian
60 Director- Finance and Chief
Financial Officer
5. Krishnapuram Ramanathan
Address:
192, Jolly Maker Apartment no. 3,
Cuffe Parade, Colaba,
Mumbai, Maharashtra,
India - 400005
Occupation: Consultant
DIN: 00243928
Term: For a period of five years with effect from
April 1, 2019 to March 31, 2024
Nationality: Indian
81
Independent Director
6. Pranav Parikh
Address:
18 A, Manek, LD Ruparel Marg,
Malabar Hill, Mumbai
Maharashtra, India- 400 006
Occupation: Business
DIN: 00318726
Term: For a period of five years with effect from
April 1, 2019 to March 31, 2024
Nationality: Indian
77 Independent Director
120
S.No. Name, Address, Occupation, DIN, Term and
Nationality
Age (in
years) Designation
7. Paresh Saraiya
Address:
18, Charotar Society,
Old Padra Road, Akota,
Vadodara, Gujarat,
India - 390020
Occupation: Business
DIN: 00063971
Term: For a period of five years with effect from
April 1, 2019 to March 31, 2024
Nationality: Indian
66 Independent Director
8. Archana Hingorani
Address:
701, Orchid Breeze,
7th Floor 16th Road,
Opposite Khar Gymkhana Ground Khar,
Mumbai, Maharashtra,
India– 400 052
Occupation: Business
DIN: 00028037
Term: For a period of five years with effect from
February 4, 2020 to February 3, 2025
Nationality: Indian
54 Independent Director
Biographies of the Directors
Chirayu Amin is the Executive Chairman and CEO of our Company. He has been a Director in our Company
since 2010. He holds a bachelor’s degree in science from Maharaja Sayajirao University of Baroda, and a master’s
degree in business administration from Seton Hall University, New Jersey, USA. He is currently associated as
trustee with Bhailal Amin General Hospital, Uday Education Society, and Bal Utkarsh Society. He also serves as
a director on the boards of Alembic Limited, Shreno Limited, Elecon Engineering Company Limited, Nirayu
Limited and Paushak Limited.
Pranav Amin is the Managing Director of our Company and heads our International Business Unit. He has been
a Director in our Company since 2011 and was appointed as a joint managing director in 2015 and thereafter
Managing Director in April 2016. He also serves as a director on the board of Incozen Therapeutics Private
Limited.
Shaunak Amin is the Managing Director of our Company and heads the branded formulation business of our
Company. He has been a Director in our Company since 2013. He also serves as a director on the boards of Shreno
Limited and Incozen Therapeutics Private Limited.
Raj Kumar Baheti is the Director- Finance and Chief Financial Officer of our Company. He has been a Director
in our Company since 2010. He is a fellow member of the Institute of Chartered Accountants of India and the
Institute of Company Secretaries of India. He has prior experience in finance, accounts, tax and management. He
also serves as a director on the board of Aleor Dermaceuticals Limited.
Krishnapuram Ramanathan is an Independent Director of our Company. He has been a Director in our Company
since 2011. He holds a bachelor’s degree in science from the University of Madras. He has served as an officer in
121
the Indian Administrative Services, Government of India, having been associated in various positions. He was
also earlier the chairman and managing director of Indian Petrochemicals Corporation Limited. He is also the
president of the governing council of the Indian Centre for Plastics in the Environment.
Pranav Parikh is an Independent Director of our Company. He has been a Director in our Company since 2011.
He is the chairman and managing director of Technova Imaging Systems Private Limited. He also serves as a
director on the boards of Lee and Muirhead Private Limited, Shree Luxmi Woollen Mills Estate Private Limited,
Technova Graphics Private Limited and Technova Prepress Solutions Private Limited.
Paresh Saraiya is an Independent Director of our Company. He has been a Director in our Company since 2011.
He holds a bachelor’s degree in mechanical engineering from the Maharaja Sayajirao University of Baroda. He
has earlier been associated with Transpek Industry Limited, subsequent to which he assumed charge as the
executive director of Transpek-Silox Industry Private Limited. He has also held the position of senior vice
president of Federation of Gujarat Industries (FGI) – Vadodara. He also serves as a director on the boards of
Transpek Silox Industry Private Limited, Shroffs Engineering Limited, Excel Genetics Limited, Dinesh Remedies
Limited, Technokraft Products Private Limited, SIAMP India Private Limited, Aatapi Seva Foundation and
Vantage Chemical Industries Private Limited.
Archana Hingorani is an Independent Director of our Company. She has been a Director in our Company since
2015. She holds a bachelor’s degree in economics from St. Xavier’s College, University of Mumbai, a master’s
degree in business administration from The Graduate School of Business, University of Pittsburg and a Ph.D from
Joseph M. Katz Graduate School of Business, University of Pittsburgh, USA. She is, currently, the managing
partner at Siana Capital Management LLP. She also serves as a director on the boards of Den Networks Limited,
5Paisa Capital Limited, SIDBI Venture Capital Limited, Grindwell Norton Limited and SBI Mutual Fund Trustee
Company Private Limited.
Relationship between Directors
Except as disclosed below, none of the Directors of our Company are related to each other:
(i) Chirayu Amin and Pranav Amin are related to each other as father and son;
(ii) Chirayu Amin and Shaunak Amin are related to each other as father and son; and
(iii) Pranav Amin and Shaunak Amin are related to each other as brothers.
Borrowing powers of the Board
In accordance with the Articles of Association and subject to the provisions of the Companies Act, the Board may,
from time to time, by a resolution passed at a meeting of the Board, accept deposits from members of our Company
either in advance on calls or otherwise and generally to raise or borrow or secure the repayment of any sum of
money for any purpose. Pursuant to a resolution of the Shareholders dated July 27, 2018, which allowed the Board
to borrow money for an amount not exceeding ` 2,500 crore and a subsequent resolution of the Board dated
September 10, 2018, the Board delegated authority to the Executive Directors to borrow monies for an amount
not exceeding ` 1,500 crore.
Shareholding of Directors
The following table sets forth details regarding the shareholding of the Directors as of the date of this Placement Document:
Name of the Director Number of Equity Shares held Percent of the issued and paid-up
Equity Share capital (in %)
Chirayu Amin* 45,21,465 2.40
Pranav Amin 10,09,800 0.54
Shaunak Amin 10,06,980 0.53
Raj Kumar Baheti Nil Nil
Krishnapuram Ramanathan Nil Nil
Pranav Parikh^ 19,410 0.01
Paresh Saraiya^ 4,824 0.00
122
Name of the Director Number of Equity Shares held Percent of the issued and paid-up
Equity Share capital (in %)
Archana Hingorani Nil Nil
* Including 10,73,250 Equity Shares held in the representatives capacity of Karta of Chirayu Ramanbhai Amin HUF.
^ Jointly with immediate relatives.
Remuneration of the Directors
In accordance with applicable laws, our Company pays a sitting fee of ₹ 60,000 per meeting of the Board, ₹ 30,000 per meeting of the Audit Committee and ₹ 10,000 for other committee meetings, to each of our Non-Executive Directors.
The following table sets forth the remuneration (including sitting fees, commission and perquisites) paid by or
provided for our Company to the Directors during the last three Fiscals and the three month period ended June
30, 2020: (In ₹ crore)
Executive Directors
Chirayu Amin, Executive Chairman & CEO
Chirayu Amin was appointed as an Executive Chairman and CEO of our Company pursuant to a resolution
passed by the Shareholders of our Company on July 29, 2016, for a period of five years commencing from
April 1, 2016.
Set out hereunder are the details of the terms and conditions of appointment (including remuneration) of
Chirayu Amin, which are subject from to time, to internal policies and decisions of the Board and the
Shareholders:
Terms and Conditions of Appointment
Particulars Date/Remuneration/Details
Period With effect from April 1, 2016 for a period of five years i.e., up to March 31, 2021.
Basic salary Maximum cost to company of ₹ 12 crore per annum with effect from April 1, 2016
Perquisites:
(i) Company leased housing accommodation or house rent allowance; (ii) Leave travel concession for self and family; (iii)
Medical reimbursement, medical insurance and personal accident insurance; (iv) Conveyance; (v) Free telephone facility
at the residence; (vi) Contribution to provident fund, superannuation fund and gratuity fund; and (vii) Other perquisites,
allowances, benefits and amenities as per the service rules of our Company.
All of the above as per the rules of our Company as applicable from time to time.
Commission
In addition to salary, perquisites, allowances and others, commission calculated with reference to net profits of our
Company in a particular financial year, as may be determined by the Board of Directors at the end of each Fiscal or a part
of the year, subject to overall ceilings stipulated in Section 197 of the Companies Act.
Total Remuneration
The total remuneration including commission, payable to Chirayu Amin as Executive Director shall not exceed 8% of the
net profit of our Company for the relevant Fiscal.
Name Between April 1, 2020 to
June 30, 2020 Fiscal 2020 Fiscal 2019 Fiscal 2018
Chirayu Amin 6.62 26.50 25.50 22.00
Pranav Amin 5.12 19.50 17.45 15.65
Shaunak Amin 5.12 19.50 17.45 15.66
Raj Kumar Baheti 1.17 4.09 3.65 3.35
Krishnapuram Ramanathan 0.02 0.15 0.14 0.11
Pranav Parikh 0.02 0.15 0.13 0.11
Paresh Saraiya 0.02 0.16 0.14 0.12
Archana Hingorani 0.02 0.14 0.14 0.11
123
Pranav Amin, Managing Director
Pranav Amin was appointed as a Managing Director of our Company pursuant to a resolution passed by the
Shareholders of our Company on July 29, 2016, for a period of five years commencing from April 1, 2016.
Set out hereunder are the details of the terms and conditions of appointment (including remuneration) of Pranav
Amin:
Terms and Conditions of Appointment
Particulars Date/Remuneration/Details
Period With effect from April 1, 2016 for a period of five years i.e., up to March 31, 2021.
Basic salary Maximum cost to company of ₹ 18 crore per annum with effect from April 1, 2018
Perquisites
(i) Company leased housing accommodation or house rent allowance; (ii) Leave travel concession for self and family; (iii)
Medical reimbursement, medical insurance and personal accident insurance; (iv) Conveyance; (v) Free telephone facility
at the residence; (vi) Contribution to provident fund, superannuation fund and gratuity fund; and (vii) Other perquisites,
allowances, benefits and amenities as per the service rules of our Company.
All of the above as per the rules of our Company as applicable from time to time.
Commission
In addition to salary, perquisites, allowances and others, Commission calculated with reference to net profits of our
Company in a particular Fiscal, as may be determined by the Board of Directors at the end of each Fiscal, not exceeding
1% of the net profits of our Company for the respective Fiscal, subject to overall ceilings stipulated in Section 197 of the
Companies Act.
Shaunak Amin, Managing Director
Shaunak Amin was appointed as a Managing Director of our Company pursuant to a resolution passed by the
Shareholders on July 27, 2018, for a period of five years, commencing from May 2, 2018. Set out hereunder are
the details of the terms and conditions of appointment (including remuneration) of Shaunak Amin:
Terms and Conditions of Appointment
Particulars Date/Remuneration/Details
Period With effect from May 2, 2018 for a period of five years i.e., up to May 1, 2023.
Basic salary Maximum cost to company of ₹ 18 crore per annum with effect from May, 2, 2018
Perquisites
(i) Company leased housing accommodation or house rent allowance; (ii) Leave travel concession for self and family; (iii)
Medical reimbursement, medical insurance and personal accident insurance; (iv) Conveyance; (v) Free telephone facility
at the residence; (vi) Contribution to provident fund, superannuation fund and gratuity fund; and (vii) Other perquisites,
allowances, benefits and amenities as per the service rules of our Company.
All of the above as per the rules of our Company as applicable from time to time.
Commission
In addition to salary, perquisites, allowances and others, Commission calculated with reference to net profits of our
Company in a particular Fiscal, as may be determined by the Board of Directors at the end of each Fiscal, not exceeding
1% of the net profits of our Company for the respective Fiscal, subject to overall ceilings stipulated in Section 197 of the
Companies Act.
Raj Kumar Baheti, Director- Finance and Chief Financial Officer
Raj Kumar Baheti was appointed as a Director- Finance and Chief Financial Officer of our Company pursuant
to a resolution passed by the Shareholders of our Company on July 29, 2016, for a period of five years
commencing from April 1, 2016.
124
Set out hereunder are the details of the terms and conditions of appointment (including remuneration) of Raj
Kumar Baheti:
Terms and Conditions of Appointment
Particulars Date/Remuneration/Details
Period With effect from April 1, 2016 for a period of five years i.e., up to March 31, 2021.
Basic salary Maximum cost to company of ₹5 crore per annum with effect from April 1, 2016
Perquisites
(i) Company leased housing accommodation or house rent allowance; (ii) Leave travel concession for self and family; (iii)
Medical reimbursement, medical insurance and personal accident insurance; (iv) Conveyance; (v) Free telephone facility
at the residence; (vi) Contribution to provident fund, superannuation fund and gratuity fund; and (vii) Other perquisites,
allowances, benefits and amenities as per the service rules of our Company.
All of the above as per the rules of our Company as applicable from time to time.
Key Management Personnel
The following are the KMPs of our Company, in addition to our Executive Chairman and CEO, Managing
Directors and Director – Finance and Chief Financial Officer:
Charandeep Singh Saluja is the Company Secretary and Compliance Officer of our Company. He holds a
bachelor’s degree in commerce and a post graduate diploma in taxation laws and practice from Maharaja Sayajirao
University, Baroda. He is an associate member of the Institute of Company Secretaries of India. He has significant
experience in compliance functions, including eight years at the Alembic group of companies. He has been
associated with our Company since June 1, 2018. He also has experience in corporate secretarial and corporate
restructuring functions.
Relationship of Key Management Personnel
Except as disclosed in “Relationship between Directors” on page 121, none of the other KMPs of our Company
are related to each other.
Shareholding of Key Management Personnel
Other than as disclosed above in “Shareholding of Directors”, none of our other KMPs hold any Equity Shares in the
Company.
Interest of our Directors and Key Management Personnel
Except as stated in “Related Party Transactions” on page 71, and to the extent of respective shareholding,
remuneration including commission received on net profit, reimbursement of expenses and other benefits to which
they are entitled as per their respective terms and conditions of appointment, our Directors and KMPs do not have
any other interest in our Company or its business. Our Directors and KMPs may also be deemed to be interested
to the extent of any dividend payable to them and other distributions in respect of the said Equity Shares, held by
them, any other benefit arising out of such holding and transactions with the companies with which they are
associated as directors or members. Our Non-Executive Directors and Independent Directors may also be deemed
to be interested to the extent of sitting fees payable to them for attending meetings of our Board or a committee
thereof as well as to the extent of commission and reimbursement of expenses payable to them.
Other than as disclosed in this Placement Document, there are no outstanding transactions other than in the
ordinary course of business undertaken by our Company in which the Directors and KMPs are interested parties.
Certain of our Directors and KMPs may also be regarded as interested in the Equity Shares held by, or
subscribed by and allotted to, the companies, firms and trusts, in which they are interested as directors, members,
partners or trustees.
Except as otherwise stated in this Placement Document, our Company has not entered into any contract,
agreement or arrangement during the preceding two years from the date of this Placement Document in which
any of the Directors and KMPs are interested, directly or indirectly, and no payments have been made to them
in respect of any such contracts, agreements, arrangements which are proposed to be made with them.
125
Further, our Company has neither availed of any loans from, nor extended any loans to the Directors and KMPs
which are currently outstanding.
Our Company has entered into an agreement with our Promoter, Alembic Limited, for purchase of land. Our
Executive Chairman and CEO is indirectly interested in this transaction by way of being a chairman on the
board of directors of both the companies.
Corporate governance
The Board of Directors presently consists of eight Directors. In compliance with the requirements of the SEBI
Listing Regulations, the Board of Directors has four Independent Directors. Our Company is in compliance with
the corporate governance requirements including the constitution of Board and committees thereof, as prescribed
under the SEBI Listing Regulations.
Committees of the Board of Directors
The Board of Directors have constituted committees, in accordance with the relevant provisions of the Companies
Act and the SEBI Listing Regulations.
The following table sets forth the members of the aforesaid committees as of the date of this Placement Document:
Committee Members
Audit Committee • Chairman: Paresh Saraiya
• Krishnapuram Ramanathan
• Pranav Parikh
• Archana Hingorani
Nomination and Remuneration Committee • Chairman: Krishnapuram Ramanathan
• Chirayu Amin
• Pranav Parikh
• Paresh Saraiya
Stakeholders’ Relationship Committee • Chairman: Paresh Saraiya
• Raj Kumar Baheti
• Pranav Amin
Risk Management Committee • Chairman: Paresh Saraiya
• Pranav Amin
• Raj Kumar Baheti
• Vinod Kamath
• Shreekumar Nair
Corporate Social Responsibility
Committee
• Chairman: Chirayu Amin
• Krishnapuram Ramanathan
• Paresh Saraiya
Senior Management Personnel
Our Senior Management Personnel as of the date of this Placement Document, are as follows:
Ajay Desai is the senior vice president, business finance of our Company. He holds a bachelor’s degree in
commerce from the University of Calcutta. He is a chartered accountant from the Institute of Chartered
Accountants of India, a company secretary from the Institute of Company Secretaries of India, a management
accountant from the Chartered Institute of Management Accountants and an associate of the Institute of Cost and
Works Accountants of India. He has been associated with the Alembic group of companies since September 29,
2008 and with our Company since April 1, 2011.
Chandrahas Shetty is the senior vice president, human resources of our Company. He holds a bachelor’s degree
in arts from Sri Bhuvanendra College, Karkala and a master’s degree in personnel management from Bharati
Institute of Management, Pune, University of Pune. Additionally, he holds a diploma in management studies from
Kishinchand Chellaram College, University of Mumbai and a diploma in personnel management from the Tata
Institute of Social Sciences. He has been associated with the Alembic group of companies since December 11,
126
2006 and with our Company since April 1, 2011.
Craig Salmon is the president of the U.S operations of our Company. He holds a bachelor’s degree in business
management and economics from the North Carolina State University, U.S.A. He has been associated with our
Company since May 26, 2015.
Jesal Shah is head, strategy of our Company. He holds a master’s degree in management studies from the
Sydenham Institute of Management Studies, Research and Entrepreneurship Education, University of Bombay.
He has previously been associated with JM Financial Institutional Securities Private Limited as the head of
research (executive director) in its research department. He has been associated with our Company since July 29,
2013.
Mitanshu Shah is the head, IBU finance of our Company. He holds a bachelor’s degree in commerce from the
Maharaja Sayajirao University, Baroda. He is also a cost and management accountant from the Institute of Cost
and Works Accountants of India. He has previously been associated with LK India Private Limited in the capacity
of head of finance and legal. He has been associated with the Alembic group of companies since May 8, 2006 and
with our Company since April 1, 2011.
Dr. Petla Y Naidu is the head, research and development (sterile formulations) of our Company. He holds a
master’s degree in science and a PhD. from the Andhra University. He has previously been associated with
Hospira Healthcare India Private Limited as senior vice president of manufacturing science and technology. He
has been associated with our Company since April 9, 2016.
Dr. Pankaj Kumar Khapra is the head, research and development (formulations and clinical affairs) of our
Company. He holds a master’s degree in pharmacy from the Doctor Harisingh Gour Vishwavidyalaya, Sagar,
Madhya Pradesh and a Ph.D. in pharmaceutics from the University of Indore. He has previously been associated
with Abdi Ibrahim Pharmaceuticals. He has been associated with our Company since January 24, 2013.
Shreekumar Nair is the senior vice president (supply chain management and operations) of our Company. He
holds a bachelor’s degree in science from the University of Bombay and a diploma in materials management from
the Ghatkopar Institute of Management, Mumbai. He has been associated with the Alembic group of companies
since October 12, 2009 and with our Company since April 1, 2011.
Vinod Kamath is the head, technical operations of our Company. He holds a bachelor’s degree in technology in
mechanical engineering from the Indian Institute of Technology, Madras and a post graduate diploma in
management from the Indian Institute of Management, Bangalore. He has been associated with our Company
since February 14, 2014.
Vittal T.V.S.K is the head, research and development (API) of our Company. He holds a master’s degree in science
in chemistry from the University of Hyderabad and a Ph.D in chemistry from Osmania University, Hyderabad.
He has previously been associated with Solara Active Pharma Sciences Limited as senior vice president (research
and development). He has been associated with our Company since July 23, 2018.
Other confirmations
None of the Directors, Promoters or Key Management Personnel of our Company has any financial or other
material interest in the Issue.
Our Company does not have any bonus or profit-sharing plan with its Directors or Key Management Personnel.
None of the Directors or the companies with which they are or were associated as promoters, directors are debarred
from accessing the capital markets under any order or direction passed by the SEBI or any other governmental
authority. Neither our Company, nor our Promoters or the companies with which our Promoters is or has been
associated with a promoter or a person in control have been debarred from accessing capital markets under any
order or direction passed by SEBI or any other governmental authority.
Neither our Company, nor any of our Directors or Promoters have been declared as a Wilful Defaulter in the last
ten years.
None of our Directors or Promoters have been declared as a Fugitive Economic Offender.
127
Employee Stock Option Schemes
The Company does not have any employee stock option schemes.
Related Party Transactions
For details in relation to the related party transactions entered by our Company during the last three Fiscals
immediately preceding the date of this Placement Document, please see the section "Related Party Transactions”
on page 71.
128
PRINCIPAL SHAREHOLDERS AND OTHER INFORMATION
The following tables present information regarding the ownership of Equity Shares by the Shareholders as of June 30, 2020:
Summary statement showing the shareholding pattern of our Company
Category of shareholder Nos. of
shareholders
No. of fully paid up
equity shares held
Total nos.
shares held
Shareholding as a % of total no.
of shares (calculated as per
SCRR, 1957) As a % of
(A+B+C2)
No. of Voting
Rights
Total as a % of
Total Voting right
Number of equity shares
held in dematerialized
form
(A) Promoter & Promoter Group 26 13,75,59,973 13,75,59,973 72.97 13,75,59,973 72.97 13,75,59,973
(B) Public 64,344 5,09,55,941 5,09,55,941 27.03 5,09,55,941 27.03 4,90,69,600
(C) Non Promoter- Non Public - - - 0.00 - 0.00 -
(C1) Shares underlying DRs - - - 0.00 - 0.00 -
(C2) Shares held by Employee Trusts - - - 0.00 - 0.00 -
Total 64,370 18,85,15,914 18,85,15,914 100.00 18,85,15,914 100.00 18,66,29,573
Statement showing shareholding pattern of the Promoter and Promoter Group
Category of shareholder Nos. of shareholders No. of fully paid up
equity shares held Total nos. shares held
Shareholding as a % of
total no. of shares
(calculated as per SCRR,
1957)As a % of (A+B+C2)
Number of equity shares held
in dematerialized form
A1) Indian
Individuals / Hindu Undivided Family 10 96,64,175 96,64,175 5.13 96,64,175
Chirayu Ramanbhai Amin* 1 45,21,465 45,21,465 2.40 45,21,465
Malika Chirayu Amin 1 30,05,730 30,05,730 1.59 30,05,730
Pranav Chirayu Amin 1 10,09,800 10,09,800 0.54 10,09,800
Shaunak Chirayu Amin 1 10,06,980 10,06,980 0.53 10,06,980
Inaaya Shaunak Amin 1 30,000 30,000 0.02 30,000
Naintara Shaunak Amin 1 30,000 30,000 0.02 30,000
Ranvir Pranav Amin 1 30,000 30,000 0.02 30,000
Samira Pranav Amin 1 30,000 30,000 0.02 30,000
Barkha Pranav Amin 1 100 100 0.00 100
Krupa Shaunak Amin 1 100 100 0.00 100
Any Other (Specify) 15 12,68,88,818 12,68,88,818 67.31 12,68,88,818
Alembic Limited 1 5,55,51,528 5,55,51,528 29.47 5,55,51,528
Shreno Ltd 1 100 100 0.00 100
Nirayu Limited 1 7,00,35,435 7,00,35,435 37.15 7,00,35,435
Paushak Limited 1 855 855 0.00 855
Alembic City Limited 1 100 100 0.00 100
Shreno Publications Limited 1 100 100 0.00 100
129
Category of shareholder Nos. of shareholders No. of fully paid up
equity shares held Total nos. shares held
Shareholding as a % of
total no. of shares
(calculated as per SCRR,
1957)As a % of (A+B+C2)
Number of equity shares held
in dematerialized form
Vidyanidhi Trust - - - 0.00 -
Arogyavardhini Society - - - 0.00 -
Utkarsh Vidyakendra - - - 0.00 -
Ujjwal Vidyalaya - - - 0.00 -
Bhailal Amin General Hospital 1 2,80,950 2,80,950 0.15 2,80,950
Uday Education Society 1 10,18,050 10,18,050 0.54 10,18,050
Laburnum Family Trust 1 200 200 0.00 200
Virsad Family Trust 1 200 200 0.00 200
Laksh Trust 1 100 100 0.00 100
Gallup Trust 1 100 100 0.00 100
Grace Star Trust 1 100 100 0.00 100
Satori Trust 1 100 100 0.00 100
Viramya Packlight LLP 1 900 900 0.00 900
Sub Total A1 25 13,65,52,993 13,65,52,993 72.44 13,65,52,993
A2) Foreign 0.00
Individuals (NonResident Individuals/ Foreign
Individuals)
1 10,06,980 10,06,980 0.53 10,06,980
Udit Chirayu Amin 1 10,06,980 10,06,980 0.53 10,06,980
Tishya Udit Amin - - - 0.00 -
Sub Total A2 1 10,06,980 10,06,980 0.53 10,06,980
A=A1+A2 26 13,75,59,973 13,75,59,973 72.97 13,75,59,973
* Including 10,73,250 Equity Shares held in the representatives capacity of Karta of Chirayu Ramanbhai Amin HUF.
Statement showing shareholding pattern of the public shareholder*
Category & Name of the Shareholders No. of
shareholder
No. of fully paid up
equity shares held
Total no. shares
held
Shareholding %
calculated as per
SCRR, 1957 As a
% of (A+B+C2)
No of Voting
Rights
Total as a %
of Total
Voting right
Number of equity
shares held in
dematerialized form
(Not Applicable)
B1) Institutions
Mutual Funds/ 18 93,88,836 93,88,836 4.98 93,88,836 4.98 93,88,836
DSP Midcap Fund 1 40,47,376 40,47,376 2.15 40,47,376 2.15 40,47,376
Alternate Investment Funds 6 1,44,924 1,44,924 0.08 1,44,924 0.08 1,44,924
Foreign Portfolio Investors 189 1,37,57,436 1,37,57,436 7.30 1,37,57,436 7.30 1,37,57,436
Elara India Opportunities Fund Limited 1 19,42,662 19,42,662 1.03 19,42,662 1.03 19,42,662
Financial Institutions/ Banks 10 2,19,085 2,19,085 0.12 2,19,085 0.12 2,03,985
Insurance Companies 3 36,27,157 36,27,157 1.92 36,27,157 1.92 36,27,157
HDFC Life Insurance Company Limited 1 25,62,157 25,62,157 1.36 25,62,157 1.36 25,62,157
Any Other (specify) 1 3,250 3,250 0.00 3,250 0.00 3,250
130
Category & Name of the Shareholders No. of
shareholder
No. of fully paid up
equity shares held
Total no. shares
held
Shareholding %
calculated as per
SCRR, 1957 As a
% of (A+B+C2)
No of Voting
Rights
Total as a %
of Total
Voting right
Number of equity
shares held in
dematerialized form
(Not Applicable)
Foreign Bank 1 3,250 3,250 0.00 3,250 0.00 3,250
Sub Total B1 227 2,71,40,688 2,71,40,688 14.40 2,71,40,688 14.40 2,71,25,588
B2) Central Government/ State Government(s)/
President of India
- - - 0.00 - 0.00 -
B3) Non-Institutions
Individual share capital upto Rs. 2 Lacs 60,635 1,56,92,973 1,56,92,973 8.32 1,56,92,973 8.32 1,38,35,257
Individual share capital in excess of Rs. 2 Lacs 13 47,30,595 47,30,595 2.51 47,30,595 2.51 47,30,595
NBFCs registered with RBI 3 1,235 1,235 0.00 1,235 0.00 1,235
Any Other (specify) 3,466 33,90,450 33,90,450 1.80 33,90,450 1.80 33,76,925
Trusts 8 9,299 9,299 0.00 9,299 0.00 6,449
HUF 1,137 5,67,156 5,67,156 0.30 5,67,156 0.30 5,67,156
Non-Resident Indian (NRI) 1,701 5,73,371 5,73,371 0.30 5,73,371 0.30 5,72,696
Unclaimed Suspense Account* 1 1,46,993 1,46,993 0.08 1,46,993 0.08 1,46,993
IEPF 1 10,99,859 10,99,859 0.58 10,99,859 0.58 10,99,859
Clearing Members 159 1,54,862 1,54,862 0.08 1,54,862 0.08 1,54,862
Bodies Corporate 458 8,38,810 8,38,810 0.44 8,38,810 0.44 8,28,810
Foreign Portfolio Investor (Category - III) 1 100 100 0.00 100 0.00 100
Sub Total B3 64,117 2,38,15,253 2,38,15,253 12.63 2,38,15,253 12.63 2,19,44,012
B=B1+B2+B3 64,344 5,09,55,941 5,09,55,941 27.03 5,09,55,941 27.03 4,90,69,600
*As on 30th June, 2020 there are 321 shareholders whose equity shares are lying in Unclaimed Suspense Account and hence remain unclaimed.
Statement showing shareholding pattern of the Non Promoter- Non Public shareholder
Category & Name of the Shareholders (I) No. of
shareholder (III)
No. of fully paid up
equity shares held
(IV)
Total No. shares held
(VII = IV+V+VI)
Shareholding % calculated as per
SCRR, 1957 As a % of (A+B+C2)(VIII)
Number of equity shares held in
dematerialized form (XIV)(Not
Applicable)
C1) Custodian/DR Holder - - - 0.00 -
C2) Employee Benefit Trust - - - 0.00 -
Details of disclosure made by the trading members holding 1% or more of the total number of shares of the Company
Name of the Trading Member Name of the Beneficial Owner No. of shares held % of total no. of shares Date of reporting by the Trading Member
Nil Nil Nil Nil Nil
131
ISSUE PROCEDURE
The following is a summary intended to present a general outline of the procedure relating to the application,
payment of Bid Amount, Allocation and Allotment of the Equity Shares. The procedure followed in the Issue may
differ from the one mentioned below and investors are assumed to have apprised themselves of the same from our
Company or the BRLMs. Prospective Investors are advised to inform themselves of any restrictions or limitations
that may be applicable to them. Also see “Selling Restrictions” and “Purchaser Representations and Transfer
Restrictions” on pages 145 and 152, respectively.
Our Company, the BRLMs and their respective directors, officers, agents, advisors, shareholders, employees,
counsel, affiliates and representatives are not liable for any amendment or modification or change to applicable
laws or regulations, which may occur after the date of this Placement Document. Eligible QIBs are advised to
make their independent investigations and satisfy themselves that they are eligible to apply. Eligible QIBs are
advised to ensure that any single Bid from them does not exceed the investment limits or maximum number of
Equity Shares that can be held by them under applicable law or regulation or as specified in this Placement
Document. Further, Eligible QIBs are required to satisfy themselves that their Bids would not result in triggering
an open offer under the SEBI Takeover Regulations and shall be solely responsible for compliance with all the
applicable provisions of the SEBI Takeover Regulations, the SEBI Insider Trading Regulations, and other
applicable laws.
Qualified Institutions Placement
THE ISSUE IS MEANT ONLY FOR ELIGIBLE QIBs ON A PRIVATE PLACEMENT BASIS AND IS
NOT AN OFFER TO THE PUBLIC OR TO ANY OTHER CLASS OF INVESTORS.
The Preliminary Placement Document and this Placement Document has not been, and will not be, filed as a
prospectus with the RoC and, no Equity Shares will be offered in India or overseas to the public or any members
of the public or any other class of investors, other than Eligible QIBs.
The Issue is being made to Eligible QIBs in reliance upon Chapter VI of the SEBI Regulations and Section 42
and other applicable provisions of the Companies Act, through the mechanism of a QIP. Under Chapter VI of the
SEBI Regulations and Section 42 of the Companies Act and other applicable provisions of the Companies Act, a
company may issue equity shares to Eligible QIBs provided that certain conditions are met.
Some of these conditions are set out below:
• the shareholders of the issuer have passed a special resolution approving such QIP. Such special resolution
must inter alia specify that, (a) the allotment of securities is proposed to be made pursuant to the QIP; and
(b) the “relevant date”;
• the explanatory statement to the notice to the shareholders for convening the general meeting must disclose,
among other things, the particulars of the issue including the date of passing the board resolution, the kind
of securities being offered and the price at which they are offered, amount which the company intends to
raise by way of such securities and the material terms of raising such securities, proposed issue schedule,
the purpose or objects of offer, the contribution made by the promoters or directors either as part of the
offer or separately in furtherance of the objects, and the basis or justification for the price (including
premium, if any) at which the offer or invitation is being made;
• under Regulation 172(1)(b) of the SEBI Regulations, equity shares of the same class of such issuer, which
are proposed to be allotted through the QIP, are listed on a recognised stock exchange in India having
nation-wide trading terminals for a period of at least one year prior to the date of issuance of notice to its
shareholders for convening the meeting to seek approval of the shareholders for the above-mentioned
special resolution;
• invitation to apply in the QIP must be made through a private placement offer-cum-application form serially
numbered and addressed specifically to the Eligible QIBs to whom the QIP is made either in writing or in
electronic mode, within 30 days of recording the name of such person in accordance with applicable law;
the issuer shall have completed allotments with respect to any earlier offer or invitation made by the issuer
or shall have withdrawn or abandoned such invitation or offer made by the issuer, except as permitted under
the Companies Act;
132
• the issuer shall not make any subsequent qualified institutions placement until the expiry of two weeks
from the date of the qualified institutions placement; and
• the promoters and directors of the issuer shall not be Fugitive Economic Offenders.
At least 10% of the equity shares issued to Eligible QIBs shall be available for Allocation to Mutual Funds,
provided that, if this portion, or any part thereof to be allotted to Mutual Funds remains unsubscribed, it may be
allotted to other Eligible QIBs.
Bidders are not allowed to withdraw or revise downwards their Bids after the Bid/ Issue Closing Date.
Additionally, there is a minimum pricing requirement under the SEBI Regulations. The floor price of the equity
shares issued under the QIP shall not be less than the average of the weekly high and low of the closing prices of
the issuer’s equity shares of the same class quoted on the stock exchanges during the two weeks preceding the
relevant date as calculated in accordance with Chapter VI of the SEBI Regulations. Our Company has also offered a
discount of ₹ 48.75 per Equity Share (4.97% on the Floor Price), in accordance with and in terms of Regulation 176 of the
SEBI Regulations.
The “relevant date” in case of allotment of equity shares, refers to the date of the meeting in which the board of
directors or the committee of directors duly authorised by the board of the issuer decides to open the proposed
issue and “stock exchange” means any of the recognised stock exchanges in India on which the equity shares of
the issuer of the same class are listed and on which the highest trading volume in such shares has been recorded
during the two weeks immediately preceding the relevant date.
The securities must be allotted within 365 days from the date of the shareholders’ resolution approving the QIP
and also within 60 days from the date of receipt of subscription money from the relevant Eligible QIBs.
The Equity Shares to be issued pursuant to the Issue must be issued on the basis of the Preliminary Placement
Document and this Placement Document, that shall contain all material information including the information
specified in Schedule VII of the SEBI Regulations and the requirements prescribed under PAS Rules and Form
PAS-4. The Preliminary Placement Document and this Placement Document are private documents provided to
only select Eligible QIBs through serially numbered copies and are required to be placed on the website of the
concerned Stock Exchanges and of our Company with a disclaimer to the effect that it is in connection with an
issue to Eligible QIBs and no offer is being made to the public or to any other category of investors. Please note
that if you have not receive a serially numbered copy of the Preliminary Placement Document and this Placement
Document addressed to you, you may not rely on the Preliminary Placement Document or this Placement
Document uploaded on the website of the Stock Exchanges or our Company for making an application to subscribe
to Equity Shares pursuant to the Issue.
The minimum number of allottees for each QIP shall not be less than:
• two, where the issue size is less than or equal to ₹250 crore; and
• five, where the issue size is greater than ₹250 crore.
No single Allottee shall be Allotted more than 50% of the Issue Size.
Eligible QIBs that belong to the same group or that are under common control shall be deemed to be a single
Allottee for the purpose of the Issue. For details of what constitutes “same group” or “common control”, see “—
Bid Process—Application Form” on page 137.
Equity Shares being Allotted pursuant to the Issue shall not be sold for a period of one year from the date of
Allotment, except on the floor of a recognised stock exchange.
We have applied for and received the in-principle approval of the Stock Exchanges under Regulation 28(1)(a) of
the SEBI Listing Regulations for listing of the Equity Shares to be issued pursuant to the Issue on the Stock
Exchanges. We have filed a copy of the Preliminary Placement Document and this Placement Document with the
Stock Exchanges.
We shall also make the requisite filings with the RoC within the stipulated period as required under the Companies
Act and the PAS Rules.
133
The Issue has been authorised and approved by our Board pursuant to its resolution(s) passed on May 22, 2020
and July 27, 2020 and our Shareholders’ through a special resolution passed on July 22, 2020.
Allotments made to VCFs and AIFs in the Issue are subject to the rules and regulations that are applicable
to each of them respectively, including in relation to lock-in requirement. VCFs and AIFs should
independently consult their own counsel and advisors as to investment in and related matters concerning
the Issue.
The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities
Act, or the securities laws of any state of the United States and may not be offered or sold in the United
States except pursuant to an exemption from, or in a transaction not subject to, the registration
requirements of the U.S. Securities Act and any applicable state securities laws. The Equity Shares offered
in the Issue are being offered and sold only outside the United States in “offshore transactions”, as defined
in and in reliance on Regulation S under the U.S. Securities Act. (“Regulation S”). See “Selling Restrictions”
on page 145 for information about eligible offerees for the Issue and “Purchaser Representations and
Transfer Restrictions” on page 152 for information about transfer restrictions that apply to the Equity
Shares sold in the Issue. For a description of certain restrictions on transfer of the Equity Shares, see
“Purchaser Representations and Transfer Restrictions” on page 152.
The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other
jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such
jurisdiction, except in compliance with the applicable laws of such jurisdiction.
Issue Procedure
1. On Bid / Issue Opening Date, our Company and/or the BRLMs have circulated serially numbered copies
of the Preliminary Placement Document cum Application Form, either in electronic or physical form to the
identified Eligible QIBs and the Application Form will be specifically addressed to such Eligible QIBs. In
terms of Section 42(3) of the Companies Act, our Company shall maintain complete records of Eligible
QIBs in the form and manner prescribed under the PAS Rules, to whom the serially numbered copies of
the Preliminary Placement Document, this Placement Document and the serially numbered Application
Form have been dispatched. Our Company will make the requisite filings with RoC within the stipulated
time period as required under the Companies Act in relation to the Issue.
2. The list of QIBs to whom the Preliminary Placement Document cum Application Form have been
delivered, have been determined by our Company in consultation with the BRLMs, at their sole discretion.
Unless a serially numbered Preliminary Placement Document along with the serially numbered
Application Form, which includes the details of the bank account wherein the Bid Amount is to be
deposited, is addressed to a particular Eligible QIB, no invitation to subscribe shall be deemed to
have been made to such Eligible QIB. Even if such documentation were to come into the possession of
any person other than the intended recipient, no offer or invitation to offer shall be deemed to have been
made to such person and any application that does not comply with this requirement shall be treated as
invalid.
3. The Application Form may be signed physically or digitally, if required under applicable law in the relevant
jurisdiction applicable to each Eligible QIB and as permitted under such applicable law. An Eligible QIB
may submit an unsigned copy of the Application Form, as long as the Bid Amount is paid along with
submission of the Application Form within the Bid/Issue Period. Once a duly filled Application Form is
submitted by an Eligible QIB, whether signed or not, and the Bid Amount has been transferred to the
Escrow Account, such Application Form constitutes an irrevocable offer and cannot be withdrawn or
revised downwards after the Bid/Issue Closing Date. In case Bids are being made on behalf of the Eligible
QIB and the Application Form is unsigned, it shall be assumed that the person submitting the Application
Form and providing necessary instructions for transfer of the Bid Amount to the Escrow Account, on behalf
of the Eligible QIB is authorised to do so.
4. Eligible QIBs may submit an Application Form, including any revisions thereof, along with the Bid
Amount transferred to the escrow account specified in the application form and a copy of the PAN card or
PAN allotment letter and/or any other documents mentioned in the Application Form, during the Bid/ Issue
Period to the BRLMs.
134
5. Bidders will be required to indicate the following in the Application Form:
• full official name of the Bidder to whom Equity Shares are to be Allotted, complete address, e-mail
id, PAN details, phone number and bank account details;
• number of Equity Shares Bid for;
• price at which they are agreeable to subscribe for the Equity Shares and the aggregate Bid Amount
for the number of Equity Shares Bid for;
• details of the depository account to which the Equity Shares should be credited;
• equity shares held by the Bidder in our Company prior to the Issue; and
• it has agreed to certain other representations set forth in the Application Form.
NOTE: Eligible FPIs are required to indicate the SEBI FPI registration number in the Application Form.
The Bids made by the asset management companies or custodian of Mutual Funds shall specifically state
the names of the concerned schemes for which the Bids are made. In case of a Mutual Fund, a separate
Bid can be made in respect of each scheme of the Mutual Fund registered with SEBI and such Bids in
respect of more than one scheme of the Mutual Fund will not be treated as multiple Bids provided that the
Bids clearly indicate the scheme for which the Bid has been made. Application by various schemes or funds
of a Mutual Fund will be treated as one application from the Mutual Fund. Bidders are advised to ensure
that any single Bid from them does not exceed the investment limits or maximum number of Equity Shares
that can be held by them under applicable laws.
6. Eligible QIBs shall be required to make the entire payment of the Bid Amount for the Equity Shares Bid
for, along with the Application Form, only through electronic transfer to the Escrow Account opened in the
name of “Alembic Pharmaceuticals Ltd-QIP Escrow” with the Escrow Bank, within the Bid/Issue Period
as specified in the Application Form sent to the respective Bidders. Please note that any payment of Bid
Amount for the Equity Shares shall be made from the bank accounts of the relevant Bidders and our
Company shall keep a record of the bank account from where such payment has been received. Bid Amount
payable on Equity Shares to be held by joint holders shall be paid from the bank account of the person
whose name appears first in the Application Form. Until Allotment, and the filing of return of Allotment
by our Company with the RoC, or receipt of final listing and trading approvals from the Stock Exchanges,
whichever is later, Bid Amount received for subscription of the Equity Shares shall be kept by our Company
in the Escrow Account and shall be utilised only for the purposes permitted under the Companies Act.
7. Once a duly completed Application Form is submitted by a Bidder and the Bid Amount is transferred to
the Escrow Account, such application constitutes an irrevocable offer and the Bid cannot be withdrawn or
revised downwards after the Bid/ Issue Closing Date. In case of an upward revision before the Bid/ Issue
Closing Date, an additional amount shall be required to be deposited towards the Bid Amount in the Escrow
Account along with the submission of such revised Bid. The Bid/ Issue Closing Date shall be notified to
the Stock Exchanges and the Eligible QIBs shall be deemed to have been given notice of such date after
receipt of the Application Form.
8. Upon receipt of the duly completed Application Form and the Bid Amount in the Escrow Account, on or
after the Bid/ Issue Closing Date, our Company shall, in consultation with BRLMs determine the final
terms, including the Issue Price of the Equity Shares to be issued pursuant to the Issue, the number of
Equity Shares to be Allocated to each Successful Bidder and the Successful Bidders to whom such Equity
Shares shall be Allocated. Upon such determination, the BRLMs will send the serially numbered CAN to
the Successful Bidders. The dispatch of a CAN, and the Placement Document (when dispatched) to a
Successful Bidder shall be deemed a valid, binding and irrevocable contract for the Successful Bidders to
subscribe to the Equity Shares Allocated to such Successful Bidders at an aggregate price equivalent to the
product of the Issue Price and Equity Shares Allocated to such Successful Bidders. The CAN shall contain
details such as the number of Equity Shares Allocated to the Successful Bidders, Issue Price and the
aggregate amount received towards the Equity Shares Allocated. Please note that the Allocation will be
at the absolute discretion of our Company and shall be in consultation with the BRLMs.
135
9. Upon determination of the Issue Price and before Allotment of Equity Shares to the Successful Bidders,
the BRLMs, shall, on our behalf, send a serially numbered Placement Document either in electronic form
or through physical delivery to each of the Successful Bidders who have been Allocated Equity Shares
pursuant to dispatch of a serially numbered CAN.
10. Upon dispatch of the serially numbered Placement Document, our Company shall Allot Equity Shares as
per the details in the CANs sent to the Successful Bidders. Our Company will inform the Stock Exchanges
of the details of the Allotment.
11. After passing the resolution for Allotment and prior to crediting the Equity Shares into the beneficiary
account of the Successful Bidders maintained by the Depository Participant, as specified in the records of
the depositories or as indicated in their respective Application Form, our Company shall apply to the Stock
Exchanges for listing approvals in respect of the Equity Shares Allotted pursuant to the Issue.
12. After receipt of the listing approvals of the Stock Exchanges, our Company shall credit the Equity Shares
Allotted pursuant to this Issue into the beneficiary accounts of the respective Allottees.
13. Our Company will then apply for the final trading approvals from the Stock Exchanges.
14. The Equity Shares that would have been credited to the beneficiary account with the Depository Participant
of the Successful Bidders shall be eligible for trading on the Stock Exchanges only upon the receipt of final
trading and listing approvals from the Stock Exchanges.
15. As per applicable law, the Stock Exchanges will notify the final listing and trading approvals, which are
ordinarily available on their websites, and our Company may communicate the receipt of the listing and
trading approvals to those Eligible QIBs to whom the Equity Shares have been Allotted. Our Company and
the BRLMs shall not be responsible for any delay or non-receipt of the communication of the final trading
and listing permissions from the Stock Exchanges or any loss arising from such delay or non-receipt.
Investors are advised to apprise themselves of the status of the receipt of the permissions from the Stock
Exchanges or our Company.
Eligible QIBs
Only Eligible QIBs are eligible to invest in the Equity Shares pursuant to the Issue, provided that with respect to
foreign portfolio investors, only Eligible FPIs applying under Schedule II of the FEMA Rules will be considered
as Eligible QIBs. FVCIs are not permitted to participate in the Issue. Currently, QIBs, who are eligible to
participate in the Issue and also as defined under Regulation 2(1)(ss) of the SEBI Regulations, are set forth
below:
• Eligible FPIs other than Category II FPI, registered with SEBI;
• insurance companies registered with the Insurance Regulatory and Development Authority of India;
• insurance funds set up and managed by army, navy or air force of the Union of India;
• insurance funds set up and managed by the Department of Posts, India.
• multilateral and bilateral development financial institutions;
• Mutual Funds, VCFs, AIFs, registered with the SEBI;
• pension funds with minimum corpus of ₹25 crore;
• provident funds with minimum corpus of ₹25 crore;
• public financial institutions;
• scheduled commercial banks;
• state industrial development corporations;
• systemically important non-banking financial companies; and
136
• the National Investment Fund set up by resolution no. F. No. 2/3/2005-DDII dated November 23, 2005 of
the Government published in the Gazette of India.
ELIGIBLE FPIS ARE PERMITTED TO PARTICIPATE UNDER SCHEDULE II OF FEMA RULES IN
THIS ISSUE. ELIGIBLE FPIS ARE PERMITTED TO PARTICIPATE IN THE ISSUE SUBJECT TO
COMPLIANCE WITH ALL APPLICABLE LAWS AND SUCH THAT THE SHAREHOLDING OF THE
FPIS DO NOT EXCEED SPECIFIED LIMITS AS PRESCRIBED UNDER APPLICABLE LAWS IN
THIS REGARD. FVCIS ARE NOT PERMITTED TO PARTICIPATE IN THIS ISSUE.
In terms of the SEBI FPI Regulations, the Equity Shares issued to a single Eligible FPI or an investor group
(multiple entities registered as FPIs and directly or indirectly, having common ownership of more than fifty per
cent or common control) should not exceed 10% of post-Issue Equity Share capital of our Company. Further, in
terms of the FEMA Rules, the total holding of each FPI shall be below 10% of the total paid-up Equity Share
capital of our Company on a fully diluted basis.
In case the holding of an FPI including its investor group increases to 10% or more of the total paid-up equity
capital, on a fully diluted basis, the FPI including its investor group is required to divest the excess holding within
five trading days from the date of settlement of the trades resulting in the breach. In the event that such divestment
of excess holding is not done, the total investment made by such FPI together with its investor group will be re-
classified as FDI as per procedure specified by SEBI and the FPI and its investor group will be prohibited from
making any further portfolio investment in our Company under the SEBI FPI Regulations. However, in
accordance with Regulation 22(4) of the SEBI FPI Regulations, the FPIs who are: (i) appropriately regulated
public retail funds; (b) public retail funds where the majority is owned by appropriately regulated public retail
fund on look through basis; or (c) public retail funds and investment managers of such foreign portfolio investors
are appropriately regulated, the aggregation of the investment limits of such FPIs having common control, shall
not be applicable.
Pursuant to the SEBI Circular dated April 5, 2018 (Circular No: IMD/FPIC/CIR/P/2018/61), our Company has
appointed CDSL as the designated depository to monitor the level of FPI/NRI shareholding in our Company on a
daily basis and once the aggregate foreign investment of a company reaches a cut-off point, which is 3% below
the overall limit a red flag shall be activated. The depository is then required to inform the Stock Exchanges about
the activation of the red flag. The Stock Exchanges are then required to issue the necessary circulars/ public
notifications on their respective websites. Once a red flag is activated, the FPIs must trade cautiously, because in
the event that there is a breach of the sectoral cap, the FPIs will be under an obligation to disinvest the excess
holding within five trading days from the date of settlement of the trades.
In terms of the FEMA Rules, for calculating the aggregate holding of FPIs in a company, holding of all registered
FPIs shall be included. For a description of the restrictions applicable to the offer and sale of the Equity Shares in
the Issue in certain jurisdictions, see “Selling Restrictions” and “Purchaser Representations and Transfer
Restrictions” beginning on pages 145 and 152, respectively.
Restriction on Allotment
Pursuant to Regulation 179(2)(b) of the SEBI Regulations, no Allotment shall be made pursuant to the Issue,
either directly or indirectly, to any Eligible QIB being a Promoter, or any person related to the Promoters. QIBs,
which have all or any of the following rights, shall be deemed to be persons related to the Promoters:
• rights under a shareholders’ agreement or voting agreement entered into with the Promoters or members of
the Promoter Group;
• veto rights; or
• a right to appoint any nominee director on the Board,
Provided, however, that an Eligible QIB which does not hold any Equity Shares in our Company and which has
acquired the aforesaid rights in the capacity of a lender shall not be deemed to be related to the Promoters.
Our Company, the BRLMs and any of their respective shareholders, employees, counsel, officers, directors,
representatives, agents, advisors or affiliates shall not be liable for any amendment or modification or
change to applicable laws or regulations, which may occur after the date of this Placement Document.
137
Eligible QIBs are advised to make their independent investigations and satisfy themselves that they are
eligible to apply. Eligible QIBs are advised to ensure that any single application from them does not exceed
the investment limits or maximum number of Equity Shares that can be held by them under applicable law
or regulation or as specified in the Preliminary Placement Document or this Placement Document. Further,
Eligible QIBs are required to satisfy themselves that their Bids would not eventually result in triggering a
tender offer under the SEBI Takeover Regulations, and ensure compliance with applicable laws.
A minimum of 10% of the Equity Shares offered in the Issue shall be Allotted to Mutual Funds. In case of
undersubscription in such portion, such portion or part thereof may be Allotted to other Eligible QIBs.
Note: Affiliates or associates of the BRLMs who are Eligible QIBs may participate in the Issue in compliance
with applicable laws.
Bid Process
Application Form
Eligible QIBs shall only use the serially numbered Application Forms (which are addressed to them) circulated
by our Company and/or the BRLMs in either electronic form or by physical delivery for the purpose of making a
Bid (including revision of a Bid) in terms of the Preliminary Placement Document.
By making a Bid (including the revision thereof) for Equity Shares through Application Forms and pursuant to
the terms of the Preliminary Placement Document, the Eligible QIB will be deemed to have made all the following
representations and warranties and the representations, warranties and agreements made under “Notice to
Investors”, “Representations by Investors”, “Selling Restrictions” and “Purchaser Representations and Transfer
Restrictions” on pages 1, 3, 145 and 152, respectively:
1. Each Eligible QIB confirms that it is a QIB in terms of Regulation 2(1)(ss) of the SEBI Regulations and is
not excluded under Regulation 179(2)(b) of the SEBI Regulations, has a valid and existing registration
under the applicable laws in India (as applicable) and is eligible to participate in this Issue;
2. Each Eligible QIB confirms that it is not a Promoter and is not a person related to the Promoters, either
directly or indirectly and its Application Form does not directly or indirectly represent the Promoters or
Promoter Group or persons related to the Promoters;
3. Each Eligible QIB confirms that it has no rights under a shareholders’ agreement or voting agreement with
the Promoters or members of the Promoter Group, no veto rights or right to appoint any nominee director
on the Board other than those acquired in the capacity of a lender not holding any Equity Shares which
shall not be deemed to be a person related to the Promoters;
4. Each Bidder confirms that in the event it is resident outside India, it is an Eligible FPI, having a valid and
existing registration with SEBI under the applicable laws in India or a multilateral or bilateral development
financial institution, and is eligible to invest in India under applicable law, including the FEMA Rules, as
amended, and any notifications, circulars or clarifications issued thereunder, and has not been prohibited
by SEBI or any other regulatory authority, from buying, selling, dealing in securities or otherwise accessing
the capital markets and is not an FVCI;
5. Each Eligible QIB acknowledges that it has no right to withdraw or revise its Bid downwards after the Bid
/ Issue Closing Date;
6. Each Eligible QIB confirms that if Equity Shares are Allotted through this Issue, it shall not, for a period
of one year from Allotment, sell such Equity Shares otherwise than on the Stock Exchanges;
7. The Bidder confirms that in the event it is resident outside India, it is an Eligible FPI, and not an FVCI;
8. Each Eligible QIB confirms that the Eligible QIB is eligible to Bid and hold Equity Shares so Allotted
together with any Equity Shares held by it prior to the Issue, if any. Each Eligible QIB further confirms
that the holding of the Eligible QIB, does not and shall not, exceed the level permissible as per any
applicable regulations applicable to the Eligible QIB;
138
9. Each Eligible QIB confirms that its Bids would not eventually result in triggering a tender offer under the
SEBI Takeover Regulations;
10. The Eligible QIB agrees that it will make payment of its Bid Amount along with submission of the
Application Form within the Bid/Issue Period. Each Eligible QIB agrees that once a duly filled Application
Form is submitted by an Eligible QIB, whether signed or not, and the Bid Amount has been transferred to
the Escrow Account, such Application Form constitutes an irrevocable offer and cannot be withdrawn or
revised downwards after the Bid/Issue Closing Date;
11. The Eligible QIB agrees that although the Bid Amount is required to be paid by it along with the
Application Form within the Issue Period in terms of provisions of the Companies Act, our Company
reserves the right to Allocate and Allot Equity Shares pursuant to this Issue on a discretionary basis in
consultation with the BRLMs. The Eligible QIB further acknowledges and agrees that the payment of Bid
Amount does not guarantee Allocation and/or Allotment of Equity Shares Bid for in full or in part;
12. The Eligible QIB acknowledges that in terms of the requirements of the Companies Act, upon Allocation,
our Company has disclosed names as “proposed Allottees” and percentage of post-Issue shareholding of
the proposed Allottees in this Placement Document and such QIB consents of such disclosure, if any Equity
Shares are Allocated to it. However, the Eligible QIB further acknowledges and agrees that, disclosure of
such details as “proposed Allottees” in this Placement Document does not guarantee Allotment to them, as
Allotment in the Issue shall continue to be at the sole discretion of our Company, in consultation with the
BRLMs.
13. The Eligible QIB confirms that the number of Equity Shares Allotted to it pursuant to the Issue, together
with other Allottees that belong to the same group or are under common control, shall not exceed 50% of
the Issue. For the purposes of this representation:
(a) QIBs “belonging to the same group” shall mean entities where (a) any of them controls, directly or
indirectly, through its subsidiary or holding company, not less than 15% of the voting rights in the
other; (b) any of them, directly or indirectly, by itself, or in combination with other persons, exercise
control over the others; or (c) there is a common director, excluding nominee and Independent
Directors, amongst an Eligible QIB, its subsidiary(ies) or holding company and any other QIB; and
(b) ‘Control’ shall have the same meaning as is assigned to it by Regulation 2(1)(e) of the SEBI
Takeover Regulations;
14. The Eligible QIBs acknowledge that no Allocation shall be made to them if the price at which they have
Bid for in the Issue is lower than the Issue Price.
15. Each Eligible QIB confirms that it shall not undertake any trade in the Equity Shares credited to its
beneficiary account maintained with the Depository Participant until such time that the final listing and
trading approvals for the Equity Shares issued pursuant to this Issue, are issued by the Stock Exchanges.
16. Each Eligible QIB acknowledges, represents and agrees that its total voting rights in our Company does
not exceed 10% of the total issued share capital of our Company.
ELIGIBLE QIBs MUST PROVIDE THEIR NAME, COMPLETE ADDRESS, PHONE NUMBER,
EMAIL ID, BANK ACCOUNT DETAILS, BENEFICIARY ACCOUNT DETAILS, PAN, DEPOSITORY
PARTICIPANT’S NAME, DEPOSITORY PARTICIPANT IDENTIFICATION NUMBER AND
BENEFICIARY ACCOUNT NUMBER IN THE APPLICATION FORM. ELIGIBLE QIBs MUST
ENSURE THAT THE NAME GIVEN IN THE APPLICATION FORM IS EXACTLY THE SAME AS
THE NAME IN WHICH THEIR BENEFICIARY ACCOUNT IS HELD.
IF SO REQUIRED BY THE BRLMs, THE ELIGIBLE QIBs SUBMITTING A BID, ALONG WITH THE
APPLICATION FORM, WILL ALSO HAVE TO SUBMIT REQUISITE DOCUMENT(S) TO THE
BRLMs TO EVIDENCE THEIR STATUS AS A "QIB" AS DEFINED HEREINABOVE.
IF SO REQUIRED BY THE BRLMs, ESCROW BANK OR ANY STATUTORY OR REGULATORY
139
AUTHORITY IN THIS REGARD, INCLUDING AFTER BID/ISSUE CLOSING DATE, THE ELIGIBLE
QIBs SUBMITTING A BID AND/OR BEING ALLOTTED EQUITY SHARES IN THE ISSUE, WILL
ALSO HAVE TO SUBMIT REQUISITE DOCUMENT(S) TO FULFILL THE APPLICABLE KNOW
YOUR CUSTOMER (KYC) NORMS.
Demographic details such as address and bank account will be obtained from the Depositories as per the
Depository Participant account details provided in the Application Form. However, for the purposes of refund of
all or part of the Bid Amount submitted by the Bidder, the bank details as mentioned in the Application Form
from which the Bid Amount shall be remitted for the Equity Shares applied for in the Issue, will be considered.
The submission of an Application Form and payment of the Bid Amount pursuant to the Application Form by a
Bidder shall be deemed a valid, binding and irrevocable offer for such Bidder and becomes a binding contract on
a Successful Bidder upon issuance of the CAN and the Placement Document (when dispatched) by our Company
(by itself or through the BRLMs) in favour of the Successful Bidder.
Submission of Application Form
All Application Forms must be duly completed with information including the number of Equity Shares applied
for along with proof of payment and a copy of the PAN card or PAN allotment letter. The Bid Amount shall be
deposited in the Escrow Account as is specified in the Application Form and the Application Form shall be
submitted to the BRLMs either through electronic form or through physical delivery at either of the following
addresses:
Name Address Contact Person Email
Phone (Telephone)
Monarch
Networth
Capital
Limited
Monarch House, Opp.
Prahaladbhai Patel
Garden, Nr. Ishwar
Bhuwan, Commerce Six
Roads, Navarangpura,
Ahmedabad- 380 009,
Gujarat
Jenny Bagrecha /
Anshit Acharya [email protected]
+91 96389 71425/
+91 99989 44599
HDFC Bank
Limited
Investment Banking
Group,
Unit No 401 & 402, 4th
Floor, Tower B,
Peninsula Business Park,
Lower Parel, Mumbai ‐
400 013
Ravi Sharma /
Harsh Thakkar [email protected]
+91 75063 77488/ +91
99203 27474
The BRLMs shall not be required to provide any written acknowledgement of the receipt of the Application Form
and the Bid Amount.
Bidders shall pay the entire Bid Amount along with the submission of the Application Form, within the Bid/Issue
Period.
Payment of Bid Amount
Our Company has opened the Escrow Account in the name of “Alembic Pharmaceuticals Ltd-QIP Escrow” with
the Escrow Bank, in terms of the Escrow Agreement. Each Bidder will be required to deposit the Bid Amount
payable for the Equity Shares Bid by it along with the submission of the Application Form and during the Bid/Issue
Period. Bidders can make payment of the Bid Amount only through electronic transfer of funds from their own
bank account.
Note: Payments are to be made only through electronic fund transfer. Payments made through cash or
cheques are liable to be rejected. Further, if the payment is not made favoring the Escrow Account, the
Application Form is liable to be rejected.
Pending Allotment, our Company undertakes to utilise the amount deposited in the Escrow Account only for the
purposes of (i) adjustment against Allotment of Equity Shares in the Issue; or (ii) repayment of Bid Amount if our
Company is not able to Allot Equity Shares in the Issue.
140
Pricing and Allocation
There is a minimum pricing requirement under the SEBI Regulations. The Floor Price shall not be less than the
average of the weekly high and low of the closing prices of the Equity Shares quoted on the stock exchange during
the two weeks preceding the Relevant Date. Our Company has also offered a discount of ₹ 48.75 per Equity Share, in
accordance with and in terms of Regulation 176 of the SEBI Regulations.
The “Relevant Date” referred to above will be the date of the meeting in which the Board or a duly constituted
committee of the Board, decides to open the Issue and “stock exchange” means any of the recognized stock
exchanges in India on which the Equity Shares of the Company of the same class are listed and on which the
highest trading volume in such Equity Shares has been recorded during the two weeks immediately preceding the
Relevant Date.
Build up of the Book
The Eligible QIBs shall submit their Bids (including any revision thereof) through the Application Forms within
the Bid/Issue Period to the BRLMs. Such Bids cannot be withdrawn or revised downwards after the Bid/ Issue
Closing Date. The book shall be maintained by the BRLMs.
Method of Allocation
Our Company shall determine the Allocation in consultation with the BRLMs on a discretionary basis and in
compliance with Chapter VI of the SEBI Regulations.
Application Forms received from the Eligible QIBs at or above the Issue Price shall be grouped together to
determine the total demand. The Allocation to all such Eligible QIBs will be made at the Issue Price. Allocation
to Mutual Funds for up to a minimum of 10% of the Issue Size shall be undertaken subject to valid Bids being
received at or above the Issue Price.
In case of cancellations or default by the Bidders, Company in consultation with BRLMs have the right to
reallocate the Equity Shares at the Issue Price among existing or new Bidders at their sole and absolute discretion
subject to the applicable laws.
THE DECISION OF OUR COMPANY IN CONSULTATION WITH THE BRLMs IN RESPECT OF
ALLOCATION SHALL BE FINAL AND BINDING ON ALL ELIGIBLE QIBs. ELIGIBLE QIBs MAY
NOTE THAT ALLOCATION OF EQUITY SHARES IS AT THE SOLE AND ABSOLUTE
DISCRETION OF OUR COMPANY AND ELIGIBLE QIBs MAY NOT RECEIVE ANY ALLOCATION
EVEN IF THEY HAVE SUBMITTED VALID APPLICATION FORMS AND PAID THE ENTIRE BID
AMOUNT AT OR ABOVE THE ISSUE PRICE WITHIN THE ISSUE PERIOD. NEITHER OUR
COMPANY NOR THE BRLMs ARE OBLIGED TO ASSIGN ANY REASON FOR ANY NON-
ALLOCATION.
CAN
Based on receipt of the serially numbered Application Forms and Bid Amount, our Company, in consultation with
the BRLMs, in their sole and absolute discretion, shall decide the Successful Bidders to whom the serially
numbered CAN shall be dispatched, pursuant to which the details of the Equity Shares Allocated to them, the
Issue Price and the Bid Amount for the Equity Shares Allocated to them shall be notified to such Successful
Bidders. Additionally, the CAN will include the probable Designated Date, being the date of credit of the Equity
Shares to the Successful Bidders’ account, as applicable to the respective Successful Bidder.
The Successful Bidders would also be sent a serially numbered Placement Document (which will include the
names of the proposed Allottees along with the percentage of their post-Issue Shareholding in our Company)
either in electronic form or by physical delivery.
The dispatch of the serially numbered CAN and the Placement Document (when dispatched), to the Eligible QIBs
shall be deemed a valid, binding and irrevocable contract for the Eligible QIBs to subscribe to the Equity Shares
Allocated to such Successful Bidders. Subsequently, our Board or a duly constituted committee of the Board, will
approve the Allotment of the Equity Shares to the Allottees in consultation with the BRLMs.
141
QIBs are advised to instruct their Depository Participant to accept the Equity Shares that may be Allotted
to them pursuant to the Issue.
By submitting the Application Form, an Eligible QIB would have deemed to have made the representations and
warranties as specified in section “Notice to Investors” on page 1 and further that such Eligible QIB shall not
undertake any trade on the Equity Shares credited to its Depository Participant account pursuant to the Issue until
such time as the final listing and trading approval are issued by Stock Exchanges.
Designated Date and Allotment of Equity Shares
1. Subject to the satisfaction of the terms and conditions of the Placement Agreement, our Company will
ensure that the Allotment of the Equity Shares is completed by the Designated Date provided in the CAN.
2. In accordance with the SEBI Regulations, Equity Shares will be issued and Allotment shall be made only
in the dematerialized form to the Allottees. Allottees will have the option to re-materialize the Equity
Shares, if they so desire, as per the provisions of the Companies Act and the Depositories Act. However,
no transfer in physical form is permitted as per Regulation 40 of the SEBI Listing Regulations.
3.
Our Company, at its sole discretion, reserves the right to cancel the Issue at any time up to Allotment
without assigning any reasons whatsoever.
4. Following the Allotment of the Equity Shares pursuant to the Issue, our Company shall apply to the Stock
Exchanges for listing approvals and post receipt of the listing approvals from the Stock Exchanges, our
Company shall credit the Equity Shares into the beneficiary accounts of the Eligible QIBs.
5. Following the credit of Equity Shares into the successful Bidders’ beneficiary accounts, our Company will
apply for the final listing and trading approvals from the Stock Exchanges.
6. The monies lying to the credit of the Escrow Account shall not be released until the final listing and trading
approvals of the Stock Exchanges for the listing and trading of the Equity Shares issued pursuant to this
Issue are received by our Company and our Company files the return of Allotment in connection with the
Issue with the RoC.
7. After finalization of the Issue Price, our Company has updated the Preliminary Placement Document with
the Issue details and is filing such document with the Stock Exchanges as this Placement Document, which
will include names of the proposed Allottees and the percentage of their post-Issue shareholding in the
Company. Pursuant to a circular dated March 5, 2010 issued by the SEBI, Stock Exchanges are required to
make available on their websites the details of those Allottees in Issue who have been allotted more than
5% of the Equity Shares offered in the Issue, namely, names of the Allottees, and number of Equity Shares
Allotted to each of them, pre and post Issue shareholding pattern of our Company along with this Placement
Document.
Refunds
In the event that the number of Equity Shares Allocated to a Bidder is lower than the number of Equity Shares
applied for through the Application Form and towards which Bid Amount has been paid by such Bidder, or the
Bidder has deposited the Bid Amount arrived at using a price higher than the Issue Price or Equity Shares are not
Allocated to a Bidder for any reasons or the Issue is cancelled prior to Allocation, or a Bidder lowers or withdraws
the Bid prior to the Bid/ Issue Closing Date, any excess Bid Amount paid by such Bidder will be refunded to the
same bank account from which Bid Amount was remitted as set out in the Application Form. The Refund Amount
will be transferred to the relevant Bidders within two Working Days from the issuance of the CAN.
In the event that we are unable to issue and Allot the Equity Shares offered in the Issue or if the Issue is cancelled
within 60 days from the date of receipt of Bid Amounts, our Company shall repay the application monies within
15 days from the expiry of 60 days, failing which our Company shall repay that monies with interest at such rate
and in such manner as prescribed under the Companies Act. The Bid Amount paid by Bidders will be refunded
by us to the same bank account from which Bid Amount was remitted as set out in the Application Form.
We, at our sole discretion, reserve the right to cancel the Issue at any time up to Allotment without assigning any
reason whatsoever.
142
Following the Allotment and credit of Equity Shares into the Eligible QIBs’ Depository Participant accounts, we
will apply for final trading and listing approvals from the Stock Exchanges. In the event of any delay in the
Allotment or credit of Equity Shares, or receipt of trading or listing approvals or cancellation of the Issue, no
interest or penalty would be payable by us.
Release of Funds to our Company
The monies lying to the credit of the Escrow Account shall not be released until the final listing and trading
approvals of the Stock Exchanges for the listing and trading of the Equity Shares issued pursuant to this Issue are
received by our Company and our Company files the return of Allotment in connection with the Issue with the
RoC.
Other Instructions
Permanent Account Number or PAN
Each Bidder should mention its PAN (except Bids from any category of Bidders, which may be exempted from
specifying their PAN for transacting in the securities market) allotted under the IT Act. A copy of PAN card is
required to be submitted with the Application Form. Further, the Application Forms without this information will
be considered incomplete and are liable to be rejected. It is to be specifically noted that applicants should not
submit the GIR number instead of the PAN as the Application Form is liable to be rejected on this ground.
Right to Reject Applications
Our Company, in consultation with the BRLMs, may reject Bids, in part or in full, without assigning any reason
whatsoever. The decision of our Company in consultation with the BRLMs in relation to the rejection of Bids
shall be final and binding. In the event the Bid is rejected by our Company, the Bid Amount paid by the Bidder
shall be refunded to the same bank account from which the Bid Amount was remitted by such Bidder as set out
in the Application Form. For details, see “ - Bid Process” and “- Refunds” on pages 137 and 141 respectively.
Equity Shares in dematerialised form with NSDL or CDSL
The Allotment of the Equity Shares in this Issue shall be only in dematerialised form (i.e., not in physical
certificates but be fungible and be represented by the statement issued through the electronic mode).
An Eligible QIB applying for Equity Shares to be issued pursuant to the Issue must have at least one beneficiary
account with a Depository Participant of either NSDL or CDSL prior to making the Bid. Equity Shares Allotted
to a Successful Bidder will be credited in electronic form directly to the beneficiary account (with the Depository
Participant) of the Successful Bidder, as indicated in the Application Form.
Equity Shares in electronic form can be traded only on the stock exchanges having electronic connectivity with
NSDL and CDSL. The Stock Exchanges have electronic connectivity with NSDL and CDSL.
The trading of the Equity Shares to be issued pursuant to the Issue would be in dematerialised form only for all
QIBs in the demat segment of the respective Stock Exchanges.
Our Company and the BRLMs shall not be responsible or liable for the delay in the credit of Equity Shares to be
issued pursuant to the Issue due to errors in the Application Form or otherwise on the part of the Bidders.
143
PLACEMENT
The BRLMs have entered into the Placement Agreement with our Company, pursuant to which the BRLMs have
agreed, subject to certain conditions, to manage this Issue and to act as placement agents in connection with the
proposed Issue and procure subscription to Equity Shares on a reasonable efforts basis.
The Equity Shares will be placed to QIBs pursuant to this Issue under Chapter VI of the SEBI Regulations and
Section 42 of the Companies Act and the rules made thereunder. The Placement Agreement contains customary
representations and warranties, as well as indemnities from our Company and is subject to termination in
accordance with the terms contained therein.
Applications shall be made to list the Equity Shares issued pursuant to this Issue and admit them to trading on the
Stock Exchanges. No assurance can be given as to the liquidity or sustainability of the trading market for such
Equity Shares, the ability of holders of the Equity Shares to sell their Equity Shares or the price at which holders
of the Equity Shares will be able to sell their Equity Shares.
The Preliminary Placement Document and this Placement Document has not been, and will not be, registered as
a prospectus with the Registrar of Companies, and no Equity Shares will be offered in India or overseas to the
public or any members of the public in India or any other class of investors, other than QIBs.
Relationship with the Book Running Lead Managers
In connection with the Issue, the Book Running Lead Managers or its affiliates may, for their own accounts,
subscribe to the Equity Shares or enter into asset swaps, credit derivatives or other derivative transactions relating
to the Equity Shares to be issued pursuant to the Issue at the same time as the offer and subscription or sale of the
Equity Shares, or in secondary market transactions. As a result of such transactions, the Book Running Lead
Managers may hold long or short positions in such Equity Shares. These transactions may comprise a substantial
portion of the Issue and no specific disclosure will be made of such positions. Affiliates of the Book Running
Lead Managers may purchase the Equity Shares or be Allotted Equity Shares for proprietary purposes and not
with a view to distribute or in connection with the issuance of P-Notes. Please see the section “Offshore Derivative
Instruments”.
From time to time, the Book Running Lead Managers, and their affiliates and associates have engaged in or may
in the future engage in transactions with and perform services including but not limited to investment banking,
advisory, banking, trading services for our Company, our Subsidiaries, group companies, affiliates and the
Shareholders, as well as to their respective associates and affiliates, pursuant to which fees and commissions have
been paid or will be paid to the Book Running Lead Managers and their respective affiliates and associates.
Lock-up
Our Company undertakes that it will not for a period commencing from the date hereof and of 30 days from the
date of Allotment in the Issue, without the prior written consent of the Book Running Lead Managers, directly or
indirectly, (a) offer, issue, contract to issue, issue or offer any option or contract to purchase, lend, sell purchase
any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of,
any Equity Shares or any securities convertible into or exercisable for Equity Shares (including, without limitation,
securities convertible into or exercisable or exchangeable for Equity Shares which may be deemed to be
beneficially owned), or file any registration statement under the U.S. Securities Act of 1933, as amended, with
respect to any of the foregoing, or (b) enter into any swap or other agreement or any transaction that transfers, in
whole or in part, directly or indirectly, any of the economic consequences associated with the ownership of any
of the Equity Shares or any securities convertible into or exercisable or exchangeable for Equity Shares (including,
without limitation, securities convertible into or exercisable or exchangeable for Equity Shares regardless of
whether any of the transactions described in clause (a) or (b) is to be settled by the delivery of Equity Shares or
such other securities, in cash or otherwise), or (c) deposit Equity Shares with any other depositary in connection
with a depositary receipt facility, (d) enter into any transaction (including a transaction involving derivatives)
having an economic effect similar to that of an issue, offer, sale or deposit of the Equity Shares in any depository
receipt facility, (e) publicly announce any intention to enter into any transaction falling within (a) to (d) above or
enter into any transaction (including a transaction involving derivatives) having an economic effect similar to that
of an issue or offer or deposit of Equity Shares in any depositary receipt facility or publicly announce any intention
to enter into any transaction falling within (a) to (d) above; provided, however, that the foregoing restrictions do
not apply to any issue or offer to the extent such issue or offer is required by Indian law.
144
Our Company acknowledges that each Promoter and one of the members of our Promoter Group namely Nirayu
Limited have undertaken that it will not for a period of commencing from the date hereof and 30 days from the
date of Allotment in the Issue, without the prior written consent of the Book Running Lead Managers, directly or
indirectly, do the following, (a) offer, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any
Equity Shares, except as mentioned herein, any securities convertible into or exercisable for Equity Shares or file
any registration statement under the U.S. Securities Act, with respect to any of the foregoing, or (b) enter into any
swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, any of the
economic consequences associated with the ownership of any of the Equity Shares or any securities convertible
into or exercisable or exchangeable for Equity Shares (including, without limitation, securities convertible into or
exercisable or exchangeable for Equity Shares regardless of whether any of the transactions described in clause
(a) or (b) is to be settled by the delivery of Equity Shares or such other securities, in cash or otherwise), or (c)
deposit Equity Shares with any other depositary in connection with a depositary receipt facility, or (d) sell, lend,
contract to sell, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or
otherwise transfer or dispose of, directly or indirectly, any shares or interest in an entity which holds any Equity
Shares; or (e) publicly announce any intention to enter into any transaction falling within (a) to (c) above or enter
into any transaction (including a transaction involving derivatives) having an economic effect similar to that of a
sale or deposit of Equity Shares in any depositary receipt facility or publicly announce any intention to enter into
any transaction falling within (a) to (c) above.
145
SELLING RESTRICTIONS
The distribution of this Placement Document and the offer, sale or delivery of the Equity Shares in this Issue is
restricted by law in certain jurisdictions. Therefore, persons who may come into possession of this Placement
Document are advised to consult with their own legal advisors as to what restrictions may be applicable to them
and to observe such restrictions. This Placement Document may not be used for the purpose of an offer or
invitation in any circumstances in which such offer or invitation is not authorised.
General
No action has been taken or will be taken that would permit a public offering of the Equity Shares to occur in
any jurisdiction other than India, or the possession, circulation or distribution of this Placement Document or any
other material relating to our Company or the Equity Shares in any jurisdiction where action for such
purpose is required. Accordingly, the Equity Shares may not be offered or sold, directly or indirectly, and
neither this Placement Document nor any offering materials or advertisements in connection with the Equity
Shares may be distributed or published in or from any country or jurisdiction except under circumstances that
will result in compliance with any applicable rules and regulations of any such country or jurisdiction. The
Issue will be made in compliance with the applicable SEBI Regulations, Section 42 of the Companies Act,
2013 read with Rule 14 of the PAS Rules and other applicable provisions of the Companies Act, 2013 and the rules
made thereunder. Each purchaser of the Equity Shares in the Issue will be deemed to have made
acknowledgments and agreements as described under “Purchaser Representations and Transfer Restrictions” on
page 152.
Republic of India
This Placement Document may not be distributed directly or indirectly in India or to residents of India and any
Equity Shares may not be offered or sold directly or indirectly in India to, or for the account or benefit of, any
resident of India except as permitted by applicable Indian laws and regulations, under which an offer is strictly on
a private and confidential basis and is limited to Eligible QIBs and is not an offer to the public. This Placement
Document has not been and will not be registered as a prospectus with the RoC, and will not be circulated or
distributed to the public in India or any other jurisdiction, and will not constitute a public offer in India or any
other jurisdiction.
Australia
This document does not constitute a prospectus or other disclosure document under the Corporations Act 2001
(Cth) (“Australian Corporations Act”) and does not purport to include the information required of a disclosure
document under the Australian Corporations Act. This document has not been lodged with the Australian
Securities and Investments Commission (“ASIC”) and no steps have been taken to lodge it as such with ASIC.
Any offer in Australia of the Equity Shares under this document may only be made to persons who are
“sophisticated investors” (within the meaning of section 708(8) of the Australian Corporations Act), to
“professional investors” (within the meaning of section 708(11) of the Australian Corporations Act) or otherwise
pursuant to one or more exemptions under section 708 of the Australian Corporations Act so that it is lawful to
offer the Equity Shares in Australia without disclosure to investors under Part 6D.2 of the Australian Corporations
Act.
If you are acting on behalf of, or acting as agent or nominee for, an Australian resident and you are a recipient of
this Placement Document, and any offers made under this Placement Document, you represent to the Company
and the Book Running Lead Managers that you will not provide this Placement Document or communicate any
offers made under this Placement Document to, or make any applications or receive any offers for the Equity
Shares for, any Australian residents unless they are a “sophisticated investor” or a “professional investor” as
defined by section 708 of the Australian Corporations Act.
Any offer of the Equity Shares for on-sale that is received in Australia within 12 months after their issue by our
Company, or within 12 months after their sale by a selling security holder (or a Book Running Lead Manager)
under the Issue, as applicable, is likely to need prospectus disclosure to investors under Part 6D.2 of the Australian
Corporations Act, unless such offer for on-sale in Australia is conducted in reliance on a prospectus disclosure
exemption under section 708 of the Australian Corporations Act or otherwise. Any persons acquiring the Equity
Shares should observe such Australian on-sale restrictions.
146
Bahrain
The Central Bank of Bahrain, the Bahrain Bourse and the Ministry of Industry, Commerce and Tourism of the
Kingdom of Bahrain take no responsibility for the accuracy of the statements and information contained in this
Placement Document or the performance of the Equity Shares, nor shall they have any liability to any person,
investor or otherwise for any loss or damage resulting from reliance on any statements or information contained
herein. This Placement Document is only intended for accredited investors as defined by the Central Bank of
Bahrain. We have not made and will not make any invitation to the public in the Kingdom of Bahrain to subscribe
to the Equity Shares and this Placement Document will not be issued, passed to, or made available to the public
generally. The Central Bank of Bahrain has not reviewed, nor has it approved, this Placement Document or the
marketing thereof in the Kingdom of Bahrain. The Central Bank of Bahrain is not responsible for the performance
of the Equity Shares.
Cayman Islands
No offer or invitation to subscribe for Equity Shares may be made to the public in the Cayman Islands to subscribe
for any of the Equity Shares but an invitation or offer may be made to sophisticated persons (as defined in the
Cayman Islands Securities Investment Business Law (the “SIBL”), high net worth persons (as defined in the
SIBL) or otherwise in accordance with the SIBL.
Dubai International Financial Centre
This Placement Document may not be distributed into, or circulated in, the Dubai International Financial Centre
(the “DIFC”) other than as an “Exempt Offer” in accordance with the Markets Rules of the Dubai Financial
Services Authority (“DFSA”) Rulebook (the “MKT Module”). The DFSA has not approved this Placement
Document or any associated documents nor taken any steps to verify the information set out in, and has no
responsibility for, this Placement Document.
This Placement Document may only be provided to Professional Clients, as defined in the DFSA Rulebook
Conduct of Business Module (the “COB Module”). The offer of the Equity Shares is not directed at Retail Clients
as defined in the COB Module.
Accordingly, the Equity Shares will not be offered to any person in the DIFC unless such offer is:
(a) an Exempt Offer in accordance with the MKT Module; and
(b) made only to persons who meet the Professional Client criteria set out in Rule 2.3.3 of the COB Module.
European Economic Area
In relation to each Member State of the European Economic Area (each a “Member State”), no Equity Shares
have been offered or will be offered pursuant to the Issue to the public in that Member State prior to the publication
of a prospectus in relation to the Equity Shares which has been approved by the competent authority in that
Member State or, where appropriate, approved in another Member State and notified to the competent authority
in that Member State, all in accordance with the Prospectus Regulation), except that offers of Equity Shares may
be made to the public in that Member State at any time under the following exemptions under the Prospectus
Regulation:
• to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
• to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of Book Running Lead Manager for any such offer; or
• in any other circumstances falling within Article 1(4) of the Prospectus Regulation,
provided that no such offer of Shares shall require the Issuer or the Book Running Lead Manager to publish a
prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23
of the Prospectus Regulation.
147
For the purposes of this provision, the expression an “offer to the public” in relation to any Equity Shares in any
Member State means the communication in any form and by any means of sufficient information on the terms of
the offer and any Equity Shares to be offered so as to enable an investor to decide to purchase or subscribe for any
Equity Shares, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129.
Hong Kong
This Placement Document has not been delivered for registration to the registrar of companies in Hong Kong, and
its contents have not been reviewed or authorized by any regulatory authority in Hong Kong. Accordingly: (i) the
Equity Shares have not been and will not be offered or sold in Hong Kong, by means of any document, other than to
persons that are considered “professional investors” within the meaning of the Securities and Futures Ordinance
(Cap. 571) of Hong Kong (“SFO”) and any rules made thereunder, or in other circumstances which do not result in
this document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions)
Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the
Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong and as permitted under
the SFO; and (ii) no invitation, advertisement or other document relating to the Equity Shares has been or will be
issued (or possessed for the purpose of issue), whether in Hong Kong or elsewhere, which is directed at, or the
contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under
the securities laws of Hong Kong) other than with respect to the Equity Shares which are or are intended to be
disposed of only to persons outside Hong Kong or only to “professional investors” within the meaning of the SFO
and any rules made thereunder.
WARNING: The contents of this Placement Document have not been reviewed by any regulatory authority in Hong
Kong. You are advised to exercise caution in relation to the Issue. If you are in any doubt about any of the contents
of this document, you should obtain independent professional advice.
Japan
The Equity Shares have not been and will not be registered under the Financial Instruments and Exchange Act of
Japan (Law. No. 25 of 1948 as amended) (the “FIEA”) and disclosure under the FIEA has not been and will not
be made with respect to the Equity Shares. No Equity Shares have, directly or indirectly, been offered or sold, and
may not, directly or indirectly, be offered or sold in Japan or to, or for the benefit of, any resident of Japan as
defined in the first sentence of Article 6, Paragraph 1, Item 5 of the Foreign Exchange and Foreign Trade Law of
Japan (“Japanese Resident”) or to others for re-offering or re-sale, directly or indirectly in Japan or to, or for the
benefit of, any Japanese Resident except (i) pursuant to an exemption from the registration requirements of the
FIEA and (ii) in compliance with any other relevant laws, regulations and governmental guidelines of Japan.
If an offeree does not fall under a “qualified institutional investor” (tekikaku kikan toshika), as defined in Article
10, Paragraph 1 of the Cabinet Office Ordinance Concerning Definition Provided in Article 2 of the Financial
Instruments and Exchange Act (the “Qualified Institutional Investor”), the Equity Shares will be offered in
Japan by a private placement to small number of investors (shoninzu muke kanyu), as provided under Article 23-
13, Paragraph 4 of the FIEA, and accordingly, the filing of a securities registration statement for a public offering
pursuant to Article 4, Paragraph 1 of the FIEA has not been made.
If an offeree falls under the Qualified Institutional Investor, the Equity Shares will be offered in Japan by a private
placement to the Qualified Institutional Investors (tekikaku kikan toshikamuke kanyu), as provided under Article
23-13, Paragraph 1 of the FIEA, and accordingly, the filing of a securities registration statement for a public
offering pursuant to Article 4, Paragraph 1 of the FIEA has not been made. To subscribe the Equity Shares (the
“QII Equity Shares”) such offeree will be required to agree that it will be prohibited from selling, assigning,
pledging or otherwise transferring the QII Equity Shares other than to another Qualified Institutional Investor
148
Republic of Korea
We are not making any representation with respect to the eligibility of any recipients of this document to acquire
the Equity Shares therein under the laws of Korea, including, but without limitation, the Foreign Exchange
Transaction Law and Regulations thereunder. The Equity Shares have not been and will not be registered under
the Financial Investment Services and Capital Markets Act of Korea (the “FSCMA”). Accordingly, the Equity
Shares may not be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or
indirectly, in Korea or to, or for the account or benefit of, any resident of Korea (as such term is defined under the
Foreign Exchange Transaction Law of Korea and its Enforcement Decree), for a period of one year from the date
of issuance of the Equity Shares, except (i) where relevant requirements are satisfied, the Equity Shares may be
offered, sold or delivered to or for the account or benefit of a Korean resident which falls within certain categories
of qualified professional investors as specified in the FSCMA, its Enforcement Decree and the Regulation on
Securities Issuance and Disclosure promulgated thereunder, or (ii) as otherwise permitted under applicable Korean
laws and regulations.
Furthermore, the Equity Shares may not be re-sold to Korea residents unless the purchaser of the Equity Shares
complies with all applicable regulatory requirements (including, but not limited to, governmental approval
requirements under the Foreign Exchange Transaction Law and its subordinate decrees and regulations) in
connection with purchase of the Equity Shares.
Kuwait
This document and does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, the
Equity Shares in the State of Kuwait. The Equity Shares have not been licensed for offering, promotion, marketing,
advertisement or sale in the State of Kuwait by the Capital Markets Authority or any other relevant Kuwaiti
government agency. The offering, promotion, marketing, advertisement or sale of the Equity Shares in State of
Kuwait on the basis of a private placement or public offering is, therefore, prohibited in accordance with Law No.
7 of 2010 and the Executive Bylaws for Law No. 7 of 2010, as amended, which govern the issue, offer, marketing
and sale of financial services/products in the State of Kuwait (“Kuwait Securities Laws”). No private or public
offering of the Equity Shares is or will be made in the State of Kuwait, and no agreement relating to the sale of
the Equity Shares will be concluded in the State of Kuwait and no marketing or solicitation or inducement
activities are being used to offer or market the Equity Shares in the State of Kuwait.
Malaysia
No approval from the Securities Commission of Malaysia has been applied for or will be obtained for the offer or
invitation in respect of the Issue under the Capital Markets and Services Act 2007. Neither has a prospectus been
or will be registered with the Securities Commission of Malaysia in connection with the Issue in Malaysia.
Accordingly, this Placement Document or any amendment or supplement hereto or any other offering document
in relation to the Issue may not be distributed in Malaysia directly or indirectly for the purpose of any offer of the
Equity Shares. The Equity Shares may not be offered or sold in Malaysia except pursuant to, and to persons
prescribed under, Part I of Schedule 6 of the Malaysian Capital Markets and Services Act and no person may offer
for subscription or purchase any of the Equity Shares directly or indirectly to anyone in Malaysia.
Mauritius
The public of the Republic of Mauritius is not invited to subscribe for the interests offered hereby. This document
relates to a private placement and does not constitute an offer to the public in Mauritius to subscribe for the
interests offered hereby. The interests are only being offered to a limited number of sophisticated investors
meeting the eligibility criteria. No regulatory approval has been sought for the offer in Mauritius and it must be
distinctly understood that the Mauritius Financial Services Commission does not accept any responsibility for the
financial soundness of or any representations made in connection with the Company. The document is for the use
only of the named addressee and should not be given or shown to any other person.
New Zealand
This Placement Document has not been registered, filed with or approved by any New Zealand regulatory
authority under the Financial Markets Conduct Act 2013 (the “FMC Act”). This Issue is not an offer of financial
products that requires disclosure under Part 3 of the FMC Act and no product disclosure statement, register entry
or other disclosure document under the FMC Act will be prepared in respect of this Issue. The Equity Shares are
149
not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other
than to a person who:
(a) is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
(b) meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
(c) is large within the meaning of clause 39 of Schedule 1 of the FMC Act; or
(d) is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act.
If, in the future, any person in New Zealand to whom the Equity Shares are issued or sold elects to sell any Equity
Shares, they must not do so in any manner which will, or is likely to, result in this Issue, or such sale, being viewed
as an offer to which Part 3 of the FMC Act is applicable.
Qatar
This Placement Document is provided on an exclusive basis to the specifically intended recipient, upon that
person’s request and initiative, and for the recipient’s personal use only and is not intended to be available to the
public. Nothing in this prospectus constitutes, is intended to constitute, shall be treated as constituting or shall be
deemed to constitute, any offer or sale of the Equity Shares in the State of Qatar or in the Qatar Financial Centre
or the inward marketing of an investment fund or an attempt to do business, as a bank, an investment company or
otherwise in the State of Qatar or in the Qatar Financial Centre. This Placement Document and the underlying
instruments have not been reviewed, approved, registered or licensed by the Qatar Central Bank, The Qatar
Financial Centre Regulatory Authority, The Qatar Financial Markets Authority or any other regulator in the State
of Qatar. Any distribution of this Placement Document by the recipient to third parties in Qatar or the Qatar
Financial Centre beyond these terms is not authorised and shall be at the liability of the recipient.
Saudi Arabia
This Placement Document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are
permitted under the Rules on the Offer of Securities and Continuing Obligations as issued by the board of the
Saudi Arabian Capital Market Authority (“CMA”) pursuant to resolution number 3-123-2017 dated December
27, 2017 as amended by resolution number 1-104-2019 dated September 30, 2019, as amended (the “CMA
Regulations”). The CMA does not make any representation as to the accuracy or completeness of this Placement
Document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon,
any part of this Placement Document. Prospective purchasers of the Equity Shares offered hereby should conduct
their own due diligence on the accuracy of the information relating to the Equity Shares. If you do not understand
the contents of this Placement Document, you should consult an authorized financial adviser.
Singapore
This Placement Document has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, each Book Running Lead Manager has represented, warranted and agreed that it has not offered or
sold any Equity Shares or caused the Equity Shares to be made the subject of an invitation for subscription or
purchase and will not offer or sell any Equity Shares or cause the Equity Shares to be made the subject of an
invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this
Placement Document or any other document or material in connection with the offer or sale, or invitation for
subscription or purchase, of the Equity Shares, whether directly or indirectly, to any person in Singapore other
than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of
Singapore, as modified or amended from time to time (the “SFA”)) pursuant to Section 274 of the SFA, (ii) to a
relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person
pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the
SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of
the SFA.
Where the Equity Shares are subscribed or purchased under Section 275 of the SFA by a relevant person which
is:
150
(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or
(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor,
securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that
corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred
within six months after that corporation or that trust has acquired the Equity Shares pursuant to an offer made
under Section 275 of the SFA except:
(a) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section 275(1A) or Section 276(4)(i)(B) of the SFA;
(b) where no consideration is or will be given for the transfer;
(c) where the transfer is by operation of law;
(d) as specified in Section 276(7) of the SFA; or
(e) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018.
Singapore SFA Product Classification: In connection with Section 309B of the SFA and the CMP Regulations
2018, unless otherwise specified before an offer of Equity Shares, the Issuer has determined, and hereby notifies
all relevant persons (as defined in Section 309A(1) of the SFA), that the Equity Shares are ‘‘prescribed capital
markets products’’ (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in
162 PI External MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-
N16: Notice on Recommendations on Investment Products).
Sultanate of Oman
This Placement Document and the Equity Shares to which it relates may not be advertised, marketed, distributed
or otherwise made available to any person in Oman without the prior consent of the Capital Market Authority
(“CMA”) and then only in accordance with any terms and conditions of such consent. In connection with the
offering of Equity Shares, no prospectus has been filed with the CMA. The offering and sale of Equity Shares
described in this Placement Document will not take place inside Oman. The Placement Document is strictly
private and confidential and is being issued to a limited number of sophisticated investors, and may neither be
reproduced, used for any other purpose, nor provided to any other person than the intended recipient hereof.
Switzerland
The Equity Shares may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the
Swiss Financial Services Act (“FinSA”) and no application has or will be made to admit the Equity Shares to
trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this Placement
Document nor any other offering or marketing material relating to the Equity Shares constitutes a prospectus
pursuant to the FinSA, and neither this Placement Document nor any other offering or marketing material relating
to the Equity Shares may be publicly distributed or otherwise made publicly available in Switzerland.
The Equity Shares may, however, be offered in Switzerland to professional clients within the meaning of the
FinSA, without any public offer and only to investors who do not purchase the Equity Shares with the intention
to distribute them to the public. The investors will be individually approached from time to time. This Placement
Document may only be used by those investors to whom it has been handed out in connection with the Offer
described herein and may neither directly nor indirectly be distributed or made available to other persons without
our express consent.
United Kingdom
151
This document does not constitute an approved prospectus for the purposes of and as defined in section 85 of
Financial Services and Markets Act 2000 (“FSMA”), has not been prepared in accordance with the prospectus
rules issued by the Financial Conduct Authority (“FCA”) pursuant to section 73A of the FSMA and has not been
approved by or filed with the FCA. The Equity Shares may not be offered or sold and will not be offered or sold
to the public in the United Kingdom (within the meaning of section 85 and 102B of the FSMA) save in the
circumstances where it is lawful to do so without an approved prospectus (within the meaning of section 85 of the
FSMA) being made available to the public before the offer is made.
This document is not to be distributed, delivered or passed on to any person resident in the United Kingdom,
unless it is being made only to, or directed only at (a) persons falling within the categories of “investment
professionals” as defined in Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order
2005 as amended (the “Financial Promotion Order”), (b) persons falling within any of the categories of persons
described in Article 49(2) of the Financial Promotion Order (high net worth companies, unincorporated
associations etc.), or (c) any other person to whom it may otherwise lawfully be made (all such persons together
being referred to as “relevant persons”).
This document must not be acted on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only to relevant persons and will be engaged
in only with relevant persons. Persons of any other description in the United Kingdom may not receive and should
not act or rely on this document or any other marketing materials relating to the Equity Shares.
Potential investors in the United Kingdom are advised that all, or most, of the protections afforded by the United
Kingdom regulatory system will not apply to an investment in the Equity Shares and that compensation will not
be available under the United Kingdom Financial Services Compensation Scheme.
If the recipient of this document is in any doubt about the investment to which this document relates, they should
consult a person authorized under the FSMA who specializes in advising on investing in securities.
United States
The Equity Shares have not been and will not be registered under the U.S. Securities Act, or the securities laws
of any state of the United States and, unless so registered, may not be offered or sold within the United States,
except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S.
Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and
sold only outside the United States in ‘offshore transactions’ (as defined in Regulation S) in reliance on
Regulations S and the applicable laws of the jurisdiction where those offers and sales are made. For further
information, see “Purchaser Representations and Transfer Restrictions” on page 152.
152
PURCHASER REPRESENTATIONS AND TRANSFER RESTRICTIONS
Due to the following restrictions, investors are advised to consult their legal counsel prior to subscribing for
Equity Shares or making any resale, pledge or transfer of the Equity Shares.
Pursuant to Chapter VI of the SEBI Regulations, any resale of Equity Shares, except on a recognized stock
exchange, is not permitted for a period of one year from the date of Allotment. Investors are advised to consult
legal counsels prior to making any resale, pledge or transfer of our Equity Shares. In addition to the above,
allotments made to Eligible QIBs, including VCFs and AIFs, in the Issue may be subject to lock-in requirements,
if any, under the rules and regulations that are applicable to them. For more information, see “Selling Restrictions”
on page 145.
U.S. TRANSFER RESTRICTIONS
The Equity Shares have not been and will not be registered under the U.S. Securities Act and may not be offered
or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the U.S. Securities Act and applicable state securities laws.
• Each purchaser of the Equity Shares outside the United States is deemed to have represented, agreed and
acknowledged as follows:
• It is authorised to consummate the purchase of the Equity Shares in compliance with all applicable laws
and regulations.
• It acknowledges (or if it is a broker-dealer acting on behalf of a customer, its customer has confirmed to it
that such customer acknowledges) that the Equity Shares are being issued in reliance upon Regulation S
and such Equity Shares have not been and will not be registered under the U.S. Securities Act.
• It certifies that either (A) it is, or at the time the Equity Shares are purchased will be, the beneficial owner
of the Equity Shares and is located outside the United States (within the meaning of Regulation S) or (B)
it is a broker-dealer acting on behalf of its customer and its customer has confirmed to it that (i) such
customer is, or at the time the Equity Shares are purchased will be, the beneficial owner of the Equity
Shares, and (ii) such customer is not located outside the United States (within the meaning of Regulation
S).
• It is aware of the restrictions of the offer, sale and resale of the Equity Shares pursuant to Regulation S.
• The Equity Shares have not been offered to it by means of any “directed selling efforts” as defined in
Regulation S.
• It understands that the Equity Shares are being offered in a transaction not involving any public offering in
the United States within the meaning of the U.S. Securities Act, that the Equity Shares have not been and
will not be registered under the U.S. Securities Act and that if in the future it decides to offer, resell, pledge
or otherwise transfer any of the Equity Shares, such Equity Shares may be offered, resold, pledged or
otherwise transferred in compliance with the U.S. Securities Act and other applicable securities laws only
outside the United States in a transaction complying with the provisions of Rule 903 or Rule 904 of
Regulation S or in a transaction otherwise exempt from the registration requirements of the U.S. Securities
Act.
• It is a sophisticated investor and has such knowledge and experience in financial, business and investments
as to be capable of evaluating the merits and risks of the investment in the Equity Shares. It is experienced
in investing in private placement transactions of securities of companies in a similar stage of development
and in similar jurisdictions. It and any accounts for which it is subscribing to the Equity Shares (i) are each
able to bear the economic risk of the investment in the Equity Shares, (ii) will not look to the Company or
any of the BRLMs for all or part of any such loss or losses that may be suffered, (iii) are able to sustain a
complete loss on the investment in the Equity Shares, (iv) have no need for liquidity with respect to the
investment in the Equity Shares, and (v) have no reason to anticipate any change in its or their
circumstances, financial or otherwise, which may cause or require any sale or distribution by it or them of
all or any part of the Equity Shares. It acknowledges that an investment in the Equity Shares involves a
153
high degree of risk and that the Equity Shares are, therefore, a speculative investment. It is seeking to
subscribe to the Equity Shares in this Issue for its own investment and not with a view to distribution.
• It has been provided access to the Preliminary Placement Document and this Placement Document, which
it has read in its entirety.
• It agrees to indemnify and hold the Company and each of the BRLMs harmless from any and all costs,
claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any
breach of these representations and warranties. It will not hold any of the Company or the BRLMs liable
with respect to its investment in the Equity Shares. It agrees that the indemnity set forth in this paragraph
shall survive the resale of the Equity Shares.
• Where it is subscribing to the Equity Shares for one or more managed accounts, it represents and warrants
that it is authorised in writing, by each such managed account to subscribe to the Equity Shares for each
managed account and to make (and it hereby makes) the acknowledgements and agreements herein for and
on behalf of each such account, reading the reference to “it” to include such accounts.
• It agrees that any resale or other transfer, or attempted resale or other transfer, of the Equity Shares made
other than in compliance with the above-stated restrictions shall not be recognised by the Company.
• If such person is a dealer (as such term is defined under the U.S. Securities Act), it may not resell the Equity
Shares in the United States prior to 40 days from the commencement of the offering of the Equity Shares.
It acknowledges that the Company and the BRLMs and their respective affiliates and others will rely upon
the truth and accuracy of the foregoing acknowledgements, representations and agreements and agrees that,
if any of such acknowledgements, representations or agreements is no longer accurate, it will promptly
notify the Company and the BRLMs. It agrees that the terms and provisions of the foregoing
acknowledgements, representations and agreements shall inure to the benefit of and any document
incorporating such acknowledgements, representations and agreements shall be enforceable by the
Company, its successors and its permitted assigns, and the terms and provisions hereof shall be binding on
its permitted successors in title, permitted assigns and permitted transferees. It understands that these
acknowledgments, representations and undertakings are required in connection with United States
securities laws and irrevocably authorizes the Company to produce these acknowledgments,
representations and undertakings (or any document incorporating them) to any interested party in any
administrative or legal proceedings or official enquiry with respect to the matters covered herein.
154
THE SECURITIES MARKET OF INDIA
The information in this section has been extracted from documents available on the website of SEBI and the Stock
Exchanges and has not been prepared or independently verified by our Company, the BRLMs or any of their
respective affiliates or advisors.
The Indian Securities Market
India has a long history of organised securities trading. In 1875, the first stock exchange was established in
Mumbai. The BSE and the NSE together hold a dominant position among the stock exchanges in terms of the
number of listed companies, market capitalisation and trading activity.
Stock Exchanges Regulation
Indian stock exchanges are regulated primarily by SEBI, as well as by the Government acting through the Ministry
of Finance, Capital Markets Division, under the SCRA and the SCRR. SEBI, in exercise of its powers under the
SCRA and the SEBI Act, notified the SCR (SECC) Rules, which regulate inter alia the recognition, ownership
and internal governance of stock exchanges and clearing corporations in India together with providing for
minimum capitalisation requirements for stock exchanges. The SCRA, the SCRR and the SCR (SECC) Rules
along with various rules, bye-laws and regulations of the respective stock exchanges, regulate the recognition of
stock exchanges, the qualifications for membership thereof and the manner, in which contracts are entered into,
settled and enforced between members of the stock exchanges.
The SEBI Act empowers SEBI to regulate the Indian securities markets, including stock exchanges and
intermediaries in the capital markets, promote and monitor self-regulatory organisations and prohibit fraudulent
and unfair trade practices. Regulations concerning minimum disclosure requirements by public companies, rules
and regulations concerning investor protection, insider trading, substantial acquisitions of shares and takeover of
companies, buy-backs of securities, employee stock option schemes, stockbrokers, merchant bankers,
underwriters, mutual funds, foreign institutional investors, credit rating agencies and other capital market
participants have been notified by the relevant regulatory authority.
Listing and Delisting of Securities
The listing of securities on a recognised Indian stock exchange is regulated by the applicable Indian laws including
the Companies Act, the SCRA, the SCRR, the SEBI Act, SEBI Listing Regulations and various guidelines and
regulations issued by the SEBI and the stock exchanges. The SCRA empowers the governing body of each
recognised stock exchange to suspend trading of or withdraw admission to dealings in a listed security for breach
of or non-compliance with any conditions or breach of company’s obligations under the SEBI Listing Regulations
or for any reason, subject to the issuer receiving prior written notice of the intent of the exchange and upon granting
of a hearing in the matter.
SEBI has notified the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, in
relation to the voluntary and compulsory delisting of equity shares from the stock exchanges. In addition, certain
amendments to the SCRR have also been notified in relation to delisting.
Minimum Level of Public Shareholding
All listed companies are required to ensure a minimum public shareholding at 25%. Further, where the public
shareholding in a listed company falls below 25% at any time, such company is required to bring the public
shareholding to 25% within a maximum period of 12 months from the date of such fall. Consequently, a listed
company may be delisted from the stock exchanges for not complying with the above-mentioned requirement.
Our Company is in compliance with this minimum public shareholding requirement. Further, pursuant to the
budget 2019-2020, SEBI has been authorised to consider increasing the minimum public shareholding
requirement to 35%.
Index-Based Market-Wide Circuit Breaker System
In order to restrict abnormal price volatility in any particular stock, the SEBI has instructed stock exchanges to
apply daily circuit breakers which do not allow transactions beyond a certain level of price volatility. The index-
based market-wide circuit breaker system (equity and equity derivatives) applies at three stages of the index
155
movement, at 10%, 15% and 20%. These circuit breakers, when triggered, bring about a co-ordinated trading halt
in all equity and equity derivative markets nationwide. The market-wide circuit breakers are triggered by
movement of either the SENSEX of the BSE or the S&P CNX NIFTY of the NSE, whichever is breached earlier.
In addition to the market-wide index-based circuit breakers, there are currently in place individual scrip-wise
circuit breakers. However, no price bands are applicable on scrips on which derivative products are available or
scrips included in indices on which derivative products are available.
The stock exchanges in India can also exercise the power to suspend trading during periods of market volatility.
Margin requirements are imposed by stock exchanges that are required to be paid by the stockbrokers.
BSE
Established in 1875, it is the oldest stock exchange in India. In 1956, it became the first stock exchange in India
to obtain permanent recognition from the Government under the SCRA. It has evolved over the years into its
present status as one of the premier stock exchanges of India.
NSE
The NSE was established by financial institutions and banks to provide nationwide online, satellite-linked, screen-
based trading facilities with market-makers and electronic clearing and settlement for securities including
government securities, debentures, public sector bonds and units. It has evolved over the years into its present
status as one of the premier stock exchanges of India. The NSE was recognised as a stock exchange under the
SCRA in April 1993 and commenced operations in the wholesale debt market segment in June 1994. The capital
market (equities) segment commenced operations in November 1994 and operations in the derivatives segment
commenced in June 2000. NSE launched the NSE 50 Index, now known as S&P CNX NIFTY, on April 22, 1996
and the Mid-cap Index on January 1, 1996.
Internet-based Securities Trading and Services
Internet trading takes place through order routing systems, which route client orders to exchange trading systems
for execution. Stockbrokers interested in providing this service are required to apply for permission to the relevant
stock exchange and also have to comply with certain minimum conditions stipulated by SEBI. The NSE became
the first exchange to grant approval to its members for providing internet-based trading services. Internet trading
is possible on both the “equities” as well as the “derivatives” segments of the NSE.
Trading Hours
Trading on both the NSE and the BSE occurs from Monday to Friday, between 9:15 a.m. and 3:30 p.m. IST
(excluding the 15 minutes pre-open session from 9:00 a.m. to 9:15 a.m.). The BSE and the NSE are closed on
public holidays. The recognised stock exchanges have been permitted to set their own trading hours (in the cash
and derivatives segments) subject to the condition that (i) the trading hours are between 9.00 a.m. and 5.00 p.m.;
and (ii) the stock exchange has in place a risk management system and infrastructure commensurate to the trading
hours.
Trading Procedure
In order to facilitate smooth transactions, the BSE replaced its open outcry system with BSE On-line Trading
facility in 1995. This totally automated screen based trading in securities was put into practice nation-wide. This
has enhanced transparency in dealings and has assisted considerably in smoothening settlement cycles and
improving efficiency in back-office work.
NSE has introduced a fully automated trading system called NEAT, which operates on strict time/price priority
besides enabling efficient trade. NEAT has provided depth in the market by enabling large number of members
all over India to trade simultaneously, narrowing the spreads.
156
SEBI Listing Regulations
Public listed companies are required under the SEBI Listing Regulations to prepare and circulate to their
shareholders audited annual accounts which comply with the disclosure requirements and regulations governing
their manner of presentation and which include sections relating to corporate governance, related party
transactions and management’s discussion and analysis as required under the SEBI Listing Regulations. In
addition, a listed company is subject to continuing disclosure requirements pursuant to the terms of the SEBI
Listing Regulations.
SEBI Takeover Regulations
Disclosure and mandatory bid obligations for listed Indian companies are governed by the SEBI Takeover
Regulations which provide specific regulations in relation to substantial acquisition of shares and takeover. The
SEBI Takeover Regulations prescribes certain thresholds or trigger points in the shareholding a person or entity
has in the listed Indian company, which give rise to certain obligations on part of the acquirer. Acquisitions up to
a certain threshold prescribed under the SEBI Takeover Regulations mandate specific disclosure requirements,
while acquisitions crossing particular thresholds may result in the acquirer having to make an open offer of the
shares of the target company. The SEBI Takeover Regulations also provides for the possibility of indirect
acquisitions, imposing specific obligations on the acquirer in case of such indirect acquisition.
SEBI Insider Trading Regulations
The SEBI Insider Trading Regulations have been notified to prohibit and penalise insider trading in India. An
insider is, among other things, prohibited from dealing in the securities of a listed company when in possession
of unpublished price sensitive information (“UPSI”). The SEBI Insider Trading Regulations, inter alia, impose
certain restrictions on the communication of information by listed companies. Under the SEBI Insider Trading
Regulations, (i) no insider shall communicate, provide or allow access to any UPSI relating to such companies
and securities to any person including other insiders; and (ii) no person shall procure or cause the communication
by any insider of UPSI relating to such companies and securities, except in furtherance of legitimate purposes,
performance of duties or discharge of legal obligations. However, UPSI may be communicated, provided or
allowed access to or procured, under certain circumstances specified in the SEBI Insider Trading Regulations.
The SEBI Insider Trading Regulations make it compulsory for listed companies and certain other entities that are
required to handle UPSI in the course of business operations to establish an internal code of practices and
procedures for fair disclosure of UPSI and to regulate, monitor and report trading by insiders. To this end, the
SEBI Insider Trading Regulations provide principles of fair disclosure for purposes of code of practices and
procedures for fair disclosure of UPSI and minimum standards for code of conduct to regulate, monitor and report
trading by insiders. There are also initial and continuing shareholding disclosure obligations under the SEBI
Insider Trading Regulations. The SEBI Insider Trading Regulations also provides for disclosure obligations for
promoters, employees and directors, with respect to their shareholding in the company, and the changes therein.
Depositories
The Depositories Act provides a legal framework for the establishment of depositories to record ownership details
and effect transfer in book-entry form. Further, SEBI framed regulations in relation to the registration of such
depositories, the registration of participants as well as the rights and obligations of the depositories, participants,
companies and beneficial owners. The depository system has significantly improved the operation of the Indian
securities markets.
Derivatives (Futures and Options)
Trading in derivatives is governed by the SCRA, the SCRR and the SEBI Act. The SCRA was amended in
February 2000 and derivatives contracts were included within the term “securities”, as defined by the SCRA.
Trading in derivatives in India takes place either on separate and independent derivatives exchanges or on a
separate segment of an existing stock exchange. The derivatives exchange or derivatives segment of a stock
exchange functions as a self-regulatory organisation under the supervision of the SEBI.
157
DESCRIPTION OF THE EQUITY SHARES
The following is information relating to the Equity Shares including a brief summary of the Memorandum and
Articles of Association and the Companies Act. Bidders are urged to read the Memorandum and Articles of
Association carefully, and consult with their advisers, as the Memorandum and Articles of Association and
applicable Indian law, and not this summary, govern the rights attached to the Equity Shares.
Share Capital
The authorised share capital of our Company is ₹ 40,00,00,000 divided into 20,00,00,000 Equity Shares^ of face
value of ₹ 2 each. For further details, see "Capital Structure" on page 68. ^ The records currently maintained by the RoC, erroneously indicate the authorised share capital of our Company to be ₹ 48 crores. Our Company has written to the RoC on numerous occasions, requesting for this error to be rectified in the RoC master data, including by way
of its letter dated October 22, 2019.
Dividends
Under Indian law, a company pays dividends upon a recommendation by its board of directors and approval by a
majority of the shareholders at the AGM held each Fiscal. Subject to certain conditions laid down by Section 123
of the Companies Act, no dividend can be declared or paid by a company for any Fiscal except out of the profits
of the company for that year, calculated in accordance with the provisions of the Companies Act or out of the
profits of the company for any previous Fiscal(s) arrived in a manner laid down by the Companies Act and
remaining undistributed or out of both or out of money provided by the Central Government or a State Government
for the payment of dividend by the company in pursuance of a guarantee given by that Government.
Further, as per the Companies Act read with the Companies (Declaration and Payment of Dividend) Rules, 2014,
in the event of inadequacy or absence of profits in any year, a company may declare dividend out of free reserves,
provided: (a) the rate of dividend declared shall not exceed the average of the rates at which dividend was declared
by it in the three years immediately preceding that year; provided, this shall not apply to a company, which has
not declared any dividend in each of the three preceding financial years (b) the total amount to be drawn from
such accumulated profits shall not exceed one-tenth of the sum of the paid up share capital of the company and
free reserves of the company as per the most recent audited financial statement; (c) the amount so drawn shall be
first utilised to set off the losses incurred by the company in the financial year in which the dividend is declared
before any dividend in respect of equity shares is declared; and (d) the balance of reserves of the company after
such withdrawal shall not fall below 15% of the company's paid up share capital as per the most recent audited
financial statement of the company.
Our Board may retain any dividends on which our Company may have a lien and may apply the same towards the
satisfaction of the debts or liabilities in respect of which the lien exists. No member shall be entitled to receive
payment of interest and dividend in respect of his Equity Shares while any money may be due or owing from him
to our Company and our Board may deduct from any dividend payable to any member all sums of money, if any,
payable by him to the Company on account of calls in relation to the Equity Shares of the Company or otherwise.
All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the Equity
Shares during any portion or portions of the period in respect of which the dividend is paid but if any Equity Share
is issued on terms providing that it shall rank for dividends as from a particular date, such Equity Share shall rank
for dividend accordingly. A transfer of Equity Shares shall not pass the right to any dividend declared therein
before the registration of the transfer unless the registered holder of the Equity Shares authorises the Company to
pay the dividend to the transferee.
According to the Articles of Association, dividends may be paid to the members according to their respective
rights but the amount of dividend shall not exceed the amount recommended by our Board of Directors. However,
our Company may declare a smaller dividend in the general meeting. In addition, as is permitted by the Articles
of Association, our Board of the Directors may pay interim dividends as in the judgement of our Board of
Directors, the profits of our Company justifies, subject to the requirements of the Companies Act.
Unclaimed and unpaid dividend shall not be forfeited by our Company. Subject to applicable provisions of the
Companies Act, if our Company has declared a dividend but which has not been paid or claimed or dividend
warrant or such other instrument has not been posted within 30 days from the date of declaration to any member
entitled to the payment of the dividend, our Company shall within seven days from the date of the expiry of the
aforesaid 30 days period transfer the total amount of dividend which remains unpaid or unclaimed to a special
account to be opened in that behalf in any scheduled bank called unpaid dividend account.
158
Capitalisation of Profits and issue of bonus shares
In addition to permitting dividends to be paid out of current or retained earnings as described above, the
Companies Act permits the board of directors of a company subject to approval of shareholders in a general
meeting to issue fully paid up bonus shares to its members out of (a) the free reserves of the company, (b) the
securities premium account, or (c) the capital redemption reserve account. However, a company may capitalise
its profits or reserves for issue of fully paid up bonus shares, provided: (a) its authorised by articles, (b) it has
been, on the recommendation of the board of directors, been authorised by the shareholders in a general meeting,
(c) it has not defaulted in payment of interest or principal in respect of fixed deposits or debt securities issued by
it, (d) it has not defaulted on payment of statutory dues such as contribution to provident fund, gratuity and
bonus(e) there are no partly paid-up shares. The issue of bonus shares once declared cannot be withdrawn.
These bonus shares must be distributed to shareholders in proportion to the number of ordinary shares owned by
them as recommended by the board of directors. No issue of bonus shares may be made by capitalizing reserves
created by revaluation of assets, and no bonus shares shall be issued in lieu of dividend. Further, any issue of
bonus shares would be subject to the SEBI Regulations.
Our Company may by a resolution passed in a general meeting of the Shareholders, upon a recommendation by
the Board, resolve to capitalise whole or any part of the amount for the time being standing to the credit of any of
our Company’s reserve accounts or to the credit of the profit and loss account or otherwise available for
distribution and distribute amongst such of the shareholders as would be entitled to receive the same if distributed
by way of dividend and in the same proportions and that all or any part of such capitalized fund shall be applied
on behalf of such shareholders in paying up any amounts for the time being unpaid on any Equity Shares held by
such Shareholders and/or in paying up in full, unissued shares of our Company to be allotted and distributed,
credited as fully paid up in the proportion aforesaid, provided that a share premium account and a capital
redemption reserve fund may, for the purposes of the Articles, be applied in the paying of any unissued shares to
be issued to members of our Company as fully paid bonus shares. The Board has the power to make such
provisions, by the issue of fractional certificates or by payment in cash or otherwise as it thinks fit, in the case of
shares becoming distributable in fractions; and it also authorises any person to enter, on behalf of all the members
entitled thereto, into an agreement with the Company providing for the allotment to them respectively, credited
as fully paid-up, of any further shares to which they may be entitled upon such capitalisation, or as the case may
require, for the payment by the Company on their behalf, by the application thereto of their respective proportions
of profits resolved to be capitalised, of the amount or any part of the amounts remaining unpaid on their existing
shares.
Pre-Emptive Rights and Alteration of Share Capital
Subject to the provisions of the Companies Act, our Company may increase its share capital by issuing new shares
on such terms and with such rights as it, by action of its shareholders in a general meeting may determine.
According to Section 62(1)(a) of the Companies Act such new shares shall be offered to existing Shareholders in
proportion to the amount paid up on those shares at that date. The offer shall be made by notice specifying the
number of shares offered and the date (being not less than 15 days and not exceeding 30 days from the date of the
offer) within which the offer, if not accepted, will be deemed to have been declined. After such date the board
may dispose of the shares offered in respect of which no acceptance has been received which shall not be
disadvantageous to the Shareholders. The offer is deemed to include a right exercisable by the person concerned
to renounce the shares offered to him in favour of any other person.
Under the provisions of Section 62(1)(c) of the Companies Act, new shares may be offered to any persons whether
or not those persons include existing shareholders, either for cash or for a consideration other than cash, if the
price of such shares is determined by the valuation report of a registered valuer subject to such conditions as may
be prescribed, if a special resolution to that effect is passed by our shareholders in a general meeting.
The Articles of Association authorise us, by means of an ordinary resolution, to increase our share capital by such
sum, to be divided into shares of such amount as specified in the resolution.
The Articles of Association provide that our Company, subject to compliance with requirements under the
Companies Act, or any other applicable law in force in the general meeting, from time to time, may consolidate,
divide or sub-divide its share capital by way of an ordinary resolution.
159
Subject as aforesaid, our Company in general meeting may also cancel shares which have not been taken or agreed
to be taken by any person and diminish the amount of its share capital by the amount of shares so cancelled. In
case of shares converted to stock, the holders of the stock may transfer the same or any part thereof subject to the
minimum amount of stock transferrable as fixed by the Board and further, ensuring that the minimum shall not
exceed the nominal amount of the shares from which the stock arose. The holders of stock shall, according to the
amount of stock held by them, have the same rights, privileges and advantages in relation to dividends, voting at
meetings of the company, and other matters, as if they held the shares from which the stock arose; but no such
privilege or advantage (except participation in the dividends and profits of the Company and in the assets on
winding up) shall be conferred by an amount of stock which would not, if existing in shares, have conferred that
privilege or advantage Our Company may reduce the share capital, capital redemption reserve account, share
premium account or any other reserve available, in accordance with the provisions of the Companies Act and rules
made thereunder.
General Meetings of Shareholders
There are two types of general meetings of the shareholders, namely, AGM and EGM. Our Company is required
to hold its AGM within six months after the expiry of each Fiscal provided that not more than 15 months shall
elapse between two AGMs, unless extended by the RoC at its request for any special reason for a period not
exceeding three months. Our Board of Directors may convene an EGM suo motu when it deems fit or at the
requisition of a shareholder or shareholders holding in the aggregate not less than one tenth of our Company’s
issued paid up share capital carrying a right to vote on such date.
Notices, along with statement containing material facts concerning each special item, either in writing or through
electronic mode, convening a meeting setting out the date, day, hour, place and agenda of the meeting must be
given to every member or the legal representative of a deceased member, auditors of the company and every
director of the company, at least 21 clear days prior to the date of the proposed meeting. A general meeting may
be called after giving shorter notice if consent is received, in writing or electronic mode, from not less than 95%
of the shareholders entitled to vote. Further, a general meeting, other than an annual general meeting may be called
after giving a shorter notice if consent is received, by the majority in number of shareholders of the company who
are entitled to vote and who represent not less than 95% of the paid up share capital of the company. Unless, the
Articles of Association provide for a larger number, (i) five shareholders present in person, if the number of
shareholders as on the date of meeting is not more than 1,000; (ii) 15 shareholders present in person, if the number
of shareholders as on the date of the meeting is more than 1,000 but up to 5,000; and (iii) 30 shareholders present
in person, if the number of shareholders as on the date of meeting exceeds 5,000, shall constitute a quorum for a
general meeting of our Company, whether AGM or EGM. The quorum requirements applicable to shareholder
meetings under the Companies Act have to be physically complied with.
A company intending to pass a resolution relating to matters such as, but not limited to, amendments to the objects
clause of the Memorandum, a variation of the rights attached to a class of shares or debentures or other securities,
buy-backs of shares, giving loans or extending guarantees in excess of limits prescribed, is required to obtain the
resolution passed by means of a postal ballot instead of transacting the business in our Company’s general
meeting. A notice to all the shareholders shall be sent along with a draft resolution explaining the reasons thereof
and requesting them to send their assent or dissent in writing on a postal ballot within a period of 30 days from
the date of posting the letter. Postal ballot includes voting by electronic mode.
Voting Rights
At a general meeting, every member holding shares is entitled to vote through e-voting process. Upon a poll, the
voting rights of each shareholder entitled to vote and present in person or by proxy is in the same proportion as
the capital paid up on each share held by such holder bears to our Company’s total paid up capital. The Chairman
of the meeting has a casting vote or second vote. In the case of joint holders, the vote of the senior who tenders a
vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and
seniority shall be determined by the order in which the names stand in the register of members.
Ordinary resolutions may be passed by simple majority of those present and voting. Special resolutions require
that the votes cast in favour of the resolution must be at least three times the votes cast against the resolution. A
shareholder may exercise his voting rights by proxy to be given in the form prescribed. The instrument appointing
a proxy is required to be lodged with our Company at least 48 hours before the time of the meeting. A proxy may
not vote except on a poll and does not have a right to speak at meetings. No proxy shall be entitled to vote on a
show of hands unless such proxy is present on behalf of a company or corporation. A vote given in accordance
160
with the terms of an instrument appointing a proxy shall be valid notwithstanding the previous death or insanity
of the principal or revocation of the instrument or transfer of the Equity Share in respect of which the vote is given
provided no intimation in writing of the death or insanity, revocation or transfer shall have been received at the
office of our Company before the general meeting. Provided that the chairman of any general meeting shall be
entitled to require such evidence as he may in his discretion think fit of the due execution of an instrument of
proxy and that the same has not been revoked. A person can act as proxy on behalf of the members not exceeding
50 and holding in aggregate not more than 10% of the total share capital of the Company carrying voting rights.
Registration of Transfers and Register of Members
Our Company is required to maintain a register of members wherein the particulars of the members of our
Company are entered. We recognize as shareholders only those persons whose names appear on the register of
shareholders and cannot recognize any person holding any share or part of it upon any express, implied or
constructive trust, except as permitted by law. In respect of electronic transfers, the depository transfers shares by
entering the name of the purchaser in its books as the beneficial owner of the shares. In turn, the name of the
depository is entered into our records as the registered owner of the shares. The beneficial owner is entitled to all
the rights and benefits as well as the liabilities with respect to the shares held by a depository. For the purpose of
determining the shareholders, entitled to corporate benefits declared by our Company, the register may be closed
for such period not exceeding 45 days in any one year or 30 days at any one time at such times, as the Board of
Directors may deem expedient in accordance with the provisions of the Companies Act. Under the SEBI Listing
Regulations of the stock exchanges on which our Company’s outstanding Equity Shares are listed, our Company
may, upon at least seven working days’ (excluding the date of intimation and the record date) advance notice to
such stock exchanges, set a record date and/or close the register of shareholders in order to ascertain the identity
of shareholders. The trading of Equity Shares and the delivery of certificates in respect thereof may continue while
the register of shareholders is closed.
Liquidation Rights
The Articles of Association of our Company provide that our Company may be wound up when necessary in
accordance with the provisions of the Companies Act.
Buy Back
Our Company may buy back its own Equity Shares or other specified securities subject to the provisions of the
Companies Act and any related SEBI guidelines issued in connection therewith.
161
STATEMENT OF SPECIAL TAX BENEFITS
Statement of Possible Tax Benefits Available to the Company and Its Shareholders under the Applicable
Laws in India
August 1, 2020
The Board of Directors
Alembic Pharmaceuticals Limited
Alembic Road, Gorwa,
Vadodara 390003,
Gujarat, India
Dear Sirs,
Subject: Proposed Qualified Institutions Placement (“QIP” or the “Issue”) of equity shares of face value of
₹ 2 each (the “Equity Shares”) of Alembic Pharmaceuticals Limited (the “Company”)
We hereby confirm that the enclosed Annexure, accurately and adequately states the possible tax benefits available
to the Company, and its shareholders under the Income-Tax Act, 1961 (“Act”), as amended and presently in force
in India. These benefits are dependent on the Company, or its shareholders fulfilling the conditions prescribed
under the relevant provisions of the Act. Hence, the ability of the Company, or its shareholders to derive the tax
benefits is dependent upon fulfilling such conditions, which based on the business imperatives, the Company may
or may not choose to fulfil.
The benefits discussed in the enclosed Annexure are not exhaustive. We are informed that this statement is only
intended to provide general information to the investors and hence is neither designed nor intended to be a
substitute for professional tax advice. In view of the individual nature of the income-tax consequences and
changing income-tax laws, each investor is advised to consult with his or her own tax consultant with respect to
the specific tax implications arising out of their participation in the proposed offer of qualified institutions
placement for sale of equity shares by the Company.
Neither are we suggesting nor are we advising the investor to invest money based on this Annexure.
Our confirmation is based on the information, explanations and representations obtained from the Company and
on the basis of our understanding of the business activities and operations of the Company.
We do not express any opinion or provide any assurance as to whether:
(i) the Company, its material subsidiaries or its shareholders will continue to obtain these possible tax benefits
in future;
(ii) the conditions prescribed for availing the possible tax benefits, where applicable have been/would be met;
or
(iii) The revenue authorities/courts will concur with the views expressed herein.
The enclosed statement is issued in connection with the Issue and the contents of the statements, in full or in part,
can be disclosed in the Preliminary Placement Document, the Placement Document and other documents or
materials in relation to the Issue. The aforesaid information/extracts thereof may be relied upon by the book
running lead managers and the legal counsels appointed for the Issue and may be submitted to the Stock
Exchanges, the Securities and Exchange Board of India, Registrar of Companies, Gujarat, at Ahmedabad and any
other regulatory or statutory authority in respect of the Issue and for the records to be maintained by the Book
Running Lead Managers in connection with the Issue.
For K. C. Mehta & Co.
Chartered Accountants
Firm Registration Number: 106237W
Peer Review Number: 010702
162
Vishal P. Doshi
Partner
Membership Number: 101533
UDIN: 20101533AAAACW9611
Place: Vadodara
Date: August 1, 2020
163
Annexure
INVESTORS ARE ADVISED TO CONSULT THEIR OWN TAX CONSULTANT WITH RESPECT TO
THE INDIAN TAX IMPLICATIONS AND CONSEQUENCES OF PURCHASING, OWNING AND
DISPOSING OF EQUITY SHARES IN YOUR PARTICULAR SITUATION.
STATEMENT OF POSSIBLE TAX BENEFITS AVAILABLE TO ALEMBIC PHARMACEUTICALS
LIMITED AND ITS SHAREHOLDERS UNDER THE INCOME-TAX ACT, 1961 (‘the Act’)
I. SPECIAL TAX BENEFITS AVAILABLE TO THE COMPANY
No special tax benefits are available to the Company
II. GENERAL TAX BENEFITS AVAILABLE TO THE COMPANY
1. Lower Corporate Tax Rate under section 115BAA of the Act
A new section 115BAA has been inserted by the Taxation Laws (Amendment) Act, 2019 (‘the
Amendment Act, 2019’) w.e.f. AY 2020-21 (FY 2019-20) granting an option to domestic companies
to compute corporate tax at a reduced rate of 25.17% (22% plus surcharge of 10% and cess of 4%),
provided such companies do not avail specified exemptions/incentives (e.g. deduction under section
10AA, 32(1)(iia), 35(2AB), 80-IA etc.)
The Amendment Act, 2019 further provides that domestic companies availing such option will not be
required to pay Minimum Alternate Tax (‘MAT’) under section 115JB of the Act. The CBDT has
further issued Circular 29/2019 dated October 2, 2019 clarifying that since the MAT provisions under
section 115JB of the Act itself would not apply where a domestic company exercises option of lower
tax rate under section 115BAA of the Act, MAT credit would not be available. Corresponding
amendment has been inserted under section 115JAA of the Act dealing with MAT credit.
The Company is eligible to exercise the above option.
2. Additional depreciation under section 32 of Act
The Company engaged in the business of manufacture or production of any article or thing or in the
business of generation, transmission or distribution of power is entitled to claim additional depreciation
under section 32(1)(iia) of the Act of a sum equal to 20% of the actual cost of new plant or machinery
acquired and installed by the Company (other than ships and aircrafts) subject to certain conditions
specified in said section. In case such new plant and machinery is acquired and put to use for less than
180 days during the first year, additional depreciation is restricted at 10% in year one. The balance 10%
additional depreciation is allowed in the next year.
3. Deduction under section 35 of the Act in respect of Research and Development expenditure
In accordance with and subject to the provisions of section 35(2AB) of the Act, the Company is eligible
for a deduction of a sum equal to 150% of expenditure (not being in the nature of cost of any land or
building) on in-house scientific research and development facility as approved by the prescribed
authority (Department of Scientific & Industrial Research). With effect from AY 2021-22, the
deduction under section 35(2AB) shall be limited to 100% of expenditure actually incurred.
The Company is also eligible to claim deduction under sections 35(1)(iv) read with section 35(2) of the
Act, of a sum equal to 100% of any capital expenditure (except expenditure on acquisition of land
including interest in land) incurred on scientific research related to the business carried on by the
Company.
Where a deduction is allowed under section 35(1)(iv) of the Act in respect of expenditure represented
wholly or partly by an asset, depreciation under section 32(1)(ii) of the Act shall not be allowed in
respect of that asset.
164
4. Deduction under section 80-IA of the Act
The Company has installed a windmill which qualifies as the power generating unit as per provisions
of section 80-IA of the Act. Accordingly, the Company is entitled to claim deduction of an amount
equal to 100% of the profits and gains derived from the such power generation undertaking under
section 80-IA of the Act. The said deduction is available for a period of ten consecutive years out of
the fifteen years beginning from the year in which the undertakings begins to generate power.
However, as per section 115JB of the Act, the Company shall be required to pay MAT at the rate of
15% (plus applicable surcharge, education cess and secondary & higher education cess) on book profits,
irrespective of this tax benefit.
5. Deduction under Section 80-IE of the Act
The Company has set up an industrial undertaking in Sikkim in November 2015. As per provisions of
section 80-IE of the Act, the Company is entitled to deduction of 100% of profits and gains derived by
such undertaking from manufacture or production of any eligible article or thing for 10 years beginning
with the year in which the undertaking begins to manufacture/produce such eligible article or thing.
Financial Year 2020-2021 is the sixth year of claiming deduction under section 80-IE and the Company
is eligible to claim the deduction till FY 2024-25.
However, as per section 115JB of the Act, the Company shall be required to pay MAT at the rate of
15% (plus applicable surcharge, education cess and secondary & higher education cess) on book profits,
irrespective of this tax benefit.
6. Deduction under section 80JJAA of the Act
The Company, being subjected to tax audit under section 44AB, is entitled to claim deduction equal to
30% of the additional employee cost incurred in the course of its business for 3 years from the year in
which such additional employees are taken on board, subject to fulfilment of other conditions specified
therein.
The Company shall continue to be entitled for this deduction even if it opts for the benefit of lower rate
of tax under section 115BAA of the Act as discussed at paragraph 1 above.
7. Deduction under section 80M of the Act
A new section 80M is inserted vide the Finance Act, 2020 w.e.f. AY 2021-22 (FY 2020-21), which
allows deduction in respect of income by way of dividends received from any other domestic company
or a foreign company or a business trust in computing the total income of Company. However, such
deduction shall not exceed the amount of dividend distributed by it on or before the due date. Due date
for the purpose of section 80M of the Act means the date one month prior to the date for furnishing the
return of income under section 139(1) of the Act.
The Company shall continue to be entitled for this deduction even if it opts for the benefit of lower rate
of tax under section 115BAA of the Act as discussed at paragraph 1 above.
However, as per section 115JB of the Act, the Company shall be required to pay MAT at the rate of
15% (plus applicable surcharge, education cess and secondary & higher education cess) on book profits,
irrespective of this tax benefit.
8. Deduction under section 80G of the Act
The Company is eligible to claim deduction equal to 100% or 50%, as the case may be, of donation
made to certain specified entities, if any, under section 80G of the Act while computing the total income
of the Company.
165
9. Section 35D- Amortisation of certain preliminary expenses
The Company will be entitled to amortise certain preliminary expenditure, specified under section
35D(2) of the Act, subject to the limit specified in Section 35D(3). The deduction is allowable for an
amount equal to one-fifth of such expenditure for each of five successive assessment years beginning
with the assessment year in which the business commences
STATEMENT OF POSSIBLE GST BENEFITS AVAILABLE TO ALEMBIC PHARMACEUTICALS
LIMITED UNDER THE GST REGIME:
Ministry of Commerce & Industry has announced vide Notification no. F. No. 10(1)/2017-DBA-II/NER dated
05th October, 2017 to provide budgetary support to the existing eligible manufacturing units operating in the
States of Jammu & Kashmir, Uttarakhand, Himachal Pradesh and North Eastern States including Sikkim under
different Industrial Promotion Schemes of the Government of India, for a residual period for which each of the
units is eligible, a new scheme is being introduced. The new scheme is offered, as a measure of goodwill, only to
the units which were eligible for drawing benefits under the earlier excise duty exemption/refund schemes but has
otherwise no relation to the erstwhile schemes. The Company has set up an industrial undertaking in Sikkim in
November 2015. The Company is eligible for partial GST refund out of GST paid in cash on goods manufactured
and supplied from this undertaking. This benefit is available for the period of 10 years from the date of
commencement of commercial production.
III. SPECIAL TAX BENEFITS AVAILABLE TO THE SHAREHOLDERS
No special tax benefits are available to the shareholders of the Company.
IV. RESIDENT SHAREHOLDERS
Taxation of dividend income and withholding tax
1. Erstwhile, dividend payment by the Company was subjected to dividend distribution tax under section
115-O of the Act and accordingly dividend income earned on shares of the Company was exempt in
the hands of shareholders under section 10(34) of the Act, except for cases covered by section
115BBDA wherein dividend in excess of INR 10 lakhs was chargeable to tax in hands of specified
shareholders.
However, the Finance Act, 2020 has omitted section 115-O and section 115BBDA. Now, w.e.f. April
1, 2020 dividend income shall be taxable in the hands of shareholders at the normal rate and the
Company is not required to pay any DDT. The recipient shareholder shall be entitled to deduction of
the interest expenditure incurred under section 57 of the Act, subject to the maximum limit of 20% of
the dividend income or income from a mutual funds.
In case of Corporate Shareholder being a domestic company, benefit may be availed under section
80M of the Act, newly inserted vide the Finance Act, 2020 w.e.f. AY 2021-22 (FY 2020-21), which
allows deduction in respect of income by way of dividends received from any other domestic company
or a foreign company or a business trust in computing the total income. However, such deduction shall
not exceed the amount of dividend distributed by such Corporate shareholder on or before the due date.
Due date for the purpose of section 80M of the Act means the date one month prior to the date for
furnishing the return of income under section 139(1) of the Act
The Company will be liable to deduct tax at source (‘TDS’) at the rate of 10% (7.5% w.e.f. May 14,
2020 up to March 31, 2021) in case of resident shareholders. TDS will have to be deducted at a higher
rate of 20% in case Permanent Account Number (‘PAN’) is not available.
No TDS will be deducted in case of resident individual shareholder if –
(a) Dividend distributed or paid or likely to be distributed or paid does not exceeds or is not likely to
exceed INR 5000/- during the financial year, or
(b) A declaration in prescribed Form 15G or 15H (as may be applicable) is verified and submitted in
prescribed manner and time by the shareholder.
166
Taxation of capital gains
2. The characterization of gains/losses, arising from sale of shares, as capital gains or business income
would depend on the nature of holding (whether for investment or carrying on trading in shares) in the
hands of the shareholder and various other factors including clarifications/ instructions issued by the
Central Government in this regard. The tax incidence on such gains would accordingly be different.
3. Capital assets held as investment may be categorized into short-term capital assets or long-term capital
assets based on its period of holding. Capital assets being securities listed in a recognized stock
exchange in India held by an assessee for a period of more than 12 months are considered as long-term
capital assets. Capital assets which are not long-term capital assets are short-term capital assets.
Consequently, capital gains arising on sale of long-term capital assets is long-term capital gains
(LTCG). Capital gains arising on sale of short-term capital assets is short-term capital gains (STCG)
4. Long term capital gains (exceeding INR 1,00,000/-) arising to the shareholders of the Company on
transfer of shares of the Company shall be taxed under section 112A of the Act at a concessional rate
of 10% (plus applicable surcharge and cess), if STT has been paid on both acquisition and transfer in
case of equity shares. The benefit of indexation under the second proviso to section 48 of the Act shall
not be applicable for computing long-term capital gains taxable under section 112A of the Act.
As per section 112A(4) of the Act read with Notification No 60/2018 dated October 1, 2018, the
Central Government has specified following transactions of acquisition of equity shares as exempt
from the condition of payment of STT:
(a) share acquisitions undertaken prior to October 1, 2004
(b) share acquisitions undertaken on or after October 1, 2004, subject to certain specified exceptions.
5. Long-term capital gains arising to the shareholders of the Company from the transfer of shares of the
Company, not covered under the section 112A of the Act, shall be taxed under section 112 of the Act,
at the rate of 20% (plus applicable surcharge and cess) with indexation benefit i.e. after indexing the
cost of acquisition/ improvement or at the concessional rate of 10% (plus applicable surcharge and
cess) without indexing benefit.
6. In case of an individual or Hindu Undivided Family (HUF), being a resident, where the total taxable
income as reduced by long-term capital gains is below the basic exemption limit, such long-term
capital gains will be reduced to the extent of the shortfall and only the balance long term capital gains
will be subjected to such tax in accordance with the proviso to section 112A(1) and proviso to section
112(1) of the Act. Further, no deduction under Chapter VI-A would be allowed against LTCG subject
to tax under section 112A and section 112 of the Act.
7. Short-term capital gains arising to shareholders of the Company on transfer of the shares of the
Company will be chargeable to tax at the rate of 15% (plus applicable surcharge and cess) as per the
provisions of section 111A of the Act if such transaction is chargeable to securities transaction tax. If
transaction is not subjected to STT, then short-term capital gains shall be chargeable at normal rates.
In case of an individual or HUF, being a resident, where the total taxable income as reduced by short-
term capital gains is below the basic exemption limit, the short-term capital gains will be reduced to
the extent of the shortfall and only the balance short-term capital gains will be subjected to such tax in
accordance with the proviso to section 111A(1) of the Act. Further, no deduction under Chapter VI-A
would be allowed against STCG subject to tax under section 111A of the Act.
8. As per provisions of Section 54EE of the Act, long term capital gains arising to an shareholder on
transfer of shares of the Company shall not be chargeable to tax to the extent such capital gains are
invested in certain notified units within six months after the date of transfer. If only part of the capital
gain is so invested, the exemption shall be proportionately reduced.
However, if the said notified units are transferred within three years from their date of acquisition, the
amount of capital gain exempted earlier would become chargeable to tax as long term capital gains in
the year in which units are transferred. Further, in case where loan or advance on the security of such
167
notified units is availed, such notified units shall be deemed to have been transferred on the date on
which such loan or advance is taken. However, the amount of exemption with respect to the investment
made in the aforesaid notified units during the financial year in which such debentures are transferred
and the subsequent financial year, should not exceed INR 50 lacs.
9. As per the provisions of section 54F of the Act, any long-term capital gains arising to an shareholder
who is an individual or HUF on transfer shares of the Company, is exempt from tax if the entire net
sales consideration is utilized, within a period of one year before, or two years after the date of transfer
in purchase of a new residential house, or three years after the date of transfer for construction of
residential house. If part of such net sales consideration is invested within the prescribed period in a
residential house, then such gains would be chargeable to tax on a proportionate basis.
This exemption is available, subject to the condition that the shareholder does not own more than one
residential house (other than the new residential house referred above) at the time of such transfer. If
the residential house in which the investment has been made is transferred within a period of three
years from the date of its purchase or construction, the amount of capital gains tax exempted earlier
would become chargeable to tax as long-term capital gains in the year in which such residential house
is transferred. Similarly, if the shareholder purchases within a period of two years or constructs within
a period of three years after the date of transfer of shares of the Company, another residential house
(other than the new residential house referred above), then the original exemption will be taxed as
capital gains in the year in which the additional residential house is acquired.
10. As per section 70 read with section 74 of the Act, short-term capital loss suffered during the year is
allowed to be set- off against short-term as well as long-term capital gains of the said year. Balance
loss, if any could be carried forward for eight years for claiming set-off against subsequent years’
short-term as well as long-term capital gains. Long-term capital loss suffered during the year is allowed
to be set-off only against long-term capital gains. Balance loss, if any, could be carried forward for
eight years for claiming set-off against subsequent year’s long-term capital gains.
As per Section 71 of the Act, short-term capital loss or long-term capital loss for the year cannot be
set-off against income under any other heads for the same year.
Further, section 94(7) of the Act provides that losses arising from the sale/ transfer of shares purchased
within a period of three months prior to the record date and sold/ transferred within three months after
such date, is to be ignored to the extent of dividend income on such shares is claimed as exempt from
tax. However, since the dividend income has become taxable w.e.f. FY 2020-21 (AY 2021-22),
provisions of section 94(7) would not be applicable to such shares.
11. In case shares are held as stock in trade, the income on transfer of shares would be taxed as business
income or loss in accordance with and subject to the provisions of the Act.
12. Where the gains arising on the transfer of shares of the Company are included in the business income
of an assessee assessable under the head “Profits and Gains from Business or Profession” and on which
securities transaction tax has been charged, such securities transaction tax shall be a deductible expense
from the business income as per the provisions of section 36(1)(xv) of the Act.
However, no deduction of STT amount will be allowed in computing the income chargeable to tax as
capital gains.
13. No income tax is deductible at source from income by way of capital gains arising to a resident
shareholder under the present provisions of the Act.
V. NON-RESIDENTS SHAREHOLDERS [OTHER THAN FOREIGN PORTFOLIO INVESTORS
(‘FPIs’)/ FOREIGN INSTITUTIONAL INVESTORS (‘FIIs’)]
Taxation of dividend income and withholding tax
1. Dividend income is taxable in the hands of non-resident shareholders at the normal rates w.e.f. April
1, 2020. The Company shall be responsible for withholding taxes at the rate 20% (plus applicable
surcharge and cess) subject to tax treaty benefits, if any.
168
Taxation of capital gains
2. The characterization of gains/losses, arising from sale of shares, as capital gains or business income
would depend on the nature of holding (whether for investment or carrying on trading in shares) in the
hands of the shareholder and various other factors including clarifications/ instructions issued by the
Central Government in this regard. The tax incidence on such gains would accordingly be different.
3. Capital assets held as investment may be categorized into short-term capital assets or long-term capital
assets based on its period of holding. Capital assets being securities listed in a recognized stock
exchange in India held by an assessee for a period of more than 12 months are considered as long-term
capital assets. Capital assets which are not long-term capital assets are short-term capital assets.
Consequently, capital gains arising on sale of long-term capital assets is long-term capital gains
(LTCG). Capital gains arising on sale of short-term capital assets is short-term capital gains (STCG).
4. Long term capital gains (exceeding INR 1,00,000/-) arising to the shareholders of the Company on
transfer of shares of the Company shall be taxed under section 112A of the Act at a concessional rate
of 10% (plus applicable surcharge and cess), if STT has been paid on both acquisition and transfer in
case of equity shares. The benefit of indexation under the second proviso to section 48 of the Act shall
not be applicable for computing long-term capital gains taxable under section 112A of the Act.
As per section 112A(4) of the Act read with Notification No. 60/2018 dated 1 October 2018, the
Central Government has specified that following transactions of acquisition of equity shares which
shall be exempt from the condition of payment of STT:
(a) share acquisitions undertaken prior to October 1, 2004
(b) share acquisitions undertaken on or after October 1, 2004, subject to certain specified exceptions.
Further, no deduction under Chapter VI-A would be allowed against LTCG subject to tax under section
112A of the Act.
5. Long-term capital gains arising to the shareholders of the Company from the transfer of shares of the
Company, not covered under the section 112A of the Act, shall be taxed under section 112 of the Act
as follows:
(a) Where the equity shares of the Company are acquired in INR, long-term capital gains shall be
taxed at the rate of 20% (plus applicable surcharge and cess) with indexation benefit i.e. after
indexing the cost of acquisition/ improvement or at the concessional rate of 10% (plus applicable
surcharge and cess) without indexation benefit.
(b) Where the equity shares of the Company are acquired in convertible foreign exchange, the same
taxed at the rate of 10% (plus applicable surcharge and cess) without indexation benefit on the
amount of capital gains computed in a manner provided as under:
In accordance with, and subject to section 48 of the Act read with Rule 115A of the Income Tax
Rules, 1962 capital gains arising on transfer of shares of the Company which are acquired in
convertible foreign exchange shall be computed by converting the cost of acquisition, expenditure in
connection with such transfer and full value of the consideration received or accruing as a result of
the transfer into the same foreign currency as was initially utilised in the purchase of shares and the
capital gains computed in such foreign currency shall be reconverted into Indian currency, such that
the aforesaid manner of computation of capital gains shall be applicable in respect of capital gains
accruing/ arising from every reinvestment thereafter.
Further, no deduction under Chapter VI-A would be allowed against LTCG subject to tax under
section 112 of the Act
6. Short-term capital gains arising to shareholders of the Company on transfer of the shares of the
Company will be chargeable to tax at the rate of 15% (plus applicable surcharge and cess) as per the
provisions of section 111A of the Act if such transaction is chargeable to securities transaction tax.
If transaction is not subjected to STT, then short-term capital gains shall be chargeable at normal
169
rates. Further, no deduction under Chapter VI-A would be allowed against STCG subject to tax
under section 111A of the Act.
7. As per provisions of Section 54EE of the Act, long term capital gains arising to an shareholder on
transfer of shares of the Company shall not be chargeable to tax to the extent such capital gains are
invested in certain notified units within six months after the date of transfer. If only part of the capital
gain is so invested, the exemption shall be proportionately reduced.
However, if the said notified units are transferred within three years from their date of acquisition,
the amount of capital gain exempted earlier would become chargeable to tax as long term capital
gains in the year in which units are transferred. Further, in case where loan or advance on the security
of such notified units is availed, such notified units shall be deemed to have been transferred on the
date on which such loan or advance is taken. However, the amount of exemption with respect to the
investment made in the aforesaid notified units during the financial year in which such debentures
are transferred and the subsequent financial year, should not exceed INR 50 lacs.
8. As per the provisions of section 54F of the Act, any long-term capital gains arising to an shareholder
who is an individual or HUF on transfer shares of the Company, is exempt from tax if the entire net
sales consideration is utilized, within a period of one year before, or two years after the date of
transfer in purchase of a new residential house, or three years after the date of transfer for
construction of residential house. If part of such net sales consideration is invested within the
prescribed period in a residential house, then such gains would be chargeable to tax on a
proportionate basis.
This exemption is available, subject to the condition that the shareholder does not own more than
one residential house (other than the new residential house referred above) at the time of such
transfer. If the residential house in which the investment has been made is transferred within a period
of three years from the date of its purchase or construction, the amount of capital gains tax exempted
earlier would become chargeable to tax as long-term capital gains in the year in which such
residential house is transferred. Similarly, if the shareholder purchases within a period of two years
or constructs within a period of three years after the date of transfer of shares of the Company,
another residential house (other than the new residential house referred above), then the original
exemption will be taxed as capital gains in the year in which the additional residential house is
acquired.
9. As per section 70 read with section 74 of the Act, short-term capital loss suffered during the year is
allowed to be set- off against short-term as well as long-term capital gains of the said year. Balance
loss, if any could be carried forward for eight years for claiming set-off against subsequent years’
short-term as well as long-term capital gains. Long-term capital loss suffered during the year is
allowed to be set-off only against long-term capital gains. Balance loss, if any, could be carried
forward for eight years for claiming set-off against subsequent year’s long-term capital gains.
As per Section 71 of the Act, short term capital loss or long-term capital loss for the year cannot be
set-off against income under any other heads for the same year.
Further, section 94(7) of the Act provides that losses arising from the sale/ transfer of shares
purchased within a period of three months prior to the record date and sold/ transferred within three
months after such date, is to be ignored to the extent of dividend income on such shares is claimed
as exempt from tax. However, since the dividend income has become taxable w.e.f. FY 2020-21
(AY 2021-22), provisions of section 94(7) would not be applicable to such shares.
10. In case shares are held as stock in trade, the income on transfer of shares would be taxed as business
income or loss in accordance with and subject to the provisions of the Act.
11. Where the gains arising on the transfer of shares of the Company are included in the business income
of an assessee assessable under the head “Profits and Gains from Business or Profession” and on
which securities transaction tax has been charged, such securities transaction tax shall be a
deductible expense from the business income as per the provisions of section 36(1)(xv) of the Act.
170
However, no deduction of STT amount will be allowed in computing the income chargeable to tax
as capital gains.
12. As per the provisions of section 195 of the Act, any income by way of capital gains payable to non-
residents may be subject to withholding of tax at the rate under the domestic tax laws, subject to tax
treaty benefits if any.
VI. NON-RESIDENT INDIAN SHAREHOLDERS (‘NRIs’)
1. A non-resident Indian has an option to be governed by Chapter XII-A of the Act in respect of dividend
income and long-term capital gains arising from shares of the Company acquired or purchased with or
subscribed to in convertible foreign exchange. Provisions of Part IV shall apply in case of items of
income not covered by this Chapter or in case non-resident does not opt to be governed by this Chapter.
2. The provisions contained in Chapter XII-A are given in brief as under:
Meaning of NRI
As per section 115C(e) of the Act, the term “non-resident Indian” means an individual, being a citizen of
India or a person of Indian origin who is not a “resident”. A person shall be deemed to be of Indian origin
if he, or either of his parents or any of his grandparents, was born in undivided India.
Taxability
(a) As per section 115E of the Act, investment income (dividend income) from shares acquired or
purchased with or subscribed to in convertible foreign exchange shall be taxed at 20%, whereas, long-
term capital gains on transfer of such shares shall be taxed at 10% without indexation benefit.
(b) As per section 115F of the Act, long-term capital gains arising to a non-resident Indian from transfer
of shares acquired or purchased with or subscribed to in convertible foreign exchange will be exempt
from capital gain tax if the net consideration is invested within six months after the date of transfer of
the shares in any specified asset or in any saving certificates referred to in section 10(4B) of the Act in
accordance with and subject to the provisions contained therein.
However, if the new assets are transferred or converted into money within a period of three years from
their date of acquisition, the amount of capital gains exempted earlier would become chargeable to tax
as long-term capital gains in the year in which the new assets are transferred or converted into money.
Other relaxations
(a) As per section 115G of the Act, it shall not be necessary for a non-resident Indian to file a return of
income under section 139(1) of the Act, if his total income consists only of investment income as
defined under section 115C and/or long term capital gains earned on transfer of such investment
acquired out of convertible foreign exchange, and the tax has been deducted at source from such
income under the provisions of Chapter XVII-B of the Act in accordance with and subject to the
provisions contained therein.
(b) In accordance with and subject to the provisions of section 115-I of the Act, a non-resident Indian
may opt not to be governed by the provisions of Chapter XII-A of the Act.
VII. FPIs and FIIs:
1. As per section 2(14) of the Act, transfer of any securities by FPIs/ FIIs being invested in accordance
with the regulations made under the Securities and Exchange Board of India Act, 1992 shall be treated
as capital assets.
2. In accordance with and subject to the provisions of section 115AD of the Act, LTCG on transfer of
shares by FIIs/FPIs are taxable at 10% (plus applicable surcharge and cess). In case of LTCG arising
on long term capital assets referred to in section 112A of the Act i.e. transfer of listed shares subject to
171
securities transaction tax, the gains are chargeable to tax at 10% (plus applicable surcharge and cess)
on income exceeding one lakh rupees. The benefit of cost indexation and foreign currency fluctuations
is not available to FIIs/FPIs.
3. In accordance with and subject to the provisions of section 115AD of the Act, STCG on transfer of
shares by FIIs/FPIs are taxable at 30% (plus applicable surcharge and cess). However, STCG arising
on transfer of listed shares are chargeable to tax at the rate of 15% (plus applicable surcharge and cess)
if such transaction is chargeable to securities transaction tax under section 111A of the Act.
4. As per section 196D of the Act,
(a) no deduction of tax at source will be made in respect of income by way of capital gains arising to
FIIs/FPIs from the transfer of securities referred in section 115AD of the Act
(b) dividend payment shall be subjected to withholding taxes at the rate 20% (plus applicable
surcharge and cess). Beneficial tax rate under treaty is not available at the time of withholding tax
on dividend payments to FIIs/FPIs.
5. The CBDT has issued a Notification No. 9 dated 22 January 2014 which provides that Foreign Portfolio
Investors (FPIs) registered under SEBI (Foreign Portfolio Investors) Regulations, 2014 shall be treated
as FII for the purpose of section 115AD of the Act.
VIII. MUTUAL FUNDS
1. Under section 10(23D) of the Act, any income earned by a Mutual Fund registered under the Securities
and Exchange Board of India Act, 1992, or a Mutual Fund set up by a public sector bank or a public
financial institution, or a Mutual Fund authorised by the Reserve Bank of India would be exempt from
income-tax, subject to such conditions as the Central Government may by notification in the Official
Gazette specify in this behalf.
2. As per section 196 of the Act, no tax is to be deducted from any income payable to a Mutual Fund
specified under section 10(23D) of the Act.
IX. VENTURE CAPITAL COMPANIES/ FUNDS
1. In terms of section 10(23FB) of the Act, income of:
(a) Venture Capital company which has been granted a certificate of registration under the Securities
and Exchange Board of India Act, 1992; and
(b) Venture Capital Fund, operating under a registered trust deed or a venture capital scheme made
by Unit trust of India, which has been granted a certificate of registration under the Securities and
Exchange Board of India Act, 1992, from investment in a Venture Capital Undertaking,
is exempt from income tax,
2. As per Section 115U of the Act, any income derived by a person from his investment in Venture
Capital Company/ Venture Capital Fund would be taxable in the hands of the person making an
investment in the same manner as if it were the income accruing or arising to or received by such
person had the investments been made directly in the Venture Capital Undertaking.
X. INVESTMENT FUNDS
1. Income of an Investment Fund, being a Trust, Company, Limited Liability Partnership or a body
corporate which has been granted a certificate of registration and is regulated under SEBI (Alternative
Investment Funds) Regulations, 2012 as Category I or Category II Alternate Investment Fund, other
than the income chargeable under the head ‘profits and gains of business and profession’, shall be
exempt from tax under section 10(23FBA) of the Act.
2. The income (other than income chargeable under the head ‘profits and gains of business or profession’)
would be taxable in the hands of the person making an investment in the same manner as if it were the
income accruing or arising to or received by such person had the investments been made directly in the
Investment Fund as per section 115UB(1) of the Act.
172
3. The income chargeable under the head ‘profits and gains of business and profession’ shall be taxed in
the hands of the Investment Fund depending on the legal status (i.e. a company, a limited liability
partnership, body corporate or a Trust) of the Fund, at the rate or rates as specified in the Finance Act
of the relevant year where Investment Fund is company or a firm and at maximum marginal rates in
any other case as per section 115UB(4) of the Act.
4. Further, the income accruing or arising to or received by the Investment Fund if not paid or credited to
a person (who has made investments in an Investment Fund) shall be deemed to have been credited to
the account of the said person on the last day of the previous year in the same proportion in which such
person would have been entitled to receive the income had it been paid in the previous year as per
section 115UB(6) of the Act.
5. Investment Funds have withholding tax obligation under section 194LBB of the Act while making
distribution to unit holders at the rate of 10% where the payee is resident and at the rates in force where
payee is non-resident.
6. Taxation of income of AIF Category III and its investors are governed by the other / normal provisions
of the Act.
XI. REQUIREMENT TO FURNISH PERMANENT ACCOUNT NUMBER (PAN) UNDER THE ACT
1. Section 139A(5A) of the Act requires every person receiving any sum or income or amount from which
tax has been deducted under Chapter XVII-B of the Act to furnish his PAN to the person responsible
for deducting such tax.
2. Section 206AA of the Act requires every person entitled to receive any sum or income or amount, on
which tax is deductible under Chapter XVIIB (‘deductee’) to furnish his PAN to the deductor, failing
which tax shall be deducted at the higher of the following rates:
(i) at the rate specified in the relevant provision of the I.T. Act; or
(ii) at the rate or rates in force; or
(iii) at the rate of twenty per cent.
3. As per Rule 37BC of the Income-tax Rules, the higher rate under section 206AA of the Act shall not
apply to a non-resident, not being a company, or to a foreign company, if the non-resident deductee
furnishes the prescribed details (Tax Residency Certificate (TRC), Tax Identification Number (TIN)
etc.).
4. A declaration under Section 197A(1) or 197A(1A) or 197A(1C) shall not be valid unless the person
furnishes his PAN in such declaration.
5. Where a wrong PAN is provided, it will be regarded as non-furnishing of PAN and Para (2) above will
apply apart from penal consequences
XII. TREATY BENEFITS
As per section 90(2) of the Act, in the case of a remittance to a country with which a Double Tax Avoidance
Agreement (tax treaty) is in force, may be subject to withholding of tax at the rates in force under the
domestic tax laws or under applicable tax treaty, whichever is beneficial to the non-resident. However,
treaty benefits are subject to fulfilment of anti-abuse provisions under the Tax Treaty and submission of
TRC and other documents/declarations as required by the Company.
XIII. GIFT TAX
There is no gift tax payable at present in India. However, under section 56(2)(x) of the Act and subject to
exception provided therein, if any person receives from any person, any property, including, inter alia,
shares of a company, without consideration or for inadequate consideration, the following shall be treated
as 'Income from other sources' in the hands of the recipient:
(a) where the shares are received without consideration, aggregate Fair Market Value (‘FMV’) exceeds
Rs.50,000/- the whole FMV;
173
(b) where the shares are received for a consideration less than FMV but exceeding Rs. 50,000/-, the
aggregate FMV in excess of the consideration paid.
Rule 11UA of the Income-tax Rules, 1962 provides for the method for determination of the FMV of various
properties
XIV. GENERAL ANTI-AVOIDANCE RULES
1. The Government of India has made amendments in the existing income tax laws to incorporate
provisions relating to General Anti-Avoidance Rules (GAAR). GAAR is effective from FY 2017-18
(AY 2018-19).
2. Several of the above tax benefits are dependent on the security holders fulfilling the conditions
prescribed under the relevant tax laws and subject to General Anti Avoidance Rules covered under
Chapter X-A of the Act.
Notes:
1. The statement of tax benefits enumerated above is as per the Income-tax Act, 1961, as amended by the Finance
Act, 2020.
2. Legislation, its judicial interpretations and the policies of the regulatory authorities are subject to change
from time to time, and these may have a bearing on the above. Accordingly, any change or amendment in the
law or relevant regulations would necessitate a review of the above.
3. The above statement sets out the provisions of law in a summary manner only and is not a complete analysis
or listing of all potential tax consequences of the purchase, ownership and disposal of equity shares.
4. No assurance is given that the revenue authorities/courts will concur with the views expressed herein. Our
views are based on the existing provisions of law and its interpretation, which are subject to changes from
time to time. We do not assume responsibility to update the views consequent to such changes.
5. This statement is only intended to provide general information to the investors and is neither designed nor
intended to be a substitute for professional tax advice. In view of the individual nature of the tax
consequences, the changing tax laws, each investor is advised to consult his or her own tax consultant with
respect to the specific tax implications arising out of their participation in the issue.
174
LEGAL PROCEEDINGS
Our Company is involved in various legal proceedings from time to time, which involve matters pertaining to,
amongst others, patent infringement proceedings, criminal proceedings and civil proceedings, pending before
various adjudicating forums.
This section discloses outstanding legal proceedings considered material in accordance with our Company’s
“Policy on Determining Materiality of Events/Information” (“Materiality Policy”) framed in accordance with
Regulation 30(4)(ii) of the SEBI Listing Regulations, adopted by the Board of Directors at its meeting held on
October 27, 2015.
As on the date of this Placement Document, except as disclosed in this section, there are no outstanding: (i)
actions initiated by statutory or regulatory authorities (such as SEBI, Stock Exchanges or such similar authorities)
which involve our Company or our Subsidiaries; (ii) civil litigation or tax litigation involving our Company or
Subsidiaries where the amount involved exceeds ₹460.00 crores (being 10 % (ten percent) of the annual
consolidated turnover of the Company as per the latest audited financial statements) (“Materiality Threshold”);
(iii) criminal litigation against our Company and our Subsidiaries; and (iv) any other outstanding litigation
involving our Company, Subsidiaries, Promoters or Directors which may be considered material by our Company
in connection with the Issue.
It is clarified that for the purposes of the above, pre-litigation notices received by our Company, Subsidiaries, or
Directors shall, unless otherwise decided by our Board, not be considered as litigation until such time that our
Company or our Subsidiary(ies) or Director(s), as the case may be, is impleaded as a defendant in litigation
proceedings before any judicial forum.
Capitalized terms used herein shall, unless otherwise specified, have the meanings ascribed to such terms in this
section.
I. Litigation against our Company
Criminal proceedings
1. Magic Holidays (“Complainant”) filed a criminal complaint (“Complaint”) before the Metropolitan
Magistrate, Borivali, Mumbai (“Court”), against our Company, Chirayu Amin, Shaunak Amin, and
others (“Accused”) for alleged contravention of Section 420, 426, 406 and 120(b) of the Indian Penal
Code, 1860. The Complainant alleged criminal breach of trust, cheating and mischief in lieu of non-
payment of dues by the Accused, for the provision of services by the Complainant. The Complainant
has sought damages amounting to approximately ₹ 14,64,857 with interest at the rate of 24% p.a. The
Court granted an order to issue process (“Order”) against the Accused under various provisions of the
Indian Penal Code, 1860. Subsequently, the Accused filed a writ petition dated April 11, 2014 (“Writ
Petition”) before the Bombay High Court on the grounds that, inter alia, the Complainant’s claims were
settled and that the Complaint was untenable due to the civil nature of the transaction, and prayed for
the (i) quashing and setting aside the Order, (ii) a stay on the Order pending the Writ Petition, and (iii)
striking down and quashing the Complaint. The Bombay High Court granted an order staying the
proceedings on September 16, 2014. The matter is currently pending.
2. The Assistant Drugs Controller, Belgaum Circle (“Complainant”) filed a criminal complaint under
Section 200 of the Code Of Criminal Procedure, 1973 (“Complaint”) before the Court of Second
J.M.F.C, Belgavi (“Court”), against our Company, Chirayu Amin, Raj Kumar Baheti and others
(“Accused”), for alleged contravention of Section 18(a)(i) of the Drugs and Cosmetics Act, 1940
(“Act”) and punishable under Section 27(d) of the Act. The Complainant had alleged that a certain drug
manufactured by our Company was “Not of Standard Quality” (“NSQ”) with respect to “Description”
contained in Form 13, and sought that the Court take cognizance of the offence under Section 27(d) of
the Act. The Court took cognizance of the offence, vide order dated September 13, 2017 (“Order”), and
issued summons to the Accused. Subsequently, our Company, Chirayu Amin and another filed a
memorandum of criminal petition under Section 482, Code of Criminal Procedure, 1973, before the
High Court of Karnataka, Circuit Bench at Dharwad (“High Court”) for the quashing of the Order on
the grounds that, inter alia, there is no offence under Section 18 as the allegation does not state that the
drug in question falls under the NSQ prescribed parameters of adulteration/spurious/misbranded drugs.
The High Court, vide order dated September 28, 2018, quashed the Order on the grounds that, inter alia,
175
the accused’s residence was beyond the jurisdiction of the Magistrate and that the Magistrate ought to
have conducted enquiry before taking cognizance, remanded the matter back to the Court, and held that
the magistrate proceed on the Complaint in accordance with laws in the light of the observation made.
The matter is currently pending enquiry.
3. The Drugs Inspector in the office of Assistant Commissioner, Food and Drug Administration
(“Complainant”) filed a complaint (“Complaint”), before the Court of Chief Judicial Magistrate,
Alibaug, Raigad against our Company and others (“Accused”) alleging that a certain drug sold and
distributed by our Company was not a standard quality drug as defined under Section 16 of the Drugs
and Cosmetics Act, 1940 (“Act”) and is therefore, an offence under Section 18(a)(i), read with Section
16, Section 34, punishable under Section 27(d) of the Act. The matter is currently pending.
4. The Drug Inspector, Vishakhapatnam (“Complainant”) filed a complaint (“Complaint”) under Section
3, Essential Commodities Act 1955, read with paragraph 14(1) and 14(2) of the Drugs (Price Control)
Order, 2013, punishable under Section 7(1) (a) (ii) of the Essential Commodities Act, 1955 before the
Court of Metropolitan Magistrate, Visakhapatnam (“Court”) against our Company and another
(“Accused”) for the contravention of paragraph 14(1) and 14(2) of Drugs (Price Control) Order, 2013.
The Complainant alleged that our Company was retailing a certain drug at a price which exceeded the
price fixed by the Government of India, and sought that the Court take cognizance of the offence and
penalise the Accused accordingly. The Court, vide order dated July 22, 2015, took cognizance of the
offence and ordered for issue of summons. Thereafter, the Court issued summons dated October 8,
2015, for the appearance of the Accused. The Accused filed a memorandum of quash petition under
Section 482, Code of Criminal Procedure, 1973 before the High Court of Judicature at Hyderabad, State
of Telangana and Andhra Pradesh (“High Court”) on December 9, 2015 seeking quashing of the
Complaint on the grounds that, inter alia, the Complainant had failed to recognize that the Accused,
vide order dated March 30, 2005, was given a specific retail price under paragraph 8 of the DPCO, 1995
and that the Complainant had never issued a show cause notice or a demand notice to intimate the
Complainant of the allegations being levelled against them. The matter is currently pending.
5. A first information report (“FIR”) was filed against Dr. P Anand, our Company (represented by the
Managing Director) and others (“Accused”) on July 31, 2015, alleging offences under various
provisions of the Indian Penal Code, 1860 and the Prevention of Corruption Act, 1988. It was alleged
that Dr. P Anand, a public servant, conspired with the Accused by procuring drugs produced by them,
by suppressing the quotations of the other pharmaceutical companies who had put forth quotations for
their products. Pursuant to the FIR, a charge sheet (“Chargesheet”) was filed in the Court of City Civil
and Session Judge and Principal Special Judge for CBI Cases, Bangalore (“Court”) against the Accused
on January 1, 2017 alleging: (i) abetment in cheating and criminal conspiracy to the tune of ₹ 1,34,997,
and (ii) contravention of the Prevention of Corruption Act, 1988. Subsequently, our Company filed a
discharge application before the Court on May 29, 2018 seeking that our Company be discharged as an
Accused from the matter owing to the baseless nature of the allegations and the absence of any prima
facie evidence of conspiracy in the Chargesheet. The matter is currently pending.
6. A complaint (“Complaint”) was filed by the labor superintendent cum inspector, Jamshedpur
(“Complainant”) against our Company and others (“Accused”) under Section 5 and Rule 22(1) along
with Section 7 and Rules 23(a) (b) (c) and (d) of the Sales Promotions Employees (Conditions of
Services) Act, 1976 (“Act”). The Court of the Judicial Magistrate, Jamshedpur (“Magistrate Court”)
vide its order dated November 28, 2017 took cognizance of the offence (“Magistrate Court Order”).
Challenging the Magistrate Court Order, the Accused filed a criminal miscellaneous petition in the High
Court of Jharkhand at Ranchi (“High Court”). The High Court, vide an order dated November 18, 2019,
stayed the Magistrate Court Order. The matter is currently pending.
II. Litigation against our Promoters and Directors
Criminal proceedings
1. A first information report (“FIR”) was filed with the Police Station at Vadodara, Gujarat on December 23,
2016 against Chirayu Amin, Pranav Amin, Shaunak Amin and Krishnapuram Ramanathan and others
(“Accused”) alleging violation of various provisions of the Gujarat Prohibition Act, 1949. Pursuant to the
FIR, a chargesheet was filed before the 10th Additional Civil Judge and Judicial Magistrate First Class,
Vadodara by the police on December 3, 2018. The matter is currently pending.
176
2. Hemendra Kumar (“Complainant”) filed a criminal complaint (“Complaint”) before the Court of
Additional Chief Judicial Magistrate, Aligarh against Chirayu Amin and others (“Accused”) alleging
criminal breach of trust and cheating under Section 406 and 420 of the Indian Penal Code, 1860. The
Complainant alleged that he had failed to obtain the benefits and gains which were assured to him in his
appointment as the super stockiest for four districts, owing to which, he had consequently incurred a loss
of ₹1,94,036. He, therefore, sought that the Accused be summoned and penalized under relevant provisions
of the Indian Penal Code, 1860. The Court passed an order on November 1, 2010 summoning the Accused
to face trial. Subsequently, non-bailable warrants were issued by the Court vide order dated May 20, 2011.
Thereafter, Chirayu Amin, filed a Criminal Miscellaneous Application in the High Court of Judicature,
Allahabad (“High Court”) under Section 482, Code of Criminal Procedure (“Application”) on July 11,
2011, seeking that the Complaint and consequential proceedings be quashed, and that the subsisting
proceedings be stayed during the pendency of the Application, on the grounds that, inter alia, criminality
cannot be attributed owing to the civil nature of the transaction and the Complainant’s failure to achieve
its monthly targets had in fact caused the Company to suffer losses. The High Court vide its order date July
20, 2011 directed that no coercive action be taken against Chirayu Amin until the next date of hearing. The
matter is currently pending.
3. Magic Holidays filed a complaint dated April 2, 2013 before the Metropolitan Magistrate presiding over
17th Court at Borivali, Mumbai against Chirayu Amin, Shaunak Amin and others for alleged contravention
of Sections 420, 426, 406 and 120B of the Indian Penal Code, 1860. For more information, see “Litigation
against our Company – Criminal Proceedings” on page 174.
4. The Assistant Drugs Controller, Belgaum Circle filed a private complaint dated September 6, 2017 before
the Court of Second J.M.F.C, Belgavi against Chirayu Amin, Raj Kumar Baheti and others, for alleged
contravention Section 18(a) (i), Drugs and Cosmetics Act, 1940. For more information, see “Litigation
against our Company – Criminal Proceedings” on page 174.
5. A first information report (“FIR”) was filed against Dr. P Anand, our Company (represented by the
Managing Director) and others (“Accused”) on July 31, 2015, alleging offences under various provisions
of the Indian Penal Code, 1860 and the Prevention of Corruption Act, 1988. For more information, see
“Litigation against our Company – Criminal Proceedings” on page 174.
III. Litigation, inquiries, inspections, or investigations initiated or conducted under the Companies Act or any
previous company law against our Company and / or our Subsidiaries in the last three years
There is no litigation, inquiries, inspections or investigations initiated or conducted under the Companies
Act or any previous company law, against our Company and / or our Subsidiaries in the last three years
immediately preceding the date of this Placement Document.
IV. Prosecutions filed against, fines imposed on, or compounding of offences by our Company and / or our
Subsidiaries under the Companies Act in the last three years
There is no prosecutions filed against, fines imposed on, or compounding of offences by our Company and/or
our Subsidiaries under the Companies Act in the last three years immediately preceding the date of this
Placement Document.
V. Details of acts of material fraud committed against our Company in the last three years, if any, and if so,
the action taken by our Company
There has been no material fraud committed against our Company in the last three years immediately
preceding the date of this Placement Document.
VI. Defaults by our Company in respect of dues payable including therein the amount involved, duration of
default and present status of repayment of statutory dues, debentures (including interest thereon),
deposits (including interest thereon) and loans (including interest thereon)
As of the date of this Placement Document, except for the following, there are no outstanding instances of
defaults* in payment of undisputed or disputed statutory dues by the Company and its Material Subsidiary,
being Alembic Pharmaceuticals Inc:
177
S No. Nature of dues
Amount not
deposited (₹ in
crores)
Forum where dispute is pending Period
1 Sales Tax, interest
and penalty 0.13 High Court 1999-2000
1.64 Asst. Commissioner Demand 2003-04
0.0045 Additional Commissioner 2004-05
0.02 Revisional Board (Tribunal) 2006-07
0.08 Jt. Commissioner Appeals 2006-07
0.08 Maharashtra Tribunal 2009-10
0.02 Additional Commissioner April 1, 2006 to
November 30, 2008
0.15 Additional Commissioner 2007-08
0.16 Revisional Authority 2015-16
0.48 Revisional Authority 2012-13
2 Central Sales Tax 0.02 Addl. Commissioner Sales Tax
April 1, 2006 to
November 30, 2008
0.01 Jt. Commissioner Appeals 2006-07
0.03 Jt. Commissioner Appeals 2010-11
0.11 Dy. Commissioner II 2006-07
3 Entry Tax 0.03 Revisional Authority 2013-14
4 Professional Tax 0.05 Jt. Commissioner 2014-15
5 Excise duty, interest
& penalty 0.24 Commissioner Appeals 2013-14
*Any delay in payment of an undisputed statutory due shall be considered as a default in payment only if it has remained outstanding for a period of more than six months as required under Section 143(11) of the Companies Act, 2013.
Further, there are no outstanding defaults in repayment of debentures and interest thereon, repayment of
deposits and interest thereon, and repayment of loan from any bank or financial institution and interest thereon
by our Company and its Material Subsidiary, being Alembic Pharmaceuticals Inc.
VII. Litigation or legal action pending or taken against our Promoters by any Ministry or Department of the
Government or any statutory authority in the last three years immediately preceding the year of circulation
of this Placement Document and directions issued by such Ministry or Department or statutory authority
upon conclusion of such litigation or legal action
There is no litigation or legal action pending or taken against our Promoters by any Ministry or Department
of the Government or any statutory authority in the last three years immediately preceding the year of
circulation of this Placement Document and directions issued by such Ministry or Department or statutory
authority upon conclusion of such litigation or legal action.
VIII. Details of default in annual filings under the Companies Act or rules made thereunder
There has been no default by our Company in the annual filings under the Companies Act or the rules made
thereunder.
IX. Details of significant and material orders passed by any Regulator, Court or Tribunal, impacting the
going concern status of our Company and/or its future operations
There has been no order passed by any regulator, court or tribunal which impacts the going concern status of our
Company and/or its future operations.
178
OUR STATUTORY AUDITORS
M/s K.C. Mehta & Co., Chartered Accountants, have been appointed as Statutory Auditors of our Company by
the shareholders at their AGM held on July 22, 2020, for a period of five years. The Statutory Auditors of our
Company are independent auditors with respect to our Company, as required by the Companies Act and in
accordance with the guidelines issued by the ICAI.
The Audited Consolidated Financial Statements included in this Placement Document have been audited by the
Previous Statutory Auditors, M/s. K.S Aiyar & Co., Chartered Accountants.
179
GENERAL INFORMATION
• Our Company was originally incorporated as a public limited company under the name of Alembic Pharma
Limited on June 16, 2010 under the Companies Act, 1956. The Company commenced its business on July
1, 2010 pursuant to the certificate of commencement of business issued by the Assistant Registrar of
Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the name of our Company was changed to its
present name, pursuant to a certificate of incorporation consequent upon change of name dated March 12,
2011 issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli.
• Our Registered and Corporate Office is located at Alembic Road, Vadodara 390 003, Gujarat, India.
• The pharmaceutical undertaking of Alembic Limited (our Promoter) was demerged and transferred to the
Company, with effect from April 1, 2010, further to an order dated January 24, 2011 of the High Court of
Gujarat approving a scheme of arrangement. Thereafter, the Company made a listing application and was
listed on BSE Limited and National Stock Exchange of India Limited since September 20, 2011, in terms
of the scheme of arrangement.
• The Issue was authorised and approved by our Board of Directors pursuant to its resolution(s) passed on
May 22, 2020 and July 27, 2020. Our Shareholders have approved the Issue by way of a special resolution
passed on July 22, 2020.
• Our Company has received in-principle approvals in terms of Regulation 28(1) of the SEBI Listing
Regulations from each of BSE and NSE on August 3, 2020 to list the Equity Shares to be issued pursuant
to the Issue on the Stock Exchanges. We will apply for final listing and trading approvals of the Equity
Shares to be issued pursuant to the Issue on the Stock Exchanges.
• Copies of our Memorandum and Articles of Association will be available for inspection between 10:00 am
to 5:00 pm on any weekday (except Saturdays and public holidays) during the Issue Period at our Registered
and Corporate Office.
• Copies of the Memorandum and Articles of Association will be available for inspection electronically on
our website at https://www.alembicpharmaceuticals.com/.
• Except as disclosed in this Placement Document, there has been no material adverse change in our financial
position since March 31, 2020, the date of the latest Audited Consolidated Financial Statements prepared
in accordance with Ind AS included in this Placement Document.
• Our Company confirms that it is in compliance with the minimum public shareholding requirements as
specified in the SEBI Listing Regulations and the SCRR.
• The Floor Price is ₹980.75 per Equity Share, calculated in accordance with the provisions of Chapter VI of
the SEBI Regulations. Our Company has also offered a discount of ₹48.75 per Equity Share, which is a
4.97% discount on the Floor Price.
• Our Company has obtained necessary consents, approvals and authorizations required in connection with
the Issue.
• The Company and the BRLMs accept no responsibility for statements made otherwise than in this
Placement Document and anyone placing reliance on any other source of information, including our
website, would be doing it at his or her own risk.
180
FINANCIAL STATEMENTS
S.No. Financial Information* Page No.
1. Audited consolidated financial statements for Fiscal 2020 F-1 to F-40
2. Audited consolidated financial statements for Fiscal 2019 F-41 to F-73
3. Audited consolidated financial statements for Fiscal 2018 F-74 to F-105 *For details of our significant accounting policies, see “Significant Accounting Policies” on page 77.
To the Members of Alembic Pharmaceuticals Limited
Report on the Audit of the Consolidated Financial Statements
OpinionWe have audited the accompanying consolidated financial statements of Alembic Pharmaceuticals Limited (hereinafter referred to as the ‘Holding Company”) and its subsidiaries (Holding Company and its subsidiaries together referred to as “the Group”), its associates and jointly controlled entities, which comprise the consolidated Balance Sheet as at 31st March, 2020, and the consolidated Statement of Profit and Loss (including Other comprehensive income), the consolidated Statement of Changes in equity and the consolidated Cash Flow Statement for the year then ended, and Notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as “the consolidated financial statements”).
In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (‘the Act”) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, its associates and jointly controlled entities as at 31st March, 2020, of consolidated profit (including other comprehensive income), consolidated changes in equity and its consolidated cash flows for the year then ended.
Basis for OpinionWe conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in India in terms of the Code of Ethics issued by Institute of Chartered Accountants of India and the relevant provisions of the Companies Act, 2013, and we have fulfilled our
Independent Auditor’s Report
other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Key Audit MattersKey audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The following Key Audit Matters have been identified by us and as reported by the component Auditors.
1. Provision for return of non-saleable goods (Expiry,Breakage and Spoilage) in the market in India (In thecase of Holding Company) This is considered as key audit matter in view of significant estimates and judgements made by the managementfor recognition and measurement for the same.
The Company, under the prevailing trade practice, has an obligation to accept returns of expiry, breakage and spoilage (EBS) products, from the stockiest (customers) in India. The methodology and assumptions used to estimate the accruals of EBS are monitored and adjusted regularly by the management in the light of the obligations, historical trends, past experience and prevailing market conditions.
The Company makes provision for accrual of EBS estimated in future out of the sales effected during the current period. The said provision is used for settling claims made by the customers in future. Actual returns on account of EBS can vary materially from period to period based upon actual sales volume, product mix, etc.
Principal Audit Procedures We verified management’s calculations in respect of estimate made by the management towards provision for accruals of EBS. We have examined the methodology and the assumptions made by the management while making this provision.
F-1
2. Impairment testing of ‘Intangible assets under development’ (In the case of a Subsidiary Company) Auditors of Aleor Dermaceuticals Limited (“Aleor”), subsidiary company, have reported the following for thekey audit matter:
Sr. No. Particulars Auditor’s Response
1 Impairment testing of “Intangible Assets under development”The Company is developing various Generic products. The eligible cost related to above are included under “Intangible Assets under development”. The above ‘Intangible assets under development” are tested for Impairments.
This is a key audit matter because there is use of significant estimates and judgments by the management which are required for testing the same for impairments.
Principal Audit Procedures:• We have assessed the company’s valuation methodology to ensure
the recoverable value of Intangible assets under development.
• We have considered the recoverable value based on value in use derived from discounted cash flows working provided by the managementand certified by the independent external valuer.
• We have evaluated the assumptions applied to key inputs such asdiscount rates, sales volume and prices, long term growth rates andterminal values.
• We discussed potential changes in key drivers as compared to previous year/actual performance with management to evaluate whether theinputs and assumptions used in the cash flow forecasts were suitable.
• We have verified the application made by the company to externalagencies for approval of its various products and also the approvalreceived by the company for some of the products.
“Information Other than the Consolidated Financial Statements and Auditor’s Report Thereon”The Holding Company’s Board of Directors is responsible for the other information. The other information comprises the information included in the Board’s Report and Annexures thereto and Report on Corporate Governance but does not include the consolidated financial statements and our auditor’s report thereon.
Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.
We have been provided the aforesaid reports and based on the work we have performed, we did not observe any material misstatement of this other information and accordingly, we have nothing to report in this regard.
Responsibilities of Management and Those Charged with Governance for the Consolidated Financial StatementsThe Holding Company’s Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 (the Act) that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group including its associates and jointly controlled entities in accordance with the accounting principles generally
accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.
In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities is responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.
Independent Auditor’s Report (Contd.)
F-2
Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
• Identify and assess the risks of material misstatementof the consolidated financial statements, whether dueto fraud or error, design and perform audit proceduresresponsive to those risks, and obtain audit evidencethat is sufficient and appropriate to provide a basisfor our opinion. The risk of not detecting a materialmisstatement resulting from fraud is higher than forone resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, orthe override of internal control.
• Obtain an understanding of internal control relevantto the audit in order to design audit procedures thatare appropriate in the circumstances. Under section143(3)(i) of the Companies Act, 2013, we are alsoresponsible for expressing our opinion on whetherthe company has adequate internal financial controlssystem in place and the operating effectivenessof such controls.
• Evaluate the appropriateness of accounting policiesused and the reasonableness of accounting estimatesand related disclosures made by management.
• Conclude on the appropriateness of management’suse of the going concern basis of accounting and,based on the audit evidence obtained, whethera material uncertainty exists related to events orconditions that may cast significant doubt on theability of the Group and its associates and jointlycontrolled entities to continue as a going concern.
If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements
or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the consolidated financial statements, including thedisclosures, and whether the consolidated financialstatements represent the underlying transactions andevents in a manner that achieves fair presentation.
• Obtain sufficient appropriate audit evidence regardingthe financial information of the entities or businessactivities within the Group and its associates andjointly controlled entities to express an opinion on theconsolidated financial statements. We are responsiblefor the direction, supervision and performance ofthe audit of the financial statements of such entitiesincluded in the consolidated financial statementsof which we are the independent auditors. For theother entities included in the consolidated financialstatements, which have been audited by otherauditors, such other auditors remain responsiblefor the direction, supervision and performance ofthe audits carried out by them. We remain solelyresponsible for our audit opinion.
We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.
F-3
Other Matters1. (a) The consolidated Financial Statements
include the audited Financial Statements of 10 subsidiaries whose Financial Statements / financial information reflect total assets of ` 1901.79 Crores as at 31/03/2020, total revenue of ` 2211.69 Crores for the year ended on 31/03/2020 and cash flows (net cash outflow) of ` 23.00 Crores for the period year ended on 31/03/2020, as considered in the consolidated Financial Statements, which have been audited/ subjected to limited review by their respective independent auditors. The independent auditors’ reports on financial statements /financial information of these subsidiaries have been furnished to us and our opinion on the consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors.
(b) The consolidated Financial Statements includethe Group’s share of net profit in 4 associates of` 0.05 Crores for the year ended on 31/03/2020which have been audited/ subjected to limitedreview by their respective independent auditors.The independent auditors’ reports on financialstatements /financial information of theseassociates have been furnished to us and ouropinion on the consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these associates, is basedsolely on the report of such auditors.
(c) Audited financial statements for the year inrespect of 1 Joint venture of the Group have notbeen received by the Group. No further share ofloss in that joint venture is required to be borneby the Group as the entire Equity capital and loangiven to it, is fully provided for, pending formallegal process for dis-association which is still tobe initiated by the Group.
2. Re: Subsidiary Company, i.e., Aleor DermaceuticalsLimited. (Aleor)
Aleor’s auditors have modified their audit opinion in financial statements for the year ended on 31st March, 2020 regarding the fact that Aleor has measured its financial liability of Non-convertible Redeemable Debentures (NCRD) issued to the Holding Company is valued at cost and is not at amortised cost as mandated by Ind AS 109-Financial Instruments. Had the NCRD been measured at Amortized Cost,
(a) the borrowing cost for the year to be includedin the Property, plant and equipment (PPE),Intangible assets and qualifying asset CapitalWork-in Progress and Intangible assets underdevelopment would have been higher by ` 49.71Crores (PY: ` .40.35 Crores)
(b) the borrowing costs for the year to be recognizedas expense would be higher by ̀ 16.14 Crores (PY:` Nil) on account of borrowing costs attributableto Property, plant and equipment and Intangibleassets capitalized during the year.
As a result of the above, the amount of Property, plant and equipment, Intangible assets and qualifying assets of Capital work in progress and Intangible assets under development as at 31st March, 2020 would be higher by 111.34 Crores (PY: 61.63 Crores) and the corresponding financial liability of NCRD would have been higher by ` 127.48 Crores.
Corresponding interest income up to 31st March, 2020 of ` 127.48 Crores (PY: 61.63 Crores) has not been recognized by the Holding Company (Alembic Pharmaceuticals Limited - APL) and is considered as contingent assets. The said NCRD have been carried at cost in separate financial statements of APL as per Ind AS 27.
On consolidation of financial statements (a) the said investment by APL and Financial liability of Aleor and (b) borrowing cost of Aleor and interest income of APL gets eliminated. Therefore it does not have any financial impact on the Group’s Consolidated Financial statements.
Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters.
Report on Other Legal and Regulatory RequirementsAs required by Section 143(3) of the Act, we report, to the extent applicable, that:
(a) We have sought and obtained all the information andexplanations which to the best of our knowledge andbelief were necessary for the purposes of our audit ofthe aforesaid consolidated financial statements.
(b) In our opinion, proper books of account as requiredby law relating to preparation of the aforesaidconsolidated financial statements have been kept sofar as it appears from our examination of those booksand the reports of the other auditors.
Independent Auditor’s Report (Contd.)
F-4
(c) The Consolidated Balance Sheet, the ConsolidatedStatement of Profit and Loss (including othercomprehensive income), the Consolidated Statementof Changes in Equity and the Consolidated Cash FlowStatement dealt with by this Report are in agreementwith the relevant books of account maintained forthe purpose of preparation of the consolidatedfinancial statements.
(d) In our opinion, the aforesaid consolidated financialstatements comply with the Accounting Standardsspecified under Section 133 of the Act read with Rule7 of the Companies (Accounts) Rules, 2014.
(e) On the basis of the written representations receivedfrom the directors of the Holding Company as on31st March, 2020 taken on record by the Board ofDirectors of the Holding Company and the reportsof the statutory auditors of its subsidiary companies,associate companies and jointly controlled companiesincorporated in India, none of the directors ofthe Group companies, its associate companiesand jointly controlled companies incorporated inIndia is disqualified as on 31st March, 2020 frombeing appointed as a director in terms of Section164(2) of the Act.
(f) With respect to the adequacy of internal financialcontrols over financial reporting of the Group and theoperating effectiveness of such controls, refer to ourseparate report in Annexure A.
(g) With respect to the other matters to be included in theAuditor’s Report in accordance with the requirementsof section 197(16) of the Act, as amended, in our opinion and to the best of our information and according tothe explanations given to us, the remuneration paidby the Holding Company to its Directors during theyear is in accordance with the provisions of section197 of the Act and is not in excess of the limit laiddown under this section. In the case of a subsidiarycompany incorporated in India, the managerial
remuneration has not been paid or provided and accordingly, the requisite approvals mandated by the provisions of Section197 read with Schedule V of the Act are not required;
(h) With respect to the other matters to be included inthe Auditor’s Report in accordance with Rule 11 ofthe Companies (Audit and Auditor’s) Rules, 2014, inour opinion and to the best of our information andaccording to the explanations given to us:
i. The consolidated financial statements disclose the impact of pending litigations on the consolidatedfinancial position of the Group, its associates andjointly controlled entities – Refer Note 33(2)(ii) tothe consolidated financial statements.
ii. The Group, its associates and jointly controlledentities did not have any long-term contractsincluding derivative contracts, for which therewere any material foreseeable losses;
iii. There has been no delay in transferring amounts,required to be transferred, to the InvestorEducation and Protection Fund by the HoldingCompany and its subsidiary companies, associate companies and jointly controlled companiesincorporated in India.
For K. S. Aiyar & CoChartered AccountantsFirm’s Registration No.100186W
UDIN: 20038526AAAABD1779
Rajesh S. JoshiPartnerMembership No.38526
Place: Mumbai
Date: 22nd May, 2020
F-5
ANNEXURE A to the Independent Auditor’s Report
(Referred to in paragraph f under ‘Report on Other Legal and Regulatory Requirements’ section of our report of even date to the Members of Alembic Pharmaceuticals Limited)
Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31st March, 2020, we have audited the internal financial controls over financial reporting of Alembic Pharmaceuticals Limited (hereinafter referred to as “the Holding Company”) and its subsidiary companies, its associate companies and jointly controlled company, which are companies incorporated in India, as of that date.
Management’s Responsibility for Internal Financial ControlsThe respective Board of Directors of the Holding company, its subsidiary companies, its associate companies and jointly controlled companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient co nduct of its bu siness, in cluding ad herence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.
Auditor’s ResponsibilityOur responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the ICAI and the Standards on Auditing, issued by ICAI prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.
Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial
controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors of the subsidiary companies, associate companies and joint venture companies, which are companies incorporated in India, in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting of the Holding Company, its subsidiary companies, its associate companies and its joint venture company, which are companies incorporated in India.
Meaning of Internal Financial Controls Over Financial ReportingA company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions arerecorded as necessary to permit preparation of financialstatements in accordance with generally acceptedaccounting principles, and that receipts and expendituresof the company are being made only in accordancewith authorisations of management and directors of thecompany; and (3) provide reasonable assurance regardingprevention or timely detection of unauthorised acquisition,use, or disposition of the company’s assets that could havea material effect on the financial statements.
Inherent Limitations of Internal Financial Controls Over Financial ReportingBecause of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become
F-6
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
OpinionIn our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors referred to in the ‘Other Matter’ paragraph below, the Holding Company, its subsidiary companies, and its associates and jointly controlled companies, which are companies incorporated in India, have, in all material respects, an internal financial controls system with reference to consolidated financial statements over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.
Other MattersOur aforesaid report under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting in so far as it relates to one subsidiary company and one associate company, which are companies incorporated in India, is based on the corresponding reports of the auditors of such companies incorporated in India.
Our opinion is not modified in respect of the above matter.
For K. S. Aiyar & CoChartered AccountantsFirm’s Registration No.100186W
UDIN: 20038526AAAABD1779
Rajesh S. JoshiPartnerMembership No.38526
Place: Mumbai
Date: 22nd May, 2020
F-7
Consolidated Balance Sheet as at 31st March, 2020
` in Crores
Particulars Note NoAs at
31st March, 2020As at
31st March, 2019
I. ASSETS(1) Non-Current Assets(a) Property, Plant and Equipment 6 1,524.90 1,098.41(b) Capital work-in-progress 1,574.10 1,341.40(c) Goodwill 7 - 3.61(d) Other Intangible assets 7 26.94 56.43(e) Intangible assets under development 272.08 209.83(f) Financial Assets:-
(i) Investments 8 0.45 0.45(ii) Investment accounted for using Equity Method 9 17.17 48.31
(g) Other non-current assets 10 110.66 61.59Total non-current assets 3,526.30 2,820.03(2) Current Assets(a) Inventories 11 1,187.53 967.26(b) Financial Assets
(i) Trade receivables 12 864.75 488.92(ii) Cash and cash equivalents 13 71.84 199.07(iii) Bank balances other than cash and cash equivalents 14 8.91 6.55(iv) Others financial assets 15 8.65 9.10
(c) Current Tax Assets (Net) 33(10) 30.98 -(d) Other current assets 16 290.08 286.86Total current assets 2,462.75 1,957.76TOTAL ASSETS 5,989.05 4,777.79
II. EQUITY AND LIABILITIESEQUITY(a) Equity Share capital 17 37.70 37.70(b) Other Equity 18 3,181.71 2,681.12Equity attributable to owners of the Company 3,219.41 2,718.82Non-controlling interests (28.96) (0.79)Total Equity 3,190.45 2,718.04LIABILITIES(1) Non-Current Liabilities(a) Financial Liabilities
(i) Borrowings 19 886.99 499.30(ii) Other financial liabilities 20 73.30 -
(b) Provisions 21 74.51 52.03(c) Deferred tax liabilities (Net) 22 12.19 18.74Total non-current liabilities 1,046.99 570.08(2) Current liabilities(a) Financial Liabilities
(i) Borrowings 23 860.50 429.13(ii) Trade payables 24
A) Total outstanding dues of Micro and Small enterprises 7.11 5.09B) Total outstanding dues of others 618.82 639.25
(iii) Other financial liabilities 25 121.92 292.19(b) Other current liabilities 26 105.06 87.99(c) Provisions 27 38.19 32.39(d) Current Tax Liabilities (Net) 33(10) - 3.61
Total current liabilities 1,751.60 1,489.66TOTAL EQUITY AND LIABILITIES 5,989.05 4,777.79The accompanying notes form an integral part of these Consolidated financial statements. 1-33
For and on behalf of the Board Chirayu Amin Paresh Saraiya Chairman & CEODIN: 00242549
Director DIN: 00063971
R. K. Baheti Charandeep Singh SalujaDirector Finance & CFODIN: 00332079
Company Secretary
As per our report of even dateFor K. S. Aiyar & Co. Chartered Accountants Firm Registration No.: 100186W
Rajesh S. JoshiPartner Membership No.: 38526
Mumbai, 22nd May, 2020 Vadodara, 22nd May, 2020
F-8
Consolidated Statement of Profit and Loss for the year ended 31st March, 2020
` in Crores
Particulars Note No
For the year ended
31st March, 2020
For the year ended
31st March, 2019
I Revenue from Operations 28 4,605.75 3,934.68
II Other Income 29 4.94 9.38
III Total Income 4,610.69 3,944.06
IV ExpensesCost of Materials Consumed 30 979.05 850.04Purchase of Stock-in-Trade 270.93 234.93Changes in Inventories of Finished Goods, Stock-in-Trade and Work in Progress 30 (210.59) (92.27)Employee Benefits Expense 31 906.44 746.69Finance costs 27.16 18.41Depreciation and Amortization expense 6 & 7 157.32 115.23Other Expenses 32 1,436.89 1,321.71Total Expense (IV) 3,567.22 3,194.74
V Profit/(loss) before exceptional items and tax (III-IV) 1,043.47 749.32
VI Exceptional Item 43.65 -
VII Profit Before Tax (V-VI) 999.82 749.32
VIII Tax Expense 33(10)(i) Current Tax 204.57 178.14(ii) Deferred Tax (4.30) (17.29)(iii) Short/Excess Tax Provision (1.09) (4.10)
IX Profit after Tax Before Share of Profit of Associate and Joint Ventures (VII-VIII)
800.64 592.57
X Share of Profit/(Loss) of an associate and a joint venture 0.05 (9.28)
XI Profit for the period before Non controlling Interest (IX+X) 800.70 583.29
XII Non- controlling Interest 28.12 1.08
XIII Profit for the period attributable to Owners of the Company 828.82 584.37
XIV Other Comprehensive IncomeA Items that will not be reclassified to Profit and Loss(i) Re-measurements of post-employment benefit obligations (11.42) (2.47)(ii) Income tax relating to Re-measurements of post-employment benefit obligations 1.97 0.53
(9.46) (1.93)B Items that will be reclassified to Profit or Loss(i) Exchange differences in translating the financial statements of a foreign operations 7.64 7.76
7.64 7.76Total Other Comprehensive Income (A+B) (1.82) 5.83
XV Total Comprehensive Income for the year (XI+XIV) 798.88 589.12Other Comprehensive Income for the year Attributable to:(i) Non- controlling Interest (0.05) (0.01)(ii) Owners of the Company (1.77) 5.84Total Comprehensive Income for the year Attributable to:(i) Non- controlling Interest (28.17) (1.09)(ii) Owners of the Company 827.05 590.21
XVI Earnings per equity share (FV ` 2/- per share):Basic & Diluted (in `) 33(1) 43.97 31.00
The accompanying notes form an integral part of these Consolidated financial statements. 1-33
As per our report of even date For and on behalf of the Board For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh SalujaPartner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Mumbai, 22nd May, 2020 Vadodara, 22nd May, 2020
F-9
A. Equity Share CapitalParticulars No of Shares ` in Crores
Equity shares of ` 2/- each issued, subscribed and fully paidBalance at 1st April, 2018
Equity shares of ` 2/- each 18,85,15,914 37.70
Changes in equity share capital during the year - -
Balance at 31st March, 2019 18,85,15,914 37.70
Balance at 1st April, 2019
Equity shares of ` 2/- each 18,85,15,914 37.70
Changes in equity share capital during the year - -
Balance at 31st March, 2020 18,85,15,914 37.70
B. Other Equity` in Crores
Particulars
Reserve & Surplus OCI Attributable to owners of Parent
Company
Non-controlling
interests
Total
Capital Reserve
General Reserve
Debenture Redemption
ReserveRetained earnings
Foreign Currency
Translation reserve
Balance at 1st April, 2018 (I) 0.30 1,237.12 937.00 8.03 2,182.44 0.31 2,182.75
Other Comprehensive Income (1.92)* 7.76 5.84 (0.01) 5.83
Profit for the period 584.37 584.37 (1.08) 583.29
Total Comprehensive Income for the year (II)
- - - 582.45 7.76 590.21 (1.09) 589.12
Dividends paid including Tax on Dividend (90.91) (90.91) (90.91)
Reversal of Deferred Tax Asset (0.62) (0.62) (0.62)
Provision for debenture redemption 41.67 (41.67) - -
Profit transferred to General Reserve 100.00 (100.00) - -
Transaction for the year (III) - 99.38 41.67 (232.57) - (91.53) - (91.53)
Balance at 31st March, 2019 (I+II+III) 0.30 1,336.50 41.67 1,286.87 15.79 2,681.12 (0.79) 2,680.33
Balance at 1st April, 2019 (I) 0.30 1,336.50 41.67 1,286.87 15.79 2,681.12 (0.79) 2,680.33
Other Comprehensive Income (9.41)* 7.64 (1.77) (0.05) (1.82)
Profit for the period 828.82 828.82 (28.12) 800.70
Total Comprehensive Income for the year (II)
- - - 819.41 7.64 827.05 (28.17) 798.88
Dividends paid including Tax on Dividend (325.97) (325.97) (325.97)
Reversal of Deferred Tax Asset (0.49) (0.49) (0.49)
Transfer to General Reserve (0.30) 0.30 - -
Provision for debenture redemption 41.67 (41.67) - -
Profit transferred to General Reserve 200.00 (200.00) - -
Transaction for the year (III) (0.30) 199.81 41.67 (567.64) - (326.47) - (326.47)
Balance at 31st March, 2020 (I+II+III) - 1,536.30 83.33 1,538.64 23.43 3,181.71 (28.96) 3,152.75
Note:*Represents remeasurements of the defined plans.
The accompanying notes are an integral part of the Consolidated financial statements (note 1-33).
For and on behalf of the Board Chirayu Amin Paresh Saraiya Chairman & CEODIN: 00242549
Director DIN: 00063971
R. K. Baheti Charandeep Singh SalujaDirector Finance & CFODIN: 00332079
Company Secretary
As per our report of even dateFor K. S. Aiyar & Co. Chartered Accountants Firm Registration No.: 100186W
Rajesh S. JoshiPartner Membership No.: 38526
Mumbai, 22nd May, 2020 Vadodara, 22nd May, 2020
Consolidated Statement of Changes in Equity
F-10
Consolidated Cash Flow Statement for the year ended 31st March, 2020
` in Crores
Particulars
For the year ended
31st March, 2020
For the year ended
31st March, 2019
A CASH FLOW FROM OPERATING ACTIVITIES:Net Profit before tax 999.82 749.32
Adjustments for:
Depreciation and Amortisation 157.32 115.23
Interest charged 27.16 18.41
Interest Income (1.73) (2.58)
Dividend Income /Gain on Sale of Investments (0.93) (2.12)
Unrealised foreign exchange gain (net) 15.95 (23.83)
Provision / write off for doubtful trade receivables 8.55 16.69
Impairment goodwill and other intangible assets 53.71
Impairment in value of investments (net) 33.65 -
Sundry balances written Back (net) (2.82) (0.58)
Remeasurement of Defined benefit obligations (11.42) (2.47)
Loss/(Profit) on sale of Asset (1.16) (1.18)
Operating Profit before change in working capital 1,278.09 866.88
Working capital changes:
(Increase) In Inventories (220.27) (233.33)
(Increase)/Decrease In Trade Receivables (358.26) 36.19
(Increase)/Decrease In Other Assets (18.95) 175.13
(Decrease) In Trade Payables (21.11) (50.31)
Increase /(Decrease) In Other Liabilities (2.52) 177.09
Increase In Provisions 28.27 6.79
Cash generated from operations 685.24 978.45
Direct taxes paid (Net of refunds) (236.11) (166.48)
Net Cash inflow from Operating Activities (A) 449.13 811.96
B CASH FLOW FROM INVESTING ACTIVITIES:Proceeds from Sale Asset 0.60 1.28
Government assistance - 17.15
Interest received 1.73 2.58
Dividend Income /Gain on Sale of Investments received 0.93 2.12
Purchase of property, plant & equipments, intangible assets and Capital Advance (672.65) (653.93)
Investment in Associate - (14.36)
Intangible assets under development (62.25) (110.44)
Net Cash inflow from Investing Activities (B) (731.63) (755.60)
F-11
Consolidated Cash Flow Statement for the year ended 31st March, 2020
` in Crores
Particulars
For the year ended
31st March, 2020
For the year ended
31st March, 2019
C CASH FLOW FROM FINANCING ACTIVITIES:Proceeds from borrowings 378.02 603.70
Repayment of borrowings (200.00) (604.39)
Net increase / (decrease) in working capital demand loans 431.37 221.35
Payment of lease liabilities (17.49) -
Increase in Restricted Bank Balances other than Cash & Cash Equivalents (0.02) (0.38)
Dividends paid (including distribution tax) (325.97) (90.91)
Interest and other finance costs (including borrowing cost capitalised) (111.06) (70.34)
Net Cash inflow from Financing Activities (C) 154.85 59.04
I Net (decrease)/increase in cash and cash equivalents (A+B+C) (127.64) 115.40
II. a) Cash and cash equivalents at the beginning of the Year 199.07 83.74
b) Effect of exchange differences on restatement of foreign currency cash and cash equivalents 0.41 (0.07)
III. Cash and cash equivalents at the end of the Year (I+II) 71.84 199.07
IV. Cash and cash equivalents at the end of the YearBalances with Banks 71.48 198.84
Cash on hand 0.36 0.23
Cash and cash equivalents 71.84 199.07
The accompanying notes are an integral part of the Consolidated financial statements (note 1-33).
As per our report of even date For and on behalf of the Board For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh SalujaPartner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Mumbai, 22nd May, 2020 Vadodara, 22nd May, 2020
F-12
Notes to the Consolidated Financial Statements as on 31st March, 2020
1 General information Alembic Pharmaceuticals Limited is in the business of development, manufacturing, and marketing of Pharmaceuticals products. The Company is the public limited Company domiciled in India and is incorporated under the provision of the Companies Act applicable in India. Its shares are listed on the two recognised Stock Exchanges in India. The registered office of the Company is located at Alembic Road, Vadodara – 390 003, India.
The consolidated financial statements are approved by the company’s board of directors on May 22, 2020.
The Financial Statement of the subsidiaries, associates and Joint Venture used in the consolidation is drawn up to the same reporting date as that of the Alembic Pharmaceuticals Limited (“the Holding Company”), namely 31st March, 2020.
2 Significant accounting policiesStatement of compliance The Group has prepared its consolidated financial statements for the year ended March 31, 2020 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) together with the comparative period data as at and for the year ended March 31, 2019.
Principles of Consolidation: The Consolidated Financial Statements consist of Alembic Pharmaceuticals Limited (“the Holding Company”) and its subsidiaries (collectively referred to as “the Group”), associates and Joint Venture. The Consolidated Financial Statements have been prepared on the following basis:
The financial statements of the Holding Company and its subsidiaries have been consolidated on a line-by-line basis by adding together the book values of
like items of assets, liabilities, income and expenses, after eliminating intra-group balances and intra-group transactions resulting in unrealised profits as per Ind As 110 “Consolidated Financial Statements” specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules, 2015.
Investment and share of profit of associate and Joint Venture have been consolidated as per the equity method as per Ind AS 28 – “Investments in Associates” and “Ind AS 111 Joint Arrangements” respectively specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules 2015.
For the purposes of presenting these consolidated financial statements, the assets and liabilities of Group’s foreign operations, are translated to the Indian Rupees at exchange rates at the end of each reporting period. The income and expenses of such foreign operations are translated at the average exchange rates for the period. Resulting foreign currency differences are recognised as Foreign Currency Translation Reserve through other comprehensive income.
The Group accounts for its share of post-acquisition changes in net assets of associates, after eliminating unrealised profits resulting from transactions between the Group and its associates to the extent of its share, through its Consolidated Statement of Profit and Loss and Other Comprehensive Income, if any, to the extent such change is attributable to the associates’ Statement of Profit and Loss and through its reserves, if any, for the balance.
Change in Owenership interest Changes in the Group’s ownership interest in subsidiaries that do not result in the group losing control over the subsidiaries are accounted for as equity transactions.
F-13
Notes to the Consolidated Financial Statements as on 31st March, 2020
3 Companies Included in Consolidation:
NameCountry of Incorporation Nature Proportion of Ownership Interest As on 31.03.2019
Alembic Global Holding SA (AGH SA) Switzerland Subsidiary 100% subsidiary of Alembic Pharmaceuticals Limited India. (APL)
Alembic Pharmaceutical Inc.(AP Inc) U.S.A Subsidiary 100% Subsidiary of Alembic Pharmaceuticals Limited - from 17.03.2020 and ceases to be Subsidiary of Alembic Global Holding SA from said date
Aleor Dermaceuticals Limited India Subsidiary 60% subsidiary of APL
Incozen Therapeutics Pvt Limited India Associate 50% shareholding of APL
Alembic Pharmaceuticals Australia Pty Ltd Australia Subsidiary
100% subsidiary of AGH SA
Alembic Pharmaceuticals Europe Limited Malta Subsidiary
Alnova Pharmaceuticals SA Switzerland Subsidiary
Alembic Pharmaceuticals Canada Ltd Canada Subsidiary
Genius LLC Ukraine Subsidiary
Orit Laboratories LLC USASubsidiary 100% subsidiary of AP Inc.
Okner Realty LLC USA
Alembic Mami SPA Algeria Joint Venture 49% shareholding of AGH SA
Rhizen Pharmaceuticals SA (RP SA) Switzerland Associate 50% shareholding of AGH SA
Dahlia Theraputics SA Switzerland Subsidiary of Associate 100% subsidiary of RP SA
Rhizen Pharmaceuticals Inc USA
4. Significant Accounting Policies: The accounting policies of the parent company and that of its subsidiaries, associates and joint venture are similar andas per generally accepted accounting principles in India please refer page no. 95.
5. Translation of Accounts: In Consolidated Financial Statements, the Financial Statements of subsidiary companies and proportionateshare of associates and Joint Venture have been translated into INR as prescribed under Ind AS 21 “the Effects ofChanges in Foreign Exchange Rates” specified under Section 133 of the Companies Act 2013 read with Companies(Accounts) Rules 2015.
F-14
Notes to the Consolidated Financial Statements as on 31st March, 2020
6. Property, Plant and Equipment (PPE):` in Crores
Property, Plant and Equipment
Free Hold Land
Lease Hold Land Buildings
Plant & Equipment
R&D Equipment
Furniture & Fixtures Vehicles
Office Equipments
Right to Use
Building # Total
Gross Carrying amount
Carrying Amount as at 1st April 2018
53.31 18.58 287.77 582.66 195.15 16.73 12.13 6.21 1,172.56
Additions 29.62 1.77 22.03 171.09 45.03 4.42 2.45 0.78 277.19
Disposals - - - (0.33) - (0.02) (0.01) (0.07) (0.43)
Foreign Exchange Adjustments 0.06 - 0.51 (0.10) - 0.00 - 0.00 0.47
Closing Gross Carrying Amount 83.00 20.35 310.31 753.32 240.18 21.14 14.57 6.92 1,449.78
Accumulated Depreciation - 10.72 31.99 159.49 33.34 2.98 5.22 1.81 245.53
Depreciation charge during the year - 0.21 12.92 66.50 21.78 1.94 1.67 1.13 106.14
Disposals - - - (0.25) - (0.00) (0.00) (0.04) (0.30)
Foreign Exchange Adjustments - - 0.00 (0.05) - 0.05 - (0.00) 0.00
Closing Accumulated Depreciation - 10.92 44.91 225.69 55.12 4.97 6.88 2.89 351.38
Net Carrying Amount as at 1st April, 2018
53.31 7.87 255.79 423.17 161.82 13.75 6.91 4.40 927.02
Net Carrying Amount as at
31st March, 2019
83.00 9.43 265.40 527.63 185.07 16.16 7.68 4.03 1,098.41
Gross Carrying amount
Carrying Amount as at
1st April, 2019
83.00 20.35 310.31 753.32 240.18 21.14 14.57 6.92 - 1,449.78
Additions 7.76 - 137.62 270.22 47.98 7.52 2.21 3.97 92.43 569.72
Disposals - - - - - - (0.72) - - (0.72)
Foreign Exchange Adjustments 0.13 - 0.72 0.39 - 0.10 - (0.06) - 1.28
Closing Gross Carrying Amount 90.89 20.35 448.65 1,023.93 288.17 28.75 16.06 10.83 92.43 2,020.06
Accumulated Depreciation
As at 1st April, 2019 - 10.92 44.91 225.69 55.12 4.97 6.88 2.89 - 351.38
Depreciation charge during the year - 0.23 15.26 82.40 27.83 1.63 1.72 1.29 13.37 143.74
Disposals - - - - - - (0.09) - - (0.09)
Foreign Exchange Adjustments - - 0.05 0.04 - 0.05 - (0.02) - 0.13
Closing Accumulated Depreciation - 11.15 60.22 308.13 82.95 6.66 8.51 4.16 13.37 495.16
Net Carrying Amount as at 1st April, 2019
83.00 9.43 265.40 527.63 185.07 16.16 7.68 4.03 - 1,098.41
Net Carrying Amount as at 31st March, 2020
90.89 9.21 388.43 715.80 205.22 22.09 7.55 6.67 79.06 1,524.90
Note:
1 The Company does not have any restrictions on the title of its property, plant and equipment.
2 Sales proceeds are deducted from gross cost where cost is unascertainable.
3 #Please Refer Note No 2(2.20) & 33 (22).
F-15
Notes to the Consolidated Financial Statements as on 31st March, 2020
7. Goodwill and Other Intangible Assets` in Crores
Goodwill Other Intangible Assets
As at 31st March, 2020
As at 31st March, 2019
As at 31st March, 2020
As at 31st March, 2019
Carrying Amount 4.20 3.94 68.58 65.95
Addition 1.51 - 31.30 -
Foreign Exchange Adjustments 0.39 0.26 6.38 2.62
Closing Gross Carrying Amount 6.10 4.20 106.26 68.58
Accumulated Amortisation (0.60) (0.17) (12.14) (3.37)
Amortisation expense (0.43) (0.42) (13.15) (8.66)
Impairment (4.69) - (49.02) -
Foreign Exchange Adjustments (0.39) (0.01) (5.01) (0.12)
Closing Accumulated Amortisation (6.10) (0.60) (79.32) (12.14)
Net Carrying Amount - 3.61 26.94 56.43
8. Non-Current Financial Investment ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Investments in Preference Shares
Valued at Amortised cost
1% Cumulative Redeemable Non-Convertible Preference Shares 4,50,000 (PY: 4,50,000) of ` 10 each fully paid up in EICL (Redemption date 14.12.2031)
0.45 0.45
0.45 0.45
9. Investment accounted for using Equity Method ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Investments in Equity Instruments -Unquoted
Valued at Cost
(i) Investment in Associates
10,00,000 (PY: 10,00,000) equity shares of ` 10 each at a premium of ` 20 each fully paid up in Incozen Therapeutics Pvt. Ltd
1.68 1.65
Add Share in Profit / (loss) for the period (0.07) 0.03
a 1.61 1.68
62,000 (PY: 62,000) equity shares of CHF 1 each fully paid up in Rhizen Pharmaceuticals SA (Including ` 14.18 Crores Good will)
14.13 14.69
Add Share in Profit / (loss) for the period 0.12 0.10
Add Impact of Foreign Currency translations 1.30 -0.66
b 15.56 14.13
(ii) Investment in Joint Venture
34,297 (PY: 34,297) equity shares of DZD 1000 each fully paid up representing 49% of equity in Alembic Mami SPA, Algeria
32.50 39.19
Add /(Less): Share in Profit / (loss) for the period - (9.40)
Add/(Less):Provision for impairment Loss (33.65)
Add/(Less):Impact of Foreign Currency translations 1.15 2.71
c - 32.50
Aggregate amount of unquoted Investments (a+b+c) 17.17 48.31
F-16
Notes to the Consolidated Financial Statements as on 31st March, 2020
10. Other Non-Current Assets ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Capital Advances 47.72 14.85
Balance with Government Authorities 62.94 46.73
110.66 61.59
11. Inventories (Refer note No. 4)
` in Crores
As at 31st March, 2020
As at 31st March, 2019
Raw Materials 294.09 300.24
Packing Materials 52.19 46.67
Work-in-Process 55.43 50.02
Finished Goods 674.29 415.67
Stock-in-trade 72.42 102.34
Goods in Transit 18.19 41.71
Stores and Spares 20.93 10.62
1,187.53 967.26
Note:
(i) Out of above Inventories of Alembic Pharmaceuticals Limited are hypothecated as security for borrowings.
12. Trade Receivables ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Unsecured, Considered good a 864.75 488.92
Trade Receivables which have significant increase in credit Risk 19.89 10.44
Less Allowance for doubtful debts (expected credit loss allowance) 19.89 10.44
b - -
(a+b) 864.75 488.92
Note:Out of above Receivables of Alembic Pharmaceuticals Limited are hypothecated as security for working capital borrowings.Refer Note No 33 (8) (I) for related party receivable.
13 Cash and Cash Equivalents ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Balances with Banks 71.48 198.84
Cash on hand 0.36 0.23
71.84 199.07
14. Bank Balances Other than Cash and Cash Equivalents ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Earmarked Balance with Bank
Unpaid Dividend Account 7.12 4.79
Margin Money Deposit Account 1.78 1.76
8.91 6.55
F-17
Notes to the Consolidated Financial Statements as on 31st March, 2020
15. Other Financial Assets (Current) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Security Deposits 8.65 9.10
8.65 9.10
Refer note No 33(8)(I) for Related Party Deposits.
16. Other Current Assets (Unsecured, considered good) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Advance to Employees 7.84 5.60
Advance to Suppliers 78.44 86.88
Pre-paid Expense 28.10 18.24
Balances with Government Authorities 175.70 176.14
290.08 286.86
17. Equity Share Capital ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Authorized
20,00,00,000 - Equity shares of ` 2/- each 40.00 40.00
Shares issued, subscribed and fully paid
18,85,15,914 - Equity shares of ` 2/- each 37.70 37.70
37.70 37.70
Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period
` in Crores
Particulars
As at 31st March, 2020 As at 31st March, 2019
Numbers ` in Crores Numbers ` in Crores
At the beginning of the year 18,85,15,914 37.70 18,85,15,914 37.70
Outstanding at the end of the year 18,85,15,914 37.70 18,85,15,914 37.70
The rights, preferences and restrictions including restrictions on the distribution of dividends and the repayment of capitalThe company is having only one class of shares i.e. Equity carrying a nominal value of ` 2/- per share Every holder of the equity share of the Company is entitled to one vote per share held. In the event of liquidation of the Company, the equity shareholders will be entitled to receive remaining assets of the Company after the distribution / repayment of all creditors. The distribution to the equity shareholders will be in proportion of the number of shares held by each shareholder.
The Company declares and pays dividend on the equity shares in Indian Rupees. Dividend proposed by the Board of Directors is subject to approval of the shareholders at the ensuing Annual General Meeting, except in case of interim dividend.
Shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held
Particulars
As at 31st March, 2020 As at 31st March, 2019
Numbers % held Numbers % held
1 Alembic Limited 5,55,51,528 29.47% 5,55,51,528 29.47%
2 Nirayu Limited* 7,00,35,435 37.15% 4,93,36,655 26.17%
3 Shreno Limited* 100 0.00% 2,06,98,780 10.98%
* Pursuant to the Order passed by the Hon’ble National Company Law Tribunal, Ahmedabad Bench dated 26th July, 2019 in the matter of Composite Scheme of Arrangement between Alembic Limited, Shreno Limited and Nirayu Private Limited, the equity shares held by Shreno Limited in the Company are transferred to Nirayu Private Limited. Further, Nirayu Private Limited has been converted into a Public Limited company and its name has been changed to Nirayu Limited pursuant to the Certificate of Incorporation dated 3rd October, 2019 issued by the Registrar of Companies, Gujarat in this regard.
F-18
Notes to the Consolidated Financial Statements as on 31st March, 2020
18. Other Equity(Refer statement of changes in equity for detailed movement in other equity balance)
` in Crores
As at 31st March, 2020
As at 31st March, 2019
(a) Capital Reserve - 0.30
(b) General Reserve 1,536.30 1,336.50
(c) Retained Earnings 1,538.64 1,286.87
(d) Debenture Redemption Reserve 83.33 41.67
(e) Foreign Currency Translation reserve 23.43 15.79
Total Other Equity 3,181.71 2,681.12
Nature and purpose of each ReserveCapital Reserve:- Capital Reserve was created on receipt of Government subsidy for setting up factory in backward area, transferred to general reserve in current year.
General Reserve:- The reserve is created by transfer of a portion of the net profit.
Debenture redemption reserve: Debenture redemption reserve : The company has created and continue to create debenture redemption reserve out of the profits as prudent practice in accordance with erstwhile provision of Companies Act, 2013.
Foreign Currency Translation reserve:- Exchange differences relating to the translation of the results and net assets of the Group’s foreign operations from their functional currencies to the Group’s presentation Currency (i.e.INR) are recognised in the other comprehensive income and accumulated in foreign currency translation reserve.
19. Borrowings (Non-Current) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Unsecured
From BanksTerm Loan 387.53 -
Non-Convertible debentures 499.46 499.30
886.99 499.30
(i) Maturity profile and rate of interest of term loan and non-convertible debentures are set out as below:
Particulars Term Loan
External Commercial Borrowings
Non-Convertible debentures
Effective Rate of Interest spread of 1.70%
over 1 year G-sec
with annual
interest reset
6M LIbor + 1.25% 8.42% to 9.05%
Maturity profile2021-22 - - ` 300.00 Crores
2022-23 ` 200.00 Crores $ 8.33 Million ` 200.00 Crores
2023-24 - $ 8.33 Million -
2024-25 - $ 8.34 Million -
Total ` 200.00 Crores $ 25.00 Million ` 500.00 Crores
Total Equivalent INR as on 31.3.2020 ` 200.00 Crores ` 188.75 Crores ` 500.00 Crores
Amortised Cost Adjustment - (` 1.22 Crores) (` 0.54 Crores)
Closing Balance ` 200.00 Crores ` 187.53 Crores ` 499.46 Crores
(ii) Term loan of ` 200.00 Crores classified as current in previous year paid during the year - Interest @ rate of six monthsT Bills plus spread of 87 bps (Refer Note No 25).
F-19
Notes to the Consolidated Financial Statements as on 31st March, 2020
20. Other Financial Liabilities ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Lease Liability (Refer Note No. 33(22) 73.30 -
73.30 -
21. Provisions (Non-Current) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Provision for Employee Benefits (Refer Note No. 33(4))
Provision for Gratuity 0.77 0.36
Provision for Leave benefits 31.73 23.74
Provision for Non-Saleable return of goods (Refer Note No. 33(14)) 42.01 27.93
74.51 52.03
22. Deferred Tax Liabilities (Net) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Deferred Tax LiabilitiesDepreciation a 160.25 140.86
Deferred Tax AssetsProvision for Doubtful debts 0.78 0.74
MAT Credit Entitlement 91.57 78.40
Intangible Asset 1.47 1.96
Others 54.25 41.03
b 148.06 122.12
(a-b) 12.19 18.74
23. Borrowings (Current) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Loans repayable on demand
From Banks
Secured
Working Capital Demand Loan 0.04 34.93
First charge on Pari-Passu basis by hypothecation of Inventory and Trade Receivables at interest rate ranging between 7% to 10% repayable on demand
Unsecured
Working Capital Demand Loan, (Interest @ 3-month LIBOR plus 100 bps) 60.46 69.15
Overdraft facility @ 6 month MCLR - 75.05
Working Capital Demand Loan, Interest rate vary in range from 6.75% to 7.75% 250.00 -
From Other Parties
Unsecured
Commercial Paper 550.00 250.00
Carrying interest rate ranging between 5.50% to 5.98%, Repayable in April 20 & June 20
860.50 429.13
F-20
Notes to the Consolidated Financial Statements as on 31st March, 2020
24. Trade Payables ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Due to Micro and Small Enterprises (Refer Note No. 33(13)) 7.11 5.09
Others 618.82 639.25
625.93 644.34
Refer Note No. 33(8)(I) for Related Party Payables.
25. Other Financial Liabilities ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Current maturities of long-term debt (Refer Note No. 19) - 200.00Lease Liability (Refer Note No. 33(22) 9.90 -Payables on purchase of property, plant and equipment 46.64 57.98Interest accrued but not due on borrowings 10.78 11.46Unpaid dividends 7.12 4.79Trade Deposits 11.98 11.84Unpaid / Unclaimed matured deposits and interest accrued thereon 0.06 0.06Unrealised Foreign Exchange Loss 35.44 6.07
121.92 292.19
26. Other Current Liabilities ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Statutory dues 41.89 21.35
Advance from Customers 6.49 3.65
Employee benefits payables 56.68 62.99
105.06 87.99
27. Provisions (Current) ` in Crores
As at 31st March, 2020
As at 31st March, 2019
Provision for Employee Benefits (Refer Note No. 33(4)&(5))
Provision for Gratuity 10.39 4.07
Provision for Leave benefits 2.37 7.42
Others 4.53 -
Provision for Non-Saleable return of goods (Refer Note No. 33(14)) 20.91 20.90
38.19 32.39
28. Revenue from Operations ` in Crores
For the year ended
31st March, 2020
For the year ended
31st March, 2019
Sale of products- Domestic 1,585.86 1,500.02- Exports 2,906.12 2,306.60
4,491.97 3,806.61
Other Operating Revenues- Export Incentives 78.98 88.20- Royalty 20.85 32.28- Miscellaneous 13.95 7.59
4,605.75 3,934.68
F-21
Notes to the Consolidated Financial Statements as on 31st March, 2020
29. Other Income ` in Crores
For the year ended
31st March, 2020
For the year ended
31st March, 2019
Dividend 0.01 2.12
Insurance Claims 1.10 1.68
Lease Rent Income 0.02 0.03
Profit /(Loss) on Sales of Assets 1.16 1.18
Profit on Sales of Investment 0.92 1.57
Interest Income 1.73 2.58
Miscellaneous income - 0.20
4.94 9.38
30. Cost of Material Consumed ` in Crores
For the year ended
31st March, 2020
For the year ended
31st March, 2019
Inventory at the beginning of the year 346.90 210.01
Add: Purchases 975.31 986.94
1,322.21 1,196.95
Less: Inventory at the end of the year 343.16 346.90
979.05 850.04
Changes in inventories of Finished Goods, Stock in Trade and Work in processWork in Process 55.43 50.02
Finished Goods 692.48 457.37
Stock-in-Trade 72.42 102.34
Inventory at the end of the year a 820.32 609.74
Work in Process 50.02 51.92
Finished Goods 457.37 354.88
Stock-in-Trade 102.34 110.66
Inventory at the beginning of the year b 609.74 517.46
(b-a) (210.59) (92.27)
31. Employee Benefits Expense ` in Crores
For the year ended
31st March, 2020
For the year ended
31st March, 2019
Salaries and Wages 831.77 688.68
Contribution to Provident and other funds 50.89 37.41
Staff welfare expense 23.78 20.60
906.44 746.69
F-22
Notes to the Consolidated Financial Statements as on 31st March, 2020
32. Other Expenses ` in Crores
For the year ended
31st March, 2020
For the year ended
31st March, 2019
Consumption of Stores, Spares, Laboratory Material and Analytical Expense 257.16 181.00
Power and Fuel 102.40 88.86
Manufacturing and Labour Charges 17.56 19.68
Repairs and Maintenance
Machinery 32.10 24.79
Buildings 10.08 8.34
Others 8.87 5.17
Freight and Forwarding Charges 133.17 119.64
Sales Promotion, Service Fees and Commission 398.02 470.64
Excise Duty - -
Rent (Refer Note No. 33(22)) 2.29 17.33
Rates and Taxes 12.60 10.23
Insurance 7.50 6.13
Travelling Expense 131.80 133.96
Communication Expenses 36.91 34.39
Legal & Professional Fees 109.23 93.45
Payment to Auditors (Refer Note No. 33(9)) 1.48 1.10
Exchange Difference (net) (8.46) (17.48)
impairment of goodwill and other intangible assets 53.71 -
Bad Debts written off 0.48 13.25
Less: Bad Debts Provision Utilised (0.48) (0.30)
Provision for Doubtful Debts 8.55 3.74
Expenses on CSR Activities 13.29 14.28
Donation 0.52 0.60
Patent Filing & Registration Fees 38.01 43.97
External Research & Development 42.64 30.27
Miscellaneous Expenses 27.46 18.66
1,436.89 1,321.71
33. Other explanatory Notes to the Consolidated Financial Statement ` in Crores
For the year ended
31st March, 2020
For the year ended
31st March, 2019
1 Earning Per Share (EPS)
a) Net Profit after non-controlling interest attributable to equity shareholders (` in Crores) 828.82 584.37
b) Weighted average numbers of equity shares 18,85,15,914 18,85,15,914
c) Basic and diluted Earnings per share before Extra-Ordinary Items in ` 43.97 31.00(Face Value per share ` 2/- each)
F-23
Notes to the Consolidated Financial Statements as on 31st March, 2020
` in Crores
As at 31st March, 2020
As at 31st March, 2019
2 Contingent Liabilities and Commitments (To The Extent Not Provided For)i Estimated amount of contracts net of advances remaining to be executed on capital
accounts 269.18 156.90
ii Contingent liabilities
(a) Letters of credit and Guarantees 113.40 94.73
(b) Liabilities Disputed in appeals
Excise duty 0.24 5.35
Sales Tax 3.43 3.18
(c) Claims against the company not acknowledged as debt 0.35 0.37
(d) Export obligation against advance licence 0.03 -
(e) Disputed liability in respect of Ministry of Industry, Department of Chemicals andPetrochemicals in respect of price of Rifampicin allowed in formulations and landedcost of import.
0.35 0.35
3 Additional InformationAs at and for the year ended 31st March, 2020
` in Crores
Particulars
Net Assets (Total Assets - Total Liabilities) Share in Profit or Loss
Share in Other Comprehensive income
Share in Total Comprehensive income
As a % of consolidated
net assets Amount
As % of consolidated profit or loss Amount
As % of consolidated
othercomprehensive
income Amount
As % of consolidated
total comprehensive
income Amount
Parent: Alembic Pharmaceuticals Limited 104.88% 3346.02 116.96% 969.40 528.18% (9.33) 116.08% 960.08
Subsidiaries:1. Indian:
Aleor Dermaceuticals Limited (2.27%) (72.34) (8.48%) (70.30) 7.34% (0.13) (8.52%) (70.43)
2. Foreign:
- Alembic Global Holding SA 0.58% 18.35 5.38% 44.55 (499.00%) 8.81 6.45% 53.37
- Alembic Pharmaceuticals, INC 1.75% 55.88 0.74% 6.15 (117.80%) 2.08 1.00% 8.24
(Wholly owned subsidiary of Alembic Pharmaceuticals Limited)
Minority interest in all subsidiaries (0.91%) (28.96) 3.39% 28.12 (2.94%) 0.05 3.41% 28.17
Associates: (Investment as per the equity method)
1. Indian: Incozen Therapeutics PvtLimited
(0.04%) (1.39) (0.01%) (0.07) Nil Nil (0.01%) (0.07)
2. Foreign: NA Nil Nil Nil Nil Nil Nil Nil Nil
Joint Venture: (As per proportionate consolidation / investment as per equity method)
1. Indian: NA Nil Nil Nil Nil Nil Nil Nil Nil
2. Foreign: NA Nil Nil Nil Nil Nil Nil Nil Nil
Intercompany Elimination and Consolidation Adjustments
(3.98%) (127.11) (17.98%) (149.05) 184.23% (3.25) (18.42%) (152.30)
100.0% 3190.45 100.0% 828.82 100.0% (1.77) 100.0% 827.05
F-24
Notes to the Consolidated Financial Statements as on 31st March, 2020
As at and for the year ended 31st March, 2019
` in Crores
Particulars
Net Assets (Total Assets - Total Liabilities) Share in Profit or Loss
Share in Other Comprehensive income
Share in Total Comprehensive income
As a % of consolidated
net assets Amount
As % of consolidated profit or loss Amount
As % of consolidated
othercomprehensive
income Amount
As % of totalcomprehensive
income Amount
Parent:Alembic Pharmaceuticals Limited 99.79% 2712.41 104.59% 611.21 (32.60%) (1.90) 103.24% 609.30
Subsidiaries:1. Indian: A G Research Pvt Ltd. 0.00% 0.0 0.00% - 0.00% 0.00 0.00% -
Aleor Dermaceuticals Limited (0.07%) (1.91) (0.46%) (2.70) (0.49%) (0.03) (0.46%) (2.73)
2. Foreign:
Alembic Global Holding SA 4.11% 111.63 (2.14%) (12.53) 136.82% 7.99 (0.77%) (4.54)
(wholly owned subsidiary of Alembic Pharmaceuticals Limited)*
Minority interest in all subsidiaries (0.03%) (0.79) 0.18% 1.08 0.20% 0.01 0.18% 1.09
Associates: (Investment as per the equity method)
1. Indian: Incozen Therapeutics PvtLimited
(0.05%) (1.32) 0.00% 0.03 Nil Nil 0.00% 0.03
2. Foreign: NA Nil Nil Nil Nil Nil Nil Nil Nil
Joint Venture: (As per proportionate consolidation / investment as per equity method)
1. Indian: NA Nil Nil Nil Nil Nil Nil Nil Nil
2. Foreign: NA Nil Nil Nil Nil Nil Nil Nil Nil
Intercompany Elimination and Consolidation Adjustments
(3.75%) (101.97) (2.18%) (12.71) (3.92%) (0.23) (2.19%) (12.94)
100.0% 2718.04 100.0% 584.37 100.0% 5.84 100.0% 590.21
4 Defined benefit plans / compensated absences - As per actuarial valuation The following table sets out the status of the gratuity plan and the amounts recognized in the Company’s financial statements as at March 31, 2020
Funded Non-funded
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
i) Change in present value of defined benefit obligation Present Value of defined benefit obligation at the beginning of
the year 50.05 39.77 0.36 0.15
Current service cost 8.65 6.73 0.26 0.17
Interest Cost 3.34 2.63 0.03 0.01
Components of actuarial gain/losses on obligations: - - - -
- Due to Change in financial assumptions 6.33 0.24 0.05 0.00
- Due to change in demographic assumption (0.04) - (0.00) -
- Due to experience adjustments 3.05 3.33 0.07 0.04
Benefits paid (4.08) (2.65) - (0.01)
Present Value of defined benefit obligation at the end of the year 67.29 50.05 0.77 0.36
F-25
Notes to the Consolidated Financial Statements as on 31st March, 2020
Funded Non-funded
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
ii) Change in fair value of plan assets
Fair Value of plan assets at the beginning of the year 45.98 31.35 - -
Expenses deducted from the fund
Interest Income 3.36 2.26 - -
Return on plan assets excluding amounts included in interest (1.97) 1.14 - -
Contributions paid by the employer 13.62 13.88 - -
Benefits paid from the fund (4.08) (2.65) - -
Fair Value of plan assets at the end of the year 56.91 45.98 - -
As at 31st March ,2020
As at 31st March ,2020
As at 31st March ,2020
As at 31st March ,2020
iii) Net asset / (liability) recognized in the Balance Sheet
Present Value of defined benefit obligation at the end of the year
(67.29) (50.05) (0.77) (0.36)
Fair Value of plan assets at the end of the year 56.91 45.98 - -
Amount recognized in the balance sheet (10.38) (4.07) (0.77) (0.36)
Net Liability - non current - - (0.77) (0.36)
Net Asset / (Liability) recognized - current (10.38) (4.07) (0.00) (0.00)
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
iv) Expense recognized in the statement of profit and lossfor the yearCurrent service cost 8.65 6.73 0.26 0.17
Net interest cost (0.02) 0.37 0.03 0.01
Total expenses included in employee benefit expenses 8.63 7.11 0.29 0.18
v) Recognized in Other Comprehensive Income for theyear
Actuarial changes arising from changes in financial assumptions
6.33 0.24 0.05 0.00
Actuarial changes arising from experience assumptions 3.05 3.33 0.07 0.04
Return on plan assets excluding amounts included in interest income
1.97 (1.14) - -
Recognized in other comprehensive income 11.35 2.43 0.12 0.04
vi) Actuarial Assumptions
Rate of Discounting 6.85% 7.35% 6.85% 7.35%
Rate of Salary Increase 5.25% 4.75% 4.75% 4.75%
Withdrawal Rates 5% at younger
ages reducing
to 1% at older
ages
5% at younger
ages reducing
to 1% at older
ages
5% at younger
ages reducing
to 1% at older
ages
5% at younger
ages reducing
to 1% at older
ages
Mortality Rate During Employment Indian Assured
Lives Mortality
(2012-14)
Indian Assured
Lives Mortality
(2006-08)
Indian Assured
Lives Mortality
(2012-14)
Indian Assured
Lives Mortality
(2006-08)
vii) Composition of the plan assets
Policy of insurance 100% 100% - -
F-26
Notes to the Consolidated Financial Statements as on 31st March, 2020
viii) Maturity profile of Defined Benefit Obligation
` in Crores
Cash Flow
Funded Non-funded
As at 31st March ,2020
As at 31st March ,2020
Year 1 11.62 0.00
Year 2 3.19 0.01
Year 3 3.23 0.03
Year 4 3.03 0.04
Year 5 3.46 0.04
Year 6 to Year 10 Cash flow 20.57 0.20
The future accrual is not considered in arriving at the above cash-flows.
Expected Contribution for the Next year (` in Crores) 10.38 0.00
Average Outstanding Terms of obligation (years) 10.97 15.68
ix) Sensitivity Analysis
Funded Non-funded
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
Delta Effect of +0.5% Change in Rate of Discounting 64.03 47.54 0.72 0.34
Delta Effect of -0.5% Change in Rate of Discounting 70.85 52.28 0.83 0.39
Delta Effect of +0.5% Change in Rate of Salary Increase 70.89 52.33 0.83 0.39
Delta Effect of -0.5% Change in Rate of Salary Increase 63.97 47.48 0.72 0.34
Delta Effect of +0.5% Change in Rate of Employee Turnover 67.30 51.04 0.78 0.36
Delta Effect of -0.5% Change in Rate of Employee Turnover 67.28 48.85 0.77 0.36
The following table sets out the non funded status of the Privilege Leave benefits and the amounts recognized in the Company’s Financial Statement as at March 31, 2020
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
i) Change in present value of defined benefit obligationPresent Value of defined benefit obligation at the beginning of the year 25.71 19.35
Current service cost 3.86 2.76
Interest Cost 1.82 1.38
Components of actuarial gain/losses on obligations:
- Due to Change in financial assumptions 3.72 0.14
- Due to change in demographic assumption (0.02) -
- Due to experience adjustments 7.40 7.61
Benefits paid (8.38) (5.54)
Present Value of defined benefit obligation at the end of the year 34.10 25.71
` in Crores
As at 31st March, 2020
As at 31st March, 2019
ii) Net asset / (liability) recognized in the Balance Sheet
Amount recognized in the balance sheet (34.10) (25.71)
F-27
Notes to the Consolidated Financial Statements as on 31st March, 2020
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
iii) Expense recognized in the statement of profit and loss for the year
Current service cost 3.86 2.76
Past service cost and loss/(gain) on
Net interest cost 1.82 1.38
Net value of remeasurements on the obligation 11.09 7.75
Total Charge to statement of profit and loss 16.77 11.89
iv) Actuarial Assumptions
Rate of Discounting 6.85% 7.35%
Rate of Salary Increase In Range of
4.75% to 5.25%
4.75%
Withdrawal Rates 5% at younger
ages reducing
to 1% at older
ages
5% at younger
ages reducing
to 1% at older
ages
Mortality Rate During Employment Indian Assured Indian Assured
Lives Mortality Lives Mortality
(2012-14) (2006-08)
v) Maturity profile of Defined Benefit Obligation
` in Crores
Cash Flow As at
31st March ,2020
Year 1 2.37
Year 2 2.25
Year 3 2.08
Year 4 1.74
Year 5 1.93
Year 6 to Year 10 Cash flow 10.32
The future accrual is not considered in arriving at the above cash-flows.
vi) Sensitivity Analysis
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
Delta Effect of +0.5% Change in Rate of Discounting 32.16 24.19
Delta Effect of -0.5% Change in Rate of Discounting 36.22 27.07
Delta Effect of +0.5% Change in Rate of Salary Increase 36.25 27.11
Delta Effect of -0.5% Change in Rate of Salary Increase 32.12 24.15
Delta Effect of +0.5% Change in Rate of Employee Turnover 34.11 26.49
Delta Effect of -0.5% Change in Rate of Employee Turnover 34.08 24.47
A description of methods used for sensitivity analysis and its limitations:Sensitivity analysis’s performed by varying single parameter while keeping all the other parameters unchanged. Sensitivity analysis fails to focus on the interrelationship between underlying parameters. Hence, the results may vary if two or more variables are changed simultaneously. The method used does not indicate anything about the likelihood of change in any parameter and the extent of the change, if any.
F-28
Notes to the Consolidated Financial Statements as on 31st March, 2020
5 Provident Fund The group is liable for any shortfall, as per terms of the Provident Fund Trust deed, in the fund assets based on the Government specified rate of return in case of Employee Benefits Plan. Such shortfall, if any, is recognised in the Statement of Profit and Loss as an expense in the year of incurring the same. ` 4.53 Crores (PY: ` Nil) short fall as at 31 March, 2020 has been provided.
6 Research and Development Expenses:
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
Material Consumption 99.38 80.58
Employees Benefit Expenses 167.84 145.61
Utilities 20.98 17.67
Depreciation 63.04 35.50
Others 293.58 224.28
Total 644.82 503.64
7 Operating SegmentThe Group Company has only one reportable segment i.e. Pharmaceuticals
Information about products and services turnover ` in Crores
a) API 707.59
b) Formulations 3,898.16
Information about Geographical Areasa) Revenue from External Customers
In India 1590.16
Outside India 3015.59
b) Non-Current Assets
In India 3495.29
Outside India 13.39
c) Information about major customers
Consolidated Revenue – exceeding 10% from each single external customer. NIL
8 Disclosures in respect of Related Parties transactions
(A) Controlling Company: Nirayu Limited (Refer note No. 17)
(B) Associate Companies:
1 Incozen Therapeutics Pvt. Limited (Associate of Alembic Pharmaceuticals Limited)
2 Rhizen Pharmaceuticals SA (Associate of Alembic Global Holding SA)
3 Dahlia Therapeutics SA (Subsidiary of Rhizen Pharmaceuticals SA)
4 Rhizen Pharmaceuticals Inc. (Subsidiary of Rhizen Pharmaceuticals SA)
(C) Joint Venture:
1 Alembic Mami SPA (Joint venture of Alembic Global Holding SA)
(D) Other Related Parties:
1 Alembic Limited 4 Viramya Packlight LLP
2 Shreno Limited 5 Shreno Publications Limited
3 Paushak Limited
F-29
Notes to the Consolidated Financial Statements as on 31st March, 2020
(E) Key Management Personnel:
1 Mr. Chirayu Amin Chairman & CEO
2 Mr. Pranav Amin Managing Director
3 Mr. Shaunak Amin Managing Director
4 Mr. R. K. Baheti Director Finance & CFO
5 Mr. K.G. Ramanathan Non-Executive Director
6 Mr. Pranav Parikh Non-Executive Director
7 Mr. Paresh Saraiya Non-Executive Director
8 Ms. Archana Hingorani Non-Executive Director
9 Mr. Charandeep Singh Saluja Company Secretary
(F) Close Member Key Management Personnel:
1 Mrs. Malika Amin 4 Mrs. Jyoti Patel
2 Mr. Udit Amin 5 Mrs. Ninochaka Kothari
3 Ms. Yera Amin 6 Mrs. Shreya Mukherjee
(G) Key Managerial Personnel Remuneration:
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
Short Term Employment Benefits 67.55 62.51
Terminal Benefits 2.19 1.86
Others 0.59 0.68
(H) Transactions with Related parties: During the year, the following transactions were carried out with related parties and relative of Key ManagementPersonnel in the ordinary course of the business:
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
(a) Sale of Goods/MEIS License (Net)
Associates
Rhizen Pharmaceutical SA 6.49 11.41
Other Related Parties 0.63 3.88
(b) Purchase of Goods
Controlling Company 0.02 -
Other Related Parties
Alembic Limited 37.15 51.59
Shreno Publications Limited 24.38 23.48
Others 0.71 2.07
(c) Reimbursement of expenses
Other Related Parties
Alembic Limited 4.33 10.50
Others 0.02 -
Associates
Rhizen Pharmaceutical SA 5.55 0.12
(d) Rent / Lease liability paid
Other Related Parties
Alembic Limited 8.74 8.21
Others 0.63 0.63
F-30
Notes to the Consolidated Financial Statements as on 31st March, 2020
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
(e) Receiving of Services
Controlling Company 0.02 -
Other Related Parties
Alembic Limited 11.08 10.75
Others 0.22 0.02
(f) Rendering of services
Associates
Rhizen Pharmaceutical SA - 0.89
(g) Purchase of Property, Plant and Equipment
Controlling Company
Nirayu Limited 18.89 -
Other Related Parties
Shreno Limited - 18.88
Paushak Limited 2.43 -
Others 0.49 -
(h) Deposit Returned
Other Related Parties
Alembic Limited - 9.92
(i) Dividend Paid
Controlling Company
Nirayu Limited 87.86 19.73
Other Related Parties
Alembic Limited 86.10 22.22
Others 20.70 8.28
Relatives to Key Management Personnel 10.73 2.79
Key Management Personnel 10.13 2.62
(j) Remuneration
Key Management Personnel 70.33 65.06
Relatives to Key Management Personnel 5.59 3.47
(I) Balance Outstanding as at the end of the year:
` in Crores
As at 31st March, 2020
As at 31st March, 2019
ReceivablesAssociate Companies: 8.35 3.86
Controlling Company 0.10 -
Joint Venture - 0.24
PayablesKey Management personnel 37.10 35.50
Relatives to Key Management Personnel 1.97 -
Other Related Parties 4.26 7.64
Deposit GivenOther Related Parties 2.48 2.48
F-31
Notes to the Consolidated Financial Statements as on 31st March, 2020
9 Auditors Fees and Expenses:
` in Crores
For the Year Ended
31st March, 2020
For the Year Ended
31st March, 2019
(a) Statutory Auditors:-
As Auditors 0.88 0.62
In Other Capacity:-
(i) Other Services
Limited Review 0.29 0.29
Others 0.15 0.11
(ii) Reimbursement of expenses 0.03 0.02
(b) Cost Auditors:-
Cost Audit Fees 0.02 0.02
(c) Tax Auditors:-
Tax Audit Fee 0.09 0.03
(d) Secretarial Auditors:-
Secretarial Audit Fee 0.03 0.02
10 Income Taxesa. Income tax expense
` In Crores
31st March, 2020 31st March, 2019
Current Tax
Current tax expense 204.57 178.14
Deferred Tax
Decrease (increase) in deferred tax assets (23.69) (39.68)
(Decrease) increase in deferred tax liabilities 19.39 22.36
Total deferred tax expenses (benefit) (4.30) (17.32)
Total Income tax expenses * 200.27 160.82
*This excludes tax benefit on other comprehensive income of ` 1.97 Crores for 31st March, 2020 & ` 0.53 Crores for 31st March,2019 respectively.
b. Reconciliation of tax expense and the accounting profit multiplied by India’s tax rate:
` in Crores
31st March, 2020 31st March, 2019
Profit before Income tax expense 999.82 749.32
Tax at the Indian Tax Rate* 174.69 161.47
Tax effect of amounts which are not deductible (taxable) in calculating taxable income
Dividend income (0.00) (0.00)
Expenditure related to exempt income 0.01 0.01
Provision for debenture redemption (7.28) (8.98)
Effect on account of overseas tax 34.53 23.77
Deferred tax (4.30) (17.32)
Others 2.63 1.86
Income Tax Expense 200.27 160.82
* The company is covered under the provisions of MAT u/s 115JB and the applicable Indian tax rate for year ended 31st March, 2020 is 17.472%and 21.5488% for 31st March, 2019.
F-32
Notes to the Consolidated Financial Statements as on 31st March, 2020
c. Current tax (liabilities)/assets
` in Crores
31st March, 2020 31st March, 2019
Opening balance (3.61) 3.45
Income tax paid 236.11 166.44
Current income tax payable for the period / year (202.61) (177.61)
Write back of income tax provision of earlier years 1.09 4.10
Net current income tax asset/ (liability) at the end 30.98 (3.61)
d. Unrecognised deferred tax assetsThe details of unrecognised deferred tax assets are summarised below:
` in Crores
As at 31st March, 2020
As at 31st March, 2019
Deductible temporary differences, net 284.36 280.59
During the year ended 31st March, 2020, the Company did not recognise deferred tax assets of ̀ 284.36 Crores on account of MAT credit entitlement, as the Company believes that utilization of same is not probable. The above MAT credit expire at various dates ranging from 2026 through 2036.
11 Financial instrumentsCategory of Financial Instrument
` In Crores
As at 31st March, 2020 As at 31st March, 2019
Fair value through profit
and loss Amortised cost
Fair value through profit
and loss Amortised cost
Financial assetsInvestment in Preference shares - 0.45 - 0.45
Trade Receivables - 864.75 - 488.92
Cash and cash equivalents - 71.84 - 199.07
Bank balances other than (iii) above - 8.91 - 6.55
Derivatives not designated as Hedge - - - -
Others - 8.65 - 9.10
Total - 954.61 - 704.10
Financial liabilitiesBorrowings - 1,747.49 - 928.44
Trade Payables - 625.93 - 644.34
Other Financial liabilities - 187.21 - 288.77
Derivatives not designated as Hedge 8.01 - 3.42 -
Total 8.01 2,560.63 3.42 1,861.55
Fair value measurement hierarchy:
As at 31st March, 2020 As at 31st March, 2019
Level of input used in Level of input used in
Level-1 Level-2 Level-3 Level-1 Level-2 Level-3
Derivatives not designated as Hedge - 8.01 - - 3.42 -
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
Level 2 inputs are inputs other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly.
Level 3 inputs are unobservable inputs for the asset or liability.
F-33
Notes to the Consolidated Financial Statements as on 31st March, 2020
In case of investment in equity instruments, cost has been considered as approximate fair value in view of materiality of value of investment.
Refer Note No 8,12,13,14,15,19.20.23,24 & 25
12 Expenses pending capitalisation included in Capital Work-In-Progress represent direct attributable expenditure for setting up of plants yet to commence commercial operation, the detail of expenses are:
` in Crores
As at 31st March, 2020
As at 31st March, 2019
Opening Balance 256.96 108.89
Capitalised during year (65.57) -
Incurred during the current year
Salaries, allowance and contribution to funds 70.12 78.75
Professional Fees 2.17 1.99
Others 96.12 67.33
Closing balance 359.80 256.96
13 Disclosure required under Micro, Small and Medium Enterprise Development Act 2006 On the basis of confirmation obtained from the supplier who are registered themselves under the Micro, Small and Medium Enterprise Development Act, 2006 (MSMED Act, 2006), details are as below.
Total Outstanding due of Micro, Small & Medium Enterprises
` in Crores
As at 31st March, 2020
As at 31st March, 2019
a The principal amount remaining unpaid to any supplier at the end of the year 13.18 * 9.20 *
b Interest due remaining unpaid to any supplier at the end of the year - -
c The amount of interest paid by the buyer in terms of section 16 , along with the amount of the payment made to the supplier beyond the appointed day during each accounting year
- -
d The amount of interest due and payable for the period of delay in making payment - -
e The amount of interest accrued and remaining unpaid at the end of each accounting year - -
f The amount of further interest remaining due and payable even in the succeeding years , until such date when the interest dues as above are actually paid to the small enterprise , for the purpose of disallowance as a deductible expenditure under section 23
- -
13.18 9.20
*Out of above, amount pertaining to Micro and Small Enterprises is ` 7.11 Crores. ( PY: ` 5.09 Crores).
14 Provision for Non-Saleable return of goods
` In Crores
As at 31st March , 2020
Balance as at 1st April, 2019 48.83
Increase during the year 35.00
Reduction during year (20.91)
Balance as at 31st March, 2020 62.92
15 Government Grant The Company is entitled to subsidy, on its investment in the property, plant and equipment on fulfilment of the conditions stated in those Scheme. During previous year company has received ` 17.15 Crores as subsidy on investment in property, plant and equipment and ` 0.06 Crores as reimbursement of expense. The same is accounted as stated in accounting policy on Government Grant ( Refer Note No 2(25)).
F-34
Notes to the Consolidated Financial Statements as on 31st March, 2020
16 Revenue Recognition The Company is engaged in Pharmaceuticals business consedering nature of products, revenue can be disaggregated as API business and Formulation business ` 707.59 Crores and ` 3,898.16 Crores respectively, and consedering Geographical business, revenue can be disaggregated as in India ̀ 1,590.16 Crores and outside India ̀ 3,015.59 Crores.
17 Borrowing cost of ` 83.21 Crores (PY: ` 60.20 Crores) capitalised @ rate of 7.64%.
18 Financial Risk managementThe Group has exposure to the following risks arising from financial instruments:
- Credit risk;
- Liquidity risk; and
- Market risk
i) Credit risk: Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument failsto meet its contractual obligations, and arises principally from the Group’s receivables from customers, Depositand other receivables.
Trade receivables The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer,demographics of the customer, default risk of the industry and country in which the customer operates. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthinessof customers to which the Group grants credit terms in the normal course of business. The Group has usedexpected credit loss (ECL) model for assessing the impairment loss.
` in Crores
As at 31st March, 2020
As at 31st March, 2019
Trade Receivables 864.75 488.92
Allowance for doubtful debts 19.89 10.44
Percentage 2.3% 2.1%
Reconciliation of loss allowance provision – Trade receivables
` In Crores
Loss allowance on April 1, 2018 1.96Changes in loss allowance 8.48Loss allowance on March 31, 2019 10.44Changes in loss allowance 9.45Loss allowance on March 31, 2020 19.89
Cash & Cash Equivalents and Other Bank Balances.As at the year end, the Group held cash and cash equivalents of ` 71.84 Crores (PY: ` 199.07 Crores). The cash and cash equivalents other Bank balances and derivatives are held with banks having good credit rating.
Other financial assetsOther financial assets are neither past over due nor impaired.
F-35
Notes to the Consolidated Financial Statements as on 31st March, 2020
ii) Liquidity risk Liquidity risk is the risk that the Group will not be able to meet its financial obligation as they fall due. The Group’sensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressedconditions. The Group has sufficient unutilised fund and non fund based working capital credit limit duly sanctionedby various banks.
The company is rated by leading credit agency CRISIL, the rating “CRISIL A1+” and “AA+/Stable” has been assigned for short term and long term facility respectively, indicating high degree of safety regarding timely payment and servicing of financial obligation.
Exposure to liquidity risk The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements
` in Crores
As at March 31, 2020 As at March 31, 2019
Less than 1 year
More than 1 Years Total
Less than 1 year
More than 1 Years Total
Non derivativeBorrowings 860.50 886.99 1,747.49 429.13 499.30 928.44
Trade payables 625.93 - 625.93 644.34 - 644.34
Other financial liabilities 113.91 73.30 187.21 288.77 - 288.77
DerivativeOptions contracts 8.01 - 8.01 3.42 - 3.42
iii) Market riskCurrency risk The Group’s foreign exchange risk arises from its foreign operations, foreign currency revenues, and expenses.The Group uses foreign exchange option contracts, to mitigate the risk of changes in foreign currency exchangerates in respect of its budgeted business transactions and recognized assets and liabilities. The Group entersinto foreign currency options contracts which are not intended for trading or speculative purposes but formitigating currency risk.
The Group’s exposure to foreign currency risk at the end of the reporting period expressed in INR, are as follows:
` in Crores
As at 31st March, 2020 US Dollars Euro Others Total
Financial assetsReceivables (net) 848.21 52.25 26.43 926.89
Cash and cash equivalents 18.72 0.00 0.00 18.72
Financial liabilitiesExternal Commercial Borrowing 188.95 0.00 0.00 188.95
Payables (net) 65.15 13.12 2.42 80.70
As at 31st March, 2019 US Dollars Euro Others Total
Financial assetsReceivables (net) 381.75 24.49 11.33 417.57
Cash and cash equivalents 138.52 0.00 0.00 138.52
Financial liabilitiesPayables (net) 108.40 0.19 1.31 109.89
Sensitivity analysis For the years ended 31st March, 2020 and 31st March, 2019 every 5% weakening of Indian Rupee as compare to the respective major currencies for the above mentioned financial assets/liabilities would increase Company’s profit and equity by approximately ` 32.6 Crores and ` 21.81 Crores respectively. A 5% strengthening of the Indian Rupee as compare to the respective major currencies would lead to an equal but opposite effect.
F-36
Notes to the Consolidated Financial Statements as on 31st March, 2020
Interest rate risk and Exposure to interest rate risk The Group has loan facilities on floating interest rate, which exposes the group to risk of changes in interest rates.
For the years ended March 31, 2020 and March 31, 2019, every 50 basis point decrease in the floating interest rate component applicable to its loans and borrowings would decrease the Group’s interest cost by approximately ` 2.24 Crores and ` 0.90 Crores respectively. A 50 basis point increase in floating interest rate would have led to an equal but opposite effect.
Commodity rate risk The Group’s operating activities involve purchase and sale of Active Pharmaceutical Ingredients (API), whose prices are exposed to the risk of fluctuation over short periods of time. Commodity price risk exposure is evaluated and managed through procurement and other related operating policies.
Other Risk Since Group significantly dealing in regulatory market, continuous compliance of all manufacturing facilities is pre requisite, any adverse action by regulatory authority of the group’s target market can adversely affect Group operation.
19 Capital ManagementThe Group’s capital management objectives are:
*to ensure the Group’s ability to continue as agoing concern; and
*to provide an adequate return to shareholdersthrough optimisation of debts and equity balance.
The Group monitors capital on the basis of the carrying amount of debt less cash and cash equivalents as presented on the face of the financial statements. The Group’s objective for capital management is to maintain an optimum overall financial structure.
ii) Dividend on equity shares paid during the year During the year Interim dividend of ̀ 188.52 Crores [Interim Dividend of ` 7/- (350%) per equity shareand an additional Special Dividend of ` 3/- (150%)
per equity share aggregating to total Interim Dividend of ` 10/- (500%) per equity share] and corporate tax of ` 12.46 Crores paid to the equity shareholders in respect of financial year 2019-20.
During the year dividend of ` 103.68 Crores (` 5.50 Per Shares i.e. 275% per equity share) and corporate tax of ` 21.31 Crores paid to the equity shareholders after the AGM approval in respect of financial year 2018-19.
20 Exceptional items Exceptional items relates to impairment provision on investment and loan given to Alembic Mami Algeria - Joint Venture held by wholly owned subsidiary of the company ` 69.06 Crores, compensation to National Green Tribunal ` 10 Crores and write back of certain provisions, refund by vendor for non performance and settlement of ` 35.42 Crores.
21 During the year company has fully provided for diminution in value of investment in Joint Venture - Alembic Mami SPA & discontinued recognition of its share in loss, as share of losses in joint venture exceeds its interest in the joint venture. The company does not carry any further liability to said Join venture or third party on account of this arrangement.
22 Lease - Effective date and transition Effective 1st April, 2019, the Company has adopted Ind As 116 Leases. Company apply retrospectively with the cumulative effect of initially applying the Standard recognised at the date of initial application. Company measure lease liability at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate at the date of initial application, and measure that right-of-use asset an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the balance sheet immediately before the date of initial application. The adoption of the standard did not have any material impact on the financial results. (Refer 2(2.20))
F-37
Notes to the Consolidated Financial Statements as on 31st March, 2020
A) The following is the movement in lease liabilities
` in Crores
For the Year Ended
31st March, 2020
Balance as on 1st April, 2019
Additions 92.43
Finance cost accrued during the period 7.88
Payment of lease liabilities (17.11)
Balance as on 31st March, 2020 83.20
B) Maturity Analysis of Lease Liabilities
` in Crores
31st March, 2020
Maturity Analysis - Contractual undiscounted Cash FlowsLess than one year 17.21
One to five years 72.94
More than five years 19.76
Total Undiscounted Lease Liabilities 109.90
Lease Liabilities included in the Statement of Financial PositionNon Current 73.30
Current 9.90
Total 83.20
C) Amount Recognized in the Statement of Profit & Loss
` in Crores
For the Year Ended
31st March, 2020
Interest on Lease Liabilities 7.88
Depreciation on Lease Asset 13.36
D) The Company has obtained certain premises for its business operations under short-term leases or leases of low-value leases. These are generally not non-cancellable and are renewable by mutual consent on mutually agreeableterms. (Refer note no 32).
E) As Leasor Operating Lease income are recognised in the statement of profit and loss under “Lease Rent Income” inNote 29.
23 As assessed by the management, Impact of Covid 19 on the financial statements of the Company is likely to be modest and for short term. Management does not foresee any medium to long term risk in company‘s ability to continue as going concern.
24 The previous year’s figures have been regrouped / rearranged wherever necessary to make it comparable with the current year.
For and on behalf of the Board Chirayu Amin Paresh Saraiya Chairman & CEODIN: 00242549
Director DIN: 00063971
R. K. Baheti Charandeep Singh SalujaDirector Finance & CFODIN: 00332079
Company Secretary
As per our report of even dateFor K. S. Aiyar & Co. Chartered Accountants Firm Registration No.: 100186W
Rajesh S. JoshiPartner Membership No.: 38526
Mumbai, 22nd May, 2020 Vadodara, 22nd May, 2020
F-38
Notes to the Consolidated Financial Statements as on 31st March, 2020
Form
AO
C-I
(Pu
rsu
ant
to fi
rst
pro
viso
to
su
b-s
ec
tio
n (
3) o
f se
ctio
n 1
29
re
ad w
ith r
ule
5 o
f C
om
pan
ies
(Acc
ou
nts
) R
ule
s, 2
014)
Par
t “A
”: S
ub
sid
iari
es
` in
Cro
res
Sr.
N
oN
ame
of
the
su
bsi
dia
ry
Dat
e o
f ac
qu
isit
ion
Re
po
rtin
g
curr
en
cy
Exc
han
ge
rate
Sh
are
cap
ital
Re
serv
es
& s
urp
lus
Tota
l as
sets
Tota
l Li
abil
itie
sIn
vest
me
nts
Turn
ove
r
Pro
fit/
(L
oss
) b
efo
re
taxa
tio
n
Pro
visi
on
fo
r ta
xati
on
Pro
fit
/ (L
oss
) af
ter
taxa
tio
nP
rop
ose
d
Div
ide
nd
% o
f sh
are
ho
ldin
g
1A
leo
r D
erm
aceu
tical
s Li
mite
d2
3.0
5.2
01
6IN
R1
.00
0.5
0 (
72
.84
) 6
23
.28
69
5.6
2 0
.23
3.1
5 (
70
.12
) 0
.18
(7
0.3
0)
NIL
60
2A
lem
bic
Glo
bal
Ho
ldin
g S
A1
4.1
2.2
00
7U
SD7
5.5
8 3
3.6
7 1
7.0
8 1
60
.04
10
9.2
9 3
5.0
5 1
88
.79
44
.61
1.0
5 4
3.5
6N
IL1
00
3A
lno
va P
har
mac
eu
tical
s SA
17
.12
.20
12
USD
75
.58
1.5
0 (
16
.31
) 0
.02
14
.83
- -
(1
3.8
6)
0.0
1 (
13
.87
)N
IL1
00
4A
lem
bic
Ph
arm
aceu
tical
s A
ust
ralia
Pty
Ltd
18
.01
.20
13
AU
D4
6.2
4 3
.75
(4
.75
) 0
.90
1.9
0 -
0.5
2 (
1.2
9)
- (
1.2
9)
NIL
10
0
5A
lem
bic
Ph
arm
aceu
tical
s C
anad
a Lt
d2
3.0
4.2
01
4C
AD
53
.69
0.0
5 (
0.6
3)
0.0
5 0
.63
- -
(0
.10
) -
(0
.10
)N
IL1
00
6A
lem
bic
Ph
arm
aceu
tical
s E
uro
pe L
imite
d2
3.0
8.2
01
2E
UR
83
.14
13
.30
(9
.88
) 1
.44
(1
.98
) -
- (
0.1
2)
- (
0.1
2)
NIL
10
0
7A
lem
bic
Ph
arm
aceu
tical
Inc.
18
.06
.20
15
USD
75
.58
31
.13
15
3.1
21
,08
4.3
9 9
00
.14
94
.47
1,9
69
.54
89
.59
0.5
5 8
9.0
4N
IL1
00
8G
en
ius
LLC
26
.10
.20
14
UA
H2
.71
0.7
0 (
0.3
9)
0.3
2 0
.01
- -
0.0
0 -
0.0
0N
IL1
00
9O
kner
Real
ty L
LC3
1.1
0.2
01
7U
SD7
5.5
8 7
.56
(0
.37
) 7
.37
0.1
9 -
- (
0.1
5)
- (
0.1
5)
NIL
10
0
10
Ori
t La
bo
rato
ries
LLC
31
.10
.20
17
USD
75
.58
86
.91
(1
17
.92
) 2
3.9
7 5
4.9
8 -
48
.97
(7
4.0
9)
- (
74
.09
)N
IL1
00
No
tes:
1 N
ame
s o
f su
bsi
dia
rie
s w
hic
h a
re y
et
to c
om
me
nce
op
era
tio
ns
- N
A
2 N
ame
s o
f su
bsi
dia
rie
s w
hic
h h
ave b
ee
n li
qu
idat
ed
or
sold
du
rin
g t
he y
ear
- N
A
3 R
ep
ort
ing
pe
rio
d f
or
all t
he a
bo
ve s
ub
sid
iari
es
is s
ame a
s th
at o
f H
old
ing
co
mp
any.
F-39
Notes to the Consolidated Financial Statements as on 31st March, 2020
Form
AO
C-I
(Pu
rsu
ant
to fi
rst
pro
viso
to
su
b-s
ec
tio
n (
3) o
f se
ctio
n 1
29
re
ad w
ith r
ule
5 o
f C
om
pan
ies
(Acc
ou
nts
) R
ule
s, 2
014)
Par
t “B
”: A
sso
ciat
es
and
Jo
int
Ve
ntu
res
` in
Cro
res
Sr.
N
oN
ame
of
Ass
oc
iate
sD
ate
of
acq
uis
itio
n
Lat
est
A
ud
ite
d
Bal
ance
S
he
et
Dat
e
Sh
are
s o
f A
sso
ciat
e/J
oin
t V
en
ture
s h
eld
b
y th
e co
mp
any
on
th
e ye
ar e
nd
De
scri
pti
on
o
f h
ow
th
ere
is
sig
nifi
can
t in
flu
en
ce
Re
aso
n w
hy
the
asso
ciat
e/
join
t ve
ntu
re
is n
ot
con
soli
dat
ed
Ne
two
rth
at
trib
uta
ble
to
S
har
eh
old
ing
as
pe
r la
test
au
dit
ed
B
alan
ce S
he
et
Pro
fit
/ (L
oss
) fo
r th
e ye
ar
No
.
Am
ou
nt
of
Inve
stm
en
t in
Ass
oci
ate
sE
xte
nt
of
Ho
ldin
g %
Co
nsi
de
red
in
Co
nso
lid
atio
n
No
t C
on
sid
ere
d in
C
on
soli
dat
ion
1In
co
zen
Th
era
peu
tics
Pvt
. Ltd
.2
9.1
0.2
00
83
1.0
3.2
02
01
00
00
00
3.0
05
0%
NA
NA
1.6
1 (
0.0
7)
(0
.07
)
2R
hiz
en
Ph
arm
aceu
tical
s SA
06
.11
.20
08
31
.03
.20
20
62
00
0 1
5.3
45
0%
NA
NA
0.5
3 0
.18
0.1
8
3D
ahlia
SA
26
.11
.20
14
31
.03
.20
20
50
00
0 0
.37
50
%N
AN
A (
0.3
2)
(0
.06
) (
0.0
6)
4R
hiz
en
Ph
arm
aceu
tical
s In
c3
0.0
9.2
01
63
1.0
3.2
02
05
00
0 0
.04
50
%N
AN
A 0
.00
- -
5A
lem
bic
Mam
i SP
A1
7.1
0.2
01
43
1.0
3.2
01
93
42
97
51
.64
49
%N
AN
A (
14
.74
) -
-
1 N
ame
s o
f as
socia
tes
or
join
t ve
ntu
res
wh
ich
are
yet
to c
om
me
nce
op
era
tio
ns.
- N
A
2 N
ame
s o
f as
socia
tes
or
join
t ve
ntu
res
wh
ich
hav
e b
ee
n li
qu
idat
ed
or
sold
du
rin
g t
he y
ear
. - N
A
As
per
ou
r re
po
rt o
f eve
n d
ate
For
and
on
beh
alf
of
the B
oar
d
For
K. S
. Aiy
ar &
Co
. C
hir
ayu
Am
in
Par
esh
Sar
aiya
C
har
tere
d A
cco
un
tan
ts
Firm
Reg
istr
atio
n N
o.:
10
01
86
WC
hai
rman
& C
EO
DIN
: 0
02
42
54
9D
irecto
r D
IN:
00
06
39
71
Raj
esh
S. J
osh
iR
. K. B
ahet
i C
har
and
eep
Sin
gh
Sal
uja
Par
tner
M
em
bers
hip
No
.: 3
85
26
Directo
r Fi
nan
ce &
CFO
DIN
: 0
03
32
07
9C
om
pan
y Se
cre
tary
Mu
mb
ai, 2
2n
d M
ay, 2
02
0V
ado
dar
a, 2
2n
d M
ay, 2
02
0
F-40
To the Members of Alembic Pharmaceuticals Limited
Report on the Audit of the Consolidated Financial Statements
OpinionWe have audited the accompanying consolidated financial statements of Alembic Pharmaceuticals Limited (hereinafter referred to as the ‘Holding Company”) and its subsidiaries (Holding Company and its subsidiaries together referred to as “the Group”), its associates and jointly controlled entities, which comprise the consolidated Balance Sheet as at 31st March, 2019, and the consolidated statement of Profit and Loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated Cash Flows Statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as “the consolidated financial statements”).
In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (‘the Act”) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, its associates and jointly controlled entities as at 31st March, 2019, of consolidated profit (including other comprehensive income), consolidated changes in equity and its consolidated cash flows for the year then ended.
Basis for OpinionWe conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in India in terms of the Code of Ethics issued by Institute of Chartered Accountants of India and the relevant provisions of the Companies Act, 2013, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Key Audit MattersKey audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The following Key Audit Matters have been identified by us and as reported by the component Auditors.
1. Provision for return of non-saleable goods (Expiry, Breakage and Spoilage) in the market in India (In the case of Holding Company) This is considered as key audit matter in view of significantestimates and judgements made by the management forrecognition and measurement for the same.
The Company, under the prevailing trade practice, has anobligation to accept returns of expiry, breakage and spoilage (EBS) products, from the stockiest (customers) in India.The methodology and assumptions used to estimate theaccruals of EBS are monitored and adjusted regularly by themanagement in the light of the obligations, historical trends,past experience and prevailing market conditions.
The Company makes provision for accrual of EBS estimatedin future out of the sales effected during the current period.The said provision is used for settling claims made by thecustomers in future. Actual returns on account of EBS canvary materially from period to period based upon actualsales volume, product mix, etc.
Principal Audit ProceduresWe verified management’s calculations in respect ofestimate made by the management towards provision foraccruals of EBS. We have examined the methodology andthe assumptions made by the management while makingthis provision.
2. Recognition, measurement and impairment testing of “Capital Work in Progress and Intangible Assets under development”. (In the case of a Subsidiary Company)Auditors of Aleor Dermaceuticals Limited (“Aleor”), subsidiary company, have reported the following matter as akey audit matter:
Aleor is in the process of construction of Property, Plant,and Equipment of its project, which is included as CapitalWork in Progress. It is also developing various genericproducts which are included under “Intangible assetsunder development”.
This is a key audit matter because there is use ofsignificant estimates and judgements by the managementfor recognition, measurement and testing forimpairment for the same.
Principal Audit Procedures Audit approach of the auditors of the Aleor consistedof assessing the entity’s process to identify accuracy ofrecognition and measurement of assets, both tangible andintangible and related direct expenditure (as per principlesenunciated under IND AS 16 ‘Property, Plant and Equipment’ and Ind AS 36 ‘Intangible Assets’) as well as testing of designand operative effectiveness of the internal controls for thesame. The auditors of Aleor also carried out substantivetesting as follows:
• Evaluated the design of internal controls related torecognition and measurement of the said expenditure;
Independent Auditor’s Report
F-41
• Selected a sample of agreements and contracts relatedto the said expenditure which were relevant for therecognition and measurement;
• Performing the following procedures:
− Verification of costs of materials and services used;
− Verification of the costs of employee benefits attributableto the assets acquired and for the development of intangible assets;
− Review of the legal rights as per the related agreements;
− Review of the directly attributable cost as per allocated cost centre.
In addition of the above the auditors of Aleor have also verified and considered the following to ensure the recoverable value of the capital work in progress and intangible assets under development:
− Considered the recoverable value based on value in use derived from discounted cash flows working provided by the management and certified by the independent external valuer.
− Verified the application made by the subsidiary company to external agencies for approval of its various products and also the approval received by the company for some of the products.
Information Other than the Consolidated Financial Statements and Auditor’s Report Thereon” The Company’s Board of Directors is responsible for the other information. The other information comprises the information included in the Board’s Report and Annexures thereto and Report on Corporate Governance but does not include the consolidated financial statements and our auditor’s report thereon.
Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.
We have been provided the aforesaid reports and based on the work we have performed, we did not observe any material misstatement of this other information and accordingly, we have nothing to report in this regard.
Responsibilities of Management and those charged with Governance for the Consolidated Financial Statements The Holding Company’s Board of Directors are responsible for the preparation and presentation of these consolidated
financial statements in terms of the requirements of the Companies Act, 2013 (the Act) that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group including its associates and jointly controlled entities in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.
In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities is responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.
Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
F-42
As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:
• Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraudor error, design and perform audit procedures responsiveto those risks, and obtain audit evidence that is sufficientand appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting fromfraud is higher than for one resulting from error, as fraudmay involve collusion, forgery, intentional omissions,misrepresentations, or the override of internal control.
• Obtain an understanding of internal control relevant tothe audit in order to design audit procedures that areappropriate in the circumstances. Under section 143(3)(i)of the Companies Act, 2013, we are also responsible forexpressing our opinion on whether the company hasadequate internal financial controls system in place andthe operating effectiveness of such controls.
• Evaluate the appropriateness of accounting policies usedand the reasonableness of accounting estimates andrelated disclosures made by management.
• Conclude on the appropriateness of management’s useof the going concern basis of accounting and, basedon the audit evidence obtained, whether a materialuncertainty exists related to events or conditions that maycast significant doubt on the ability of the Group and itsassociates and jointly controlled entities to continue as agoing concern.
If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
• Evaluate the overall presentation, structure and contentof the consolidated financial statements, including thedisclosures, and whether the consolidated financialstatements represent the underlying transactions andevents in a manner that achieves fair presentation.
• Obtain sufficient appropriate audit evidence regarding thefinancial information of the entities or business activitieswithin the Group and its associates and jointly controlledentities to express an opinion on the consolidatedfinancial statements. We are responsible for the direction,supervision and performance of the audit of the financialstatements of such entities included in the consolidatedfinancial statements of which we are the independentauditors. For the other entities included in the consolidated financial statements, which have been audited by other
auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.
Other Matters(a) We did not audit the financial statements / financial
information of 11 subsidiaries whose financial statements /financial information reflect total assets of `1079.27 Croresas at 31st March, 2019, total revenues of `1310.08 Croresand net cash out-flows amounting to `19.48 Crores for theyear ended on that date, as considered in the consolidatedfinancial statements. The consolidated financial statementsalso include the Group’s share of net loss of `9.28 Croresfor the year ended 31st March, 2019, as considered in theconsolidated financial statements, in respect of 1 associate,and 1 jointly controlled entity whose financial statements/ financial information have not been audited by us.These financial statements / financial information havebeen audited by other auditors whose reports have beenfurnished to us by the Management and our opinion on theconsolidated financial statements, in so far as it relates tothe amounts and disclosures included in respect of thesesubsidiaries, jointly controlled entities and associates, andour report in terms of sub-section (3) of Section 143 of theAct, in so far as it relates to the aforesaid subsidiaries, jointlycontrolled entities and associates, is based solely on thereports of the other auditors.
(b) Re: Subsidiary Company, i.e., Aleor DermaceuticalsLimited. (Aleor)
F-43
Aleor’s Auditors’ have modified their audit opinion regarding the fact that the company has measured its financial liability of Non-convertible Redeemable Debentures (NCRD) at cost and not as per amortised cost as mandated by Ind AS 109-Financial Instruments. Had the NCRD been measured at Amortised Cost, the borrowing cost for the year to be included in the qualifying asset [Capital Work-in Progress (CWIP)] would be higher by ` 4,034.72 lakhs and corresponding financial liability for the NCRD and the cumulative capital work-in progress (CWIP) would be higher by ` 6,162.72 lakhs.
Corresponding interest income has not been recognized by Holding Company (Alembic Pharmaceuticals Limited - APL) and considered as contingent Assets. The said NCRD have been carried at cost in separate financial statements of APL as per Ind AS 27.
On consolidation of financial statements (a) the said investment by APL and Financial liability of Aleor and (b) borrowing cost of Aleor and interest income of APL gets eliminated. Therefore it does not have any financial impact on the Group’s Consolidated Financial statements.
Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements / financial information certified by the Management.
Report on Other Legal and Regulatory RequirementsAs required by Section 143(3) of the Act, we report, to the extent applicable, that:
(a) We have sought and obtained all the information andexplanations which to the best of our knowledge and beliefwere necessary for the purposes of our audit of the aforesaidconsolidated financial statements.
(b) In our opinion, proper books of account as required bylaw relating to preparation of the aforesaid consolidatedfinancial statements have been kept so far as it appearsfrom our examination of those books and the reports of theother auditors.
(c) The Consolidated Balance Sheet, the ConsolidatedStatement of Profit and Loss (including other comprehensive income), the Consolidated Statement of Changes in Equityand the Consolidated Cash Flow Statement dealt with bythis Report are in agreement with the relevant books ofaccount maintained for the purpose of preparation of theconsolidated financial statements.
(d) In our opinion, the aforesaid consolidated financialstatements comply with the Accounting Standards specifiedunder Section 133 of the Act read with Rule 7 of theCompanies (Accounts) Rules, 2014.
(e) On the basis of the written representations received fromthe directors of the Holding Company as on 31st March,
2019 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, associate companies and jointly controlled companies incorporated in India, none of the directors of the Group companies, its associate companies and jointly controlled companies incorporated in India is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164(2) of the Act.
(f) With respect to the adequacy of internal financial controlsover financial reporting of the Group and the operatingeffectiveness of such controls, refer to our separatereport in Annexure A.
(g) With respect to the other matters to be included in theAuditor’s Report in accordance with the requirements ofsection 197(16) of the Act, as amended, in our opinionand to the best of our information and according to theexplanations given to us, the remuneration paid by theHolding Company to its Directors during the year is inaccordance with the provisions of section 197 of the Actand is not in excess of the limit laid down under this section.In the case of a subsidiary company incorporated in India,the managerial remuneration has not been paid or providedand accordingly, the requisite approvals mandated by theprovisions of Section197 read with Schedule V of the Actare not required;
(h) With respect to the other matters to be included inthe Auditor’s Report in accordance with Rule 11 of theCompanies (Audit and Auditor’s) Rules, 2014, in our opinionand to the best of our information and according to theexplanations given to us:
i. The consolidated financial statements disclose theimpact of pending litigations on the consolidatedfinancial position of the Group, its associates andjointly controlled entities – Refer Note 32(2)(ii) to theconsolidated financial statements.
ii. The Group, its associates and jointly controlled entitiesdid not have any long-term contracts includingderivative contracts, for which there were any materialforeseeable losses;
iii. There has been no delay in transferring amounts,required to be transferred, to the Investor Educationand Protection Fund by the Holding Company and itssubsidiary companies, associate companies and jointlycontrolled companies incorporated in India.
For K.S. Aiyar & Co. Chartered AccountantsFirm’s Registration No. 100186W
Rajesh S. Joshi Partner
Membership No.38526
Place: VadodaraDate: 8th May, 2019
F-44
(Referred to in paragraph f under ‘Report on Other Legal and Regulatory Requirements’ Section of our report of even date to the Members of Alembic Pharmaceuticals Limited)
Report on the Internal Financial Controls under Clause (i) of sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31st March, 2019, we have audited the internal financial controls over financial reporting of Alembic Pharmaceuticals Limited (hereinafter referred to as “the Holding Company”) and its subsidiary companies, its associate companies and jointly controlled company, which are companies incorporated in India, as of that date.
Management’s Responsibility for Internal Financial ControlsThe respective Board of Directors of the Holding company, its subsidiary companies, its associate companies and jointly controlled companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.
Auditor’s ResponsibilityOur responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the ICAI and the Standards on Auditing, issued by ICAI prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.
Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial
controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors of the subsidiary companies, associate companies and joint venture companies, which are companies incorporated in India, in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting of the Holding Company, its subsidiary companies, its associate companies and its joint venture company, which are companies incorporated in India.
Meaning of Internal Financial Controls Over Financial ReportingA company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.
Inherent Limitations of Internal Financial Controls Over Financial ReportingBecause of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate
Annexure Ato the Independent Auditor’s Report
F-45
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
OpinionIn our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors referred to in the ‘Other Matter’ paragraph below, the Holding Company, its subsidiary companies, its associates and jointly controlled companies, which are companies incorporated in India, have, in all material respects, an internal financial controls system with reference to consolidated financial statements over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.
Other MattersOur aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting in so far as it relates to one subsidiary company and one associate company, which are companies incorporated in India, is based on the corresponding reports of the auditors of such companies incorporated in India.
Our opinion is not modified in respect of the above matter.
For K.S. Aiyar & Co. Chartered AccountantsFirm’s Registration No. 100186W
Rajesh S. JoshiPartnerMembership No.38526
Place: VadodaraDate: 8th May, 2019
F-46
Consolidated Balance Sheetas at 31st March, 2019
` in Crores
Particulars Note No. As at
31st March, 2019 As at
31st March, 2018
I. ASSETS(1) Non-Current Assets
(a) Property, Plant and Equipment 6 1,098.41 927.02 (b) Capital work-in-progress 1,341.40 910.76 (c) Goodwill 7 3.61 3.77 (d) Other Intangible assets 7 56.43 62.59 (e) Intangible assets under development 209.83 99.39 (f) Financial Assets :-
(i) Investments 8 0.45 0.45 (ii) Investment accounted for using Equity Method 9 48.31 41.19
(g) Other non-current assets10 61.59 71.14
(2) Current Assets(a) Inventories 11 967.26 733.93 (b) Financial Assets
(i) Trade receivables 12 488.89 526.34 (ii) Cash and cash equivalents 13 199.07 83.74 (iii) Bank balances other than cash and cash equivalents 14 6.55 6.18 (iv) Others financial assets 15 9.10 29.97
(c) Current Tax Assets (Net) - 3.45(d) Other current assets 16 286.86 441.13
TOTAL ASSETS 4,777.76 3,941.05
II EQUITY AND LIABILITIESEQUITY
(a) Equity Share capital 17 37.70 37.70 (b) Other Equity 18 2,681.12 2,182.44
Equity attributable to owners of the Company 2,718.82 2,220.14 Non-controlling interests (0.79) 0.31 Total Equity 2,718.04 2,220.45 LIABILITIES(1) Non-Current Liabilities
(a) Financial Liabilities(i) Borrowings 19 499.30 500.00
(b) Provisions 20 52.03 40.76 (c) Deferred tax liabilities (Net) 21 18.75 35.44
(2) Current liabilities(a) Financial Liabilities
(i) Borrowings 22 429.13 207.78 (ii) Trade payables 23
A) Total outstanding dues of Micro and Small enterprises 5.09 0.32 B) Total outstanding dues of others 697.23 759.00
(iii) Other financial liabilities 24 234.21 19.59 (b) Other current liabilities 25 87.96 123.29 (c) Provisions 26 32.39 34.41 (d) Current Tax Liabilities (Net) 3.61 -
TOTAL EQUITY AND LIABILITIES 4,777.76 3,941.05
See accompanying notes 1 to 32 of Financial Statements.The accompanying notes referred to above which form an integral part of the Financial StatementsAs per our report of even date For and on behalf of the Board
For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya
Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh Saluja
Partner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Vadodara, 8th May, 2019 Vadodara, 8th May, 2019
F-47
Consolidated Statement of Profit and Lossfor the year ended 31st March, 2019
` in Crores
Particulars Note No.
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
I Revenue from Operations 27 3,934.68 3,130.81 II Other Income 28 9.38 7.03 III Total Income 3,944.06 3,137.84
IV ExpensesCost of Materials Consumed 29 850.04 725.75 Purchase of Stock-in-Trade 234.93 201.87 Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress 29 (92.27) (42.06)Employee Benefits Expense 30 746.69 622.81 Finance costs 18.41 3.40 Depreciation and amortisation expense 6 115.23 105.46 Other Expenses 31 1,321.71 979.34 Total Expense (IV) 3,194.74 2,596.74
V Profit Before Tax (III-IV) 749.32 541.27
VI Tax Expense(i) Current Tax 178.14 123.61 (ii) Deferred Tax (17.29) (2.16)(iii) Short/(Excess) Tax Provision (4.10) (1.10)
VII Profit after Tax Before Share of Profit of Associate and Joint Ventures (V-VI) 592.57 420.91 VIII Share of Profit/(Loss) of an associate and a joint venture (9.28) (8.09)IX Profit for the period before Non controlling Interest(VII+VIII) 583.29 412.82 X Non-controlling Interest 1.08 (0.19)XI Profit for the period attributable to Owners of the Company 584.37 412.63
XII Other Comprehensive IncomeA Items that will not be reclassified to Profit and Loss
(i) Re-measurements of post-employment benefit obligations (2.47) (3.89)(ii) Income tax relating to Re-measurements of post-employment benefit obligations 0.53 0.83
(1.93) (3.06)B Items that will be reclassified to Profit or Loss
(i) Exchange differences in translating the financial statements of a foreign operations 7.76 (0.14) 7.76 (0.14)
Total Other Comprehensive Income (A+B) 5.83 (3.20)
XIII Total Comprehensive Income for the year (IX+XII) 589.12 409.63 Other Comprehensive Income for the year Attributable to:(i) Non- controlling Interest (0.01) - (ii) Owners of the Company 5.84 (3.20)Total Comprehensive Income for the year Attributable to:(i) Non- controlling Interest (1.09) 0.19 (ii) Owners of the Company 590.21 409.43
XIV Earnings per equity share (FV ` 2/- per share): 31.00 21.89 Basic & Diluted (in `) 32(1)
See accompanying notes 1 to 32 of Financial Statements.The accompanying notes referred to above which form an integral part of the Financial Statements
As per our report of even date For and on behalf of the Board
For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya
Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh Saluja
Partner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Vadodara, 8th May, 2019 Vadodara, 8th May, 2019
F-48
Consolidated Cash Flow Statementfor the year ended 31st March, 2019
` in Crores
Particulars
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
A CASH FLOW FROM OPERATING ACTIVITIES:Net Profit before tax 749.32 541.27
Adjustments for:
Depreciation 115.23 105.46
Interest charged 18.41 3.40
Interest Income (2.58) (0.62)
Dividend Income (2.12) (0.75)
Unrealised foreign exchange gain (net) (23.83) (15.62)
Provision / write-off for doubtful trade receivables 16.69 0.07
Loss/(Profit) on sale of Asset (1.18) (4.82)
Operating Profit before change in working capital 869.93 628.39
Working capital changes:(Increase) In Inventories (233.33) (101.18)
(Increase) / Decrease in Trade Receivables 35.61 (184.18)
(Increase) / DecreaseIn Other Assets 175.13 (217.64)
Increase / (Decrease) in Trade Payables (52.77) 258.84
Increase in Other Liabilities 177.09 61.60
Increase In Provisions 6.79 1.71
Cash generated from operations 978.45 447.53
Direct taxes paid (Net of refunds) (166.48) (135.11)
Net Cash inflow from Operating Activities (A) 811.96 312.42
B CASH FLOW FROM INVESTING ACTIVITIES:Proceeds from Sale Asset 1.28 14.40
Government assistance 17.15 -
Interest received 2.58 0.62
Dividend received 2.12 0.75
Purchase of property, plant & equipments, intangible assets and Capital Advance (653.93) (749.36)
Investment in Associate (14.36) -
Intangible assets under development (110.44) (72.39)
Net cash outflow on acquisition of Subsidiary - (78.41)
Net Cash inflow from Investing Activities (B) (755.60) (884.38)
F-49
Consolidated Cash Flow Statementfor the year ended 31st March, 2019
` in Crores
Particulars
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
C CASH FLOW FROM FINANCING ACTIVITIES:Proceeds from borrowings 825.05 619.05
Repayment of borrowings (604.39) -
Increase in Restricted Bank Balances other than Cash & Cash Equivalents (0.38) 0.35
Dividends paid (including distribution tax) (90.91) (90.76)
Interest and other finance costs (including borrowing cost capitalised) (70.34) (26.02)
Net Cash inflow / (outflow) from Financing Activities (C) 59.04 502.63
I. Net (decrease) / increase in cash and cash equivalents (A+B+C) 115.40 (69.34)
II. (a) Cash and cash equivalents at the beginning of the Year 83.74 153.08
(b) Effect of exchange differences on restatement of foreign currency cash and cash equivalents (0.07) - III. Cash and cash equivalents at the end of the Year (I+II) 199.07 83.74
IV. Cash and cash equivalents at the end of the Year
Balances with Banks 198.84 83.41
Cash on hand 0.23 0.34 Cash and cash equivalents (Refer note 13) 199.07 83.74
As per our report of even date For and on behalf of the Board
For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya
Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh Saluja
Partner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Vadodara, 8th May, 2019 Vadodara, 8th May, 2019
F-50
Statement of Changes in Equity
A. Equity Share CapitalNo. of Shares ` in Crores
Equity shares of ` 2/- each issued, subscribed and fully paidBalance at 1st April, 2017
Equity shares of ` 2/- each 18,85,15,914 37.70
Changes in equity share capital during the year - - Balance at 31st March, 2018 18,85,15,914 37.70
Balance at 1st April, 2018
Equity shares of ` 2/- each 18,85,15,914 37.70
Changes in equity share capital during the year - - Balance at 31st March, 2019 18,85,15,914 37.70
B. Other Equity` in Crores
Particulars
Reserve & Surplus OCI Attributable to owners of Parent Company
Non-controlling
interests
Total
Capital Reserve
General Reserve
Debenture Redemption
ReserveRetained earnings
Foreign Currency
Translation reserve
Balance at 1st April, 2017 (I) 0.30 1,137.98 718.18 8.16 1,864.63 (0.09) 1,864.54
Other Comprehensive Income* (3.06)* (0.14) (3.20) (3.20)
Profit for the period 412.63 412.63 0.19 412.82 Total Comprehensive Income for the year (II) - - - 409.57 (0.14) 409.43 0.19 409.63
Dividends paid including Tax on Dividend (90.76) (90.76) (90.76)
Reversal of Deferred Tax Asset (0.87) (0.87) (0.87)
Profit transferred to General Reserve 100.00 (100.00) - - Transaction for the year (III) - 99.13 - (190.76) - (91.62) - (91.62)
Balance at 31st March, 2018 (I+II+III) 0.30 1,237.12 - 937.00 8.03 2,182.44 0.11 2,182.55
Balance at 1st April, 2018 (I) 0.30 1,237.12 - 937.00 8.03 2,182.44 0.11 2,182.55
Other Comprehensive Income (1.92)* 7.76 5.84 (0.01) 5.83
Profit for the period 584.37 584.37 (1.08) 583.29 Total Comprehensive Income for the year (II) - - - 582.45 7.76 590.21 (1.09) 589.12
Dividends paid including Tax on Dividend (90.91) (90.91) (90.91)
Reversal of Deferred Tax Asset (0.62) (0.62) (0.62)
Provision for debenture redemption 41.67 (41.67) - -
Profit transferred to General Reserve 100 (100) - - Transaction for the year (III) - 9938 41.67 (232.57) - (91.53) - (91.53)
Balance at 31st March, 2019 (I+II+III) 0.30 1,336.50 41.67 1,286.87 15.79 2,681.12 (0.99) 2,680.13
* Represents remeasurements of the defined plans
As per our report of even date For and on behalf of the Board
For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya
Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh Saluja
Partner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Vadodara, 8th May, 2019 Vadodara, 8th May, 2019
F-51
Notes to the Consolidated Financial Statements
1. General information: The Financial Statement of the subsidiaries, associatesand Joint Venture used in the consolidation is drawnup to the same reporting date as that of the AlembicPharmaceuticals Limited ("the Holding Company"),namely 31st March, 2019.
2. Significant Accounting Policies:Statement of compliance The Group has prepared its consolidated financialstatements for the year ended 31st March, 2019 inaccordance with Indian Accounting Standards (IndAS) notified under the Companies (Indian AccountingStandards) Rules, 2015 (as amended) together with thecomparative period data as at and for the year ended31st March, 2018
Principles of Consolidation: The Consolidated Financial Statements consist of Alembic Pharmaceuticals Limited (“the Holding Company”) and its subsidiaries (collectively referred to as "the Group"), associates and Joint Venture. The Consolidated Financial Statements have been prepared on the following basis:
The financial statements of the Holding Company and its subsidiaries have been consolidated on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after eliminating intra-group balances and intra-group transactions resulting in unrealised profits as per Ind As 110
"Consolidated Financial Statements" specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules, 2015.
For the purposes of presenting these consolidated financial statements, the assets and liabilities of Group’s foreign operations, are translated to the Indian Rupees at exchange rates at the end of each reporting period. The income and expenses of such foreign operations are translated at the average exchange rates for the period. Resulting foreign currency differences are recognised as Foreign Currency Translation Reserve throgh Other Comprehensive Income.
Investment and share of profit of associate and Joint Venture have been consolidated as per the equity method as per Ind AS 28 – “Investments in Associates” and “Ind AS 111 Joint Arrangements” respectively specified under Section 133 of the Companies Act, 2013 read with Companies (Accounts) Rules 2015.
The Group accounts for its share of post-acquisition changes in net assets of associates, after eliminating unrealised profits resulting from transactions between the Group and its associates to the extent of its share, through its Consolidated Statement of Profit and Loss, and Other Comprehensive Income, if any, to the extent such change is attributable to the associates' Statement of Profit and Loss and through its reserves, if any, for the balance.
3. Companies Included in Consolidation:
NameCountry of
Incorporation NatureProportion of Ownership Interest As on 31.03.2019
Alembic Global Holding SA (AGH SA) Switzerland Subsidiary 100% subsidiary of Alembic Pharmaceuticals Limited India. (APL)AG Research Private Limited India Subsidiary
Aleor Dermaceuticals Limited India Subsidiary 60% subsidiary of APL
Incozen Therapeutics Pvt Limited India Associate 50% shareholding of APL
Alembic Pharmaceuticals Australia Pty Ltd Australia Subsidiary
100% subsidiary of AGH SA
Alembic Pharmaceutical Inc.(AP Inc) U.S.A Subsidiary
Alembic Pharmaceuticals Europe Limited Malta Subsidiary
Alnova Pharmaceuticals SA Switzerland Subsidiary
Alembic Pharmaceuticals Canada Ltd Canada Subsidiary
Genius LLC Ukraine Subsidiary
Orit Laboratories LLC USASubsidiary 100% subsidiary of AP Inc.
Okner Realty LLC USA
Alembic Mami SPA Algeria Joint Venture 49% shareholding of AGH SA
Rhizen Pharmaceuticals SA (RP SA) Switzerland Associate 50% shareholding of AGH SA
Dahlia Theraputics SA Switzerland Subsidiary of Associate
100% subsidiary of RP SARhizen Pharmaceuticals Inc USA
F-52
Notes to the Consolidated Financial Statements
4. Significant Accounting Policies: The accounting policies of the Group and that of itssubsidiaries, associates and Joint Venture are similarand as per generally accepted accounting principles inIndia please refer page no 13.
5. Translation of Accounts: In Consolidated Financial Statements, the FinancialStatements of subsidiary companies and proportionate
share of associates and Joint Venture have been translated into INR as prescribed under Ind AS 21 the Effects of Changes in Foreign Exchange Rates specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules 2015.
F-53
Notes to the Consolidated Financial Statements
6. Property, Plant and Equipment:` In Crores
Property, Plant and Equipment Freehold Land
Leasehold Land Buildings
Plant & Equipment
R&D Equipment
Furniture & Fixtures Vehicles
Office Equipments Total
Gross Carrying amount
Carrying Amount as at 1st April, 2017 1.92 19.49 265.96 511.43 125.57 10.95 11.08 3.67 950.09
Additions 50.07 - 23.52 76.99 70.09 5.91 1.07 2.91 230.56
Acquisition of a subsidiary 1.30 - 6.98 0.03 - - - - 8.31
Disposals - (0.90) (8.87) (5.80) (0.50) (0.13) (0.03) (0.38) (16.60)
Foreign Exchange Adjustments 0.02 - 0.18 0.00 - 0.00 - - 0.20
Closing Gross Carrying Amount 53.31 18.58 287.77 582.66 195.15 16.73 12.13 6.21 1,172.56
Accumulated Depreciation - 0.51 24.09 100.52 18.67 1.90 3.75 1.24 150.68
Depreciation charge during the year - 10.20 12.29 61.27 14.67 1.16 1.47 0.85 101.92
Disposals - - (4.40) (2.30) - (0.08) (0.01) (0.29) (7.08)
Foreign Exchange Adjustments - - 0.01 0.00 - 0.00 - - 0.01
Closing Accumulated Depreciation - 10.72 31.99 159.49 33.34 2.98 5.22 1.81 245.53
Net Carrying Amount as at 1st April, 2017 1.92 18.98 241.88 410.91 106.90 9.06 7.33 2.43 799.40
Net Carrying Amount as at 31st March, 2018 53.31 7.87 255.79 423.17 161.82 13.75 6.91 4.40 927.02
Gross Carrying amount
Carrying Amount as at 1st April, 2018 53.31 18.58 287.77 582.66 195.15 16.73 12.13 6.21 1,172.56
Additions 29.62 1.77 22.03 171.09 45.03 4.42 2.45 0.78 277.19
Disposals - - - (0.33) - (0.02) (0.01) (0.07) (0.43)
Foreign Exchange Adjustments 0.06 - 0.51 (0.10) - 0.00 - 0.00 0.47
Closing Gross Carrying Amount 83.00 20.35 310.31 753.32 240.18 21.14 14.57 6.92 1,449.78
Accumulated Depreciation
As at 1st April, 2018 - 10.72 31.99 159.49 33.34 2.98 5.22 1.81 245.53
Depreciation charge during the year - 0.21 12.92 66.50 21.78 1.94 1.67 1.13 106.14
Disposals - - - (0.25) - (0.00) (0.00) (0.04) (0.30)
Foreign Exchange Adjustments - - 0.00 (0.05) - 0.05 - (0.00) 0.00
Closing Accumulated Depreciation - 10.92 44.91 225.69 55.12 4.97 6.88 2.89 351.38
Net Carrying Amount as at 1st April, 2018 53.31 7.87 255.79 423.17 161.82 13.75 6.91 4.40 927.02
Net Carrying Amount as at 31st March, 2019 83.00 9.43 265.40 527.63 185.07 16.16 7.68 4.03 1,098.41
Notes:
1. During the previous year, the Company, through its wholly owned subsidiary Alembic Pharmaceutials Inc., acquired USA based generic drug
develper Orit Laboratories LLC along with Okner Realty LLC with effect from 1st November, 2017.
2. The Company does not have any restrictions on the title of its property, plant and equipment
3. Sales proceeds are deducted from gross cost where cost is unacertainable
F-54
Notes to the Consolidated Financial Statements
7. Goodwill and Other Intangible Assets ` in Crores
Goodwill Other Intangible Assets
As at 31st March, 2019
As at 31st March, 2018
As at 31st March, 2019
As at 31st March, 2018
Carrying Amount 3.94 - 65.95 - Acquisition of a subsidiary - 3.84 - 65.55Foreign Exchange Adjustments 0.26 0.10 2.62 0.40Closing Gross Carrying Amount 4.20 3.94 68.58 65.95 Accumulated Amortisation (0.17) - (3.37) - Amortisation expense (0.42) (0.15) (8.66) (3.34)Foreign Exchange Adjustments (0.01) (0.02) (0.12) (0.03)Closing Accumulated Amortisation (0.60) (0.17) (12.14) (3.37)Net Carrying Amount 3.61 3.77 56.43 62.59
8. Non-Current Financial Investment
` in Crores
As at 31st March, 2019
As at 31st March, 2018
Investments in Preference SharesValued at Amortised cost1% Cumulative Redeemable Non-Convertible Preference Shares 4,50,000 (PY: 4,50,000) of ` 10 each fully paid up in EICL (Redemption date 14.12.2031)
0.45 0.45
Aggregate amount of unquoted Investments 0.45 0.45
9. Non-Current Financial Investment
` in Crores
As at 31st March, 2019
As at 31st March, 2018
Investments in Equity Instruments - Unquoted Valued at Cost(i) Investment in Associates
10,00,000 (PY: 10,00,000) equity shares of ` 10 each at a premium of ` 20 eachfully paid up in Incozen Therapeutics Pvt. Ltd.
1.65 1.72
Add Share in Profit / (loss) for the period 0.03 (0.06)
a 1.68 1.65 62,000 (PY: 50,000) equity shares of CHF 1 each fully paid up in Rhizen Pharmaceuticals SA (Good will ` 14.18 Crores)
14.69 0.21
Add Share in Profit / (loss) for the period 0.10 0.12
Add Impact of Foreign Currency translations (0.66) 0.02
b 14.13 0.34 (ii) Investment in Joint Venture
34,297 (PY: 34,297 ) equity shares of DZD 1,000 each fully paid up representing49% of equity in Alembic Mami SPA, Algeria
39.19 47.48
Add /(Less) : Share in Profit / (loss) for the period (9.40) (8.14)
Add/(Less): Impact of Foreign Currency translations 2.71 (0.15)
c 32.50 39.19 Aggregate amount of unquoted Investments (a+b+c) 48.31 41.19
F-55
Notes to the Consolidated Financial Statements
10. Other Non-Current Assets
` in Crores
As at 31st March, 2019
As at 31st March, 2018
Capital Advances 14.85 44.96 Balance with Government Authorities 46.73 26.17
61.59 71.14
11. Inventories (Refer Note 4) ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Raw Materials 300.24 186.21
Packing Materials 46.67 23.80
Work-in-Process 50.02 51.92
Finished Goods 415.67 345.56
Stock-in-trade 102.34 110.66
Goods in Transit 41.71 9.32
Stores and Spares 10.62 6.46
967.26 733.93
Notes:
(i) Inventories are hypothecated as security for borrowings.
(ii) During the year ended 31.03.2019 the Company recorded inventory write-downs of `3.51 Crores (PY: `3.89 Crores).
12. Trade Receivables ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Unsecured, Considered good a 488.89 526.34
Trade Receivables which have significant increase in credit Risk 2.12 1.96
Less: Impairment Allowance (2.12 ) (1.96)
b - - (a+b) 488.89 526.34
Notes:
Receivables are hypothecated as security for working capital borrowings.
Refer Note No. 32(6) (I) for Related Party Receivable.
13. Cash and Cash Equivalents ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Balances with Banks 198.84 83.41
Cash on hand 0.23 0.34
199.07 83.74
F-56
Notes to the Consolidated Financial Statements
14. Bank Balances Other than Cash and Cash Equivalents ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Earmarked Balance with Bank
Unpaid Dividend Account 4.79 4.03
Margin Money Deposit Account 1.76 2.14
6.55 6.18
15. Other Financial Assets (Current) ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Security Deposits 9.10 17.79
Unrealised Foreign Exchange Gain - 12.18
9.10 29.97
Refer note No 32(6)(I) for Related Party Deposits
16. Other Current Assets (Unsecured, considered good)
` in Crores
As at 31st March, 2019
As at 31st March, 2018
Advance to Employees 5.60 5.80
Advance to Suppliers 86.88 151.94
Pre-paid Expense 18.24 15.32
Balances with Government Authorities 176.14 268.08
286.86 441.13
17. Equity Share Capital ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Authorised20,00,00,000 – Equity shares of ` 2/ – each 40.00 40.00
40.00 40.00
Shares issued, subscribed and fully paid18,85,15,914 – Equity shares of ` 2/ – each 37.70 37.70
37.70 37.70
Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period
Particulars
As at 31st March, 2019 As at 31st March, 2018
Numbers ` in Crores Numbers ` in Crores
At the beginning of the year 18,85,15,914 37.70 18,85,15,914 37.70Outstanding at the end of the year 18,85,15,914 37.70 18,85,15,914 37.70
F-57
Notes to the Consolidated Financial Statements
The rights, preferences and restrictions including restrictions on the distribution of dividends and the repayment of capitalThe Company is having only one class of shares i.e. Equity carrying a nominal value of ` 2/- per share Every holder of the equity share of the Company is entitled to one vote per share held. In the event of liquidation of the Company, the equity shareholders will be entitled to receive remaining assets of the Company after the distribution / repayment of all creditors. The distribution to the equity shareholders will be in proportion of the number of shares held by each shareholder.
The Company declares and pays dividend on the equity shares in Indian Rupees. Dividend proposed by the Board of Directors is subject to approval of the shareholders at the ensuing Annual General Meeting.
Shares in the Company held by each shareholder holding more than 5 percent shares specifying the number of shares held
Particulars
As at 31st March, 2019 As at 31st March, 2018
Numbers % held Numbers % held
1 Alembic Limited 5,55,51,528 29.47% 5,54,71,208 29.43%
2 Nirayu Private Limited 4,93,36,655 26.17% 4,93,36,655 26.17%3 Shreno Limited 2,06,98,780 10.98% 2,06,98,780 10.98%
18. Other Equity(Refer statement of changes in equity for detailed movement in other equity balance)
` in Crores
As at 31st March, 2019
As at 31st March, 2018
(a) Capital Reserve 0.30 0.30
(b) General Reserve 1,336.50 1,237.12
(c) Retained Earnings 1,286.87 937.00
(d) Debenture Redemption Reserve 41.67 -
(e) Foreign Currency Translation reserve 15.79 8.03 Total Other Equity 2,681.12 2,182.44
Nature and purpose of each ReserveCapital Reserve: Capital Reserve is created on receipt of Government subsidy for setting up factory in backward area.
General Reserve: The reserve is created by transfer of a portion of the net profit.
Debenture redemption reserve: The Company is required to create a debenture redemption reserve out of the profits in accordance with Companies Act, 2013.
Foreign Currency Translation reserve: Exchange differences relating to the translation of the results and net assets of the Group’s foreign operations from their functional currencies to the Group’s presentation Currency (i.e. INR) are recognised in the other comprehensive income and accumulated in foreign currency translation reserve.
F-58
Notes to the Consolidated Financial Statements
19. Borrowings (Non-Current) ` in Crores
As at 31st March, 2019
As at 31st March, 2018
UnsecuredFrom Bank
Term Loan (Refer Note No 24) – 500.00
Non-Convertible debentures 499.30 –
499.30 500.00
Notes:
(i) Term loan of ` 200 Crores classified as current: payable in January, 2020. Interest @ rate of six months T-Bills plus spread of 87 bps.
(ii) Term loan of ` 300 Crores: Interest @ rate of one year G-sec plus spread of 61 bps repaid during the year.
(iii) Maturity profile and rate of interest of non-convertible debentures are set out as below.
Effective Rate of Interest 2021-22 2022-23 Total Repayment Amortised
cost adjustment Closing balance
8.42% to 9.05% 300 200 500 0.70 499.30
20. Provisions (Non-Current)
` in Crores
As at 31st March, 2019
As at 31st March, 2018
Provision for Employee Benefits Provision for Gratuity 0.36 1.84
Provision for Leave benefits 23.74 18.03
Provision for Non-Saleable return of goods 27.93 20.89
52.03 40.76
21. Deferred Tax Liabilities (Net) ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Deferred Tax Liabilities Depreciation a 140.86 118.50
Deferred Tax AssetsProvision for Doubtful debts 0.74 0.68
MAT Credit Entitlement 78.40 57.85
Intangible Asset 1.96 2.58
Others 41.02 21.95
b 122.11 83.06 (a – b) 18.75 35.44
F-59
Notes to the Consolidated Financial Statements
22. Borrowings (Current) ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Loans repayable on demandFrom Banks Secured
Working Capital Demand Loan 34.93 46.53First charg on pari passu basis by hypothecation of Inventory and Trade Receivables at Interest rates ranging between 7% to 10% repayable on demand
Unsecured
Working Capital Demand Loan, interest @ 3-month LIBOR plus 1% 69.15 86.25
Overdraft facility @ 6 month MCLR 75.05 -
Working capital demand loan, Interest @ rate of 7.85% - 75.00
From Other PartiesUnsecured
Commercial Paper 250.00 –
(Carrying interest rate ranging between 7 % to 7.5%, Repayable in May 19 & June 19)
429.13 207.78
23. Trade Payables ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Due to Micro and Small Enterprises 5.09 0.32
Others 697.23 759.00
702.32 759.32
Refer Note No. 32(6)(I) for Related Party Payables.
24. Other Financial Liabilities ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Current maturities of long-term debt (Refer Note No. 19) 200.00 -
Interest accrued but not due on borrowings 11.46 2.92
Unpaid dividends 4.79 4.03
Trade Deposits 11.84 12.58
Unpaid / Unclaimed matured deposits and interest accrued thereon 0.06 0.06
Unrealised Foreign Exchange Loss 6.07 -
234.21 19.59
25. Other Current Liabilities ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Statutory dues 21.35 70.36
Advance from Customers 3.62 9.47
Employee benefits payables 62.99 43.46
87.96 123.29
F-60
Notes to the Consolidated Financial Statements
26. Provisions (Current) ` in Crores
As at 31st March, 2019
As at 31st March, 2018
Provision for Employee Benefits Provision for Gratuity 4.07 6.73
Provision for Leave benefits 7.42 6.77
Provision for Non-Saleable return of goods 20.90 20.90
32.39 34.41
27. Revenue from Operations ` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Sale of products– Domestic* 1,500.02 1,370.24
– Exports 2,306.60 1,665.42
3,806.61 3,035.67 – Export Incentives 88.20 69.73
– Royalty 32.28 19.27
Other Operating Revenues– Miscellaneous 7.59 6.14
3,934.68 3,130.81
*Revenue from operations upto 30th June, 2017 was reported inclusive of excise duty which is now subsumed in GST. Accordingly, figures ofrevenue from operations for the year ended 31st March, 2019 are not comparable with the figures of the previous period.
28. Other Income ` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Dividend 2.12 0.75
Insurance Claims 1.68 0.82
Lease Rent Income 0.03 0.03
Profit / (Loss) on Sales of Assets 1.18 4.82
Profit on Sales of Investment 1.57 -
Interest Income 2.58 0.62
Miscellaneous income 0.20 -
9.38 7.03
F-61
Notes to the Consolidated Financial Statements
29. Cost of Material Consumed ` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Inventory at the beginning of the year 210.01 152.70
Add: Purchases 986.94 783.06
1,196.95 935.76 Less: Inventory at the end of the year 346.90 210.01
850.04 725.75
Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-ProcessWork-in-Process 50.02 51.92
Finished Goods 457.37 354.88
Stock-in-Trade 102.34 110.66 Inventory at the end of the year a 609.74 517.46 Work-in-Process 51.92 30.72
Finished Goods 354.88 364.66
Stock-in-Trade 110.66 80.02 Inventory at the beginning of the year b 517.46 475.41
(b-a) (92.27) (42.06)
30. Employee Benefits Expense
` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Salaries and Wages 688.68 580.31
Contribution to Provident and other funds 37.41 28.73
Staff welfare expense 20.60 13.77
746.69 622.81
31. Other Expenses ` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Consumption of Stores, Spares, Laboratory Material and Analytical Expense 181.00 158.63 Power and Fuel 88.86 70.35 Manufacturing and Labour Charges 19.68 17.94 Repairs and Maintenance
Machinery 24.79 19.78 Buildings 8.34 7.05 Others 5.17 4.27
Freight and Forwarding Charges 119.64 64.32 Publicity Expense, Service Fees and Commission 470.40 315.89 Excise Duty - 0.63Rent 17.33 14.30Rates and Taxes 10.23 5.82Insurance 6.13 5.57Travelling Expense 133.96 114.61Communication Expenses 34.39 25.75Legal & Professional Fees 93.45 77.84Payment to Auditors 1.10 1.04 Exchange Difference (net) (17.48) (27.84)Bad Debts written-off 16.53 0.07
F-62
Notes to the Consolidated Financial Statements
` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Provision for Doubtful Debts 0.15 (0.00)Expenses on CSR Activities 14.28 7.14 Donation 0.60 6.07 Patent Filing & Registration Fees 43.97 38.50 External Reaserch & Development 30.27 36.86 Miscellaneous Expenses 18.90 14.76
1,321.71 979.34
32. Other explanatory Notes to the Standalone Financial Statement For the Year
Ended on 31st March, 2019
For the Year Ended on
31st March, 2018
1. Earning Per Share (EPS)
(a)Net Profit after non-controlling interest attributable to equity shareholders (` in Crores)
584.37 412.63
(b) Weighted average numbers of equity shares 18,85,15,914 18,85,15,914(c) Basic and diluted Earnings per share before Extra-Ordinary Items in ` 31.00 21.89
(Face Value per share ` 2/- each)
` In Crores
As at 31st March, 2019
As at 31st March, 2018
2. Contingent Liabilities and Commitments (To The Extent Not Provided For)i. Estimated amount of contracts net of advances remaining to be executed on
capital accounts 156.90 134.49
ii. Contingent liabilities(a) Letters of credit, Bank Guarantees and Corporate Guarantees 94.73 81.38 (b) Liabilities Disputed in appeals
Excise duty 5.35 5.93 Sales Tax 3.18 2.57
(c ) Claims against the Company not acknowledged as debt 0.37 0.02 (d ) Export obligation against advance licence - 3.79(e ) Disputed liability in respect of Ministry of Industry, Department of Chemicals 0.35 0.35
and Petrochemicals in respect of price of Rifampicin allowed in formulationsand landed cost of import.
31. Other Expenses (contd.)
F-63
Notes to the Consolidated Financial Statements
3. Additional InformationAs at and for the year ended 31st March, 2019
` In Crores
Particulars
Net Assets (Total Assets - Total
Liabilities) Share in Profit or LossShare in Other
Comprehensive incomeShare in Total
Comprehensive income
As a % of consolidated
Net Assets
Amount As % of consolidated profit or loss
Amount As % of consolidated
Other Com-prehensive
income
Amount As % of consolidated
Total Com-prehensive
income
Amount
Parent:Alembic Pharmaceuticals Limited 99.79% 2712.41 104.59% 611.21 (32.60%) (1.90) 103.24% 609.30
Subsidiaries:1. Indian: A G Research Pvt. Ltd. 0.00% 0.00 0.00% 0.00 0.00% 0.00 0.00% 0.00
Aleor Dermaceuticals Limited (0.07%) (1.91) (0.46%) (2.70) (0.49%) (0.03) (0.46%) (2.73)2. Foreign:
Alembic Global Holding SA(wholly owned subsidiary ofAlembic Pharmaceuticals Limited)
4.11% 111.63 (2.14%) (12.53) 136.82% 7.99 (0.77%) (4.54)
Minority interest in all subsidiaries (0.03%) (0.79) 0.18% 1.08 0.20% 0.01 0.18% 1.09
Associates: (Investment as per the equity method)1. Indian: Incozen Therapeutics
Pvt. Limited(0.05%) (1.32) 0.00% 0.03 Nil Nil 0.00% 0.03
2. Foreign: NA Nil Nil Nil Nil Nil Nil Nil Nil
Joint Venture:(As per proportionate consolidation/ investment as per equity method)1. Indian : NA Nil Nil Nil Nil Nil Nil Nil Nil2. Foreign : NA Nil Nil Nil Nil Nil Nil Nil NilIntercompany Elimination andConsolidation Adjustments
(3.75%) (101.97) (2.18%) (12.71) (3.92%) (0.23) (2.19%) (12.94)
100.00% 2718.04 100.00% 584.37 100.00% 5.84 100.00% 590.21
As at and for the year ended 31st March, 2018
` In Crores
Particulars
Net Assets (Total Assets - Total
Liabilities) Share in Profit or LossShare in Other
Comprehensive incomeShare in Total
Comprehensive income
As a % of consoli-
dated Net Assets
Amount As % of consolidat-ed profit or
loss
AmountAs % of con-
solidated Other Com-
prehensive income
Amount As % of con-solidated
Total Com-prehensive
income
Amount
Parent:Alembic Pharmaceuticals Limited 98.84% 2194.64 102.27% 421.99 95.71% (3.06) 102% 418.93
Subsidiaries:1. Indian: A G Research Pvt. Ltd. 0.00% 0.00 (0.91%) (3.74) 0.00% 0.00 (0.91%) (3.74)
Aleor Dermaceuticals Limited 0.04% 0.82 0.12% 0.49 0.00% 0.00 0.12% 0.492. Foreign :
Alembic Global Holding SA(wholly owned subsidiary ofAlembic Pharmaceuticals Limited)
5.24% 116.40 1.77% 7.30 63.81% (2.04) 1.28% 5.26
Minority interest in all subsidiaries 0.01% 0.31 (0.05%) (0.19) 0.00% 0.00 (0.05%) (0.19)
F-64
Notes to the Consolidated Financial Statements
` In Crores
Particulars
Net Assets (Total Assets - Total
Liabilities) Share in Profit or LossShare in Other
Comprehensive incomeShare in Total
Comprehensive income
As a % of consoli-
dated Net Assets
Amount As % of consolidat-ed profit or
loss
AmountAs % of con-
solidated Other Com-
prehensive income
Amount As % of con-solidated
Total Com-prehensive
income
Amount
Associates: (Investment as per the equity method)1. Indian: Incozen Therapeutics
Pvt. Limited(0.06%) (1.35) (0.02%) (0.06) Nil Nil (0.02%) (0.06)
2. Foreign: NA Nil Nil Nil Nil Nil Nil Nil Nil
Joint Venture:(As per proportionate consolidation / investment as per equity method)1. Indian : NA Nil Nil Nil Nil Nil Nil Nil Nil2. Foreign : NA Nil Nil Nil Nil Nil Nil Nil NilIntercompany Elimination andConsolidation Adjustments
(4.07%) (90.35) (3.19%) (13.15) (59.53%) 1.90 (2.75%) (11.25)
100.00% 2220.45 100.00% 412.63 100.00% (3.20) 100.00% 409.43
4. Research and Development Expenses:` In Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
Material Consumption 80.58 68.16
Employees Benefit Expenses 145.61 102.50
Utilities 17.67 12.26
Depreciation 35.50 20.76
Others 224.28 207.61
Research and Development Expenses (included in Consolidated Profit and Loss) 503.64 411.28
5. Operating Segment The Group Company has only one reportable segment i.e Pharmaceuticals ` in Crores
Information about products and services turnovera) API 770.16 b) Formulations 3,164.52 Information about Geographical Areas a) Revenue from External Customers
In India 1,507.60 Outside India 2,427.08
b) Non-Current Assets
In India 2,693.84 Outside India 126.18
c) Information about major customers
Consolidated Revenue – exceeding 10% from each single external customer. NIL
3. Additional Information (Contd.)
F-65
Notes to the Consolidated Financial Statements
6. (i) Disclosures in respect of Related Parties transactions(A) Controlling Companies: Nirayu Pvt. Limited
(B) Associate Companies:
1 Incozen Therapeutics Pvt. Limited (Associate of Alembic Pharmaceuticals Limited)
2 Rhizen Pharmaceuticals SA (Associate of Alembic Global Holding SA)
3 Dahlia Therapeutics SA (Subsidiary of Rhizen Pharmaceuticals SA)
4 Rhizen Pharmaceuticals Inc (Subsidiary of Rhizen Pharmaceuticals SA)
(C) Joint Venture
1 Alembic Mami SPA (Joint venture of Alembic Global Holding SA)
(D) Other Related Parties
1 Alembic Limited 4 Viramya Packlight LLP2 Shreno Limited 5 Shreno Publications Limited3 Paushak Limited
(E) Key Management personnel
1 Mr. Chirayu Amin Chairman & CEO
2 Mr. Pranav Amin Managing Director
3 Mr. Shaunak Amin Managing Director
4 Mr. R. K. Baheti Director Finance & CFO
5 Mr. K. G. Ramnathan Non-Executive Director
6 Mr. Pranav Parikh Non-Executive Director
7 Mr. Paresh Saraiya Non-Executive Director
8 Mr. Milin Mehta Non-Executive Director (upto 22nd January, 2019)
9 Ms. Archana Hingorani Non-Executive Director10 Mr. Ajay Kumar Desai Sr. Vice President - Finance & Company Secretary (upto
31st May, 2018)11 Mr. Charandeep Singh Saluja Company Secretary (From 1st June 2018)
(F) Relatives of Key Management Personnel:
1 Mrs. Malika Amin 4 Mrs. Jyoti Patel
2 Mr. Udit Amin 5 Mrs. Ninochaka Kothari
3 Ms. Yera Amin 6 Mrs. Shreya Mukherjee
` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
(G) Key Managerial Personal Compensation
Short Term Employment Benefits 62.51 55.97
Terminal Benefits 1.86 1.93 Others 0.68 0.57
F-66
Notes to the Consolidated Financial Statements
(H) Transactions with Related parties:During the year, the following transactions were carried out with related parties and relative of Key ManagementPersonnel in the ordinary course of the business:
` in Crores
For the Year Ended on
31st March, 2019
For the Year Ended on
31st March, 2018
(a) Sale of Goods/MEIS License (Net)
AssociatesRhizen Pharmaceutical SA 11.41 5.97
Joint Venture - 4.58
Other Related Parties 3.88 2.48(b) Purchase of Goods
Other Related PartiesAlembic Limited 51.59 50.05
Shreno Publications Limited 23.48 - Sierra Investments Pvt. Limited - 10.92
Others 2.07 9.23(f) Reimbursement of expenses
Other Related PartiesAlembic Limited 10.50 0.78
Associates 0.12 0.58 (h) Rent Paid
Other Related PartiesAlembic Limited 8.21 6.18 Others 0.63 0.62
(j) Receiving of Services
Other Related PartiesAlembic Limited 10.75 7.72 Others 0.02 4.39
(k) Rendering of services
AssociatesRhizen Pharmaceutical SA 0.89 -
(l) Purchase of Fixed Assets
Other Related PartiesShreno Limited 18.88 3.73
(m) Deposit Given
Other Related PartiesAlembic Limited - 2.84
(n) Deposit Returned
Other Related PartiesAlembic Limited 9.92 -
(o) Dividend Paid
Other Related PartiesAlembic Limited 22.22 22.00
Nirayu Pvt. Limited 19.73 5.49 Whitefield Chemtech Pvt. Limited - 7.31
Sierra Investments Pvt. Limited - 6.94
Others 8.28 8.28
Relatives to Key Management Personnel 2.79 2.79Key Management Personnel 2.62 2.62
(p) Remuneration / Compensation
Key Management Personnel 65.06 58.46 Relatives to Key Management Personnel 3.47 3.11
F-67
Notes to the Consolidated Financial Statements
(I) Balance Outstanding as at the end of the year
` in Crores
As at 31st March, 2019
As at 31st March, 2018
Receivables
Associate Companies: 3.86 3.71
Joint Venture 0.24 0.24 Payables
Key Management personnel 35.50 28.30
Other Related Parties 7.64 11.71 Corporate Guarantee
Joint Venture - 32.59Deposit Given
Other Related Parties 2.47 12.41
(ii) Nirayu Private Limited has become holding company of Alembic Pharmaceuticals Limited during the financial year 2017-18 based
on clarifications and advice received regarding direct and indirect holding through its subsidiaries and step down subsidiaries.
The disclosures made in the financial statements in related party transactions and controlling entity information have been
modified accordingly. This does not have any impact on the financials of the Company in any way.
7. Income Taxesa) Income tax expense ` In Crores
Particulars 31st March, 2019 31st March, 2018
Current TaxCurrent tax expense 178.14 123.61
Deferred TaxDecrease / (increase) in deferred tax assets (39.68) (28.63)
(Decrease) / increase in deferred tax liabilities 22.36 26.28
Total deferred tax expenses (benefit) (17.32) (2.35)
Total Income tax expenses * 160.82 121.27
*This excludes tax benefit on other comprehensive income of `0.53 Crores for 31st March, 2019 & `0.83 Crores for 31st March,2018 respectively.
b) Reconciliation of tax expense and the accounting profit multiplied by India's tax rate: ` In Crores
Particulars 31st March, 2019 31st March, 2018
Profit before Income tax expense 749.32 541.27 Tax at the Indian Tax Rate* 161.47 115.52 Tax effect of amounts which are not deductible (taxable) in calculating taxable income Dividend income (0.00) (0.04)Expenditure related to exempt income 0.01 0.02 Provision for debenture redemption (8.98) - Effect on account of overseas tax 23.77 5.85 Deferred tax (17.32) (2.35)Others 1.86 2.27Income Tax Expense 160.82 121.27
* The Company is covered under the provisions of MAT u/s 115JB and the applicable Indian tax rate for year ended 31st March,2019 is 21.5488% and 21.3416% for 31st March, 2018.
c) Current tax (liabilities)/assets ` In Crores
Particulars 31st March, 2019 31st March, 2018
Opening balance 3.45 (9.79)
Income tax paid 166.45 134.92
Current income tax payable for the period / year (177.61) (122.78)
Write back of income tax provision of earlier years 4.10 1.10 Net current income tax asset / (liability) at the end (3.61) 3.45
F-68
Notes to the Consolidated Financial Statements
8. Financial instrumentsCategory of Financial Instrument ` In Crores
Particulars
As at 31st March, 2019 As at 31st March, 2018
Fair value through profit
and loss
Fair value through other
comprehensive income
Amortised cost
Fair value through profit
and loss
Fair value through other
comprehensive income Amortised cost
Financial assetsInvestment in Preference shares - - 0.45 - - 0.45 Trade Receivables - - 488.89 - - 526.34 Cash and cash equivalents - - 199.07 - - 83.74 Bank balances other than (iii) above - - 6.55 - - 6.18 Derivatives not designated as Hedge
- - - 5.53 - -
Others - - 9.10 - - 24.44 Total - - 704.07 5.53 - 641.15
Financial liabilitiesBorrowings - - 928.44 - - 707.78 Trade Payables - - 702.32 - - 759.32 Other Financial liabilities - - 230.79 - - 19.59 Derivatives not designated as Hedge
3.42 - - - - -
Total 3.42 - 1,861.54 - - 1,486.69
Fair value measurement hierarchy: As at 31st March, 2019 As at 31st March, 2018
Particulars
Level of input used in Level of input used in
Level-1 Level-2 Level-3 Level-1 Level-2 Level-3
Derivatives not designated as Hedge - 3.42 - - 5.53 -
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
Level 2 inputs are inputs other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly.
Level 3 inputs are unobservable inputs for the asset or liability. In case of investment in equity instuments, cost has been considerd as approximate fair value in view of materiality of value of investment.
9. Expenses pending capitalisation included in Capital Work-In-Progress represent direct attributable expenditure forsetting up of plants yet to commence of commercial operation, the detail of expenses are:
` In Crores
For the year ended on As at
31st March, 2019 As at
31st March, 2018
Opening Balance 108.89 26.52 Incurred during the current year
Salaries, allowance and contribution to funds 78.75 46.05 Professional Fees 1.99 1.02 Travelling Expenses 6.46 3.38 Others 60.87 31.92
Closing balance 256.96 108.89
F-69
Notes to the Consolidated Financial Statements
10 Financial Risk managementThe Company has exposure to the following risks arising from financial instruments:– Credit risk;– Liquidity risk; and– Market risk
i) Credit risk: Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrumentfails to meet its contractual obligations, and arises principally from the Group’s receivables from customers,Deposit and other receivables.
Trade receivables The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer, demographics of the customer, default risk of the industry and country in which the customer operates. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. The Group has used Expected Credit Loss (ECL) model for assessing the impairment loss.
` In Crores As at
31st March, 2019 As at
31st March, 2018
Trade Receivables 488.89 526.34 Allowance for doubtful debts 2.12 1.96 Percentage 0.4% 0.4%
Reconciliation of loss allowance provision – Trade receivables` In Crores
Loss allowance on 1st April, 2017 7.82 Changes in loss allowance (5.86)Loss allowance on 31st March, 2018 1.96 Changes in loss allowance 0.16 Loss allowance on 31st March, 2019 2.12
Cash and cash equivalents, Other Bank Balances and Derivatives As at the year end, the Group held cash and cash equivalents of `199.07 Crores (PY: `83.74 Crores). The cash and cash equivalents other Bank balances and derivatives are held with bank with good credit rating.
Other financial assetsOther financial assets are neither past over due nor impaired.
ii) Liquidity risk
Liquidity risk is the risk that the Group will not be able to meet its financial obligation as they fall due. The Group’s ensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions. The Group has sufficient unutilised fund and non fund based working capital credit limit duly sanctioned by various banks.
The company is rated by leading credit agency CRISIL, the rating "CRISIL A1+" and "AA+/Stable" has been assigned for short-term and long-term facility respectively, indicating high degree of safety regarding timely payment and servicing of financial obligation.
F-70
Notes to the Consolidated Financial Statements
Exposure to liquidity riskThe following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements
` In Crores
As at 31st March, 2019 As at 31st March, 2018
Less than 1 year
More than 1 year Total
Less than 1 year
More than 1 year Total
Non-Derivative Borrowings 429.13 499.30 928.44 207.78 500.00 707.78
Trade payables 702.32 - 702.32 759.32 - 759.32
Other financial liabilities 230.79 - 230.79 19.59 - 19.59
DerivativeOptions contracts 3.42 - 3.42 - - -
iii) Market riskCurrency Risk The Group’s foreign exchange risk arises from its foreign operations, foreign currency revenues, andexpenses. The Group uses foreign exchange option contracts, to mitigate the risk of changes in foreigncurrency exchange rates in respect of its budgeted business transactions and recognised assets and liabilities.The Group enters into foreign currency options contracts which are not intended for trading or speculativepurposes but for hedge purposes.
The Group's exposure to foreign currency risk at the end of the reporting period expressed in INR, are as follows:
` In CroresAs at 31st March, 2019 US Dollars Euro Others Total
Financial assetsTrade receivables (net) 381.75 24.49 11.33 417.57Cash and cash equivalents 138.52 0.00 0.00 138.52Financial liabilitiesTrade payables 108.40 0.19 1.31 109.89
As at 31st March, 2018 US Dollars Euro Others Total
Financial assetsTrade receivables 452.96 26.41 16.75 496.12Cash and cash equivalents 7.95 0.75 - 8.70Financial liabilitiesTrade payables 59.83 2.05 1.89 63.77Borrowing (PCFC) 32.59 - - 32.59
Sensitivity analysis For the years ended 31st March, 2019 and 31st March, 2018 every 5% weakening of Indain Rupee as compered to the respective major currencies for the above mentioned financial assets/liabilities would increase Company’s profit and equity by approximately `21.81 Crores and `19.68 Crores respectively. A 5% strengthening of the Indian Rupee as compare to the respective major currencies would lead to an equal but opposite effect.
Interest rate risk and Exposure to interest rate risk The Group has loan facilities on floating interest rate, which exposes the group to risk of changes in interest rates.
For the years ended 31st March, 2019 and 31st March, 2018, every 50 basis point decrease in the floating interest rate component applicable to its loans and borrowings would decrease the Group’s interest cost by approximately `5.69 Crores and `3.54 Crores respectively. A 50 basis point increase in floating interest rate would have led to an equal but opposite effect.
F-71
Notes to the Consolidated Financial Statements
Commodity rate risk The Group's operating activities involve purchase and sale of Active Pharmaceutical Ingredients (API), whose prices are exposed to the risk of fluctuation over short periods of time. Commodity price risk exposure is evaluated and managed through procurement and other related operating policies.
Other Risk Since Group significantly dealing in regulatory market, continues compliance of all manufacturing facilities is pre requisite. Any adverse action by regulatory authority of the group's target market can adversely affect Group operation.
11. Capital ManagementThe Company’s capital management objectives are:
* to ensure the Group’s ability to continue as a going concern; and* to provide an adequate return to shareholders through optimisation of debts and equity balance.
The Group monitors capital on the basis of the carrying amount of debt less cash and cash equivalents as presented on the face of the financial statements. The Group’s objective for capital management is to maintain an optimum overall financial structure.
i) Dividend on equity shares paid during the year The Board of Directors has recommended dividend on Equity Shares at ` 5.50 per share i.e. 275% for theyear ended on 31st March, 2019. Dividend Proposed by the Board of Directors is subject to approval of theshareholders at the ensuing Annual General Meeting.
During the year dividend of ` 75.41 Crores (` 4.00 Per Shares i.e. 200%) and corporate tax of ` 15.35 Crores paid to the equity shareholders after the AGM approval, for financial year 2017-18.
12. LeasesThe future minimum lease payments under non-cancellable operating leases in the aggregate and for not not laterthan one year is `0.74 Crores and later than one year and not later than five years is ` 0.37 Crores.
13. The previous year's figures have been regrouped / rearranged wherever necessary to make it comparable withthe current year.
As per our report of even date For and on behalf of the Board
For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya
Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh Saluja
Partner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Vadodara, 8th May, 2019 Vadodara, 8th May, 2019
F-72
Notes to the Consolidated Financial StatementsForm AOC-I(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)
Part “A”: Subsidiaries` in Crores
Sr. No Name of the subsidiary
Date ofacquisition
Reporting currency
Exchange rate
Share capital
Reserves & surplus
Total assets
Total Liabilities Investments Turnover
Profit/ (Loss)
before taxation
Provision for
taxation
Profit / (Loss) after
taxationProposed Dividend
% of shareholding
1 Aleor Dermaceuticals Limited 23.05.2016 INR 1.00 0.50 (2.41) 491.64 493.55 0.23 - (2.78) (0.08) (2.70) NIL 602 Alembic Global Holding SA 14.12.2007 USD 69.15 30.81 94.85 225.37 99.71 109.13 193.34 (5.58) 0.26 (5.84) NIL 1003 Alnova Pharmaceuticals SA 17.12.2012 USD 69.15 1.37 (1.38) 7.90 7.90 - - (0.21) (0.00) (0.21) NIL 1004 Alembic Pharmaceuticals
Australia Pty Ltd
18.01.2013 AUD 49.03 3.97 (3.73) 0.26 0.02 - 0.20 (0.40) - (0.40) NIL 100
5 Alembic
Pharmaceuticals Canada Ltd
23.04.2014 CAD 51.13 0.05 (0.51) 0.14 0.60 - - (0.11) - (0.11) NIL 100
6 Alembic Pharmaceuticals
Europe Limited
23.08.2012 EUR 77.65 12.42 (9.12) 3.40 0.09 - - (1.51) - (1.51) NIL 100
7 Alembic Pharmaceutical Inc. 18.06.2015 USD 69.15 28.49 53.16 461.17 379.52 86.44 1,111.78 43.42 2.79 40.62 NIL 1008 Genius LLC 26.10.2014 UAH 2.52 0.65 (0.37) 0.21 (0.07) - - 1.97 0.35 1.62 NIL 1009 Okner Realty LLC 31.10.2017 USD 69.15 6.92 (0.20) 6.89 0.17 - - (0.14) - (0.14) NIL 10010 Orit Laboratories LLC 31.10.2017 USD 69.15 79.52 (35.56) 61.12 17.16 - 5.40 (29.20) - (29.20) NIL 100
Notes:1 Names of subsidiaries which are yet to commence operations - NA2 Names of subsidiaries which have been liquidated or sold during the year. - AG Research Private Limited (100% subsidiary of the Company ) was struck off by the Registrar on 22nd January, 2019
Part “B”: Associates and Joint Ventures
` In Crores
Sr. No
Name of Associates and Joint Ventures
Date ofacquisition
LatestAuditedBalance
Sheet Date
Shares of Associate/Joint Ventures held by the company on the year end Description
of how there is significant
influence
Reason why the associate/joint venture is not consolidated
Networth attributable to
Shareholding as per latest audited
Balance Sheet
Profit / (Loss) for the year
No.
Amount of Investment in
AssociatesExtent of
Holding %Considered in Consolidation
Not Considered in Consolidation
1 Incozen Therapeutics Pvt. Ltd. 29.10.2008 31.03.2019 1000000 3.00 50% NA NA 1.68 0.03 0.03
2 Rhizen Pharmaceuticals SA 06.11.2008 31.03.2019 62000 14.03 50% NA NA 0.80 0.17 0.17
3 Dahlia SA 26.11.2014 31.03.2019 50000 0.34 50% NA NA 0.09 (0.08) (0.08)
4 Rhizen Pharmaceuticals Inc 30.09.2016 31.03.2019 5000 0.03 50% NA NA 0.00 - -
5 Alembic Mami SPA 17.10.2014 31.03.2019 34297 47.24 49% NA NA (6.90) (9.40) (9.79)
1. Names of associates or joint ventures which are yet to commence operations. - NA
2. Names of associates or joint ventures which have been liquidated or sold during the year. - NA
As per our report of even date For and on behalf of the Board
For K. S. Aiyar & Co. Chirayu Amin Paresh Saraiya
Chartered Accountants Firm Registration No.: 100186W
Chairman & CEODIN: 00242549
Director DIN: 00063971
Rajesh S. Joshi R. K. Baheti Charandeep Singh Saluja
Partner Membership No.: 38526
Director Finance & CFODIN: 00332079
Company Secretary
Vadodara, 8th May, 2019 Vadodara, 8th May, 2019F-73
Consolidated financial statements
To the Members of Alembic Pharmaceuticals Limited
Report on the Consolidated Financial StatementsWe have audited the accompanying consolidated financial statements of ALEMBIC PHARMACEUTICALS LIMITED (hereinafter referred to as “the Holding Company”)and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”), its associates and jointly controlled entity comprising of the Consolidated Balance Sheet as at 31st March, 2018, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Cash Flow Statement, the Consolidated Statement of Changes in Equity, for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as “the consolidated financial statements”).
Management’s Responsibility for the Consolidated Financial StatementsThe Holding Company’s Board of Directors is responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as “the Act”) that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated cash flows and statement of changes in the equity of the Group and its Associates and Jointly controlled entity in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entity are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the respective companies and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.
Auditor’s ResponsibilityOur responsibility is to express an opinion on these consolidated financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act,
the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.
We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company’s preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company’s Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-paragraph (a) of the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.
OpinionIn our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of the other auditors on separate financial statements/financial information of the subsidiaries, associates and jointly controlled entity referred to below in the ‘Other Matters’ paragraph, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, its associates and jointly controlled entity as at 31st March, 2018, and their consolidated profit, consolidated total comprehensive income, their consolidated cash flows and consolidated statement of changes in equity for the year ended on that date.
Other MattersThe financial statements of subsidiaries, associates and jointly controlled entity have been either audited by other auditors or were subjected to a limited review by other auditors, whose
Independent Auditor’s Report
F-74
reports have been furnished to us by the Management and our opinion and report in terms of Sub-section (3) and (11) of Section 143 of the Act, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and jointly controlled entity, is based solely on the reports of the other auditors.(a) We did not audit the financial statements / financial
information of any of the eleven subsidiaries whosefinancial statements / financial information reflecttotal assets of ` 1019.29 Crores as at 31st March, 2018,total revenues of ` 906.82 Crores and net cash outflowsamounting to ` 60.59 Crores for the year ended onthat date, as considered in the consolidated financialstatements.
(b) The consolidated financial statements also include theGroup’s share of net loss of ` 8.09 Crores for the yearended 31st March, 2018 as considered in the consolidatedfinancial statements, in respect of four associates andone jointly controlled entity whose financial statements/ financial information has not been audited by us.
Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors and the financial statements/ financial information certified by the Management.
Report on Other Legal and Regulatory Requirements1. As required by Section 143(3) of the Act, based on our
audit and on the consideration of the report of otherauditors as referred to in ‘Other Matters’ paragraph above we report, to the extent applicable, that:(a) We have sought and obtained all the information
and explanations which to the best of our knowledge and belief were necessary for the purposes ofour audit of the aforesaid consolidated financialstatements.
(b) In our opinion, proper books of account as requiredby law relating to preparation of the aforesaidconsolidated financial statements have been keptso far as it appears from our examination of thosebooks and the reports of the other auditors.
(c) The Consolidated Balance Sheet, the ConsolidatedStatement of Profit and Loss (including OtherComprehensive Income), the Consolidated CashFlow Statement and Consolidated Statement ofChanges in Equity dealt with by this Report arein agreement with the relevant books of accountmaintained for the purpose of preparation of theconsolidated financial statements.
(d) In our opinion, the aforesaid consolidated financialstatements comply with the Accounting Standardsspecified under Section 133 of the Act.
(e) On the basis of the written representations receivedfrom the directors of the Holding Company as on31st March, 2018 taken on record by the Board ofDirectors of the Holding Company and the reportsof the statutory auditors of its subsidiary companiesand associate company incorporated in India,none of the directors of the Holding Companyand its subsidiary companies incorporated in Indiaand its associate company incorporated in Indiais disqualified as on 31st March, 2018 from beingappointed as a director in terms of Section 164 (2) ofthe Act.
(f) With respect to the adequacy of the internalfinancial controls over financial reporting and theoperating effectiveness of such controls; refer to ourseparate Report in “Annexure A”.
(g) With respect to the other matters to be included inthe Auditor’s Report in accordance with Rule 11 ofthe Companies (Audit and Auditor’s) Rules, 2014,as amended, in our opinion and to the best of ourinformation and according to the explanationsgiven to us:i. The consolidated financial statements disclose
the impact of pending litigations on theconsolidated financial position of the Group, its associates and jointly controlled entity– ReferNote 32(2)(ii) to the consolidated financialstatements.
ii. The Group, its associates and jointly controlledentity did not have any long-term contractsincluding derivative contracts for which therewere any material foreseeable losses.
iii. There were no amounts that were required tobe transferred to the Investor Education andProtection Fund by the Holding Company, itssubsidiary company and associate companyincorporated in India.
For K. S. AIYAR & Co.Chartered Accountants(Firm’s Registration No. 100186W)
Rajesh S. JoshiPartnerMembership No. 38526
Place of Signature: VadodaraDate: 16th May, 2018
F-75
Consolidated financial statements
Annexure A
(Referred to in paragraph f under ‘Report on Other Legal and Regulatory Requirements’ Section of our report of even date to the Members of Alembic Pharmaceuticals Limited)
Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)
In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31st March, 2018, we have audited the internal financial controls over financial reporting of ALEMBIC PHARMACEUTICALS LIMITED (hereinafter referred to as “the Holding Company”) and its subsidiary companies, its associate companies and jointly controlled companies, which are companies incorporated in India, as of that date.
Management’s Responsibility for Internal Financial ControlsThe respective Board of Directors of the of the Holding company, its subsidiary companies, its associate companies and jointly controlled companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.
Auditor’s ResponsibilityOur responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the ICAI and the Standards on Auditing, issued by ICAI prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to
obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.
Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors of the subsidiary companies, associate companies and joint venture companies, which are companies incorporated in India, in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting of the Holding Company, its subsidiary companies, its associate companies and joint venture companies, which are companies incorporated in India.
Meaning of Internal Financial Controls Over Financial ReportingA company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
to the Independent Auditor’s Report
F-76
Inherent Limitations of Internal Financial Controls Over Financial ReportingBecause of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
OpinionIn our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors referred to in the ‘Other Matter’ paragraph below, the Holding Company, its subsidiary companies, its associates and jointly controlled companies, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the
Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.
Other MattersOur aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting insofar as it relates to two subsidiary companies, one associate company, which are companies incorporated in India, is based on the corresponding reports of the auditors of such companies incorporated in India.
Our opinion is not modified in respect of the above matter.
For K. S. AIYAR & Co.Chartered Accountants(Firm’s Registration No. 100186W)
Rajesh S. JoshiPartnerMembership No. 38526
Place of Signature: VadodaraDate: 16th May, 2018
F-77
Consolidated financial statements
Consolidated Balance Sheet
` in CroresParticulars Notes As at
31st March, 2018 As at
31st March, 2017I. Assets
(1) Non-Current Assets(a) Property, Plant and Equipment 6 927.02 799.40(b) Capital Work-In-Progress 910.76 369.28(c) Goodwill 7 3.77 -(d) Other Intangible Assets 7 62.59 -(e) Intangible Assets under development 99.39 27.00(f) Financial Assets
(i) Investments 8 0.45 0.47(ii) Investment accounted for using Equity Method 9 41.19 49.41(iii) Other Financial Assets
(g) Other Non-Current Assets 10 71.14 71.24
(2) Current Assets(a) Inventories 11 733.93 632.75(b) Financial Assets
(i) Trade Receivables 12 526.34 338.82(ii) Cash and cash equivalents 13 83.74 153.08(iii) Bank balances other than cash and cash equivalents 14 6.18 6.52(iv) Others Financial Assets 15 29.97 14.10
(c) Current Tax Assets (Net) 3.45 -(d) Other Current Assets 16 441.13 227.19
Total Assets 3,941.05 2,689.26
II Equity and LiabilitiesEquity
(a) Equity Share capital 17 37.70 37.70(b) Other Equity 18 2,182.44 1,864.63
Equity attributable to owners of the Company 2,220.14 1,902.33
Non-controlling interests 0.31 0.11Total Equity 2,220.45 1,902.44
Liabilities(1) Non-Current Liabilities
(a) Financial Liabilities(i) Borrowings 19 500.00 -
(b) Provisions 20 61.66 57.22(c) Deferred Tax Liabilities (Net) 21 35.44 36.93
(2) Current Liabilities(a) Financial Liabilities
(i) Borrowings 22 207.78 88.51(ii) Trade Payables 23 759.32 500.73(iii) Other Financial Liabilities 24 19.59 16.17
(b) Other Current Liabilities 25 123.29 65.11(c) Provisions 26 13.51 12.36(d) Current Tax Liabilities (Net) - 9.79
Total Equity and Liabilities 3,941.05 2,689.26
See accompanying notes 1 to 32 of Financial StatementsThe accompanying notes referred to above which form an integral part of the Financial Statements
As at 31st March, 2018
As per our report of even dateFor K. S. Aiyar & Co. Chirayu Amin Pranav Amin Shaunak Amin K. G. Ramanathan Chartered Accountants Firm Registration No. 100186W
Chairman & CEODIN No.: 00242549
Managing DirectorDIN No.: 00245099
Managing DirectorDIN No.: 00245523
DirectorDIN No.: 00243928
Rajesh S. Joshi Milin Mehta Archana Hingorani R. K. Baheti Ajay Kumar DesaiPartner Membership No. 38526
DirectorDIN No.: 01297508
DirectorDIN No.: 00028037
Director-Finance & CFODIN No.: 00332079
Senior Vice President - Finance & Company Secretary
Vadodara: 16th May, 2018 Vadodara: 16th May, 2018
F-78
` in CroresParticulars Notes For the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017I Revenue from Operations 27 3,130.81 3,134.61II Other Income 28 7.03 2.02III Total Income 3,137.84 3,136.63
IV ExpensesCost of Materials Consumed 29 725.75 703.87Purchase of Stock-in-Trade 201.87 224.18Changes in Inventories of Finished Goods, Stock-in-Trade and Work in Progress 29 (42.06) (69.95)Employee Benefits Expense 30 622.81 558.83Finance costs 3.40 5.23Depreciation and amortization expense 6 105.46 82.97Other Expenses 31 979.34 1,102.40Total Expense (IV) 2,596.57 2,607.54
V Profit Before Tax (III-IV) 541.27 529.09
VI Tax Expense(i) Current Tax 123.61 122.40(ii) Deferred Tax (2.16) (0.21)(iii) Short/Excess Tax Provision (1.10) 0.00
VII Profit after Tax Before Share of Profit of Associate and Joint Ventures (V-VI)
420.91 406.90
VIII Share of Profit/(Loss) of an Associate and a Joint Venture (8.09) (3.83)IX Profit for the period before Non controlling Interest(VII+VIII) 412.82 403.07X Non- controlling Interest (0.19) 0.09XI Profit for the period attributable to Owners of the Company 412.63 403.16
XII Other Comprehensive IncomeA Items that will not be reclassified to Profit and Loss
(i) Re-measurement of post-employment benefit obligations (3.89) (2.71)(ii) Income tax relating to Re-measurement of post-employment benefit
obligations 0.83 0.58
(3.06) (2.13)B Items that will be reclassified to Profit or Loss
(i) Exchange differences in translating the financial statements of aforeign operations (0.14) (2.54)
(0.14) (2.54)Total Other Comprehensive Income (A+B) (3.20) (4.67)
XIII Total Comprehensive Income for the year (IX+XII) 409.63 398.41
Total Comprehensive Income for the year Attributable to:(i) Non- controlling Interest 0.19 (0.09)(ii) Owners of the Company 409.43 398.50
XIV Earnings per equity share (FV ` 2/- per share) 32-1 21.89 21.39Basic & Diluted (in `)
See accompanying notes 1 to 32 of Financial StatementsThe accompanying notes referred to above which form an integral part of the Financial Statements
Consolidated Statement of Profit and LossFor the year ended 31st March, 2018
As per our report of even dateFor K. S. Aiyar & Co. Chirayu Amin Pranav Amin Shaunak Amin K. G. Ramanathan Chartered Accountants Firm Registration No. 100186W
Chairman & CEODIN No.: 00242549
Managing DirectorDIN No.: 00245099
Managing DirectorDIN No.: 00245523
DirectorDIN No.: 00243928
Rajesh S. Joshi Milin Mehta Archana Hingorani R. K. Baheti Ajay Kumar DesaiPartner Membership No. 38526
DirectorDIN No.: 01297508
DirectorDIN No.: 00028037
Director-Finance & CFODIN No.: 00332079
Senior Vice President - Finance & Company Secretary
Vadodara: 16th May, 2018 Vadodara: 16th May, 2018
F-79
Consolidated financial statements
Consolidated Cash Flow Statement
` in CroresParticulars For the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
A Cash Flow from Operating Activities:Net Profit before tax 541.27 529.09
Depreciation 105.46 82.97Interest charged 3.40 5.23Interest Income (0.62) (1.03)Dividend Income (0.75) (0.19)Unrealised foreign exchange gain (net) (15.62) (5.29)Provision / Write off for doubtful trade receivables 0.07 1.30Loss/(Profit) on sale of Asset (4.82) 0.07
Operating Profit before change in Working capital 628.39 612.16
Working capital changes:(Increase) In Inventories (101.18) (62.96)(Increase) / Decrease In Trade Receivables (184.18) 11.71(Increase) In Other Assets (217.64) (51.07)Increase / (Decrease) In Trade Payables 258.84 (87.57)Increase / (Decrease) In Other Liabilities 61.60 (6.85)Increase In Provisions 1.71 31.10
Cash generated from operations 447.53 446.53
Direct taxes paid (Net of refunds) (135.11) (117.96)
Net Cash inflow from Operating Activities (A) 312.42 328.55
B Cash Flow from Investing Activities:Proceeds from Sale of Assets 14.40 19.41Interest received 0.62 1.03Dividend received 0.75 0.19Purchase of tangible assets & Capital Advance (749.36) (510.14)Purchase of Investments (Net) - 3.60Intangible assets under development (72.39) -Net cash outflow on acquisition of Subsidiary (78.41) -
Net Cash inflow from Investing Activities (B) (884.38) (485.91)
For the year ended 31st March, 2018
F-80
` in CroresParticulars For the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
C Cash Flow from Financing Activities:Proceeds from long-term borrowings 500.00Proceeds from short-term borrowings 119.05 -Increase in Restricted Bank Balances other than Cash & Cash Equivalents 0.35 4.98Repayment of long-term Borrowings - (4.65)Repayment of Short-term Borrowings - (33.95)Dividends paid (including distribution tax) (90.76) (90.10)Interest and other finance costs (26.02) (5.16)
Net Cash inflow from Financing Activities (C) 502.63 (128.88)
I Net (decrease)/increase in cash and cash equivalents (A+B+C) (69.34) (286.24)
II. Cash and cash equivalents at the beginning of the Year 153.08 439.32III. Cash and cash equivalents at the end of the Year (I+II) 83.74 153.08
IV. Cash and cash equivalents at the end of the YearBalances with Banks 83.41 152.91Cash on hand 0.34 0.17Cash and cash equivalents (Refer note 13) 83.74 153.08
As per our report of even dateFor K. S. Aiyar & Co. Chirayu Amin Pranav Amin Shaunak Amin K. G. Ramanathan Chartered Accountants Firm Registration No. 100186W
Chairman & CEODIN No.: 00242549
Managing DirectorDIN No.: 00245099
Managing DirectorDIN No.: 00245523
DirectorDIN No.: 00243928
Rajesh S. Joshi Milin Mehta Archana Hingorani R. K. Baheti Ajay Kumar DesaiPartner Membership No. 38526
DirectorDIN No.: 01297508
DirectorDIN No.: 00028037
Director-Finance & CFODIN No.: 00332079
Senior Vice President - Finance & Company Secretary
Vadodara: 16th May, 2018 Vadodara: 16th May, 2018
Cash Flow StatementFor the year ended 31st March, 2018
F-81
Consolidated financial statements
Consolidated Statement of Changes in Equity
Particulars No of Shares ` in Crores
A. Equity Share CapitalEquity shares of ` 2/- each issued, subscribed and fully paidBalance at 1st April, 2016Equity shares of ` 2/- each 18,85,15,914 37.70Changes in equity share capital during the yearBalance at 31st March, 2017 18,85,15,914 37.70
Balance at 1st April, 2017Equity shares of ` 2/- each 18,85,15,914 37.70Changes in equity share capital during the yearBalance at 31st March, 2018 18,85,15,914 37.70
` in CroresParticulars Reserve & Surplus Total
Capital Reserve
General Reserve
Retained earnings
Foreign Currency
Translation reserve
B. Other Equity - Attributable to ownersBalance at 1st April, 2016 (I) 0.30 839.13 707.91 10.70 1,558.04Other Comprehensive Income (2.13)* (2.54) (4.67)Profit for the period 403.16 403.16Total Comprehensive Income for the year (II) - - 401.03 (2.54) 398.50
-Dividends paid including Tax on Dividend (90.76) (90.76) Reversal of Deferred Tax Asset on account of Intangible asset Pursuant to the order of Hon'ble Gujarat High Court
(1.15) (1.15)
Amount Transfered from Retained Earnings to General Reserve 300.00 (300.00) -Transaction for the year (III) - 298.85 (390.76) - (91.91)Balance at 31st March, 2017 (I+II+III) 0.30 1,137.98 718.18 8.16 1,864.63
Balance at 1st April, 2017 (I) 0.30 1,137.98 718.18 8.16 1,864.63Other Comprehensive Income (3.06)* (0.14) (3.20)Profit for the period 412.63 412.63Total Comprehensive Income for the year (II) - - 409.57 (0.14) 409.43
-Dividends paid including Tax on Dividend (90.76) (90.76) Reversal of Deferred Tax Asset on account of Intagible asset Pursuant to the order of Hon'ble Gujarat High Court (0.87) (0.87)
Amount Transfer from Retained Earnings to General Reserve 100.00 (100.00) -Transaction for the year (III) - 99.13 (190.76) - (91.62)Balance at 31st March, 2018 (I+II+III) 0.30 1,237.12 937.00 8.03 2,182.44
*Represents Re-measurement of Defined Plans.
For the year ended 31st March, 2018
As per our report of even dateFor K. S. Aiyar & Co. Chirayu Amin Pranav Amin Shaunak Amin K. G. Ramanathan Chartered Accountants Firm Registration No. 100186W
Chairman & CEODIN No.: 00242549
Managing DirectorDIN No.: 00245099
Managing DirectorDIN No.: 00245523
DirectorDIN No.: 00243928
Rajesh S. Joshi Milin Mehta Archana Hingorani R. K. Baheti Ajay Kumar DesaiPartner Membership No. 38526
DirectorDIN No.: 01297508
DirectorDIN No.: 00028037
Director-Finance & CFODIN No.: 00332079
Senior Vice President - Finance & Company Secretary
Vadodara: 16th May, 2018 Vadodara: 16th May, 2018
F-82
Notes to the Consolidated Financial Statements
1 General information The Financial Statement of the subsidiaries, associates and Joint Venture used in the consolidation is drawn up to the same reporting date as that of the Alembic Pharmaceuticals Limited (“the Holding Company”), namely 31st March, 2018.
2 Significant accounting policiesStatement of compliance The Group has prepared its consolidated financial statements for the year ended 31st March, 2018 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) together with the comparative period data as at and for the year ended 31st March, 2018.
Principles of Consolidation: The Consolidated Financial Statements consist of Alembic Pharmaceuticals Limited (“the Holding Company”) and its subsidiaries (collectively referred to as “the Group”), associates and Joint Venture. The Consolidated Financial Statements have been prepared on the following basis:
The financial statements of the Holding Company and its subsidiaries have been consolidated on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after eliminating
intra-group balances and intra-group transactions resulting in unrealised profits or losses as per Ind AS 27 – “Consolidated and Separate Financial Statements” specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules, 2015.
On consolidation, transactions are recorded by the Group at the rate of exchange prevailing on the date of transaction. All monetary assets and monetary liabilities are converted at the rates prevailing at the end of the year. Any exchange difference arising on consolidation is recognised in the Foreign Currency Translation Reserve.
Investment and share of profit of associate and Joint Venture have been consolidated as per the equity method as per Ind AS 28 – “Investments in Associates” and Ind AS 111 - “Joint Arrangements” respectively specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules 2015.
The Group accounts for its share of post-acquisition changes in net assets of associates, after eliminating unrealised profits and losses resulting from transactions between the Group and its associates to the extent of its share, through its Consolidated Statement of Profit and Loss, to the extent such change is attributable to the associates’ Statement of Profit and Loss and through its reserves for the balance based on available information.
As at 31st March, 2018
3 Companies Included in Consolidation:Name Country of
IncorporationNature Proportion of Ownership Interest
As on 31st March, 2018
Alembic Global Holding SA (AGH SA) Switzerland Subsidiary 100% subsidiary of Alembic Pharmaceuticals Limited (APL)AG Research Private Limited India Subsidiary
Aleor Dermaceuticals Limited India Subsidiary 60% subsidiary of APL
Alembic Pharmaceuticals Australia Pty Ltd Australia Subsidiary 100% subsidiary of AGH SA
Alembic Pharmaceutical Inc. U.S.A Subsidiary
Alembic Pharmaceuticals Europe Limited Malta Subsidiary
Alnova Pharmaceuticals SA Switzerland Subsidiary
Alembic Pharmaceuticals Canada Ltd Canada Subsidiary
Genius LLC Ukraine Subsidiary
Alembic Mami SPA Algeria Joint Venture 49% shareholding of AGH SA
F-83
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
Name Country Of Incorporation
Nature Proportion Of Ownership Interest As On 31st March, 2018
Rhizen Pharmaceuticals SA (RP SA) Switzerland Associate 40.3% shareholding of AGH SA
Incozen Therapeutics Pvt Limited India Associate 50% shareholding of APL
Dahlia Theraputics SA Switzerland Subsidiary of Associate
100% subsidiary of RP SA
Rhizen Pharmaceuticals Inc USA Subsidiary of Associate
4 Significant Accounting Policies: The accounting policies of the Group and that of its subsidiaries, associates and Joint Venture are generally similar and as per generally accepted accounting principles in India please refer page no 69.
5 Translation of Accounts: In Consolidated Financial Statements, the Financial Statements of subsidiary companies and proportionate share of associates and Joint Venture have been translated into INR as prescribed under Ind AS 21 the Effects of Changes in Foreign Exchange Rates specified under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules 2015.
F-84
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
6. Property, Plant and Equipment` in Crores
Property, Plant and Equipment Free Hold Land
Lease Hold Land
Buildings Plant & Equipment
R&D Equipment
Furniture & Fixtures
Vehicles Office Equipments
Total
Gross Carrying amountCarrying Amount as at 1st April 2016 1.92 19.35 233.50 409.86 82.49 8.84 21.25 2.84 780.05Additions / Adjustment - 0.14 32.46 113.53 43.18 2.77 0.54 0.99 193.62Disposals / Adjustment - - - (11.96) (0.10) (0.67) (10.70) (0.16) (23.59)Closing Gross Carrying Amount 1.92 19.49 265.96 511.43 125.57 10.95 11.08 3.67 950.09
Accumulated Depreciation - 0.22 12.21 44.35 7.34 0.82 6.40 0.62 71.96Depreciation charge during the year - 0.30 11.88 56.27 11.33 1.07 2.03 0.72 83.60Disposals / Adjustment - - - (0.10) - - (4.68) (0.10) (4.88)Closing Accumulated Depreciation - 0.51 24.09 100.52 18.67 1.90 3.75 1.25 150.69
Net Carrying Amount as at 1st April, 2016 1.92 19.13 221.30 365.51 75.15 8.02 14.84 2.22 708.09Net Carrying Amount as at 31st March, 2017 1.92 18.98 241.88 410.91 106.90 9.06 7.33 2.43 799.40
Gross Carrying amountCarrying Amount as at 1st April, 2017 1.92 19.49 265.96 511.43 125.57 10.95 11.08 3.67 950.09Additions / Adjustment 50.07 - 23.52 76.99 70.09 5.91 1.07 2.91 230.56Acquisition of a subsidiary 8.48 - - 0.03 - - - - 8.51Disposals / Adjustment - (0.90) (8.87) (5.80) (0.50) (0.13) (0.03) (0.38) (16.60)Closing Gross Carrying Amount 60.47 18.58 280.61 582.66 195.15 16.73 12.13 6.21 1,172.56
Accumulated DepreciationAs at 1st April, 2017 - 0.51 24.09 100.52 18.67 1.90 3.75 1.25 150.69Depreciation charge during the year 0.10 10.20 12.20 61.27 14.67 1.16 1.47 0.85 101.93Disposals / Adjustment - - (4.40) (2.30) - (0.08) (0.01) (0.29) (7.08)Closing Accumulated Depreciation 0.10 10.72 31.88 159.49 33.34 2.98 5.22 1.81 245.54
Net Carrying Amount as at 1st April, 2017 1.92 18.98 241.88 410.91 106.90 9.06 7.33 2.43 799.40Net Carrying Amount as at 31st March, 2018 60.37 7.87 248.73 423.17 161.82 13.75 6.91 4.40 927.02
Note:1 During the year, the Company, through its wholly owned subsidiary Alembic Pharmaceutials Inc., acquired USA based generic drug developer
Orit Laboratories LLC along with Okner Realty LLC with effect from 1st November, 2017.2 The Company does not have any restrictions on the title of its property, plant and equipment.3 Borrowing cost capitalised during the period amounting to ` 22.61 Crores (PY ` 2.37 Crores)4 Sales proceeds are deducted from gross cost where cost is unacertainable5 Presentation had been made during the year (with corresponding restatement of comparative amounts) to continue carrying value of all its Property
Plant & Equipment as per previous GAAP, as deemed cost as on date of transition, as per Ind AS.
F-85
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
` in CroresGoodwill Other Intangible Assets
As at 31st March, 2018
As at 31st March, 2017
As at 31st March, 2018
As at 31st March, 2017
7 Goodwill and Other Intangible AssetsGross Carrying Amount - - - -Acquisition of a subsidiary 3.94 - 65.95 -Closing Gross Carrying Amount 3.94 - 65.95 -Accumulated Amortisation - - - -Amortisation expense (0.17) - (3.37) -Closing Accumulated Depreciation (0.17) - (3.37) -Net Carrying Amount 3.77 - 62.59 -
` in CroresAs at
31st March, 2018As at
31st March, 2017
8 Non-Current Financial InvestmentInvestments in Equity Instruments-UnquotedValued at Fair value through Profit & Loss
Nil (PY: 18,000) equity shares of ` 1 each fully paid up in Shivalik Solid Waste Management Ltd.
- 0.02
Investments in Preference SharesValued at Amortised cost
1% Cumulative Redeemable Non-Convertible Preference Shares 4,50,000 (PY: 4,50,000) of ` 10 each fully paid up in EICL (Redemption date 14th December, 2031) 0.45 0.45
0.45 0.47
` in CroresAs at
31st March, 2018As at
31st March, 2017
9 Investment accounted for using Equity Method Investments in Equity Instruments -UnquotedValued at Cost(i) Investment in Associates
10,00,000 (PY: 10,00,000) equity shares of ` 10 each at a premium of ` 20 each fully paid up in Incozen Therapeutics Pvt. Ltd
1.72 1.83
Add: Share in Profit / (loss) for the period (0.06) (0.12)a 1.66 1.71
50,000 (PY: 50,000) equity shares of CHF 1 each fully paid up in Rhizen Pharmaceuticals SA 0.21 0.26
Add: Share in Profit / (loss) for the period 0.12 (0.06)Add: Impact of Foreign Currency translations 0.02 (0.00)
b 0.34 0.20(ii) Investment in Joint Venture
34,297 (PY: 34,297 ) equity shares of DZD 1000 each fully paid up representing 49% of equity in Alembic Mami SPA, Algeria 47.48 51.32
Add /(Less) : Share in Profit / (loss) for the period (8.14) (3.65)Add/(Less):Impact of Foreign Currency translations (0.15) (0.19)
c 39.19 47.48 Aggregate amount of unquoted Investments (a+b+c) 41.19 49.39
F-86
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
` in CroresAs at
31st March, 2018As at
31st March, 2017
10 Other Non-Current AssetsCapital Advances 44.96 69.70Balance with Government Authorities 26.17 1.53
71.14 71.24
` in CroresAs at
31st March, 2018As at
31st March, 2017
11 Inventories (Basis of Valuation - Refer Note 2.11) Raw Materials 186.21 134.14 Packing Materials 23.80 18.56 Work-in-Progress 51.92 30.72 Finished Goods 345.56 345.02 Traded Goods 110.66 80.02 Goods-in-Transit 9.32 19.64 Stores and Spares 6.46 4.65
733.93 632.75
Note:(i) Inventories are hypothecated as security for working capital borrowings(ii) During the year ended 31st March, 2018 the Company recorded inventory write-downs of ` 3.89 Crores (PY ` 3.16 Crores).
` in CroresAs at
31st March, 2018As at
31st March, 2017
12 Trade Receivables(Unsecured, considered good, unless otherwise stated)Considered Good a 526.34 338.82
Considered Doubtful 1.96 7.82Provision for Doubtful debts (1.96) (7.82)
b - -(a+b) 526.34 338.82
Note:Receivables are hypothecated as security for working capital borrowingsRefer Note No 32(6)(g) of Related Party Receivables
` in CroresAs at
31st March, 2018As at
31st March, 2017
13 Cash and Cash Equivalents Balances with Banks 83.41 152.91 Cash on hand 0.34 0.17
83.74 153.08
F-87
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
` in CroresAs at
31st March, 2018As at
31st March, 2017
14 Bank Balances Other than Cash and Cash EquivalentsUnpaid Dividend Account 4.03 3.18Margin Money Deposit Account 2.14 3.35
6.18 6.52
` in CroresAs at
31st March, 2018As at
31st March, 2017
15 Others Financial Assets (Current)Security Deposits 17.79 14.10Unrealised Foreign Exchange Gain 12.18 -
29.97 14.10
Refer note No 32(6)(g) for Related Party Deposits
` in CroresAs at
31st March, 2018As at
31st March, 2017
16 Other Current Assets (Unsecured, considered good)Advance to Employees 5.80 3.91Advance to Suppliers 151.94 101.58Pre-paid Expense 15.32 7.55Balances with Government Authorities 268.08 114.14
441.13 227.19
` in CroresAs at
31st March, 2018As at
31st March, 2017
17 Equity Share CapitalAuthorized20,00,00,000 - Equity shares of ` 2/- each 40.00 40.00
40.00 40.00Shares issued, subscribed and fully paid18,85,15,914 - Equity shares of ` 2/- each 37.70 37.70
37.70 37.70
Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting periodAs at 31st March, 2018 As at 31st March, 2017
Numbers ` in Crores Numbers ` in CroresAt the beginning of the year 18,85,15,914 37.70 18,85,15,914 37.70Outstanding at the end of the year 18,85,15,914 37.70 18,85,15,914 37.70
The rights, preferences and restrictions including restrictions on the distribution of dividends and the repayment of capital The company is having only one class of shares i.e. Equity carrying a nominal value of ` 2/- per share Every holder of the equity share of the Company is entitled to one vote per share held. In the event of liquidation of the Company, the equity shareholders will be entitled to receive remaining assets of the Company after the distribution / repayment of all creditors. The distribution to the equity shareholders will be in proportion of the number of shares held by each shareholder.
The Company declares and pays dividend on the equity shares in Indian Rupees. Dividend proposed by the Board of Directors is subject to approval of the shareholders at the ensuing Annual General Meeting.
F-88
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Shares in the company held by each shareholder holding more than 5% specifying the number of shares held
As at 31st March, 2018 As at 31st March, 2017Numbers % held Numbers % held
1 Alembic Limited 5,54,71,208 29.43% 5,50,00,000 29.18%2 Shreno Limited 2,06,98,780 10.98% 2,06,98,780 10.98%3 Nirayu Private Limited 4,93,36,655 26.17% 1,37,13,755 7.27%4 Whitefield Chemtech Private Limited - - 1,82,85,230 9.70%5 Sierra Investments Private Limited - - 1,73,37,670 9.20%
` in CroresAs at
31st March, 2018As at
31st March, 2017
18 Other Equity(Refer statement of changes in equity for detailed movement in other equity balance)(a) Capital Reserve 0.30 0.30(b) General Reserve 1,237.12 1,137.98(c) Retained Earnings 937.00 718.18(e) Foreign Currency Translation Reserve 8.03 8.16Total Other Equity 2,182.44 1,864.63
Nature and purpose of each ReserveCapital Reserve :- Capital Reserve is created on receipt of Government subsidy for setting up factory in backward area.General Reserve :- The reserve is created by transfer of a portion of the net profit.Foreign Currency Translation Reserve :- Exchange differences relating to the translation of the results and net assets of the Group’s foreign operations from their functional currencies to the Group’s presentation Currency (i.e.INR) are recognised directly in the other comprehensive income and accumulated in foreign currency translation reserve.
` in CroresAs at
31st March, 2018As at
31st March, 2017
19 Borrowings (Non-Current)Term Loan ( Un Secured)From Bank 500.00 -
500.00 -
Notes:(i) Term loan of ` 200 Crores: Payable at the end of 30th Month from the date of first drawal (in January, 2020). Interest @ rate
of six months T Bills plus spread of 87 bps.(ii) Term loan of ` 300 Crores: Payable after 3 years from the date of disbursement. Subject to maximum up to 31st December,
2020. Interest @ rate of one year G-sec plus spread of 61 bps.
F-89
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
` in CroresAs at
31st March, 2018As at
31st March, 2017
20 Provisions (Non-Current) Provision for Employee Benefits- Gratuity 1.84 - - Leave benefits 18.03 15.42Provision for Non-Saleable return of goods 41.79 41.79
61.66 57.22
` in CroresAs at
31st March, 2018As at
31st March, 2017
21 Deferred Tax Liabilities (Net) Deferred Tax Liabilities Depreciation a 118.50 92.22 Deferred Tax Assets Provision for Doubtful debts 0.68 2.71 MAT Credit Entitlement 57.85 29.72 Intangible Asset 2.58 3.45 Others 21.95 19.42
b 83.06 55.29(a-b) 35.44 36.93
` in CroresAs at
31st March, 2018As at
31st March, 2017
22 Borrowings (Current)From BanksSecuredWorking Capital facilities 46.53 8.28
First charged on Pari-Passu basis by hypothecation of Inventory and Trade Receivables at varying rates repayable on demand
UnsecuredShort term Loans, Interest @ rate of 3 months Libor + 100 bps. 86.25 80.24Working capital demand loan, Interest @ rate of 7.85% 75.00 -
207.78 88.51
` in CroresAs at
31st March, 2018As at
31st March, 2017
23 Trade PayablesDue to Micro and Small Enterprises 0.20 1.15Others 759.12 499.58
759.32 500.73
Refer Note No 32(6)(g) for Related Party Payables
F-90
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
` in CroresAs at
31st March, 2018As at
31st March, 2017
24 Other Financial LiabilitiesInterest accrued but not due on borrowings 2.92 0.35Unpaid dividends 4.03 3.18Trade Deposits 12.58 12.57Unpaid / Unclaimed matured deposits and interest accrued thereon 0.06 0.07
19.59 16.17
` in CroresAs at
31st March, 2018As at
31st March, 2017
25 Other Current LiabilitiesStatutory dues 70.36 19.44Advance from Customers 9.47 1.35Others 43.46 44.32
123.29 65.11
` in CroresAs at
31st March, 2018As at
31st March, 2017
26 Provisions (Current) Provision for Employee Benefits Gratuity 6.73 6.04 Leave benefits 6.77 6.32
13.51 12.36
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
27 Revenue from OperationsSale of products- Domestic* 1,370.24 1,318.07- Exports 1,665.42 1,741.45
3,035.67 3,059.52- Export Incentives 69.73 53.43- Royalty 19.27 17.97
- Other Operating Revenues* 6.14 3.68 3,130.81 3,134.61
* Revenue from operations for the period 2016-17 and for the period 1st April, 2017 to 30th June, 2017 are including excise duty, however for the period from 1st July, 2017 to 31st March, 2018 is net of Goods and Service Tax (GST), Accordingly, revenue from operation are not comparable.
F-91
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
28 Other IncomeDividend 0.75 0.19Insurance Claims 0.82 1.21Lease Rent Income (Refer Note No. 32 (12)) 0.03 0.16Profit /(Loss) on Sales of Assets 4.82 (0.56)Interest Income 0.62 1.03
7.03 2.02
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
29 Cost of Material ConsumedInventory at the beginning of the year 152.70 106.44Add : Purchases 783.06 750.13
935.76 856.57Less : Inventory at the end of the year 210.01 152.70
725.75 703.87Changes in inventories of Finished Goods, Stock in Trade and Work in ProgressWork-in-Progress 51.92 30.72Finished Goods 354.88 364.66Stock-in-Trade 110.66 80.02Inventory at the end of the year a 517.46 475.41
Work-in-Progress 30.72 24.26Finished Goods 364.66 381.20Stock-in-Trade 80.02 -Inventory at the beginning of the year b 475.41 405.46
(b-a) (42.06) (69.95)
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
30 Employee Benefits ExpenseSalaries and Wages 592.30 528.32Contribution to Provident and other funds 16.74 18.72Staff welfare expense 13.77 11.79
622.81 558.83
F-92
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
31 Other ExpensesConsumption of Stores, Spares, Laboratory Material and Analytical Expense 158.63 131.10Power and Fuel 70.35 64.20Manufacturing and Labour Charges 17.94 29.55Repairs and Maintenance Machinery 19.78 16.98 Buildings 7.05 9.43 Others 4.27 4.53Freight and Forwarding Charges 64.32 40.92Publicity Expense, Service Fees and Commission 315.91 352.22Excise Duty 0.63 29.46Rent (Refer Note No. 32 (11)) 14.30 13.56Rates and Taxes 5.82 8.86Insurance 5.57 5.60Travelling Expense 114.61 113.98Communication Expenses 25.75 23.17Legal & Professional Fees 77.84 115.11Payment to Auditors 1.04 0.99Exchange Difference (net) (27.84) 5.97Bad Debts written off 0.07 1.30Expenses on CSR Activities 7.14 4.22Donation 6.07 0.02Patent Filing & Registration Fees 38.50 18.52External Research & Development 36.86 98.20Miscellaneous Expenses 14.75 14.53
979.34 1,102.40
32 Other explanatory Notes to the Consolidated Financial Statements1 Earning Per Share (EPS)
For the Year Ended on
31st March, 2018
For the Year Ended on
31st March, 2017(a) Net Profit after non-controlling interest attributable to equity shareholders (` in
Crores) 412.63 403.16
(b) Weighted average numbers of equity shares 18,85,15,914 18,85,15,914(c) Basic and diluted Earnings per share before Extra-Ordinary Items in `
( Face Value per share ` 2/- each) 21.89 21.39
F-93
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
2 Contingent Liabilities and Commitments (To The Extent Not Provided For)` in Crores
As at 31st March, 2018
As at 31st March, 2017
i Estimated amount of contracts net of advances remaining to be executed on capital accounts
134.49 227.18
ii Contingent liabilities(a) Letter of credit and Bank Guarantees 81.38 72.42(b) Liabilities Disputed in appeals
Excise duty 5.93 5.99Sales Tax 2.57 2.91Income Tax - 0.03
(c) Claims against the company not acknowledged as debt 0.02 0.37(d) Export obligation against advance licence 3.79 -(e) Disputed liability in respect of Ministry of Industry, Department of Chemicals
and Petrochemicals in respect of price of Rifampicin allowed in formulationsand landed cost of import.
0.35 0.35
iii Contingent Asset(a) As per JV agreement, the interest on NCD issued by Aleor and subscribed by company will start accruing
only when Aleor starts making cash profit. Since in pharma industry the gestation period is long and thereis significant uncertainty as to when JV will start making profit, the fair value of such contingent asset is notascertainable.
(b) The company has made application to Department of Industrial Policy and Promotion for subsidy for setting new plant in Sikkim. The same is yet to be approved by the relevant authorities. Also large number of claimsof various companies (who set up their plants much before ours) are pending. Hence the quantification offair value of such subsidy are unacertainable.
3 Additional Information` in Crores
Particulars Net Assets (Total Assets - Total Liabilities)
Share in Profit or Loss
Share in Other Comprehensive income
Share in Total Comprehensive income
As a % of consolidated
Net Assets
Amount As % of consolidated profit or loss
Amount As % of consolidated
Amount As % of consolidated
Amount
Parent :Alembic Pharmaceuticals Limited 98.85% 2194.64 102.22% 421.99 95.71% (3.06) 102% 418.93
Subsidiaries :1. Indian : A G Research
Pvt Ltd. 0.00% (0.01) (0.91%) (3.74) 63.81% (2.04) (0.91%) (3.74)
Aleor Dermaceuticals Limited 0.02% 0.51 0.12% 0.49 Nil Nil 0.17% 0.68
2. Foreign : Alembic Global Holding SA (wholly owned subsidiary of Alembic Pharmaceuticals Limited )*
5.24% 116.40 1.77% 7.30 Nil Nil 1.28% 5.26
Minority interest in all subsidiaries 0.01% 0.31 0.05% 0.19 Nil Nil (0.05%) (0.19)
F-94
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
` in CroresParticulars Net Assets
(Total Assets - Total Liabilities)Share in
Profit or LossShare in
Other Comprehensive incomeShare in
Total Comprehensive incomeAs a % of
consolidated Net Assets
Amount As % of consolidated profit or loss
Amount As % of consolidated
Amount As % of consolidated
Amount
Associates : (Investment as per the equity method)
1. Indian : IncozenTherapeutics PvtLimited
(0.06%) (1.35) (0.02%) (0.06) Nil Nil (0.02%) (0.06)
2. Foreign : NA Nil Nil Nil Nil Nil Nil Nil Nil
Joint Venture :(As per proportionate consolidation / investment as per equity method)1. Indian : NA Nil Nil Nil Nil Nil Nil Nil Nil2. Foreign : NA Nil Nil Nil Nil Nil Nil Nil NilIntercompany Elimination and Consolidation Adjustments
(4.07%) (90.35) (3.23%) (13.35) (59.53%) 1.90 (2.75%) (11.25)
100.0% 2,220.15 100.0% 412.82 100.0% (3.20) 100.0% 409.63
4 Research and Development Expenses ` in Crores
For the Year Ended on
31st March, 2018
For the Year Ended on
31st March, 2017Material Consumption 68.16 83.38Employees Benefit Expenses 102.50 75.76Utilities 12.26 9.69Depreciation 20.76 13.7Others 207.61 244.64Total 411.28 427.17
5 Operating SegmentThe Group Company has only one reportable segment i.e Pharmaceuticals
` in CroresInformation about products and services API 650.60 Formulations 2,480.21Information about Geographical Areas
a) Revenue from External CustomersIn India 1,375.38Outside India 1,755.43
b) Non-Current AssetsIn India 2,116.31Outside India -
c) Information about major customersConsolidated Revenue – exceeding 10% from each single external customer. NIL
F-95
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
6 Disclosures in respect of Related Parties transactions(a) Associate Companies:
1 Incozen Therapeutics Pvt. Limited2 Rhizen Pharmaceuticals SA (Associate of Alembic Global Holding SA)3 Dahlia Therapeutics (Wholly Owned Subsidiary of Rhizen Pharmaceuticals SA)4 Rhizen Pharmaceuticals Inc (Wholly Owned Subsidiary of Rhizen Pharmaceuticals SA)
(b) Joint Venture1 Alembic Mami SPA, (Joint venture of Alembic Global Holding SA.)
(c) Other Related Parties1 Alembic Limited2 Whitefield Chemtech Pvt. Limited (up to 12th December, 2017)3 Nirayu Pvt.Limited4 Shreno Limited5 Paushak Limited6 Quick Flight Limited (upto 9th May, 2017)7 Sierra Investments Pvt. Limited (Up to 12th December, 2017)8 Viramya Packlight LLP (Formally Known as Viramya Packlight Ltd)9 Shreno Publications Limited
(d) Key Management personnel1 Mr. Chirayu Amin Chairman & CEO2 Mr. Pranav Amin Managing Director3 Mr. Shaunak Amin Managing Director4 Mr. R. K. Baheti Director - Finance & CFO5 Mr. K.G Ramnathan Non-Executive Independent Director6 Mr. Pranav Parikh Non-Executive Independent Director 7 Mr. Paresh Saraiya Non-Executive Independent Director 8 Mr. Milin Mehta Non-Executive Independent Director 9 Ms. Archana Hingorani Non-Executive Independent Director 10 Mr. Ajay Kumar Desai Sr. Vice President - Finance & Company Secretary
(e) Relatives of Key Management Personnel :1 Mrs. Malika Amin2 Mr. Udit Amin3 Ms. Yera Amin4 Mrs. Jyoti Patel5 Mrs.Ninochaka Kothari6 Mrs. Shreya Mukherjee
F-96
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
(f) Transactions with Related parties:
During the year, the following transactions were carried out with related parties and relative of Key ManagementPersonnel in the ordinary course of the business:
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2017
AssociatesSale of Goods/DEPB 5.97 6.37Reimbursement of expenses 0.58 0.30Joint VentureCorporate Guarantee Given 13.69 10.00Sale of Goods/DEPB 4.58 10.04Key Management PersonnelShort Term Employment Benefits 28.07 20.64Terminal Benefits 1.93 1.78Commission 28.30 25.00Sitting Fees 0.17 0.13Dividend Paid 2.62 2.62Other Related PartiesPurchase of Goods/DEPB/IP Rights 74.10 73.04Dividend Paid 50.01 50.01Receiving of Services 8.22 7.41Rent Paid 6.80 5.67Purchase of Fixed Assets 3.73 2.93Deposit Given 2.84 0.88Sale of Goods/DEPB 2.48 3.38Reimbursement of expenses 0.78 (0.91)
(g) Balance Outstanding as at the end of the year` in Crores
As at 31st March, 2018
As at 31st March, 2017
Associate Companies:Trade Receivable 3.55 3.55Joint VentureCorporate Guarantee 32.59 18.81Trade Receivable 0.23 4.52Other Related PartiesTrade Payable 11.71 9.27Trade Receivable 5.87 3.55Deposit Given 12.47 9.57Key Management PersonnelCommission Payable 28.30 33.99
F-97
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
(h) Disclosure in respect of material transaction with related parties during the year.` in Crores
For the Year Ended on
31st March, 2018
For the Year Ended on
31st March, 2017Purchase of Goods/DEPB/IP Rightsi Alembic Limited 50.05 53.83ii Sierra Investments Pvt. Limited 10.92 16.48iii Shreno Publication Limited 6.01 -Sale of Goods/DEPBi Rhizen Pharmaceutical SA 5.97 6.37ii Alembic Limited 2.13 2.91Purchase of Fixed Assetsi Shreno Limited 3.73 2.87Receiving of servicesi Alembic Limited 7.72 3.18ii Shreno Limited 4.39 4.23Reimbursement of expensesi Alembic Limited 0.78 (0.91)ii Rhizen Pharmaceutical SA 0.58 0.30Rent Paidi Alembic Limited 6.18 5.14Deposit Giveni Alembic Limited 2.84 0.88Corporate Gurantee Giveni Alembic Mami SPA, Algeria 13.69 -ii Shreno Limited - 10.00Remunerationi Mr. Chirayu Amin 22.00 20.50ii Mr. Pranav Amin 15.65 11.50iii Mr. Shaunak Amin 15.66 11.50Dividend Paidi Alembic Limited 22.00 22.00ii Shreno Limited 8.28 7.35iii Sierra Investments Pvt Limited 6.94 6.87iv Nirayu Pvt Limited 5.49 6.49v Whitefield Chemtech Pvt Limited 7.31 7.31vi Mr. Chirayu Amin 1.81 1.81vii Mr. Pranav Amin 0.40 0.40viii Mr. Shaunak Amin 0.40 0.40
F-98
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
7 Income Taxesa. Income tax expense
` in CroresFor the Year
Ended on 31st March, 2018
For the Year Ended on
31st March, 2018
Current TaxCurrent tax expense 123.61 122.40 Deferred TaxDecrease / (increase) in deferred tax assets (28.63) (25.88)(Decrease) / increase in deferred tax liabilities 26.28 25.67 Total deferred tax expenses (benefit) (2.35) (0.21)Total Income tax expenses * 121.27 122.19
* This excludes tax benefit on other comprehensive income of ` 0.83 Crores for 31st March, 2018 & ` 0.58 Crores for 31st March, 2017respectively.
b. Reconciliation of tax expense and the accounting profit multiplied by India’s tax rate:` in Crores
As at 31st March, 2018
As at 31st March, 2017
Profit before Income tax expense 541.27 525.36Tax at the Indian Tax Rate* 115.52 112.12Tax effect of amounts which are not deductible (taxable) in calculating taxable incomeDividend income (0.04) (0.04)Expenditure related to exempt income 0.02 0.00Effect on account of overseas tax 5.85 8.52Others (including deferred tax) (0.08) 1.59Income Tax Expense 121.27 122.19
* The company is covered under the provisions of MAT u/s 115JB and the applicable Indian tax rate for year ended 31st March, 2018 and 31st March, 2017 is 21.3416%.
c. Current tax (liabilities)/assets` in Crores
As at 31st March, 2018
As at 31st March, 2017
Opening balance (9.79) (9.26)Income tax paid 134.92 121.29Current income tax payable for the period / year (122.78) (121.82)Written back of income tax provision of earlier years 1.10 -Net current income tax asset/ (liability) at the end 3.45 (9.79)
F-99
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
8 Financial instrumentsCategory of Financial Instrument
` in CroresParticulars As at 31st March, 2018 As at 31st March, 2017
Fair value through profit
or loss
Fair value through other
comprehensive income
Amortised cost
Fair value through profit
or loss
Fair value through other
comprehensive income
Amortised cost
Financial assetsInvestment in Equity instruments - - - 0.02 - -Investment in Preference shares - - 0.45 - - 0.45Trade Receivables - - 526.34 - - 338.82Cash and cash equivalents - - 83.74 - - 153.08Bank balances other than Cash and Cash Equivalents
- - 6.18 - - 6.52
Derivatives not designated as Hedge 5.53 - - - - -Others 24.44 - - 14.10Total 5.53 - 641.15 0.02 - 512.98Financial liabilitiesBorrowings - - 707.78 - - 88.51Trade Payables - - 759.32 - - 500.73Other Financial liabilities - - 19.59 - - 16.17Derivatives not designated as Hedge - - - 12.32 - -Total - - 1,486.69 12.32 - 605.41
Fair value measurement hierarchy :` in Crores
Particulars As at 31st March, 2018 As at 31st March, 2017‘Level of input used in ‘Level of input used in
Level-1 Level-2 Level-3 Level-1 Level-2 Level-3Investment in Equity instruments - - - - - 0.02Derivatives not designated as Hedge - 5.53 - - 12.32 -
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability.
In case of investment in equity instrument, cost has been considered as approximate fair value in view of materiality of value of investment.
9 Financial Risk managementThe Group has exposure to the following risks arising from financial instruments:(i) Credit Risk;(ii) Liquidity Risk; and(iii) Market Risk
i) Credit Risk Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails tomeet its contractual obligations, and arises principally from the Group’s receivables from customers, Deposit andother receivables.
F-100
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Trade receivables
The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer, demographics of the customer, default risk of the industry and country in which the customer operates. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. The Group has used expected credit loss (ECL) model for assessing the impairment loss.
` in CroresAs at
31st March, 2018As at
31st March, 2017Trade Receivables 526.34 338.82Allowance for doubtful debts 1.96 7.82Percentage 0.4% 2.3%
Reconciliation of loss allowance provision – Trade receivables` in Crores
Loss allowance on 1st April. 2016 6.21Changes in loss allowance 1.61Loss allowance on 31st March, 2017 7.82Changes in loss allowance (5.86)Loss allowance on 31st March, 2018 1.96
Cash and cash equivalents, Other Bank Balances and Derivatives As at the year end, the Group held cash and cash equivalents of ` 83.74 Crores (31st March, 2017 - ` 153.08 Crores). The cash and cash equivalents other Bank balances and derivatives are held with bank with good credit rating.
ii) Liquidity Risk Liquidity risk is the risk that the Group will not be able to meet its financial obligation as they fall due. TheGroup’s ensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normaland stressed conditions. The Group has sufficient unutilised fund and non fund based working capital credit limitduly sanctioned by various banks.
The company is rated by leading credit agency CRISIL, the rating “CRISIL A1+” and “AA+/Stable” has been assigned for short term and long term facility respectively, indicating high degree of safety regarding timely payment andservicing of financial obligation.
Exposure to Liquidity Risk The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.
` in CroresAs at 31st March, 2018 As at 31st March, 2017
Less than 1 year
More than 1 Years
Total Less than 1 year
More than 1 Years
Total
Non derivativeBorrowings 207.78 500.00 707.78 88.51 - 88.51Trade payables 759.32 - 759.32 500.73 - 500.73Other financial liabilities 19.59 - 19.59 16.17 - 16.17DerivativeForward / Options contracts - - - 12.32 - 12.32
F-101
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
iii) Market RiskCurrency Risk
The Group’s foreign exchange risk arises from its foreign operations, foreign currency revenues, expenses andforeign currency borrowings. The Group uses foreign exchange forward contracts and option contracts, tomitigate the risk of changes in foreign currency exchange rates in respect of its budgeted business transactionsand recognized assets and liabilities. The Group enters into foreign currency options and forward contracts whichare not intended for trading or speculative purposes but for hedge purposes.
The Group’s exposure to foreign currency risk at the end of the reporting period expressed in INR, are as follows:` in Crores
As at 31st March ,2018 US Dollars Euro Others TotalFinancial assetsTrade receivables 452.96 26.41 16.75 496.12Cash and cash equivalents 7.95 0.75 - 8.70Financial liabilitiesTrade payables 59.83 2.05 1.89 63.77Borrowing (PCFC) 32.59 - - 32.59
As at 31st March ,2017 US Dollars Euro Others TotalFinancial assetsTrade receivables 338.72 25.71 15.86 380.29Financial liabilitiesTrade payables 55.09 9.95 1.93 66.97
Sensitivity analysis For the years ended 31st March, 2018 and 31st March, 2017 every 5% weakening in the exchange rate between the Indian Rupee and the respective major currencies for the above mentioned financial assets/liabilities would increase Group’s profit and equity by approximately ̀ 19.68 Crores and ` 14.97 Crores respectively. A 5% strengthening of the Indian Rupee and the respective major currencies would lead to an equal but opposite effect.
Interest Rate Risk and Exposure to Interest Rate Risk The Group has loan facilities on floating interest rate, which exposes the group to risk of changes in interest rates.
For the years ended 31st March, 2018 and 31st March, 2017, every 50 basis point decrease in the floating interest rate component applicable to its loans and borrowings would decrease the Group’s loss by approximately ` 3.05 Crores and ̀ 0.44 Crores respectively. A 50 basis point increase in floating interest rate would have led to an equal but opposite effect.
Commodity Rate Risk The Group’s operating activities involve purchase and sale of Active Pharmaceutical Ingredients (API), whose prices are exposed to the risk of fluctuation over short periods of time. Commodity price risk exposure is evaluated and managed through procurement and other related operating policies.
Other Risk Since Group is significantly dealing in regulatory market, continuous compliance of all manufacturing facilities is pre requisite, any adverse action by regulatory authority of the group’s target market can adversely affect Group operation.
F-102
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
10 Capital ManagementThe Group’s capital management objectives are:
to ensure the Group’s ability to continue as a going concern; andto provide an adequate return to shareholders through optimisation of debts and equity balance.
The Group monitors capital on the basis of the carrying amount of debt less cash and cash equivalents as presented on the face of the financial statements. The Group’s objective for capital management is to maintain an optimum overall financial structure.
Dividend on equity shares paid during the year During the year ended 31st March, 2018 an amount of ` 4.00 ( P.Y. ` 4.00) of dividend per equity share was paid to the equity shareholders after the AGM approval. ` 75.41 Crores and corporate tax of ` 15.35 in relation to FY 2016-17.
The Board of Directors has recommended dividend on Equity Shares at ` 4 per share i.e. 200% for the year ended on 31st March, 2018. Dividend Proposed by the Board of Directors is subject to approval of the shareholders at the ensuing Annual General Meeting.
11 Leases The Group has obtained certain premises for its business operations under operating lease or leave and license agreements. These are generally not non-cancellable and are renewable by mutual consent on mutually agreeable terms.
Lease receipts / payments are recognised in the statement of profit and loss under “Lease Rent Income” & “Rent” in Note 28 and 31 respectively.
12 During the year Goodwill arise on account of acquisition of 100% interest into Orit Laboratories LLC along with Okner Realty LLC through wholly owned subsidiary Alembic Pharmaceuticals Inc., (USA) for the purpose of expansion of business operation.
13 The previous year’s figures have been regrouped / rearranged wherever necessary to make it comparable with the current year.
As per our report of even dateFor K. S. Aiyar & Co. Chirayu Amin Pranav Amin Shaunak Amin K. G. Ramanathan Chartered Accountants Firm Registration No. 100186W
Chairman & CEODIN No.: 00242549
Managing DirectorDIN No.: 00245099
Managing DirectorDIN No.: 00245523
DirectorDIN No.: 00243928
Rajesh S. Joshi Milin Mehta Archana Hingorani R. K. Baheti Ajay Kumar DesaiPartner Membership No. 38526
DirectorDIN No.: 01297508
DirectorDIN No.: 00028037
Director-Finance & CFODIN No.: 00332079
Senior Vice President - Finance & Company Secretary
Vadodara: 16th May, 2018 Vadodara: 16th May, 2018
F-103
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Consolidated financial statements
Form AOC-I(Pursuant to first proviso to Sub-section (3) of Section 129 read with rule 5 of Companies (Accounts) Rules, 2014)
Part “A”: Subsidiaries` in Crores
Name of the subsidiary Alembic Global Holding SA
A G Research Pvt Ltd
Aleor Dermaceuticals
LimitedDate since when subsidiary was acquired 14.12.2007 01.07.2015 23.05.2016Reporting period for the subsidiary 31.03.2018 31.03.2018 31.03.2018Reporting currency and Exchange rate as on the last date of the relevant Financial year
1 USD – 68.17 INR INR INR
Share capital 31.04 4.13 0.5Reserves & surplus 85.36 (4.14) 0.32Total assets 723.09 0.02 296.18Total Liabilities 606.69 0.03 295.36Investments 39.54 - 0.23Turnover 906.24 (0.00) NILProfit before taxation 14.43 (3.74) 0.49Provision for taxation 7.13 - NILProfit after taxation 7.30 (3.74) 0.49Proposed Dividend NIL NIL NIL % of shareholding 100% 100% 60%
Notes:1. The following company’s accounts are consolidated in Alembic Global Holding SA, a wholly owned subsidiary of
Alembic Pharmaceuticals Limited:a Alembic Pharmaceuticals Europe Limited (Subsidiary of Alembic Global Holding SA)b Alembic Pharmaceuticals, Inc. (Subsidiary of Alembic Global Holding SA)c Alembic Pharmaceuticals Canada Limited (Subsidiary of Alembic Global Holding SA)d Alembic Pharmaceuticals Australia Pty Limited (Subsidiary of Alembic Global Holding SA)e Alnova Pharmaceuticals SA (Subsidiary of Alembic Global Holding SA)f Genius LLC (Subsidiary of Alembic Global Holding SA)g Rhizen Pharmaceuticals SA (Associate of Alembic Global Holding SA)h Dahlia Therapeutics SA (Subsidiary of Rhizen Pharmaceuticals SA.)i Alembic Mami SPA (Joint Venture of Alembic Global Holding SF)j Rhizen Pharmaceuticals Inc (Wholly Owned Subsidiary of Rhizen Pharmaceuticals SA)k Orit Laboratories LLC (Subsidiary of Alembic Pharmaceuticals Inc)l Okner Realty LLC (Subsidiary of Alembic Pharmaceuticals Inc)
2. Names of subsidiaries which are yet to commence operations - NA
3. Names of subsidiaries which have been liquidated or sold during the year. - NA
F-104
Notes to the Consolidated Financial StatementsAs at 31st March, 2018
Part “B”: Associates and Joint Venture` in Crores
Name of Associates Incozen Therapeutics Pvt. Ltd.
1 Latest audited Balance Sheet Date 31st March, 20182 Date on which Associate was acquired 7th February, 20093 Shares of Associate/ Joint Venture held by the company on the year end no of share 10000004 Amount of Investment in Associates 35 Extent of Holding % 50%6 Description of how there is significant influence NA7 Reason why the associate/ Joint Venture Company is not consolidated NA8 Net worth attributable to Shareholding as per latest audited Balance Sheet 1.65 9 Profit / (Loss) for the year (0.13) 10 Considered in Consolidation (0.06) 11 Not Considered in Consolidation (0.06)
Notes:1 Names of associates or Joint Venture which are yet to commence operations. – NA2 Names of associates or Joint Venture which have been liquidated or sold during the year. NA
As per our report of even dateFor K. S. Aiyar & Co. Chirayu Amin Pranav Amin Shaunak Amin K. G. Ramanathan Chartered Accountants Firm Registration No. 100186W
Chairman & CEODIN No.: 00242549
Managing DirectorDIN No.: 00245099
Managing DirectorDIN No.: 00245523
DirectorDIN No.: 00243928
Rajesh S. Joshi Milin Mehta Archana Hingorani R. K. Baheti Ajay Kumar DesaiPartner Membership No. 38526
DirectorDIN No.: 01297508
DirectorDIN No.: 00028037
Director-Finance & CFODIN No.: 00332079
Senior Vice President - Finance & Company Secretary
Vadodara: 16th May, 2018 Vadodara: 16th May, 2018
F-105
181
MATERIAL DEVELOPMENTS
Sr.
No.
Financial Information Page No.
1. Limited Review Financial Information for the three-month period ended June 30,
2020.
182-188
Independent Auditor’s Limited Review Report on consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
TO THE BOARD OF DIRECTORS OF Alembic Pharmaceuticals Limited Vadodara
1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Resultsof Alembic Pharmaceuticals Limited (APL) (“the Parent”) and its subsidiaries (the Parent and itssubsidiaries together referred to as “the Group”), and its share of the net profit after tax andtotal comprehensive income of its associates and joint ventures for the quarter and the threemonths period ended on 30th June, 2020 (“the Statement”), being submitted by the Parentpursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent’s Management and approved by theParent’s Board of Directors, has been prepared in accordance with the recognition andmeasurement principles laid down in Indian Accounting Standard 34 “Interim FinancialReporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and otheraccounting principles generally accepted in India. Our responsibility is to express a conclusionon the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on ReviewEngagements (SRE) 2410 “Review of Interim Financial Information Performed by theIndependent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. Areview of interim financial information consists of making inquiries, primarily of personsresponsible for financial and accounting matters, and applying analytical and other reviewprocedures. A review is substantially less in scope than an audit conducted in accordance withStandards on Auditing and consequently does not enable us to obtain assurance that we wouldbecome aware of all significant matters that might be identified in an audit. Accordingly, we donot express an audit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities:
Subsidiaries
1. Alembic Global Holdings SA
182
2. Aleor Dermaceuticals Limited3. Alembic Pharmaceuticals Inc.4. Alembic Labs LLC (Formerly known as Orit LLC USA) (Subsidiary of Alembic
Pharmaceuticals Inc.)5. Okner LLC USA (Subsidiary of Alembic Pharmaceuticals Inc.)6. Alembic Pharmaceuticals Australia Pty Ltd. (Subsidiary of Alembic Global Holdings SA)7. Alembic Pharmaceuticals Europe Limited. (Subsidiary of Alembic Global Holdings SA)8. Alnova Pharmaceuticals SA. (Subsidiary of Alembic Global Holdings SA)9. Alembic Pharmaceuticals Canada Limited. (Subsidiary of Alembic Global Holdings SA)10. Genius LLC. (Subsidiary of Alembic Global Holdings SA)
Associates
1. Incozen Therapeutics Private Limited2. Rhizen Pharmaceuticals SA3. Dahlia Therapeutics SA (Subsidiary of Rhizen Pharmaceuticals SA)4. Rhizen Pharmaceuticals Inc. (Subsidiary of Rhizen Pharmaceuticals SA)
Joint Ventures
1. Alembic Mami SPA (Joint Venture of Alembic Global Holdings SA)2. SPH SINE Alembic (Shanghai) Pharmaceutical Technology Company Limited (Joint
Venture of Alembic Global Holdings SA)
5. Except for the matters stated at 6 below, based on our review conducted and proceduresperformed as stated in paragraph 3 above and based on the consideration of the review reportsof other auditors referred to in paragraph 7 below, nothing has come to our attention thatcauses us to believe that the accompanying Statement, prepared in accordance with therecognition and measurement principles laid down in the aforesaid Indian Accounting Standardand other accounting principles generally accepted in India, has not disclosed the informationrequired to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015, as amended, including the manner in which it is to bedisclosed, or that it contains any material misstatement.
6 Re: Subsidiary Company, i.e., Aleor Dermaceuticals Limited. (Aleor)
Aleor’s auditors have modified their audit opinion on condensed financial statements of the three months period ended on 30th June, 2020 as under:
“Basis for Modified Opinion
As mentioned in Note no. 33 (V) and for the reasons stated therein, the company has measured its financial liability of Non-convertible Redeemable Debentures (NCRD) at cost and not as per amortised cost as mandated by Ind AS 109-Financial Instruments. Had the NCRD been measured
183
at amortised cost, the borrowing cost for the period to be included in the Property, plant and equipment (PPE), intangible assets and qualifying asset Capital Work-in Progress and Intangible asset under development would be higher by Rs. 1,297.42 lakhs (PY. 4,971.12 lakhs).
Further, the borrowing costs for the period to be recognised as expense would be higher by Rs. 858.94 lakhs (PY. 1,613.78 lakhs) on account of borrowing cost attributable to Property, plant and equipment (PPE) and Intangible assets capitalised till the period ended as on 30th June, 2020, and accordingly Total Comprehensive Income and shareholders’ funds both would have been lower by Rs. Rs. 858.94 lakhs (PY. 1,613.78 lakhs) with corresponding effect on Earning Per Share (EPS) of the Company for the period ended 30th June, 2020.
As a result of above, the amount of Property, Plant and Equipment, intangible assets and qualifying assets Capital work-in progress and Intangible asset under development would be higher by Rs. 12,431.26 lakhs (PY. 11,133.84 lakhs) and the corresponding financial liability for the NCRD would have been higher by Rs. 14,903.97 lakhs (PY. 12,747.62 lakhs).”
Corresponding interest income for the quarter amounting to Rs. 21.56 Crores (cumulative interest income till date of Rs.149.04 Crores has not been recognized by the Parent Company (Alembic Pharmaceuticals Limited - APL) and is considered as contingent assets. The said NCRD have been carried at cost in separate financial statements of APL as per Ind AS 27.
On consolidation of financial statements (a) the said investment by APL and Financial liability of Aleor and (b) borrowing cost of Aleor and interest income of APL gets eliminated. Therefore it does not have any financial impact on the Group’s Consolidated Financial results.
Our review conclusion is not modified in respect of this matter.
7. We did not review the interim financial statements / financial information / financial resultsof 4 subsidiaries (namely Aleor Dermaceuticals Limited, Alembic Pharmaceuticals Inc., AlembicLabs LLC (Formerly known as Orit LLC USA) and Okner LLC USA.) that are included in theconsolidated unaudited financial results, whose interim financial statements / financialinformation / financial results reflect total assets of Rs.1406.40 Crores as at 30th June, 2020 andtotal revenues of Rs.565.23 Crores and Rs.565.23 Crores, total net loss after tax of Rs.9.00Crores and of Rs.9.00 Crores and total comprehensive loss of Rs.9.03 Crores and Rs.9.03 Crores,for the quarter ended 30th June, 2020 and for the period from 1st April, 2020 to 30th June, 2020,respectively, and cash flows (net inflow) of Rs. 55.89 Crores for the period from 1st April, 2020to 30th June, 2020, as considered in the consolidated unaudited financial results.
These interim financial statements / financial information / financial results of the aforesaid 4 subsidiaries have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.
184
Our conclusion on the Statement is not modified in respect of the above matter.
8. The consolidated unaudited financial results include the interim financial statements/financial information/ financial results of 6 subsidiaries (namely, Alembic Global Holdings SA,Alembic Pharmaceuticals Australia Pty Ltd, Alembic Pharmaceuticals Europe Limited, AlnovaPharmaceuticals SA, Alembic Pharmaceuticals Canada Limited and Genius LLC) which have notbeen reviewed/audited by their auditors and are as prepared by the management. According tothe information and explanations given to us by the Management, these interim financialstatements / financial information / financial results of the aforesaid 6 subsidiaries are notmaterial to the Group and are as prepared by the management. These interim financialstatements/ financial information/ financial results reflect total assets of Rs.141.00 Crores as at30th June, 2020 and total revenue of Rs.37.49 Crores and Rs.37.49 Crores, total net loss after taxof Rs.1.49 Crores and Rs.1.49 Crores and total comprehensive loss of Rs.1.49 Crores and Rs.1.49Crores for the quarter ended 30th June, 2020 and for the period from 1st April, 2020 to 30th
June, 2020, respectively, and cash flows (net out flow) of Rs.18.78 Crores for the period from 1st
April, 2020 to 30th June, 2020, are considered in the consolidated unaudited financial results.
Our conclusion on the Statement is not modified in respect of the above matter.
9. The consolidated unaudited financial results also includes the Group’s share of net profitafter tax of Rs.0.45 Crores and net profit after tax of Rs.0.45 Crores and total comprehensiveincome of Rs.0.45 Crores and total comprehensive income of Rs.0.45 Crores for the quarterended 30th June, 2020 and for the period from 1st April, 2020 to 30th June, 2020, respectively, asconsidered in the consolidated unaudited financial results, in respect of 4 associates (namely,Incozen Therapeutics Private Limited, Rhizen Pharmaceuticals SA, Dahlia Therapeutics SA, andRhizen Pharmaceuticals Inc. are based on their interim financial statements/ financialinformation/ financial results which have not been reviewed/audited by their auditors and areas prepared by the management. According to the information and explanations given to us bythe Management, these interim financial statements / financial information / financial resultsare not material to the Group and are as prepared by the management.
Our conclusion on the Statement is not modified in respect of the above matter.
10. (a) The consolidated unaudited financial results do not include share of profit or loss inrespect of a joint venture (namely Alembic Mami SPA) as the financial statements of the samehave not been received or prepared by the Parent Company and No further share of loss in thatjoint venture is required to be borne by the Group as the entire Equity capital and loan given toit is fully provided for in previous year. Formal legal process for dis-association which is still tobe initiated by the Parent Company.
10. (b) The consolidated unaudited financial results do not include share of profit or loss inrespect of a joint venture (namely SPH SINE Alembic (Shanghai) Pharmaceutical TechnologyCompany Limited) entered into on 7th May, 2019. We are informed that the Group has invested
185
Rs.0.47 Crores during the current quarter to acquire 44% share and the operations of the said joint venture have not started till 30th June, 2020 and therefore, there are no transactions for the reporting period.
Our conclusion on the Statement is not modified in respect of the above matter.
For K.S.Aiyar & Co. Chartered Accountants Firm’s Registration No. 100186W
Rajesh S. Joshi Partner Membership Number: 038526 UDIN: 20038526AAAACG5485
Place of signature: Mumbai Date: 22nd July, 2020
186
ALEMBIC PHARMACEUTICALS LIMITED
Regd.Office: Alembic Road, Vadodara 390 003
CIN:L24230GJ2010PLC061123
Ph #:0265 2280550 Fax #: 0265 2282506
Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2020. Rs. in Crores
Particulars 30.06.2020 31.03.2020 30.06.2019 31.03.2020
(Unaudited) (Audited) (Unaudited) (Audited)
1 Revenue from Operations 1,341.32 1,206.83 948.91 4,605.75
2 Other Income 0.32 0.89 3.29 4.94
3 Total Income 1,341.64 1,207.72 952.20 4,610.69
4 Expenses 25.18% 21.87% 21.54% 22.57%
(a) Cost of Materials consumed 257.24 273.83 232.01 979.05
(b) Purchase of stock-in-trade 49.26 34.99 81.97 270.93
(c)Changes in Inventories of finished goods, Stock in tradeand WIP
31.27 (44.93) (109.58) (210.59)
(d) Employee benefits expense 275.36 246.92 214.87 906.44
(e) Finance Costs 6.67 7.75 4.98 27.16
(f) Depreciation & Amortization Expense 41.50 44.14 35.40 157.32
(g) Other Expenses 320.83 368.50 304.73 1,436.89
Total Expenses 982.13 931.20 764.37 3,567.22
5 Profit before exceptional items and tax 359.50 276.52 187.82 1,043.47
6 Less : Exceptional Items
Expenses - 46.28 32.79 79.06
Incomes - (35.42) - (35.42)
7 Profit before tax 359.50 265.66 155.04 999.82
8 Tax Expense
(i) Current Tax 67.11 47.29 38.59 204.57
(ii) Deferred Tax (0.34) 15.94 (2.63) (4.30)
(iii) Short /(Excess) Tax Provision - (1.09) - (1.09)
9 292.73 203.52 119.08 800.64
10 Share of Profit / (Loss) of Associates & Joint Venture 0.45 (0.07) 0.41 0.05
11 293.18 203.45 119.49 800.70
12 Non-controlling interests 8.28 21.18 4.24 28.12
13 301.46 224.63 123.72 828.82
14 Other Comprehensive Income
A (i) Items that will not be reclassified to profit / (loss) (6.58) (7.34) (4.76) (11.42)
(ii)Income tax relating to items that will not be reclassified toprofit / (loss)
1.14 1.26 1.02 1.97
B (i) Items that will be reclassified to profit / (loss) (0.28) 3.51 1.44 7.64
Total Other Comprehensive Income (A+B) (5.72) (2.58) (2.30) (1.82)
15 Total Comprehensive Income for the period (11+14) 287.46 200.87 117.19 798.88
Attributable to:
- Non-controlling interests (8.30) (21.20) (4.24) (28.17)
- Owners of the Company 295.76 222.08 121.43 827.05
16 Earnings per share - Basic & Diluted (in Rs.) 15.99 11.92 6.56 43.97
17 Paid up Equity Share Capital (Face Value of Rs 2/- each) 37.70 37.70 37.70 37.70
18 Other Equity 3,181.71
Email : [email protected] Website : www.alembicpharmaceuticals.com
Quarter Ended
Net Profit after taxes, non-controlling interests and share of Profit / (Loss) of Associates and Joint Ventures
Profit for the Period before Share of Profit / (Loss) of Associates and Joint Ventures
Net Profit after taxes and Share of Profit / (Loss) of Associates and Joint Ventures but before non-controlling interests
Year Ended
187
Notes :
1
2 As additional information to investors, the Research and Development Expenses are provided here under:Rs. in Crores
30.06.2020 31.03.2020 30.06.2019 31.03.2020Research and Development 142.61 185.00 140.29 644.82
3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
4
For Alembic Pharmaceuticals Limited
Place : Vadodara Chirayu AminDate : 22nd July, 2020 Chairman and CEO
Visit us at www.alembicpharmaceuticals.com
Year Ended
The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make itcomparable with the current quarter / period.
The above consolidated results, have been reviewed by Statutory Auditors, recommended by the Audit Committeeand approved by the Board of Directors of the Company.
ParticularsQuarter Ended
188
189
DECLARATION
The Company certifies that all relevant provisions of Chapter VI read with Schedule VII of the SEBI Regulations
have been complied with and no statement made in this Placement Document is contrary to the provisions of Chapter
VI and Schedule VII of the SEBI Regulations and that all approvals and permissions required to carry on the
Company’s business have been obtained, are currently valid and have been complied with. The Company further
certifies that all the statements in this Placement Document are true and correct.
Signed by:
Chirayu Amin
(Executive Chairman and Chief Executive Officer)
Date: August 6, 2020
Place: Vadodara, Gujarat
190
DECLARATION
We, the Board of Directors of the Company certify that:
(i) the Company has complied with the provisions of the Companies Act, 2013 and the rules made thereunder;
(ii) the compliance with the Companies Act, 2013 and the rules, does not imply that payment of dividend or
interest or repayment of preference shares or debentures, if applicable, is guaranteed by the Central
Government; and
(iii) the monies received under the Issue shall be used only for the purposes and objects indicated in the Placement
Document.
For and on behalf of the Board, signed by:
Chirayu Amin
(Executive Chairman and Chief Executive Officer)
Date: August 6, 2020
Place: Vadodara, Gujarat
I am authorized by the Fund Raising Committee of the Board of Directors of the Company, vide resolution dated
August 6, 2020, to sign this form and declare that all the requirements of Companies Act, 2013 and the rules made
thereunder in respect of the subject matter of this form and matters incidental thereto have been complied with.
Whatever is stated in this form and in the attachments thereto is true, correct and complete and no information
material to the subject matter of this form has been suppressed or concealed and is as per the original records
maintained by the promoters subscribing to the Memorandum of Association and the Articles of Association.
It is further declared and verified that all the required attachments have been completely, correctly and legibly
attached to this form.
Signed by:
Chirayu Amin
(Executive Chairman and Chief Executive Officer)
Date: August 6, 2020
Place: Vadodara, Gujarat
191
ISSUER
ALEMBIC PHARMACEUTICALS LIMITED
Registered and Corporate Office
Alembic Road
Vadodara 390 003,Gujarat, India
Website: www.alembicpharmaceuticals.com
CIN: L24230GJ2010PLC061123
Company Secretary & Compliance Officer:
Charandeep Singh Saluja
Alembic Road
Vadodara 390 003,Gujarat, India
Telephone: +91 256 2280550
Fax: +91 265 2282506
E-mail: [email protected]
BOOK RUNNING LEAD MANAGERS
Monarch Networth Capital Limited
Corporate Office
Monarch House, Opposite Prahaldbhai
Patel Garden, Near Ishwar Bhuwan,
Commerce Six Road, Navrangpura,
Ahmedabad 380 009, Gujarat, India
HDFC Bank Limited
Investment Banking Group,
Unit No. 401 & 402, 4th Floor, Tower B,
Peninsula Business Park
Lower Parel Mumbai 400 013
Maharashtra, India
STATUTORY AUDITORS OF OUR COMPANY
K. C. Mehta & Co., Chartered Accountants
2nd Floor, Meghdhanush
Race Course Circle
Vadodara 390 007, Gujarat, India
INDIAN LEGAL COUNSEL TO OUR COMPANY
Khaitan & Co
One World Center
10th and 13th Floor, Tower 1C
Senapati Bapat Marg
Mumbai 400 013, Maharashtra, India
INDIAN LEGAL COUNSEL TO THE BOOK RUNNING LEAD MANAGERS
J. Sagar Associates
Vakils House, 18 Sprott Road
Ballard Estate
Mumbai 400 001
Maharashtra, India
INTERNATIONAL LEGAL COUNSEL WITH RESPECT TO SELLING AND TRANSFER
RESTRICTIONS
Squire Patton Boggs Singapore LLP
1 Marina Boulevard
#21-01 One Marina Boulevard
Singapore 018989
Republic of Singapore
192
APPLICATION FORM
APPLICATION FORM
ALEMBIC PHARMACEUTICALS LIMITED
Alembic Pharmaceuticals Limited (our “Company" or “Issuer”), was originally incorporated as a public limited company
under the name of Alembic Pharma Limited on June 16, 2010 under the Companies Act, 1956. Subsequently, the name of
our Company was changed to the present name of our Company, Alembic Pharmaceuticals Limited, pursuant to a certificate
of incorporation consequent upon change of name dated March 12, 2011. For further details with respect to changes to the
name of our Company, please see section "General Information" on page 179.
Registered and Corporate Office: Alembic Road, Vadodara 390003, Gujarat, India
Website: www.alembicpharmaceuticals.com | CIN: L24230GJ2010PLC061123
Telephone No.: +91 265 228 0550
Fax: +91 265 228 2506
Email: [email protected]
Name of the Bidder:
_____________________
Form No. _____________ Date:
__________________
QUALIFIED INSTITUTIONS PLACEMENT OF UPTO [●] EQUITY SHARES OF FACE VALUE ₹2 EACH (THE “EQUITY SHARES”) FOR
CASH, AT A PRICE OF ₹ [●] PER EQUITY SHARE (“ISSUE PRICE”) INCLUDING A PREMIUM OF ₹ [●] PER EQUITY SHARE
AGGREGATING UPTO ₹ [●] CRORE UNDER CHAPTER VI OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI REGULATIONS”) AND SECTION 42 OF THE
COMPANIES ACT, 2013 AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013, AS AMENDED AND THE RULES MADE
THEREUNDER BY THE COMPANY (HEREINAFTER REFERRED TO AS THE “ISSUE”). THE APPLICABLE FLOOR PRICE OF THE
EQUITY SHARES IS ₹980.75 PER EQUITY SHARE AND THE COMPANY MAY OFFER A DISCOUNT OF UPTO 5% ON THE FLOOR PRICE.
Only “Qualified Institutional Buyers” (“QIBs”) as defined in Regulation 2(1)(ss) of the SEBI Regulations which (i.) is not, (a) excluded pursuant to
Regulation 179(2)(b) of the SEBI Regulations or (b) restricted from participating in the Issue under the SEBI Regulations and other applicable laws,
and (ii) is a resident in India or is an eligible FPI participating through Schedule II of the FEMA Rules, defined hereinafter; can submit this Application
Form. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or the
state securities laws of any state of the United States and, unless so registered, may not be offered, sold or delivered within the United States except
pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state
securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in ‘offshore transactions’ (as defined in Regulation
S under the U.S. Securities Act) in reliance on Regulation S and the applicable laws of the jurisdiction where those offers and sales are made. You
should note and observe the solicitation and distribution restrictions contained in the sections entitled “Selling Restrictions” and “Purchaser
Representations and Transfer Restrictions” in the accompanying preliminary placement document dated August 3, 2020 (the “PPD”).
ELIGIBLE FPIs ARE PERMITTED TO PARTICIPATE UNDER SCHEDULE II OF THE FOREIGN EXCHANGE MANAGEMENT (NON-DEBT
INSTRUMENTS) RULES, 2019 (“FEMA RULES”) IN THIS ISSUE. ELIGIBLE FPIs ARE PERMITTED TO PARTICIPATE IN THE ISSUE
SUBJECT TO COMPLIANCE WITH ALL APPLICABLE LAWS AND SUCH THAT THE SHAREHOLDING OF THE ELIGIBLE FPIs DO NOT
EXCEED SPECIFIED LIMITS AS PRESCRIBED UNDER APPLICABLE LAWS IN THIS REGARD. ALLOTMENTS MADE TO AIFs AND VCFs
IN THE ISSUE SHALL REMAIN SUBJECT TO THE RULES AND REGULATIONS APPLICABLE TO EACH OF THEM RESPECTIVELY,
INCLUDING THE FEMA RULES. FVCIs ARE NOT PERMITTED TO PARTICIPATE IN THE ISSUE
To,
The Board of Directors
Alembic Pharmaceuticals Limited
Alembic Road
Vadodara 390003,
Gujarat, India
Dear Sirs,
On the basis of the serially numbered PPD of the Company, and subject to the terms
and conditions mentioned in the other sections of the PPD and in this Application
Form, we hereby submit our Bid for the Allotment of the Equity Shares at the terms
and price indicated below. We confirm that we are a QIB as defined in Regulation
2(1)(ss) of the SEBI Regulations which (i.) is not, (a) excluded pursuant to
Regulation 179(2)(b) of the SEBI Regulations or (b) restricted from participating in
the Issue under the applicable laws, and (ii) is a resident in India or is an Eligible
FPI participating through Schedule II of the FEMA Rules. We are not a promoter
(as defined in SEBI Regulations) of the Company, or any person related to the
Promoters, directly or indirectly. Further, we confirm that we do not have any right
under a shareholders’ agreement or voting agreement entered into with the Promoter
or members of the Promoter Group of the Company, veto rights or right to appoint any nominee director on the board of directors of the Company. In addition, we confirm
that we are eligible to invest in the Equity Shares under the SEBI Regulations and other applicable laws. We confirm that we are either a QIB which is resident in India, or
an Eligible FPI, participating through Schedule II of the FEMA Rules, or a multilateral or bilateral development financial institutions eligible to invest in India under
applicable laws. We confirm that our Bid for the Allotment of the Equity Shares is not in violation to the amendment made to Rule 6(a) of the FEMA Rules by the Central
Government on April 22, 2020.
We confirm that the Bid size / aggregate number of Equity Shares applied for by us and which may be Allotted to us does not exceed the relevant regulatory or approved
limits under applicable laws. We confirm that our Bid will not result in triggering an open offer under the Securities and Exchange Board of India (Substantial Acquisition
of Shares and Takeovers) Regulations, 2011, as amended (“SEBI Takeover Regulations”). We confirm, that we have a valid and existing registration under applicable
laws and regulations of India, and undertake to acquire, hold, manage or dispose of any Equity Shares that are Allotted to us, if applicable, in accordance with Chapter VI
of the SEBI Regulations and undertake to comply with the SEBI Regulations, and all other applicable laws, including any reporting obligations. We confirm that each
foreign portfolio investor as defined under the Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019, as amended (such foreign portfolio
investor, an “FPI”) (other than individuals, corporate bodies and family offices), and including persons who have been registered under these regulations (such FPIs,
“Eligible FPIs”), has submitted a separate Application Form, and asset management companies of mutual funds would have specified the details of each scheme for which
the application is being made along with the Bid Amount and number of Equity Shares to be Allotted under each fund. We undertake that we will sign all such documents,
provide such documents and do all such acts, if any, necessary on our part to enable us to be registered as the holders of the Equity Shares which may be Allotted to us. We
STATUS (Please ✓)
FI
Scheduled
Commercial Banks
and Financial
Institutions
AIF Alternative Investment
Funds
MF Mutual Funds NIF National Investment
Fund
FPI Eligible Foreign
Portfolio Investors* SI-NBFC
Systemically Important
NBFC
VCF Venture Capital
Funds IF Insurance Funds
IC Insurance
Companies FVCI
Foreign Venture Capital
Investors
OTH Others (Please
Specify)
*Foreign portfolio investors as defined under the Securities and Exchange Board of India
(Foreign Portfolio Investors) Regulations, 2019, as amended other than individuals,
corporate bodies and family offices who are not allowed to participate in the Issue.
193
confirm that the signatory is authorized to apply on behalf of the applicant and the applicant has all the relevant approvals. We authorize you to place our name in the register
of members of the Company as holders of the Equity Shares that may be Allotted to us. We note that the Company in consultation with the BRLMs namely Monarch
Networth Capital Limited and HDFC Bank Limited and are entitled, in its absolute discretion to accept or reject this Application Form without assigning any reason thereof.
We hereby accept the Equity Shares that may be Allocated to us pursuant to the Confirmation of Allocation Note (“CAN”) and request you to credit the same to our
beneficiary account as per the details given below, subject to receipt of Application Form and Bid Amount towards the Equity Shares that may be allocated to us.
We agree and consent that: (i) our names, address, PAN (if applicable), contact details, bank account details, email-id, and the number of Equity Shares Allotted, along with
other relevant information as may be required will be recorded by the Company in the format prescribed in terms of the Companies (Prospectus and Allotment of Securities
Rules, 2014, as amended (“PAS Rules”), (ii) in the event that any Equity Shares are Allocated to us in the Issue, we are aware that, pursuant to the requirements under Form
PAS-4 of the PAS Rules, our name will be included in the Placement Document as “proposed allottees”, if applicable, along with the number of Equity Shares proposed to
be Allotted to us, and the percentage of our post Issue shareholding in the Company, and (iii) in the event that Equity Shares are Allotted to us in the Issue, the Company
will place our name in the register of members of the Company as a holder of such Equity Shares that may be Allotted to us and in the Form PAS-3 filed by the Company
with the Registrar of Companies, Gujarat at Ahmedabad (“RoC”) as required in terms of the PAS Rules. We are also aware and agree that if we, together with any other
Eligible QIBs belonging to the same group or under common control, for which we shall submit necessary information to the Company and BRLMs, are Allotted more than
5% of the Equity Shares in this Issue, the Company shall be required to disclose our name, along with the name of such other Allottees and the number of Equity Shares
Allotted to us and to such other Allottees, on the website of the Stock Exchanges, and we consent to such disclosure. Further, we agree to comply with the rules and
regulations that are applicable to us, including restriction on transferability and lock-in. In this regard, we authorise the Company to issue instructions to the depositories for
such restriction on transferability, as may be applicable to us. In addition, we confirm that we are eligible to invest in Equity Shares under the SEBI Regulations, circulars
issued by the Reserve Bank of India (“RBI”), and other applicable laws.
We are aware that (i) Allocation and Allotment in the Issue shall be at the sole discretion of the Company, in consultation with the BRLMs; and (ii) in the event that Equity
Shares that we have applied for are not Allotted to us in full or at all, and/or the Bid Amount is in excess of the amount equivalent to the product of the Equity Shares that
will be Allocated to us and the Issue Price, or if the Company is unable to issue and Allot the Equity Shares offered in the Issue or if there is a cancellation of the Issue, the
Bid Amount or a portion thereof, as applicable, will be refunded to the same bank account from which the Bid Amount has been paid by us.
By signing and submitting this Application Form, we hereby confirm and agree (i) that the representations, warranties, acknowledgements and agreements as provided in
“Notice to Investors”, “Representations by Investors”, “Issue Procedure”, “Purchaser Representations and Transfer Restrictions” and “Selling Restrictions” of the PPD and
the terms, conditions and agreements mentioned herein are true and correct and acknowledge and agree that these representations, warranties, acknowledgements and
agreements are given by us for the benefit of the Company and the BRLMs for the Issue, each of whom are entitled to rely and are relying on these representations,
acknowledgements and agreements in consummating the Issue, (ii) that we have been provided a serially numbered copy of the PPD, and have read it in its entirety including
in particular, the “Risk Factors” therein, and have relied only on the information contained in the PPD and not on any other information obtained by us either from the
Company, the BRLMs, or any other source, including publicly available information, and (iii) to abide by the PPD and the Placement Document, this Application Form, the
CAN, when issued, and the terms, conditions and agreements contained therein, (iv) that if we are participating in the Issue as an eligible qualified institutional buyer, we
are not an individual, corporate body or family office, (v) Equity Shares shall be Allocated and Allotted at the discretion of the Company, in consultation with BRLMs, and
the submission of this Application Form and payment of the corresponding Bid Amount by us does not guarantee any Allocation or Allotment of Equity Shares to us in full
or in part; (vi) that we shall not trade in the Equity Shares credited to our beneficiary account maintained with the Depository Participant until the final listing and trading
approvals for the Equity Shares are issued by the Stock Exchanges, (vii) that we shall not sell such Equity Shares otherwise than on the floor of a recognised stock exchange
in India for a period of one year from the date of Allotment, (viii) that we shall not have the right to withdraw or revise our Bid after the Bid/ Issue Closing Date, (ix) in
terms of the requirements of the Companies Act, upon Allocation, the Company will be required to disclose names and percentage of the post-Issue shareholding of the
proposed Allottees in the Placement Document; however, disclosure of such details in relation to us in the Placement Document will not guarantee Allotment to us, as
Allotment in the Issue shall continue to be at the sole discretion of the Company, in consultation with the BRLMs; (x) that we, together with other persons that belong to
our same group or are under common control in terms of the SEBI Regulations), have not applied for more than 50% of the Issue and that the number of Equity Shares
Allotted to us pursuant to the Issue, together with other Allottees that belong to the same group or are under common control, shall not exceed 50% of the Issue. For the
purposes of this representation: the expression: QIBs belonging to the “same group” shall derive meaning from Regulation 180(2) of the SEBI Regulations and mean entities
where (a) any of them controls, directly or indirectly, through its subsidiary or holding company, not less than 15% of the voting rights in the other; or (b) any of them,
directly or indirectly, by itself, or in combination with other persons, exercise control over the others; or (c) there is a common director, excluding nominee and independent
directors, amongst a Eligible QIB, its subsidiary or holding company and any other Eligible QIB; and ‘Control’ shall have the same meaning as is assigned to it under
Regulation 2(1)(e) of the SEBI Takeover Regulations.
We hereby agree to accept the Equity Shares applied for, or such lesser number as may be Allocated to us, subject to the provisions of the memorandum of association and
articles of association of the Company, applicable laws and regulations, the terms of the PPD, this Application Form and the CAN, when issued and the terms, conditions
and agreements mentioned therein and request you to credit the same to our beneficiary account with the Depository Participant as per the details given below. The Bid
Amount payable by us for the Equity Shares to be Allotted in the Issue has been/will be remitted to the designated bank account prior to Bid/ Issue Closing Date, only
through electronic mode pursuant to duly completed Application Form and to the bank account mentioned in the Application Form. We acknowledge and agree that we
have not/shall not make any payment in cash or cheque. We also agree that the amount payable for the Equity Shares in the Issue is being (shall be) made from the bank
account maintained in our name, and in case we are joint holders, from the bank account of the person whose name appears first in the Application Form, and the Bid
Amount may be refunded to the same bank account in the event that (i) that the number of Equity Shares Allocated to a Bidder is lower than the number of Equity Shares
applied for through the Application Form and towards which Bid Amount has been paid by such Bidder; or (ii) Equity Shares have been Allocated to Successful Bidders
and the Company is unable to issue and Allot the Equity Shares offered in the Issue or on cancellation of the Issue; or (iii) we are unable to issue and Allot the Equity Shares
offered in the Issue or if the Issue is cancelled within 60 days from the date of receipt of application monies; or (iv) (a) any Bidder is not Allocated Equity Shares in the
Issue, (b) the Bid Amount has been arrived at using an indicative price higher than the Issue Price, or (c) any Eligible QIB lowers or withdraws their Bid after submission
of the Application Form but prior to the Bid/ Issue Closing Date. By making this application, we further represent, warrant and agree that we have such knowledge and
experience in financial and business matters that we are capable of evaluating the merits and risks of the prospective investment in the Equity Shares and we understand the
risks involved in making an investment in the Equity Shares. We satisfy any and all relevant suitability standards for investors in the Equity Shares, have the ability to bear
the economic risk of our investment in the Equity Shares, have adequate means of providing for our current and contingent needs, have no need for liquidity with respect to
our investment in the Equity Shares, and are able to sustain a complete loss of our investment in the Equity Shares.
We acknowledge that the Equity Shares have not been and will not be registered under the U.S. Securities Act, and may not be offered or sold within the United States
except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. By
signing this Application Form and checking the applicable box above, we hereby represent that we are located outside the United States and purchasing the Equity Shares
in an ‘offshore transaction’ (as defined in Regulation S) in reliance on Regulation S of the Securities Act and the applicable laws of the jurisdiction where those offers and
sales are made.
BIDDER DETAILS (in Block Letters)
NAME OF
BIDDER*
NATIONALITY
REGISTERED
ADDRESS
CITY AND PIN
CODE
194
COUNTRY
PHONE NO.
EMAIL ID
FOR FPIs** SEBI Registration Number:
For AIFs***/ MFs* / VCFs*** / SI-NBFCs /
Insurance Companies SEBI Registration Number:
*Name should exactly match with the name in which the beneficiary account is held. Any discrepancy in the name as mentioned in this Application Form with the depository records
would render the application invalid and liable to be rejected at the sole discretion of the Issuer and the BRLMs. Mutual Fund Bidders are requested to provide details of the Bids made
by each scheme of the Mutual Fund. Each Eligible FPI is required to fill a separate Application Form **In case you are an Eligible FPI holding a valid certificate of registration and eligible to invest in the Issue, please mention your SEBI FPI Registration Number *** Allotments made to AIFs and VCFs in the Issue are subject to the rules and regulations that are applicable to each of them respectively, including in relation to lock-in requirement.
AIFs and VCFs should independently consult their own counsel and advisors as to investment in and related matters concerning the Issue
We are aware that the number of Equity Shares in the Company held by us, together with the number of Equity Shares, if any, Allocated to us in the Issue will
be aggregated to disclose the percentage of our post-Issue shareholding in the Company in the Placement Document in line with the requirements under PAS-
4 of the PAS Rules. For such information, the BRLMs have relied on the information provided by the Registrar for obtaining details of our shareholding and
we consent and authorize such disclosure in the Placement Document.
Kindly make your payment only by way of electronic fund transfers, towards the Escrow Account. Payment of the entire Bid Amount should be made along with
the Application Form on or before the closure of the Bid Period i.e. within the Bid / Issue Closing Date. All payments must be made in favour of “Alembic
Pharmaceuticals Ltd-QIP Escrow”. The payment for subscription to the Equity Shares to be allotted in the Issue shall be made only from the bank account of the
person subscribing to the Equity Shares and in case of joint holders, from the bank account of the person whose name appears first in the Application Form.
DEPOSITORY ACCOUNT DETAILS
Depository Name (Please ✓) National Security Depository
Limited Central Depository Services (India) Limited
Depository Participant Name
DP – ID
Beneficiary Account Number (16 digit beneficiary account. No. to be mentioned above)
The demographic details like address, bank account details etc., will be obtained from the Depositories as per the beneficiary account given above.
However, for the purpose of refund, if any, only the bank account details as mentioned below, from which remittance towards subscription has been
made, will be considered.
BANK ACCOUNT DETAILS FOR PAYMENT OF AMOUNT THROUGH ELECTRONIC FUND TRANSFER
REMITTANCE BY WAY OF ELECTRONIC FUND TRANSFER By 3:00 p.m. (IST) on August 6, 2020
Name of the Account ALEMBIC PHARMACEUTICALS LTD-QIP ESCROW
Name of the Bank HDFC BANK LIMITED
Address of the Branch of the
Bank
MIDWAY HEIGHTS, RS NO 49, VIBHAG 1, TIKKA 24/1, LOKMANYA TILAK ROAD, OPP SSG
HOSPITAL, NEAR PANCHMUKHI, VADODARA 390 001, GUJARAT
Account Type ESCROW ACCOUNT
Account Number 57500000535488
IFSC HDFC0000429
You are responsible for the accuracy of the bank account details mentioned below. You are aware that the successful processing of refunds if, any,
shall be dependent on the accuracy of the bank account details provided by you. The Company and the BRLMs shall not be liable in any manner for
refunds that are not processed due to incorrect bank account details.
RUPEE BANK ACCOUNT DETAILS (FOR REMITTANCE)
Bank Account
Number IFSC Code
Bank Name Bank Branch
Address
NO. OF EQUITY SHARES BID BID PRICE PER EQUITY SHARE (RUPEES)
(In figures) (In words) (In figures) (In words)
BID AMOUNT (RUPEES)
(In figures) (In words)
DETAILS OF CONTACT PERSON
NAME
ADDRESS
TEL. NO.
195
OTHER DETAILS ENCLOSURES ATTACHED
PAN** Attested/ certified true copy of the following:
Copy of PAN Card or PAN allotment letter
Copy of FPI Registration Certificate /MF
Registration certificate /SEBI certificate of
registration for AIFs/VCF Certified copy of the certificate of registration
issued by the RBI as an SI-NBFC/ a scheduled
commercial bank
FIRC
Copy of IRDAI registration certificate
Certified true copy of Power of Attorney
Other, please specify:
Date of Application
Signature of Authorised
Signatory
*The application form is liable to be rejected if any information provided is incomplete or inadequate.
**It is to be specifically noted that the applicant should not submit the GIR Number or any other identification number instead of the PAN as the applications are
liable to be rejected on this ground
Note: Capitalized terms used but not defined herein shall have the same meaning as ascribed to them in the PPD, unless specifically defined herein.
The PPD sent to you and the Placement Document to be sent to you, either in physical form or both, are specific to you and you may not distribute or forward the
same and are subject to disclaimer and restrictions contained in or accompanying these documents.